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Chronic wounds are a global health problem, affecting approximately 1 – 2% of the general 
population in developed countries. Chronic wounds are also an economic burden, with the 
NHS in the UK spending approximately £4.5 – 5.1 billion per annum, after adjusting for co-
morbidities. Chronic wounds also have a negative effect on the patient’s quality of life and 
can lead to a range of psychological consequences such as depression, anxiety and 
embarrassment, all of which can lead to social isolation, further perpetuating psychological 
illness. 
Current methods to detect wound infection are lacking. Sampling techniques are often 
imprecise and cause pain to the patient. Additionally, standard microbiological techniques 
are time consuming, have to be performed by a trained specialist, and are often only able to 
identify bacteria that can be routinely grown in a laboratory. 
Owing to these aforementioned issues, there is a growing need to create novel ‘smart’ 
systems that can detect or treat pathogenic bacteria accurately and rapidly, without the need 
of invasive, painful sampling techniques, and time consuming microbiological analysis. 
This thesis outlines the development of a novel theranostic wound dressing capable of 
detecting and treating S. aureus infections. Bacteriophage K and ciprofloxacin were 
encapsulated within a pH-responsive polymer matrix, and upon a rise in pH were released 
from the system to treat the S. aureus infection. Concurrently, a novel colorimetric and 
fluorescent probe was designed to detect S. aureus, to notify the patient or health care 
practitioner to the presence of an infection. Both components of this theranostic system 
were tested against S. aureus species using a variety of microbiological techniques, 
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Chapter 1: Introduction 
1.1. Clinical Problem 
Chronic wounds are a global health problem, often affecting patients older than 60 years of 
age.1 In developed countries, chronic wounds are prevalent in 1 – 2% of the general 
population,2 and the NHS spends approximately £4.5 – 5.1 billion per annum on wound 
care, after adjusting for co-morbidities.3 In addition to physical consequences, chronic 
wounds have a negative effect on the patient’s quality of life and can lead to a range of 
psychological issues such as depression, anxiety and embarrassment, all of which can lead 
to social isolation, further perpetuating psychological illness. Renner et al reported that at 
least 30% of patients with chronic wounds have symptoms of depression and anxiety;4 
therefore, it is imperative that new management techniques are implemented to help 
diagnose, manage, and treat chronic wounds to improve patient’s lives and reduce the 
economic burden placed on healthcare settings.  
For successful management of chronic wounds, it is important to detect the presence of any 
bacterial pathogens within the wound that may be impeding healing. Methods to obtain 
bacteriological samples include swabbing, needle aspiration, and wound biopsy; the most 
common technique is wound swabbing, although this may not result in an  accurate 
depiction of the bacterial topology within the wound environment as it mainly detects 
surface colonising bacteria.5 Additionally, these techniques are often invasive and painful; 
hence, most clinicians often rely on other clinical indications (e.g., pain, erythema, and 
oedema) to diagnose wound infections before resorting to microbiological assessment.6,7  
Regardless of the sampling technique used, clinical assessment of infection is performed via 
standardised microbiological tests that have inherent limitations including the time-
consuming protocols and the need for trained specialists. Additionally, it has been stated 
that traditional culturing methodology only identifies 1% of the bacteria within chronic 
wounds,8–10 resulting in the patient receiving inaccurate antibiotic therapy, perpetuating 
antibiotic resistance and ensuing the non-healing nature of the wound.   
Owing to the issues in wound sampling and the need for rapid determination of the 
causative pathogenic bacteria, there is a growing need to create novel ‘smart’ systems that 
can accurately and rapidly detect or treat pathogenic bacteria within wounds, without the 
need of invasive, painful sampling techniques and time consuming microbiological analysis.  
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1.2. Wounds and Wound Healing 
The skin is the largest organ in the body, acting as a first line of defence against pathogenic 
microbial infections.11,12 Skin is composed of two layers, the epidermis and dermis. The 
epidermis is avascular and is composed of  keratinized, stratified squamous epithelium; 
while the dermis is composed of two layers of connective tissue containing blood and lymph 
vessels, nerves, hair follicles and sweat glands. The skin is connected to the underlying 
fibrous tissue of the bones and muscles via the hypodermis (Figure 1.1).  
 
Figure 1.1: Skin anatomy viewed in a cross-section. Reprinted from Grice et al with permission. Copyright © 
2011, Nature Publishing Group 
1.2.1. Types of Wound 
According to the Wound Healing Society, a wound is the “disruption of normal anatomic 
structure and function”.13 Wounds can be classified as either acute or chronic depending on 
the nature of the repair process.14 Acute wounds are typically caused by cuts or surgical 
incisions that complete the wound healing process in a timely and expected manner and 
result in sustained restoration of anatomic and functional integrity.13 Conversely, chronic 
wounds are wounds that fail to heal within the expected time frame due to repeated damage 
to the tissue or underlying co-morbidities that interfere with the wound healing process.15,16 
Chronic wounds are also defined as wounds that have proceeded through the healing 
process without sustained anatomical and functional integrity.13 Examples include venous 
ulcers, diabetic foot ulcers, and pressure ulcers.17  
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1.2.2. Wound Healing and the Wound Healing Cascade 
Wound healing starts immediately after injury and involves the removal of damaged tissue 
and restoration of the skin integrity.18 Healing is defined by the Wound Healing Society as 
a “complex and dynamic process that results in the restoration of anatomic continuity and 
function”.13 
The different types of wound healing (primary, secondary, or tertiary intention) are 
categorised based on the anticipated nature of the repair process.14 Wound healing by 
primary intention involves the approximation of wound edges by sutures, clips, or skin 
adhesion. Primary intention is often seen for injuries where minimal epithelialization and 
new tissue are needed to repair the skin defect, resulting in slight scarring.19,20 
Secondary intention occurs when the wound edges cannot be approximated, and as such, 
the wound is left open to heal via the production of connective tissue, following the steps of 
the wound healing cascade. Secondary intention is often witnessed for patients with 
underlying co-morbidities, or in patients with post-surgical wound dehiscence. Secondary 
intention wounds are often slow to heal and prone to complications (e.g., infections), further 
delaying the wound healing process.18 Additionally, this intention can be associated with 
substantial scarring.19,21 
 Finally, wound healing via tertiary intention is where the wound is left open until any 
contaminants, non-viable tissue, or infection is removed; after this, the wound edges are 
approximated, and healing continues via primary intention.18 This intention is also known 
as “delayed primary intention” in literature.14  
The physiologic process of wound healing is complex, consisting of a cascade of sequential 
yet overlapping physiological processes.14  For the purposes of this chapter, the general 
stages of wound healing described by Schultz are used (haemostasis, inflammation, 
proliferation, and remodelling; Figure 1.2).16 Haemostasis occurs immediately after injury 
and is usually compete within hours, inflammation begins shortly after haemostasis and 
lasts for up to 72 h after injury12 – although wounds can remain in this phase for several 
days after injury. Proliferation generally occurs 1 – 3 weeks after injury, and remodelling 




Figure 1.2: Overview of the distinct, but overlapping, phases of wound healing. 
1.2.2.1. Haemostasis 
Immediately after injury, vasoconstriction occurs to prevent further blood loss. This arises 
when clotting factors are released by the injured skin cells, activating the clotting 
cascade.22,23 Additionally, platelets adhere to the wall of the injured blood vessels and to the 
exposed collagen within the extracellular matrix, triggering the release of cytokines 
(signalling molecules that are secreted by certain cells of the immune system that mediate 
and regulate immunity, inflammation, and haematopoiesis), growth factors, and pro-
inflammatory mediators. This, in turn, results in platelet aggregation, activating the 
intrinsic and extrinsic coagulation pathways that lead to fibrin clot formation, which seals 
the exposed blood vessels, preventing further blood loss24 and creates a temporary seal over 
the wound to prevent microbial infection.14 Additionally, the fibrin clot acts as a scaffold, 
supporting the influx of fibroblasts and keratinocytes into the wound bed.25  
Platelet activation results in the release of potent cytokines that initiate the wound healing 
cascade. The specific mechanisms mediated by these cytokines include the activation of the 
inflammatory response and proliferation of new cells (epithelialization) and blood vessels 
(angiogenesis) at the injury site.14  For example, platelet-derived growth factor (PDGF) 
initiates the chemotaxis of neutrophils, macrophages, smooth muscle cells, and fibroblasts. 
Furthermore, transforming growth factor-beta (TGF-β) attracts macrophages to the wound 
area and stimulates them to produce additional cytokines, such as fibroblast growth factor 




The inflammatory response is triggered by tissue injury and the activation of the coagulation 
cascade, increasing the local vasodilation and capillary permeability, which subsequently 
allows for the migration of monocytes into the wound bed.18  
Within minutes, neutrophils accumulate within the wound bed to remove any 
microorganisms present via phagocytosis.12,14,15 Neutrophils also contribute to wound 
healing by activating local fibroblasts and epithelial cells.26 After 2 – 3 days, neutrophils 
leave the wound bed via apoptosis, unless the wound becomes infected; in which case, 
neutrophil infiltration continues until the infection is controlled.15,23   
In the absence of infection, monocytes differentiate into macrophages, which are arguably 
the most important cell within the wound healing process as any inhibition of macrophage 
function results in a delay in wound healing.18,27 Macrophages remove non-viable cells, 
bacteria-filled neutrophils, damaged extracellular matrix, debris, and any bacteria from the 
wound site; they also release PDGF and TGF-β to further attract fibroblasts and smooth 
muscle cells into the wound site.18  
The responsibility of the inflammatory phase is to control the bleeding and removal of any 
contaminants. If the wound is following the normal wound healing process, this phase 
should take approximately three days to complete; however, if the wound bed is 
contaminated, or becomes infected, then the inflammation phase will be prolonged.18  
1.2.2.3. Proliferation 
Generally, there is an overlap between the inflammation phase and the proliferation 
phase,18 with the latter focusing on re-epithelization, restoration of the  vascular integrity to 
the region, and repair of the structural integrity of the tissue defect by creating new 
connective tissue (granulation).27,28 
During the proliferative phase, the wound is hypoxic, and the partial pressure of oxygen 
decreases to about 10 mm Hg.14 This hypoxic environment induces the release of hypoxia-
inducible factor (HIF), which regulates the expression of vascular endothelial growth factor 
(VEGF). VEGF, in combination with basic fibroblast factor (bFF), and TGF-β activate 
neovascularization or angiogenesis along the wound edges.12,18 Simultaneously, the 
endothelial cells produce enzymes that breakdown the adjacent extracellular matrix to 
create tissue defects, which allow the capillary vessels to infiltrate the tissue to form a 
network to restore vascularity. As a consequence, this process of angiogenesis is 
6 
 
interdependent on the production of new extracellular matrix, which acts as a scaffold to 
support the newly formed blood vessels.18  
Re-epithelization of a wound occurs when stimulated keratinocytes proliferate and migrate 
across the wound bed,19 prior to upward migration and differentiation, which occurs until 
the epidermis regains its normal thickness and stratification.18 Keratinocytes can only 
migrate over a moist, vascular wound surface,29 if the wound surface is not moist, 
keratinocytes secrete proteolytic enzymes that enable it to burrow into the wound bed to 
find the necessary moisture for migration.15,30 When the skin is completely covered with 
epidermal cells, the wound is considered closed; it has been shown that the chance of 
developing hypertrophic scar tissue is greatly reduced by early wound closure.19 
The final mechanism of the proliferation phase is the formation of granulation tissue.14 The 
fibrin clot created in the haemostasis phase is replaced by fibronectin, hyaluronic acid, and 
other extracellular matrix components, which promote cell migration and proliferation. 
Fibroblasts are the main cell responsible for the formation of granulation tissue as they 
attach to the provisional fibrin matrix and begin collagen production. These fibroblasts 
responsible for the granulation tissue have been activated into wound fibroblasts that have 
decreased proliferative activity and increased collagen production behaviour. Initially, the 
type of collagen is ‘type 3’, with limited tensile strength. Over time, collagen matures to ‘type 
1 collagen’ that is normally found in dermal tissue.18  
It is important to mention that contraction can occur in open wounds, which is beneficial to 
the wound healing process as the less granulation tissue required, the quicker the healing 
time.31 While it is currently unknown how contraction works, three theories have been 
proposed: modified fibroblasts are responsible for generating contractile forces that pull the 
wound edges together,32 wound fibroblasts act collectively to contract the connective tissue 
matrix,33 and newly formed collagen fibres produce a pulling force on the surrounding 
tissues.34 
1.2.2.4. Remodelling 
The final stage of wound healing is remodelling, where the granulation tissue matures into 
connective and scar tissue.14 The remodelling phase can last for up to one year, during which 
fibroblasts regulate the process of wound matrix breakdown by metalloproteinases 
(MMPs). This process slowly increases the strength of the wound; however, scar tissue is 
only 80% as strong as unwounded tissue. Occasionally, an imbalance in matrix degradation 
and synthesis are disrupted, resulting in abnormal scar formation (e.g. keloid or 
hypertrophic scarring).18  
7 
 
1.2.3. Delayed Wound Healing 
There are several factors that may impede wound healing;35 they are briefly outlined in 
Table 1.1. In terms of microbial infections, the prolonged time spent within the 
inflammation phase leads to continued regulation of inflammatory cytokines, which in turn 
result in the increased production of proteases, reactive oxygen species, and MMPs that 
degrade collagen, leading to delayed wound healing.36  
Table 1.1: Local and systemic factors that may impede wound healing. Adapted from Grey et al35  
Local factors Systemic factors 
Inadequate blood supply Age and immobility  
Increased skin tension Obesity 
Poor surgical apposition Smoking 
Wound dehiscence Malnutrition 
Poor venous drainage Illness 
Infection Immunosuppressant drugs, corticosteroids, 
anticoagulants 
 
1.3. Wound Infection 
Upon a breach of the epidermal layer, the subcutaneous tissue is exposed, resulting in  a 
moist and warm environment containing devitalised tissue that is favourable for microbial 
colonisation and proliferation. Typical signs of infection include heat, pain, oedema, 
erythema, purulence, and loss of function within the wound area. Indications for chronic 
wounds also include friable granulation tissue, wound breakdown, pain, and odour.11,37  
All wounds are colonised with bacteria from either endogenous or exogenous sources,37,38  
and the development of an infection follows the “wound infection continuum” (Figure 1.3). 
This continuum consists of five stages of wound infection, ranging from contamination 
through to a systemic infection.7 However, there is no consensus as to when the wound 
shifts from colonised to infected – a phenomenon previously called “critical colonisation”7,17  
Cutting et al suggested that the critical colonisation of bacteria is where the wound has 
become compromised by bacteria, resulting in delayed wound healing without any clinical 




Figure 1.3: Wound infection continuum. Reproduced from Wounds International with permission.40 
Copyright © 2016, Wounds International 
 
Clinically, the definition of a wound infection, or a strong propensity to develop an infection, 
occurs when concentration of cultivable bacteria from a tissue biopsy or a swab exceeds 105 
colony forming units per gram (CFU/g).5,41 At this concentration, the host’s immune system 
is no longer able to control the proliferation of the bacterial species,42,43 resulting in a local 
infection, delayed wound healing, and the need for clinical intervention (e.g., antimicrobial 
treatment, debridement).38 This has been shown in literature, where wounds with >106 
CFU/g tissue, between 105 – 106 CFU/g tissue, and no microbial bioburden, healed at a rate 
of 0.05 cm, 0.15 cm, and 0.2 cm per week, respectively.44  
However, this guideline fails to consider the polymicrobial nature of the wound and the 
potential for synergistic interactions between microbes, which could result in clinically 
infected wounds at lower bacterial concentrations.5 Therefore, a system such as the “critical 
infection threshold” may be more apt as it encompasses multiple markers of infection that 
cannot be explained by the bacterial concentration alone.   
1.3.1.Microbiology of Chronic Wounds 
Traditional culturing methods to detect pathogenic bacteria in chronic wounds only identify 
approximately 1% of the pathogens present at the wound site,8 due to the bacteria within 
the wound existing as a viable, but nonculturable (VBNC) state, often in response to 
environmental triggers such as antimicrobial exposure, low pH and nutrient availability, 
and hypoxia.45,46 The VBNC state is challenging as it may lead to an underestimate of the 
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bacterial bioburden within the wound, owing to the VBNC bacteria being unable to be 
cultured on conventional agar plates.47  
The bacterial species present within chronic wounds changes over time; however, 
Staphylococcus aureus and coagulase-negative staphylococci are among the most 
frequently isolated bacterial species within chronic wounds.7 Hannson et al showed that 
S. aureus was present in 88% of venous leg ulcers that had no clinical signs of infection, 
closely followed by Enterococcus faecalis (74%), Enterobacter cloacae (29%), and 
Peptococcus magnus (29%).48 This observation was further supported by Gjødsbøl et al who 
found that S. aureus was the most frequently identified bacteria within chronic venous leg 
ulcers49 and by Frank et al, who found that 25% of chronic wounds were isolated with 
Staphylococcus spp.50  
Anaerobic bacteria are often overlooked in conventional microbiological assessments of 
chronic wounds; however, chronic wounds have a statistically higher proportion of 
anaerobes compared to acute wounds (2.0 species vs 1.1 species, respectively; p=0.05). 
Common anaerobes within chronic wounds include Prevotella spp., Peptostreptococcus 
spp., and Porphyromonas.51,52  
1.3.2. Biofilm Formation 
Bacteria can exist in a planktonic state or as sessile cells within a bacterial community, called 
a biofilm. Biofilms are defined as a complex three-dimensional community of 
microorganisms surrounded by an extracellular polymeric substance (EPS). The EPS 
consists of polysaccharides, proteins, glycoproteins, lipids, metal ions, and extracellular 
DNA (eDNA);38,53,54 the composition of the EPS determines the biofilm architecture.38  
Biofilms are reported in approximately 60 – 80% of chronic wounds55–57 and are thought to 
cause the wounds to remain in the inflammatory phase of wound healing – resulting in the 
non-healing nature that is characteristic of these types of wounds. Conversely, biofilms are 
associated with only 6% of acute wounds.55  
The development of a biofilm occurs through five discrete, well-regulated processes (Figure 
1.4); however, the exact mechanisms of biofilm formation can differ between bacterial 
species. Generally speaking, the formation of a biofilm starts with microbial attachment to 
an abiotic or biotic surface, leading to the cell proliferation and the formation of 
microcolonies within the EPS and finally towards maturation and dissemination of the 




Figure 1.4: Formation of a biofilm. Reproduced from Wounds International with permission.40 Copyright © 
2016, Wounds International 
Attachment of microbial cells onto a surface, or to each other at a surface interface (i.e., air-
water), is facilitated through weak interactions between the surface and attachment 
appendages on the microbial cell surface and adhesion molecules.38,58,59   
After attachment, the biofilm grows via the proliferation of cells or recruitment of new cells 
to the biofilm. Upon development of the biofilm, the EPS is produced to provide structure 
and integrity to the biofilm.60  
The development of a biofilm is structurally and metabolically heterogenous and is 
constantly changing.38 Upon increasing bacterial concentration, bacteria produce quorum 
sensing molecules that accumulate in the environment that aid in microbial communication 
to help co-ordinate the development of the biofilm through processes such as enzyme 
production, toxin production, and managing microbial growth rates.5,38 A developing 
biofilm is composed of approximately 10 – 20%  bacterial cells and 80 – 90% EPS.54 If the 
biofilm is polymicrobial in nature, the individual microbial species can share defence 
advantages, such as molecules that aid in antimicrobial resistance or protection from 
phagocytosis.61–63 
The three-dimensional structure develops as the biofilm becomes more complex; the 
structure is dependent on the bacteria present, but is often depicted as that of a mushroom 
(Stage 4, Figure 1.4).64–66 Water channels are formed to delivery nutrients and remove waste 
to adjourning microcolonies.38  
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To colonise new surfaces, microbial cells are removed from the biofilm via shedding, 
detachment or shearing. These released cells retain the characteristics of the parent biofilm 
before reforming on a new surface.38   
A mature biofilm can develop resistance to the host’s immune cells (e.g., neutrophils and 
macrophages) and conventional antimicrobials, making the infection harder to treat and 
further delaying the wound healing process.38 The increased resistance is due to a multitude 
of factors, including the limited diffusion of the antimicrobials through the dense and 
negatively charged EPS, induced expression of efflux pumps, and secretion of molecules and 
enzymes that bind or inactivate antimicrobial agents. Additionally, some bacteria  within a 
biofilm are metabolically inactive, further preventing the effectiveness of 
antimicrobials.62,67–73  
1.4. Staphylococcus aureus 
S. aureus is a gram-positive bacterium, whose name derives from its tendency to grow in 
grape-like clusters of golden colonies (Figure 1.5).74,75 Unlike other Staphylococci spp. (e.g., 
Staphylococcus epidermidis), S. aureus  is able to produce the pigment, carotenoid, and the 
enzyme, coagulase.74 The presence of the latter has been used extensively in microbiological 
assays to distinguish S. aureus from other Staphylococci spp. (who are frequently referred 
to as coagulase negative Staphylococci).76 While the growth of S. aureus is optimum in 
aerobic conditions at incubation temperatures between 35 – 40 °C,75 S. aureus is a 
facultative anaerobe; therefore, it is capable of growing  in anaerobic conditions.74  
 
 




S. aureus is an opportunistic pathogen, first identified in purulent fluid from a leg abscess 
by Ogston in the 1880s.77 S. aureus primarily colonises the upper respiratory tract, such as  
the throat and the anterior nares, but it has also been shown to be present on the scalp and 
hands.75  It has been reported that up to 30% of individuals have anterior nares colonised 
with S. aureus,74,77,78 although some reports have stated that it could be as high as 50%, as 
the frequency of asymptomatic carriage varies from one study to another. Researchers have 
noted two distinct patterns of colonisation: intermittent and persistent S. aureus carriage.75  
1.4.1. Virulence Factors and Regulators 
Upon breach of the skin barrier, S. aureus has the capability to produce a wide range of 
diseases, such as skin and soft tissue infection, toxic shock syndrome, necrotizing 
pneumonia, bacteraemia, and endocarditis74,77,79 The capability of S. aureus to cause such a 
myriad of disease is associated with the ability of S. aureus to produce numerous virulence 
factors that aid in invasion and dissemination of the pathogen (Section 1.4.2).74,76  
1.4.1.1. Regulators 
The genes that encode and regulate the virulence factors of S. aureus are highly regulated 
and integrate host and environmental-derived cues in a co-ordinated manner, occurring in 
tandem with bacterial growth and controlled by a quorum sensing mechanism.80,81 Two-
component systems (TCSs) detect the environmental changes via an external signal that 
activates the histidine kinase, leading to its autophosphorylation and subsequent 
phosphorylation of the response regulator. Upon phosphorylation, the response regulator 
binds to a specific DNA sequence, resulting in the alteration of the target gene expression.81 
Major virulence regulatory systems of S. aureus are shown in Table 1.2.  
Table 1.2: Major virulence regulatory systems of S. aureus. Adopted from Jenul et al.81 
Receptor System Role 
agr Cell-to-cell communication (quorum sensing) with AIP as a signal; leads to 
expression of exotoxins and enzymes 
SaeRS Induces exoprotein production 
SrrAB Repression of agr and TSST-1 
ArlRS Expression and repression of agr and autolysis 
SarA Cytoplasmic regulator of toxins and extracellular proteases 
Rot Cytoplasmic regulator of toxins and extracellular proteases 
MgrA Cytoplasmic regulator; induction of efflux pumps and capsule expression; 
repression of surface proteins 




The regulation of these virulence factors are largely controlled by the accessory gene regular 
(agr),76 first described in 1986 as a regulator of haemolysins, toxic shock syndrome toxin-1 
(TSST-1), staphylokinase, and protein A.82 agr is a quorum-sensing two-component system 
that senses a signal (an autoinducing peptide [AIP]), which accumulates in the extracellular 
environment with increasing bacterial concentration. Upon reaching a critical density of 
bacteria, the agr system is activated to adapt to the changing conditions and regulates 
virulence.82–84  
The agr system consists of two transcription units RNAII and RNAIII, driven by the 
promotors P2 and P3, respectively.85,86 RNAII contains four cistrons agrA, agrB, agrC, and 
agrD, that encode the AgrBCDA structural proteins. Together the AgrB and AgrD constitute 
the quorum-sensing system; AIP is encoded by agrD, which subsequently gets modified and 
secreted by AgrB, to drive the transcription of both P2 and P3 promoters.87 AgrC, acts as a 
histidine kinase and the AgrA acts as response regulator in a two-component system that 
senses the AIP present in the environment.80,85 
RNAIII is the effector module of the agr system, which upon the post-exponential growth 
phase of S. aureus activates the transcription of exoproteins, while repressing the 
expression of surface-associated virulence factors.80,88 This pattern of gene expression, 
where surface proteins involved in adhesion and defence against the host’s immune system 
(e.g., protein A, coagulase, fibronectin) are synthesised prior to the production of secreted 
proteins (e.g., haemolysins, cytotoxins, proteases, etc.) portray a strategy whereby S. aureus 
first establishes itself on the host before subsequent attack.80 
S. aureus virulence factors can also be regulated by the staphylococcal accessory regulator 
(SarA), which was shown to be necessary for transcription of agr RNAII and RNAIII.89 
However, SarA can act in an agr-independent manner, down regulating several proteases, 
and activating α-haemolysin, TSST-1, and staphylococcal enterotoxin B expression.90  
1.4.1.2. Virulence Factors 
S. aureus expresses an abundance of virulence factors including surface proteins, toxins, 





Figure 1.6: Selected Staphylococcus aureus virulence factors. Reproduced from Daum et al with 
permission.91 Copyright © 2011, Oxford University Press 
1.4.1.2.1. Toxins 
Enterotoxins are typically secreted superantigens, which trigger T cell activation and 
proliferation without the need for antigen processing by allowing non-specific interaction 
of the class II major histocompatibility complex MHC II with T cell receptors. S. aureus has 
been shown to produce approximately 20 different enterotoxin and enterotoxin-like toxins. 
One example is TSST-1, which causes TSS by stimulating the release of interleukins (IL-1 
and IL-2), TNF-α, and other cytokines.92  
Cytotoxic toxins cause pore formation in the membrane, leading to the efflux of vital 
molecules and metabolites; most lyse red (haemolysin) and/or while (leukotoxin) blood 
cells.92 Alpha-toxin is probably the best known toxin of S. aureus;93 it is lytic to red blood 
cells and a series of leukocytes, but not neutrophils.94 Alpha-toxin also causes apoptosis in 
human monocytes, T and B cells.95 Alpha-toxin is the model β-barrel pore-forming 
membrane-damaging cytotoxin, it creates a pore within the membrane, resulting in leakage 
of cellular contents and ultimately cell lysis.76 It is essential for infections that disrupt 
epithelial barriers such as pneumonia,96 keratoconjunctivitis and infections of the skin.76  
S. aureus also produces a number of bi-component toxins that are structurally similar to 
alpha-toxin: Panton-Valentine Leukocidin (PVL), leukocidins, and gamma-toxin.92 PVL  
has been shown to aid in S. aureus pathogenicity by lysing polymorphonuclear leukocytes, 
ultimately destroying lung tissue, prolonging the infection, and helping with the 
dissemination of the infection to adjacent tissues.97 
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Delta-toxin is a member of the secreted phenol-soluble modulins (PSMs) that are produced 
by most S. aureus strains.98,99 PSMs have multiple functions in Staphylococcal 
pathogenesis, including biofilm formation (Section 1.4.3). 99 
Exfoliating toxins A and B (ETA and ETB) are commonly associated with skin damage.100 
Approximately, 5% of S. aureus strains produce exfoliative toxins,101 which cleave the 
desmosomal cadherins of the superficial skin layers, leading to staphylococcal scalded skin 
syndrome (SSSS). 92,102 
1.4.1.2.2. Enzymes 
Most of the enzymes secreted by S. aureus degrade host molecules or interfere with the 
host’s metabolic or signalling cascades. Enzymes include: non-specific proteases, aureolysin 
and endopeptidases, staphopain A and B, and collagenase. S. aureus also produce lipases, 
nucleases and phosphatases, although their function in pathogenesis is poorly 
understood.92 
Staphylokinase  degrades the fibrin clots by activating plasminogen to plasmin, diminishing 
the ability of the fibrin clot to keep the infection localised helping to facilitate greater 
bacterial penetration through the skin.103  
S. aureus is able to produce two coagulases, staphylocoagulase and von Willebrand factor 
(vWF), which convert fibrinogen to fibrin, resulting in fibrin clots on the surface of S. aureus 
cells inhibiting phagocytosis.92,104 Additionally, the production of coagulases have been 
associated with enterotoxin production.97  
1.4.2. Biofilms 
S. aureus is frequently associated with infections of indwelling medical devices such as 
central venous catheters and prosthetic joints because of its ability to form biofilms.105,106 
S. aureus biofilms are mediated by the agr system, as this system regulates the production 
of proteases and PSMs, which are the main contributors of biofilm maturation and 
assembly.107–109 
S. aureus initially attaches to biotic or abiotic surfaces using surface adhesions,110,111 wall 
teichoic acids,112,113  cell-wall anchored (CWA) proteins, eDNA production,114 and changes in 
cell surface hydrophobicity (Figure 1.7).115 The best characterised system is the microbial 
surface components recognising adhesive matrix molecules (MSCRAMMs), which are 
CWA-proteins that promote biofilm formation by facilitating the initial attachment to the 
host matrix components.116  
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The attached bacteria then proliferate. During this stage, S. aureus starts to produce EPS, 
and dependent in the EPS composition, polysaccharide-dependent biofilms, or biofilms 
consisting of proteinaceous matrix are formed;117,118 the latter is usually found for MRSA 
isolates. Independent of EPS composition, S. aureus cells are held together within the EPS 
matrix by adhesive factors to build microcolonies, which develop into an established 
biofilm. Concurrently, biofilm development can be mediated by the polysaccharide 
intracellular adhesin (PAI) molecule – a matrix of poly-N-acetylglucosamine that surrounds 
and connects bacteria within the biofilm.116 
Staphylococcal biofilms do not grow uniformly; remodelling of the biofilm occurs via 
nucleases and phenol soluble modulins (PSMs), which help to create a mature biofilm with 
its distinctive three-dimensional tower-like structures interspaced with water channels.116 
 
Figure 1.7: Staphylococcal biofilm cycle. Adapted from Schicher with permission.116 Copyright © 2020, 
American Society for Microbiology 
1.4.3. Methicillin-resistant Staphylococcus aureus 
Methicillin-resistant Staphylococcus aureus (MRSA) was observed within one year of the 
first clinical use of methicillin; however, genomic analysis suggests that the resistance to 
methicillin predates the first clinical use of β-lactams.77   
Methicillin resistance is mediated by the mecA gene, which is acquired via horizonal gene 
transfer (HGT) of a mobile genetic element called the Staphylococcal cassette chromosome 
mec (SCCmec).119 mecA encodes for an alternative penicillin-binding protein 2a (PBP2a) 
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that is responsible for crosslinking peptidoglycan within the bacterial cell wall. PBP2a has 
a low affinity towards β-lactams, subsequently resulting in resistance to this class of 
antibiotics.80,120 
Since the 1990s, MRSA has spread rapidly within the hospital environment and the 
community, often occurring in waves, with the serial emergence of predominant strains.77 
Recent examples of emergent MRSA strains include the healthcare-associated MRSA (HA-
MRSA) clonal complex 30 (CC30) isolated in North America and Europe, community-
associated MRSA (CA-MRSA) USA300 in North America, and MRSA ST93 isolated in 
Australia.121–124  It has been estimated that MRSA is responsible for 171 200 healthcare-
related infections in Europe annually, corresponding to an extra 5400 deaths; the 30-day 
mortality of MRSA is double that observed when compared to its methicillin-sensitive 
counterparts.97 
1.5. Bacteriophage 
Bacteriophages (phages) are viruses that infect and kill bacteria. Phage have been isolated 
in a variety of different environments; one such environment is  Norwegian fjord water,125 
where it was discovered that the concentration of phage was approximately 107 Plaque 
Forming Units per millilitre (PFU/mL), with roughly 5 – 10 phage per bacterium. On the 
basis of this study, it was assumed that phage are the most ubiquitous organisms on earth. 
Today, it is thought that there are approximately 1030-31 phage present in the world126–128 
capable of infecting more than 140 different bacterial genera;129,130 however, the true 
number of phage is probably higher, with the only factor limiting their incidence is the 
presence of microbial hosts.126 
1.5.1. Discovery and Historical Use 
While Abedon et al identified at least 30 actual or presumptive “bacteriophage” references, 
some of which date back to 1895,131 the beginning of bacteriophage research is generally 
thought to have originated from the paper written by Frederick W Twort in 1915.132 Twort 
was growing viruses and found that they formed zones of clearance upon incubation with 
micrococcus bacteria. He concluded that the viruses must be multiplying while 
simultaneously killing the bacteria. Independently, Felix d’Hérelle observed this 
phenomenon in 1917 when investigating severe haemorrhagic dysentery among French 
troops stationed in Maisons-Laffite.133 d’Hérelle described a microbe that was antagonistic 
to bacteria, but needed living cells to replicate, suggesting that cell lysis was involved in the 
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multiplication process. He termed this microbe ‘bacteriophage’ – implying to “eat” or 
“devour” bacteria.125,134 
As such, both scientists are credited with the discovery of bacteriophage. However, d’Hérelle 
conducted further research, discovering that phage had steps of infection that included 
multiplication, release, and reinfection steps.125 d’Hérelle primarily focused on the 
therapeutic use of bacteriophage, isolating phage from stool samples of patients suffering 
from diarrhoea to successfully treat bacterial dysentery.133  
While the idea of phage therapy seemed promising, little was known about phage 
themselves, so unsurprisingly phage therapy led to variable success. This, in combination 
with poor documentation of the studies, resulted in controversy surrounding phage 
therapy.135 The advent of conventional antibiotics in the 1950’s further diminished phage 
research, with the West favouring conventional antibiotics for the treatment of bacterial 
infections due to a greater understanding of their mechanism of action and more 
reproducible studies.  However, phage therapy continued in the East, with the Eliava 
Institute in Tbilisi, George considered to be the pioneer in phage therapy, where research 
continues to this day.136  
1.5.2. Bacteriophage Taxonomy  
Currently, bacteriophage classification is the responsibility of the Bacterial and Archaeal 
Viruses subcommittee (BAVS) within the International Committee on the Taxonomy of 
Viruses (ICTV). The ICTV published their first report in 1971, where classification was based 
on numerous bacteriophage properties, including: genetic information (single stranded 
(ss)/double stranded (ds) DNA/RNA), sequence similarity, morphology, and host 
range.134,137 Since then, the number of bacteriophages discovered, and successfully 
sequenced, has dramatically increased, owing to the improvement of nucleotide sequencing 
techniques. Currently, there are over 400 phage genome sequences deposited into the 
GenBank database.138  
There is a remarkable diversity in phage, for instance over 500 different phage have been 
identified for a single bacterial species Mycobacterium smegmatis.139 Owing to the varying 
morphologies and size of phage, there are issues in classification. In 2015 it was suggested 
that there were 14 subfamilies, 204 genera and 873 species. However, this is constantly 
being updated as new bacteriophage are being sequenced; in 2017 two new families, eight 
sub-families, 34 genera and 91 species were proposed. The most recent literature from 
BAVS have proposed the creation of a new order (Tublavirales), 10 families, 22 sub-
families, 424 new genera and 964 new species.140 An overview of the families regarding 
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bacteriophage classification are outlined in Table 1.3. However, it is important to note that 
this list is not exhaustive, with re-classification/creation of new orders and families 
constantly ongoing due to the increasing amount of sequenced phage present in the 
literature. 
Table 1.3: Classification of phage families (non-exhaustive list). L = linear, C = circular, NC = nucleocapsid, 




While the classification system is complex, almost all (96%) of the currently classified 
bacteriophage belong to the Caudovirals and Tublavirales orders.140,141 That is, they are 
tailed and predominately contain dsDNA encapsulated in a icosahedral protein shell, known 
as a capsid.125,134,137 The size of these phage can vary, but are often between 24 – 200 nm,142 
with T4 phages being one of the largest (approx. 200 nm in length and 80-100 nm in 
width).134  
1.5.3. Bacteriophage Life Cycle 
Bacteriophage have four characterised life cycles: lytic, lysogenic, pseudo-lysogenic, and 
chronic infection, with the former two being the most prevalent (Figure 1.8). Virulent phage 
exclusively follow the lytic cycle, while temperate phage follow the lysogenic cycle until a 
stressor event occurs, causing the prophage to become induced and switch to the lytic life 
cycle of growth.143 Both virulent and temperate bacteriophage can undergo the pseudo-
lysogeny life cycle, and although the current cause of this life cycle is unknown, it is thought 
the be related to starvation stress of the bacterial host. While in the bacterial cell, the genetic 
material remains inactive in the form of a circular episome, and the development cycle is 
halted until environmental conditions improve.126 Chronic infection occurs predominately 
with filamentous phage, where they continuously release their progeny from bacteria 
without lysing the bacterial cell or causing bacterial cell death.125,144 
 
Figure 1.8: A) Structure of a typical tailed bacteriophage, and B) the steps during the bacteriophage lytic and 




Regardless of the life cycle, phage infection begins when the virion attaches to its host cell, 
in a process known as adsorption.146 For adsorption to occur, the phage must first recognise 
receptors on the target’s bacterial cell wall. For gram-negative bacteria, the receptors can be 
the transmembrane proteins, porins, selective transport proteins (e.g. LamB for phage λ), 
proteases and lipopolysaccharides (LPS). Gram-positive bacteria tend to have teichoic 
acids, lipoteichoic acids and the polysaccharide cell wall for their receptors for phage 
adsorption.143  
Bacteriophage adsorption is initiated by random collisions between phage and their 
bacterial host, usually governed by diffusion, dispersion, or Brownian motion.147 Phage 
reversibly bind to the bacterium upon contact until successful recognition of the receptor, 
leading to irreversible phage adhesion.126 This step triggers conformational rearrangements 
within the phage that allow for the insertion of genetic material into the host, and/or the  
release enzymes to help with the penetration of the bacterial cell envelope depending on the 
type of bacteriophage.126,134,148  
The aftermath of the infection depends on the host and the circumstances of infection: 
either the phage survive and undergoes it respective lifestyle, the phage dies and/or doesn’t 
produce progeny (often due to resistance mechanisms), or both the phage and bacterium 
die due to abortive infection systems. 146   
1.5.3.2. Lytic Lifecycle 
Bacteriophage that undergo the lytic lifecycle are termed lytic or virulent phage; these phage 
produce daughter progeny at the expense of the bacterial host.146 After adsorption, phage 
DNA is translocated into the bacterial cytoplasm and the host metabolism is re-directed to 
the development of viral progeny, owing to the expression of phage-encoded genes.134,149 
Newly transcribed proteins are assembled to form viral particles.146 The formation of these 
phage particles will differ depending on the phage/host; however, the viral particles are 
essentially composed of nucleic acids and a protein capsid.  
Upon a threshold number of virion particles, specific lysis proteins are released to help the 
phage particles lyse the bacterial cell. These include: holins (form pores within the plasma 
membrane), endolysins (cell wall peptidoglycan hydrolases), and spanins (destabilisation 
of the gram-negative bacterial outer membrane).150,151 These lysis proteins are responsible 
for the destruction of the bacterial host wall, and subsequent release of the phage progeny 
to the extracellular matrix, allowing for re-infection.146,152 
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1.5.3.3. Lysogenic Lifecycle  
Phage which undergo the lysogenic lifecycle are termed temperate phage. They have a stable 
relationship with their host, remaining as a prophage (where the genetic material of the 
phage is integrated within the host’s chromosome); this is termed lysogenic state,126 where 
the infections are not productive (i.e. no structural virions are produced) but rather replicate 
vertically in tandem with host replication. Therefore, daughter cells of the host inherit at 
least one copy of phage DNA.  Prophages can also exist extra-chromosomally as a stable low 
copy plasmid, e.g. Phage P1.125,146  
In the lysogenic state, the expression of lytic genes is inhibited by repressors. However, 
external factors can trigger the bacterial hosts’ SOS regulatory circuit.125 This can result in 
the temperature phage becoming ‘induced’, leading to a conversion of temperate phage to 
the lytic life cycle.126  
One potential issue with temperate phage is that they can affect the pathogenicity of the 
host bacterium. Lysogenic phage can carry non-essential genes that are not required for the 
lytic or lysogenic lifecycle, but upon incorporation of the prophage can  lead to a change in 
phenotype of the infected bacterium in a process termed ‘lysogenic conversion’.125,153,154 
Lysogenic conversion is present in many bacterial species, and the “extra” genes are likely 
maintained as they allow for a selective advantage to the host or to the phage, contributing 
to improved bacterial fitness.125,155 Lysogenic conversion has been shown to help spread 
virulence factors such as adhesions, toxins, enzymes and other proteins required for 
successful bacterial infection. Temperate phages have also been shown to influence biofilm 
development and dispersal.156 Additionally, active lysogeny can also occur where the phage 
genome affects bacterial toxin production via expression regulation, rather than expression 
of virulence factors.157 Interestingly, lysogenic conversion can still occur if the prophage 
becomes non-viable. Some examples where virulence factors have been induced by 
prophages are shown in Table 1.4   
Table 1.4: Virulence factors encoded by genes acquired via prophage integration. Adapted from Olszak et 
al.126    
Gene Name Phage Encoded Feature Host 
stx 933, H19B Shiga toxin E. coli O157:H7 
ctxAB CTXɸ Cholera toxin Vibrio cholerae 






Transduction is the process where foreign DNA is introduced into a bacterial cell by phage 
or a viral vector; often, this contributes to the pathogenicity of the bacterial host.125 
Transduction can be further split into specialised and general transduction. Specialised 
transduction is typical of temperate phage and arises when the prophage is incorrectly 
excised with an adjacent part of the host genome.126 Owing to this, specialised transduction 
involves the transfer of bacterial genes that would not normally be associated with the phage 
genome.125 After infection of a new host cell, site-specific recombination or homologous 
recombination results in the integration of the packaged DNA into the host genome.158  
General transduction was first identified by Zinder and Lederberg in 1952 for Salmonella 
phage P22. It is the accidental packaging of random bacterial DNA fragments into the virion 
particles. While the resultant virion can still adsorb to bacterial cells and is able to transfer 
the packaged bacterial DNA to a subsequent bacterium, it can no longer produce phage 
progeny. Therefore, generalised transduction does not result in serial DNA transfer. 
However, it can transfer large amounts of DNA, and both lytic and lysogenic phage are 
capable of generalised transduction.125,159  
1.5.5. Bacterial Resistance to Bacteriophage 
While the reported frequency of resistance in vivo is low,160,161 bacteria can develop 
resistance to bacteriophage through multiple mechanisms of resistance.162,163 These 
mechanisms, and how phage can overcome them, are listed below: 
• Adsorption blocking. Perhaps the main method of resistance is the ability of 
bacteria to prevent phage adsorption through modification, masking, or removal of 
receptors.126,164,165 Synthesis of exopolysaccharide (EPS) or masking proteins (e.g. 
protein A of S. aureus) are other strategies bacteria employ to prevent phage 
adsorption. However, phage have adapted to recognise these modified receptors and 
have been shown to produce polysaccharide lyase or polysaccharide hydrolase 
enzymes that degrade the EPS.134 
• DNA injection blocking. Temperate and lytic phage can prevent further infection 
by other phage (termed superinfection) through the expression of superinfection 
exclusion (SIE) proteins. SIE proteins are anchored to the cell wall or associated 
with other membrane components, and act by preventing DNA from reacting the 
cytoplasm of the host.166,167  
24 
 
• Restriction modification (R/M) of foreign DNA. Most bacteria possess R/M 
systems which utilise restriction endonucleases to digest foreign DNA that is not 
methylated at the appropriate sites.126 Phage can inactivate R/M systems by 
methylation of phage DNA (e.g. phage T4, which contain hydroxymethylcytosine 
instead of cytosine, is protected from R/M sytems) or by reducting the frequency of 
restriction sites by mutation.149  
• Clustered regulatory interspaced short palindromic repeats (CRISPR)-
Cas systems. CRISPR-Cas systems often work in tandem with R/M systems and 
allow bacteria to recognise and degrade foreign DNA entering the cell.168 CRISPR-
Cas systems have been detected in approximately 40% of bacteria. Phage can 
overcome CRISPR-Cas systems by promoting mutations in the protospacer-
adjacent motifs or preventing the formation of CRISPR-Cas sytems.126,169 
• Abortive infections. An abortive infection is an ‘altruistic’ cell death system 
activated by phage infection, whereby the bacterial cell dies to prevent phage 
multiplication. This programmed cell death of a low number of bacterial cells 
enables the larger population to survive.126,170 Currently, there are over 20 abortive 
infection systems known, including toxin-antitoxin systems, which control bacterial 
cell death via protein-protein, protein-RNA or RNA-RNA interactions. Phage can 
overcome abortive infection through the production of bacterial-like antitoxins.126  
1.5.6. Bacteriophage Therapy  
Bacteriophage therapy is facing a revival due to the development of antibiotic resistance and 
the dwindling production of novel antibiotics from pharmaceutical industries. Typically, 
phage therapy involves the use of lytic phage as they result in bacterial cell death and do not 
possess the disadvantages associated with temperate phage.137 
Prior to use, phage (as a monotherapy or in a phage mixture, known as a phage cocktail) 
must undergo strict testing to deem its suitability for phage therapy. This includes fully 
characterising the phage by determining its structure, host-range, receptor on the bacterial 
cell, stability, etc. Moreover, genetic sequencing should be undertaken to ensure the phage 
is lytic and does not possess toxic/resistant genes, Additionally, the phage suspension 
should be adequately purified to remove any harmful endotoxins, meet regulatory 





There are several advantages to bacteriophage therapy. Firstly, bacteriophage have a limited 
host range, acting as a narrow spectrum antibiotic, which reduces the chances of developing 
dysbacteriosis (an imbalance in gut microflora) and secondary infections. Conversely, 
conventional antibiotics can act on the hosts’ normal microflora, potentially leading to 
secondary infections.143 Phage are able to infect both gram-positive and negative bacteria, 
as well as remaining effective against multi-drug resistant (MDR) bacteria due to their 
different mechanism of action (MOA) compared to conventional antibiotics.172 Additionally, 
some phage have been shown to be effective in eliminating bacterial biofilms,173 and because 
of the wide distribution of phages upon systemic administration, phage are able to pass the 
blood-brain barrier and target central nervous system infections.174–176 Owing to their self-
replicating nature, phage may require less frequent administration, and to the best of the 
authors knowledge, phage been shown to be safe for human use.143,177 Bruttin and Brussow 
showed that no adverse effects were identified from participants who received an oral 
suspension of T4 phage.178 Other studies have reported minor side effects, primarily due to 
the release of endotoxins upon the lysis of the bacteria; however, this is a common 
phenomenon witnessed with conventional bactericidal antibiotics.143  
Phage are ubiquitous and easy to isolate, providing an easier route to antibiotic therapy   
than the synthesis of novel conventional antibiotics. Additionally, if bacteria become 
resistant to the therapeutic phage, there are a plethora of phage that could be used 
instead.143  
1.5.6.2. Disadvantages 
However, phage therapy is not without its disadvantages. Technical hurdles include the 
inherent specificity of the phage, resulting in the need to identify the precise etiological 
microorganism causing the infection before bacteriophage can be used successfully.  While 
this can be overcome by the use of phage cocktails to expand the host range of the phage to 
target multiple strains of a bacterial species, there are no clear standardised methods, or 
official guidelines on the preparation of phage cocktails.179,180  
One disadvantage of bacteriophage therapy has been mentioned earlier – bacteriophage 
resistance. However, this disadvantage of phage-resistant bacteria can be overcome by 
using other, susceptible phage that have a similar host range, again showing the promise of 
phage cocktails, or modified bacteriophage, as a therapy. Additionally, there may be a 
fitness cost associated with the development of phage resistance which could make the 
bacterium susceptible to conventional antibiotics.143  
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Phage need to undergo genetic sequencing before being accepted as a viable therapy; 
however, there are many genes whose function is currently unknown.181 While phages are 
easy to isolate, purification is a convoluted process. If the phage lysate is not sufficiently 
pure, the endotoxins could lead to a potentially life-threatening inflammatory cascade 
resulting in multiple organ failure.182 However, Merabishivii et al created a phage stock of 
clinical trial grade purity through the use of a commercially available endotoxin removal 
kit.179 Additionally, the majority of lysate used in research are small in volume, hence there 
may be additional issues in the scale-up of phage preparations and the long-term stability 
of such suspensions.143  
Non-technical disadvantages include the regulatory status of phage therapy and the public 
perception of using viruses to treat bacterial infections.143 Phage therapy is not presently 
recognised as a medicinal product, with current European pharmaceutical regulations, 
definitions, and standards not adequately adapted to suit phage therapy; nor is there an 
approval process in place for the multiple phage cocktails needed to combat MDR bacterial 
infections.183 Regulation of phage therapy has largely been avoided due to the unreliable 
and inconsistent results of early phage therapy trials. While today it is accepted that this 
was due to poor understanding of the phage biology, further reproducible clinical trials need 
to be conducted before regulatory approval can be granted. Furthermore, phages are 
antigenic, eliciting a response from the immune system. Some studies have suggested that 
serum antibodies have inactivated several different phages,171,184 and others have reported 
that the phage are rapidly cleared by the immune system.177,184  
1.6. Wound Dressings 
Wound dressings date back to 2500 – 1600 BC, where linen strips soaked in oil or grease 
covered in plasters were used to seal wounds.185 Previously, it was believed that wounds 
healed more quickly if kept dry and uncovered. However, there was a  shift in wound 
dressing design in the mid-20th century towards occlusive dressings, designed to protect 
and provide a moist environment to the wound. These new dressings resulted in in faster 
re-epithelialisation, collagen synthesis, angiogenesis promotion and a reduction in wound 
bed pH, leading to a decrease in wound infection.186 Following this, further dressings were 
designed that provided moisture and absorbed fluids (e.g., polyurethane foams and 
hydrocolloids) and by the mid 1990’s, synthetic polymers had been employed to further 
develop and improve wound dressings (e.g., hydrogels, hydrocolloids, and silver/collagen 




1.6.1. Characteristics of an Ideal Wound Dressing 
Usually, a dressing is selected based on the type, depth, and location of the wound.185,187 
While this list is not exhaustive, a successful dressing must be able to:185 
• Provide or maintain a moist wound environment 
• Promote epidermal migration, angiogenesis and connective tissue synthesis 
• Allow gas exchange between the wound and the environment 
• Maintain appropriate temperature and humidity to the wound to improve blood 
flow 
• Provide protection against pathogenic microbials 
• Be non-adherent and easy to remove with limited pain to the patient  
• Be sterile, non-toxic, and non-allergic.  
While there are currently over 3000 types of wound dressings available for all aspects of 
wound care, there is not one product that is superior for the treatment of chronic wounds. 
1.6.2. Traditional Wound Dressings 
Traditional wound dressings include gauze, lint, plasters, bandages, and cotton wool; they 
are used as primary or secondary wound dressings to protect the wound from microbial 
contaminants.188 These dressings are not very cost-effective as they require frequent 
changing to protect from maceration of healthy tissues.185 Additionally, once these dressings 
become moist due to wound drainage, they tend to become adherent to the wound bed, 
causing pain to the patient on removal. Traditional dressings were used for clean and dry 
wounds with mild exudate levels, or used as secondary dressings, but nowadays they are 
being replaced with modern dressings that promote faster wound healing.188 
1.6.3. Modern Wound Dressings 
Modern wound dressings are often based on synthetic polymers and can be classified as 
passive (non-occlusive), interactive (semi-occlusive/occlusive), or medicated (releasing a 




1.6.3.1. Semi-permeable Dressings 
Semi-permeable film dressings are generally composed of poly(urethane) which permits the 
transmission of water vapour, oxygen, and carbon dioxide from the wound, while providing 
autolytic debridement of eschar.189 These dressings are recommended for re-epithelializing 
wounds that superficial with low exudate; common examples include OpositeTM and 
BiooclusiveTM.190 
Semi-permeable foam dressings are also available and are typically used for lower leg ulcers 
and wounds with moderate-to-high exudate.191 Typical examples include LyofoamTM and 
AlleyynTM.185 
1.6.3.2. Hydrogels 
Hydrogels are hydrophilic polymer networks with a high water content, often created using 
polymers such as poly(vinyl alcohol), poly(methacrylate), and poly(vinyl 
pyrrolidine).185,192,193 The high water content promotes granulation and facilitates autolytic 
debridement of necrotic tissue within the wound bed. Hydrogels are often used for burns, 
surgical wounds, and pressure ulcers.187 Typical examples include Nu-gelTM and 
AquaformTM.185 A more detailed review of hydrogels can be found in Chapter 7.  
1.6.3.3. Hydrocolloids 
Hydrocolloid dressings are one of the most frequently used wound dressings, composed of 
a mixture of colloidal materials (carboxymethycellulose, gelatin, and pectin)194 and  
elastomers and alginates187 within  two layers – an inner colloidal layer and an outer, water-
impermeable layer. Hydrocolloids are used on light-to-moderate exudating wounds, such 
as pressure sores and minor burn wounds, as they are permeable to water vapour, aid in 
debridement, absorb wound exudate, and protect against microbial contamination.195,196 
Hydrocolloid dressings are also recommended for paediatric patients as they do not cause 
pain on removal.196 However, they are not appropriate for deeper wounds, or wounds that 
are heavily contaminated.197 Examples include GranuflexTM, TegasorbTM, and DuoDerm®.185 
1.6.4. Medicated dressings 
Medicated dressings are wound dressings that contain a drug which aids in the wound 
healing process (e.g., antimicrobials, growth factors, and enzymes), often used to overcome 
issues associated with topical agents.194  
29 
 
Antimicrobial-loaded wound dressings have been reported for use in the treatment of 
diabetic foot ulcers and surgical and accidental wounds.188,198 The most reported medicated 
dressings are those that incorporate silver, with silver-loaded dressings available as 
hydrocolloids, silicone gels, and poly(urethane) foam films.185,194 Antiseptics, such as 
povidone-iodine have also been used in the development of medicated wound dressings,199 
although prolonged use of iodine has been known to result in staining and skin irritation.185 
Recently, dialkylcarbamoyl chloride coated dressings have been used to combat wound 
infections by irreversibly binding to bacteria at the wound surface via hydrophobic 
interactions, removing the bacteria from the wound site upon dressing change.200 
Antibiotic-loaded wound dressings have also been investigated, with gentamicin, 
norfloxacin, and minocycline loaded chitosan films currently under investigation.188  
1.7. Overall Aims and Objectives 
The overall aim of this research was to develop novel systems that could detect and 
subsequently  treat  S. aureus infections, which could be ultimately combined to create a 
theranostic device.  
This thesis will focus on the relationship between phage and antibacterials, investigating 
the role of phage-antibiotic synergy and the efficacy of such combinations against clinically 
relevant S. aureus isolates. From here, phage K, ciprofloxacin, or a combination of both, 
would be encapsulated within a poly(lactic acid)-poly(ethylene glycol) polymer blend and 
assessed for release kinetics and microbiological efficacy. Attention will then turn to the 
development of a pH responsive system via use of a pH-responsive polymer coating.   
Concurrently, the design and synthesis of a novel fluorescent probe for the detection of S. 
aureus will be employed. Upon created of the probe, focus will turn to the optimisation of 
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Chapter 2: General Materials and Methods 
2.1. Materials 
Table 2.1: List of reagents and materials 
Material Supplier 
Acetone Sigma-Aldrich 
Acid phosphatase Sigma-Aldrich 
Alkaline phosphatase Sigma-Aldrich 
Amikacin hydrate Sigma-Aldrich 
Amoxicillin Sigma-Aldrich 
Bacteriological agar Sigma-Aldrich 
Bovine Serum albumin Sigma-Aldrich 
Brain Heart Infusion agar Sigma-Aldrich 
Chloroform Sigma-Aldrich 
Ciprofloxacin hydrochloride hydrate Fischer Scientific 




Eudragit® FS 30 D Evonik Industries 
Fetal bovine serum Sigma-Aldrich 
Glycerol Sigma-Aldrich 
Luria Broth Base (Miller’s LB Broth Base) Fischer Scientific 
Mannitol salt agar Sigma-Aldrich 
Mueller Hinton agar Sigma-Aldrich 
Mueller Hinton broth Sigma-Aldrich 
pH probe large surface flat tip, HDPE junction 662-
1769 
VWR International 
Phosphate buffered saline Sigma-Aldrich 
Poly(ethylene glycol) 400 Sigma-Aldrich 
Poly(vinyl alcohol) MW 146000 – 186000, 99+% 
hydrolysed 
Sigma-Aldrich 
Polylactic acid Mw ~60 000 Sigma-Aldrich 
Polystyrene tissue culture microplates (12-well) Sigma-Aldrich 
Polystyrene tissue culture microplates (96-well) Sigma-Aldrich 
Porcine liver esterase Sigma-Aldrich 
Protease from Streptomyces griseus Sigma-Aldrich 
Proteinase K Sigma-Aldrich 
Sodium chloride, BioXtra ≥99.5 (AT) Sigma-Aldrich 
Sodium hydroxide, BioXtra ≥98 (acidmetric) Sigma-Aldrich 
Spin-X® UF Concentrator Corning® Sigma-Aldrich 
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Tris-HCl Fischer Scientific 
Trypsin Sigma-Aldrich 
Tryptic Soy agar Sigma-Aldrich 
Tryptic Soy broth Sigma-Aldrich 
Vancomycin hydrate from Streptomyces orientalis Sigma-Aldrich 
Whatman® NucleoporeTM Track-Etched 






2.2.1.1. Bacterial Strains 
All bacterial strains used in this thesis were obtained from Professor Toby Jenkins, 
University of Bath, UK or Professor Jean-Yves Maillard, Cardiff University, UK. Bacterial 
cultures were stored at –80 °C in phosphate buffer solution (PBS) containing 20 % (v/v) 
glycerol. Working stocks were cultured from frozen by streaking onto a TSA plate and 
incubating at 37 °C for 24 h. Plates were subsequently stored at 4 °C for up to a month for 
further use. 
2.2.1.2. Principles of Bacterial Growth 
Bacteria proliferate through an asexual process called binary fission, and their growth curve 
is depicted in Figure 2.1. 
 
Figure 2.1: Typical growth curve of a closed-system bacterial culture. A) Lag phase, B) Logarithmic phase, 
C) Stationary phase, D) Death phase and E) Long-term stationary phase 
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The first stage of bacterial growth is the lag phase, where the bacteria are maturing and 
synthesising RNA, enzymes, and other molecules. Although bacterial cells are not yet able 
to divide, they are not dormant. The length of this period is dependent on the bacterial 
species and the length of time the cells have undergone starved conditions before entering 
this stage. Next, is the logarithmic (or exponential) phase, characterised by the exponential 
growth of bacteria. The slope of this line is dependent upon both the organism and the 
growth conditions.  However, as the medium becomes depleted, bacterial cells enter the 
stationary phase of growth. This arises when the rate of growth is equal to the rate of death, 
resulting in a plateau with no net increase in cell density. Upon the depletion of all nutrients 
and/or the formation of inhibitory waste products, the bacteria enter the death phase. This 
is where the number of viable bacterial cells decrease exponentially until about 90-99% of 
the population die.  
2.2.1.3. Bacterial Culture Conditions 
Bacterial overnights were routinely prepared using colonies obtained from the respective 
bacterial strain’s tryptic soy agar (TSA) plate. Colonies was grown in tryptic soy broth (TSB) 
and incubated at 37 °C with 150 rpm shaking for 18 h. After incubation, cultures were 
centrifuged at 4000 g for 10 min and re-suspended in PBS. Cultures were standardised to 
an optical density (OD) at 600 nm of 0.2 (c. 107 CFU/mL) before use, unless otherwise 
stated.  
2.2.1.4. Bacterial Enumeration 
Estimation of the total viable count of bacterial cultures were calculated using the drop 
count method, as outlined by Miles and Misra.1 The initial bacterial suspension underwent 
a series of 10-fold dilutions in PBS, and subsequently three 10 µL spots of each dilution were 
pipetted onto the surface of a TSA plate. The spots were allowed to dry for 20 min at room 
temperature before incubation at 37 °C for 18 h. The number of Colony Forming Units per 
mL (CFU/mL) was calculated as follows: 
CFU mL⁄ =  
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑜𝑙𝑜𝑛𝑖𝑒𝑠
𝑑 ∙ 𝑉
 (1) 
Where d = dilution factor and V = volume of inoculum. 
2.2.1.5. Minimum Inhibitory Concentration 
The Minimum Inhibitory Concentration (MIC) of an antimicrobial was conducted 
according to the Clinical and Laboratory Standards Institute (CLSI) guidelines.2 Briefly, 
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stock solutions of antimicrobials were prepared at twice the starting concentration in sterile 
deionised water (dH2O). Then, 100 µL of the chosen antimicrobial was added to a 96 well 
plate and serially diluted two-fold in TSB (unless otherwise stated). An overnight culture of 
bacteria, previously adjusted to an OD600 of 0.2 underwent a 10-fold dilution in fresh TSB 
to attain a concentration of 106 CFU/mL, before 100 µL of the suspension was added to all 
relevant wells in the 96 well plate. A negative (bacteria only) and positive (broth only) 
control was carried out in tandem. The plate was incubated for 18 h at 37 °C and the MIC 
was determined as the concentration of antibiotic that resulted in no detectable bacterial 
growth, assessed by measuring the OD600 using a SPECTROstar®  Omega microplate reader 
(BMG LabTech, UK). Three independent biological replicates per biological species were 
performed.  
2.2.2. In vitro Biofilm Models 
2.2.2.1. 96-Microtiter Biofilm Models 
2.2.2.1.1. Minimum Biofilm Inhibitory Concentration  
Biofilm formation was conducted in a 96-well polystyrene microtiter plate. First, the chosen 
antimicrobial was prepared at twice the starting concentration in TSB containing 1% (w/v) 
D-(+)-glucose (TSBg). Then, 100 µL of the chosen antimicrobial was added to the 96 well 
plate and serially diluted two-fold in 1% TSBg (unless otherwise stated). Next, overnight 
cultures of bacteria were sub-cultured into fresh 1% TSBg to attain a concentration of 106 
CFU/mL, before 100 µL was added into relevant wells in the plate and statically incubated 
at 37 °C for 18 h. Following incubation, plates were washed three times with sterile dH2O to 
remove planktonic bacteria and evaluated for biofilm formation via Crystal Violet (CV) 
assay (Section 2.2.2.1.3). The Minimum Biofilm Inhibitory Concentration (MBIC) was the 
concentration that resulted in no detectable biofilm growth compared to the control. 
Negative and positive controls were carried out in tandem, and three independent biological 
replicates per biological species were performed. 
2.2.2.1.2. Minimum Biofilm Eradication Concentration  
Overnight cultures of bacteria were sub-cultured into fresh 1% TSBg to attain a 
concentration of 106 CFU/mL. Next, 200 µL of the adjusted bacterial suspension was added 
into the relevant wells within the 96-well microtiter plate, and statically incubated at 37 °C 
for 24 h. Following incubation, plates were washed three times with sterile dH2O and left to 
air dry for 5 min. Concurrently, stock solutions of antimicrobials were prepared at twice the 
starting concentration in 1% TSBg (unless otherwise stated), and 100 µL was serially diluted 
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in equal volume of 1% TSBg across the microtiter plate. Finally, 100 µL of 1% TSBg was 
added to relevant wells to achieve a final volume of 200 µL per well. The plate was further 
incubated at 37 °C for 18 h, before being washed three times with sterile dH2O to remove 
planktonic bacteria and evaluated for biofilm formation by the CV assay (Section 2.2.2.1.3). 
The Minimum Biofilm Eradication Concentration (MBEC) was the concentration that 
resulted in no detectable biofilm growth, compared to the control after incubation with the 
antimicrobials. Negative and positive controls were carried out in tandem, and three 
independent biological replicates per biological species were performed. 
2.2.2.1.3. Crystal Violet Assay 
Biofilms of the bacterial isolates were prepared as outlined in Section 2.2.2.1.1 and 2.2.2.1.2. 
After washing three times in sterile dH2O, the microtiter plate was left to dry for 20 min at 
room temperature. Next, 220 µL of 0.1% CV was added to all relevant wells, and the 
microtiter plate was incubated at room temperature for 30 min. After incubation, the stain 
was removed, and the plate was washed three times with sterile dH2O before being left to 
dry for at least 3 h at room temperature. To quantify the biofilm biomass, 220 µL of 33 % 
acetic acid was added to the CV-stained biofilms for 15 min at room temperature, after 
which 100 µL was transferred to a new microtiter plate and the optical density at 590 nm 
(OD590) was measured using a SPECTROstar® Omega microplate reader (BMG LabTech, 
UK).  
2.2.2.2. Colony Biofilm Model 
The colony biofilm model was prepared as outlined in Thet et al  with some modifications 
(Figure 2.2.).3 Polycarbonate membranes (19 mm) were UV sterilised for 10 min on Brain 
Heart Infusion (BHI) agar before addition of 30 µL of Artificial Wound Fluid (AWF; 50% 
fetal bovine serum in 50% peptone water [0.9% sodium chloride in 0.1% peptone]). The 
AWF was left to dry at room temperature. After, 50 µL of a sub-cultured bacterial isolate 
(106 CFU/mL) was placed onto the membrane and left to dry at room temperature. 
Inoculated plates were then incubated for 24 h at 32 °C or 37 °C depending on experimental 
procedure. After incubation, the membranes were placed into 10 mL of PBS and the biofilms 
were stripped by sonication (44 KHz) for 15 min twice, with a 60 s interval of vortexing 




Figure 2.2: Schematic of the Colony Biofilm Model. AWF = Artificial Wound Fluid. 
 
2.2.3. Bacteriophage 
Bacteriophage K used in this project was provided by American Type Culture Collection 
(ATCC; Manassas, Virginia, United States).  
2.2.3.1. Principles of Bacteriophage Growth  
Immediately following phage incubation with bacteria, phage enter the latent period, 
whereby there is no release of virions. After the latent period, the host cells are rapidly lysed, 
releasing the phage into the extracellular environment. This is known as the rise period, and 
the term “burst size” is used in relation to the number of phage released from a single 
infected bacterium.4  
2.2.3.2. Bacteriophage Propagation 
2.2.3.2.1. Soft Overlay Method  
Propagation of bacteriophage using the soft agar overlay method used molten top agar (65% 
strength TSA) stored at 60 °C until required. Briefly, 100 µL of phage lysate and 100 µL of 
an overnight culture of host S. aureus H560 (c. 109 CFU/mL) were added to 5 mL of cooling 
molten agar and vortexed. The mixture was then poured onto TSA plates and spread to 
ensure uniform coverage. After overnight incubation at 37 °C, 5 mL of PBS was added to 
plates that displayed confluent lysis and left for 20 min. Using a sterile L-shaped spreader, 
the solution and top agar were collected from the plate and centrifuged at 4000 g for 15 min 
to remove agar and cell debris. The supernatant was subsequently filter-sterilised using 




2.2.3.2.2. Liquid Lysate 
Briefly, 1 mL of standardised S. aureus H560 suspension (c.106 CFU/mL) was added to 
19 mL of TSB and incubated at 37 °C with 150 rpm shaking for 3 h to achieve early-
exponential phase bacteria. After this, 100 µL of phage lysate was added at a multiplicity of 
infection (MOI) of approximately 0.1 (c. 106 PFU/mL), and the suspension was incubated 
for a further 18 h at 37 °C. Following incubation, the suspension was centrifuged (4000 g, 
15 min) to remove cell debris, filter sterilised (0.22 µM filter), enumerated, and stored at 4 
°C until further use.  
2.2.3.3. Bacteriophage Enumeration 
Total viable count for bacteriophage suspensions were performed using an adapted drop 
counting method (Figure 2.3). For this, 100 µL of an overnight culture of host strain 
S. aureus H560 (c. 109 CFU/mL) was added to 5 mL of TSA molten top agar, vortexed, 
poured onto TSA plates and left to air dry at room temperature for 15 min. Meanwhile, the 
initial bacteriophage suspension underwent a series of 10-fold dilutions in PBS buffer, 
before three 10 µL of selected dilutions were pipetted onto the surface of the agar plates and 
allowed to dry for 15 min at room temperature. The plates were subsequently incubated at 
37 °C for 18 h. Following incubation, plaques (clearings in the bacterial lawn) were counted 
and the plaque forming units per millilitre (PFU/mL) was calculated as follows: 




Where d = dilution factor, and V = volume of inoculum.  
 
 
Figure 2.3: Schematic of plaque counting (PFU/mL) for bacteriophage enumeration.  
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2.2.3.4. Increasing Bacteriophage Titre 
In instances where a high bacteriophage titre was needed, bacteriophage lysate solutions 
were concentrated using Spin-X® UF Concentrator Corning® centrifuge tubes (Sigma- 
Aldrich, Poole, UK) Briefly, 20 mL of phage lysate were added into the Spin-X® UF 
Concentrator Corning® centrifuge tubes and centrifuged until concentrated to a volume of 
1 mL. Once concentrated, the lysate was filter sterilised (0.22 µm filter) and enumerated as 
outlined in Section 2.2.3.3   
2.2.4. Data Analysis and Statistics 
All data analysis and statistical modelling was performed using GraphPad Prism, version 
7.0. All experiments undertaken in this thesis were carried out in triplicate using three 
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Chapter 3: Evaluation of Phage-Antibiotic 
Synergy 
3.1. Overview of Chapter 
The research presented in this chapter investigated the antibiotic efficacy of phage K and 
antibiotics against isolates of S. aureus, both individually and as a combination therapy. 
Herein, this chapter aims to discover whether interactions between phage and  antibiotics 
were synergistic , and if so, why this was occurring.  
3.2. Introduction 
3.2.1. Phage-Antibiotic Synergy  
One potential treatment strategy in clinical environments is to combine phage with  
antibiotics.1 It is thought that the efficacy of specific phage and antibiotic combinations may 
be better than that of the individual therapies at targeting and eliminating pathogenic 
bacteria at an infection site.  As such, there has been an increasing interest in phage-
antibiotic combinations, with current research looking promising.2–4 
The positive interaction between phage and antibiotics was first reported by Comeau et al 
in 2007, who termed this interaction “phage-antibiotic synergy” (PAS).4 PAS was originally 
used to describe the phenomenon where sub-lethal concentrations of antibiotics increase 
the host bacterium’s production of virulent phage.4–6 Nowadays, it is frequently used to 
describe interactions between phage and antibiotics that result in a  significant decrease in 
bacterial concentration.5,7 However, the term “synergy” is not well defined in the literature 
regarding PAS; hence, often encompasses “true synergy”, where the outcome of the 
combined treatment is greater than both of the monotherapies acting independently, and 
“facilitation/additive,” where the combined treatment is better than the best monotherapy, 
but is no better than both the monotherapies acting independently.7 
One of the main advantages of phage-antibiotic combinations is that they could increase the 
therapeutic efficacy of antibiotics in vivo; therefore, antibiotics that have lost all clinical 
utility could potentially be used in phage-antibiotic combinations, resulting in improved 




3.2.2. Phage-Antibiotic Synergy Studies 
Previous studies have investigated the role of PAS in several phage-antibiotic combinations 
(See below). Currently, several phage-antibiotic combinations have been shown to be 
effective in targeting bacterial species including: P. aeruginosa (P. aeruginosa),7–10 
S. aureus,11,12 Escherichia coli (E. coli),4,5 Burkholderia cepacia (B. cepacia),13 
Pseudomonas fluorescens (P. fluorescens),14 Klebsiella pneumoniae (K. pneumoniae),2 and 
Acinetobacter baumannii (A. baumannii).15 Research into PAS has utilised planktonic 
bacterial suspensions, biofilm models, and in vivo testing to determine the clinical utility of 
phage-antibiotic combinations. However, there is no consensus as to what experimental 
procedure must be performed to confirm synergy between therapies, and as such many 
studies cannot be compared. This introduction will briefly highlight a selection of studies 
within in this field, outlining the many ways in which PAS has been defined.  
3.2.2.1. Planktonic Studies 
Originally, PAS was identified by increasing plaque size and phage concentration, assayed 
by incubating phage on soft-agar impregnated with varying concentrations of antibiotics. 
The phenomenon of PAS was thought to be attributed to antibiotics increasing the burst 
size or reducing the latent period of the phage lifecycle.5 Ryan et al found that increasing 
sub-lethal concentrations of cefotaxime led to increased T4 plaque sizes and concurrent 
increase in phage concentration.5 This finding was confirmed by Jansen et al, who observed 
an increase in A. baumannii phage burst sizes upon combination with meropenem; 
hypothesising that the increased phage propagation was due to a cellular stress response.15 
Alternatively, in a study conducted by Knezevic and co-workers, they termed “synergy” as 
phage-antibiotic concentrations that decreased bacterial concentration (CFU/mL) by >2 
log, compared to the most potent single therapy.16 A summary of studies using planktonic 
bacterial suspensions is shown in Table 3.1. 
Table 3.1: Examples of PAS in planktonic bacteria. Adapted from Malik et al17 and  Morrisette et al.18 
Bacteria Phage + Antibiotic Outcome Reference 
Plaque assays  
E. coli 
Phage ΦMFP + aztreonam, 
cefixime, cefotaxime, 
ceftazidime, ceftriaxone 
Increase in plaque size and < 7-fold 




Phage RB32, RB33, T3, T4, T7 
+ cefotaxime 
Increase in plaque size 
Comeau 
20074 
E. coli Phage T4 + cefotaxime 






Table 3.1 (cont).: Examples of PAS in planktonic bacteria. Adapted from Malik et al17 and  Morrisette et al.18 
Bacteria Phage + Antibiotic Outcome Reference 
Bacterial cell viability  
P. aeruginosa  Phage LUZ7 + streptomycin 
Up to a 6 log decrease in bacterial 





Phage KS12 and KS14 + 
ciprofloxacin, levofloxacin, 
ceftazidime, tetracycline, 
minocycline, and meropenem 





Phage Pf3 and Pf1 + 
Carbenicillin, gentamicin, 
tetracycline, chloramphenicol 
Decline in bacterial viability after 60 
min, with a 3 log reduction after 6 h 
Hagens 
200620 
P. aeruginosa Phage Sigma-1 + ceftriaxone 





Phage KP22 + ceftazidime and 
piperacillin 
Decrease in bacterial turbidity  
Uchiyama 
201821 
E. coli Phage ECA2 + ciprofloxacin 
4 log reduction compared to the 
best monotherapy  
Valério 
201722 
S. aureus Phage SA5 + gentamicin 




Phage vB_AbaM-KARL-1 + 
ciprofloxacin, colistin, 
meropenem. 
Decrease in bacterial turbidity  
Jansen 
201815 
3.2.2.2. Biofilm Models 
PAS has been shown to be effective in killing bacterial biofilms5 including, S. aureus23 and 
P. aeruginosa24 due to the phage and antibiotic working synergistically to modify the 
biofilm structure, increasing susceptibility.25,26 Ryan et al  found that there was a marked 
decrease in antibiotic MBEC upon on the addition of T4 phage, which was enhanced with 
higher phage concentrations,5 and Chan et al found that phage-resistant P. aeruginosa 
biofilms were more susceptible to the antibiotics tested compared with non-resistant 
strains.9 
The presence of PAS in biofilms has also been attributed to phage-antibiotic combinations 
reducing the frequency of plasmid-borne resistance by targeting the plasmid-bearing cells.27 
Experiments conducted by Verma et al, found that there was a  statistically significant 
decrease in the resistant variant population (p<0.0001) in K. pneumoniae biofilms treated 
with a phage-antibiotic (ciprofloxacin) combination compared to either antibiotic or phage 
treatment alone.28 PAS is thought to help eradicate bacterial biofilms as phage produce 
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enzymes that breakdown the EPS, leading to better penetration of  antibiotics into the 
bacterial biofilm. Additionally, if phage eliminate the bacteria at the exterior of the biofilm, 
the interior bacterial cells have increased metabolic activity due to the increased 
oxygenation and nutrient exposure, and therefore become  more susceptible to both phage 
and antibiotics.7,29,30 A summary of studies using biofilm models is shown in Table 3.2.  
3.2.2.3. In vivo Models 
Recently, several studies have used animal models to investigate PAS in vivo (Table 3.3).  
Kamal et al found that some antibiotics induce increased phage production of several Bcc 
phage in Galleria mellonella larvae.13 Owing to this, there was increased survival of Galleria 
mellonella larvae 48 h post-infection when treated with the phage-antibiotic combination 
(88% survival) compared to phage K12 (33% survival) or meropenem (20% survival) 
alone.13 Additionally, Blasco et al showed that infected Galleria mellonella were more likely 
to survive when treated with a combination of a phage and antibiotic, compared to 
treatment with the individual components.31  
Murine models have also been used to investigate PAS; local administration of phage MR-
10, combined with the oral administration of the antibiotic linezolid was used to treat acute 
hindpaw MRSA infections in 48 diabetic mice.12 Additionally, Oechslin et al explored the 
efficacy of an anti-Pseudomonas phage cocktail (PP1131; 12 phage) in combination with 
ciprofloxacin for the treatment of P. aeruginosa endocarditis in a rat model.3 The results 
showed enhanced killing with the combination therapy  (residual bacterial titre of <2  log 
CFU/g), compared to the monotherapy groups (residual bacterial titres of >6 log CFU/g; 
p<0.0001). Interestingly, no phage-resistant bacterial isolates were isolated after 24 h 
incubation with the combination therapy.3  Another study investigated phage-antibiotic 
combinations for the treatment of implant-related biofilm MRSA and P. aeruginosa 
osteomyelitis in rat models.32 Antibiotics were administered intraperitoneally once daily for 
14 days, while phage were administered directly into the medullary canal once daily for 3 
days. Combination therapy was more effective than individual phage and antibiotics, 
resulting in a 6.2- and 3.4- fold lower bacterial cell count, respectively.32  
Research has shifted to focus on the efficacy of phage-antibiotic concentrations in treating  
complex multi-drug resistant (MDR) bacterial infections in humans,33–35 with Chan et al 
showing the utility of PAS in treating a patient with a P. aeruginosa infected wound 




Table 3.2: Examples of PAS in bacterial biofilms. Adapted from Malik et al17 and  Morrisette et al.18 
Bacteria Phage + Antibiotic Outcome Results 
K. pneumoniae  Phage + amoxicillin 
Statistically significant (p < 0.01) 
reduction in bacterial count 
Bedi 20092 
E. coli  T4 + cefotaxime Significant reduction in bacterial count Ryan 20125 
E. coli  T4 + tobramycin 
99% and 39% reduction in antibiotic 




P. aeruginosa  PB-1 phage + tobramycin 
2 log reduction and 60% reduction in 
antibiotic and phage-resistant bacterial 
cell count, respectively. 
Coulter  
201436 
P. aeruginosa  
Phage NP1 and NP3 + 
ceftazidime, ciprofloxacin,  
tobramycin 
Greater than 2 log reduction observed 
when antibiotics were combined with 





Phage KP22 + ceftazidime, 
piperacillin 
Synergistic effects observed when 
106 and 104 PFU/mL of phage KP22 was 
incubated with 10 nm/mL of 




Phage KPO1K2 + 
ciprofloxacin 
No statistical difference between 
biofilm log reduction between the 
combination treatment and phage-
treated biofilms; however, statistically 








Using 8-day old biofilms, a significant 
reduction in bacterial biofilm biomass 
was observed after incubation with the 





Phage KPO1K2 + 
ciprofloxacin 
Phage-antibiotic combinations resulted 
in slightly increased biofilm eradication 





Phage SAP-26 + 
azithromycin, rifampicin, 
vancomycin 
Approximately 5 log reduction of 24 h 
biofilms of S. aureus when treated with 




Phage PYO + ciprofloxacin, 
tetracycline 
The addition of phage to low 
concentrations of antibiotics (2xMIC) 







Table 3.3 Examples of PAS in in vivo assays. Adapted from Morrisette et al.18 
Bacteria Phage + Antibiotic Outcome Results 
Animal models 
P. aeruginosa Phage Pf1 + gentamicin 
Greatest survival when treated with 
1010 PFU/mL phage and 0.8 mg/kg 




vB_PasP pAT14 + 
imipenem/cilastatin, amikacin 
Reduced bacterial density when 
phage-antibiotic combination used 
compared to the control 
Yilmaz 
201332 
P. aeruginosa PP131 cocktail + ciprofloxacin 
Phage-antibiotic combination highly 
synergistic, successfully treating 
64% of rats 
Oechslin 
20173 
S. aureus Phage MR-10 + linezolid 
The combination therapy was more 
successful in arresting the entire 
infection process (bacterial load, 




S. aureus Phage Sb-1 + teicoplanin 
Reduced bacterial density and lack 
of biofilm observed when phage-
antibiotic combination used 





Phages EFDG1 and EFLK1 + 
ampicillin 
Combined bacteriophage-antibiotic 
therapy leads to the most significant 





Phage OMKO1 + ceftazidime, 
ciprofloxacin 
Following a single application of the 
combination therapy, the infection 
resolved with no signs of recurrence 
Chan 20188 
A. baumannii  dIV cocktail + minocycline 





3.2.3. Mechanism of Action 
The mechanism behind PAS is somewhat disputed; it has been suggested that PAS is a result 
of sub-lethal antibiotic concentrations altering the morphology and biosynthetic capacity of 
bacterial cells, which in turn can lead to increased phage propagation.  Comeau et al 
suggested that this change in bacterial morphology can enhance phage infection, increasing 
the rate of phage maturation and cell lysis. Sub-lethal concentrations of β-lactam and 
fluoroquinolone antibiotics can induce morphological changes to bacterial cell walls, as they 
inhibit cell wall synthesis and cell division, ultimately resulting in bacterial cell 
62 
 
filamentation.4 Other studies have suggested that this phenomenon could  increase phage 
production as they have increased accessibility to the receptors,13 increased precursors 
available for phage propagation,4,18 and easier cell lysis, potentially contributing to 
increased burst sizes.39  
Furthermore, Kim et al suggested that sub-inhibitory concentrations of antibiotics act as a 
“stress-inducer”, resulting in a delay in bacterial lysis, leading to increased phage 
production.39 They also identified synergistic interactions between phage and other SOS-
response inducing compounds (e.g., hydrogen peroxide [H2O2]) and suggested that PAS is 
dependent on either bacterial filamentation and/or SOS response; both do not need to be 
present for PAS to occur.39  
Other researchers have suggested that PAS is beneficial from a genetic perspective, as it was 
thought that targeting bacteria with two different antibiotic agents, with different 
mechanisms of actions, may suppress the emergence of phage and/or antibiotic resistance 
during treatment.6,28 Allen et al found that there was minimal cross-resistance between 
phage and antibiotics compared to two different types of antibiotics, or two different types 
of phage.40 Further studies have confirmed that there is little cross-resistance between 
phage and antibiotics, as simultaneous multiple mutations are required for bacterial 
resistance.14 This was termed “evolutionary synergy” by Chan and co-workers,9 with studies 
suggesting that resistant mutants arising from the combined therapy are less virulent than 
those resistant to either the phage or antibiotic.14,28 
Owing to their different mechanisms of action, phage-antibiotic combinations can be used 
to target MDR bacterial pathogens, as they can still be killed by phage.13,28 Alternatively, 
phage-resistant bacterial isolates remain susceptible to antibiotics.28 From an evolutionary 
point of view, this has been called the “see-saw effect”18 – where phage impose a selection 
pressure on the bacteria, resulting in the emergence of phage-resistant isolates; this 
ultimately leads to the bacteria re-gaining their sensitivity to antibiotics, to lower the fitness 
cost for the bacteria.9  
While there doesn’t seem to be a specific type of phage or class of antibiotic that universally 
results in PAS,17,18 it seems that it is dependent on the combination of phage, antibiotic, and 
bacterial strain under investigation.13 Multiple studies have found that synergy was both 
strain-dependent and dependent on the specific antibiotic used,39,41 with Kamal et al 
showing that there was a change in efficacy when different phage were used in combination 
with the same antibiotic against the same B. cepacia strain.13  
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An important thing to note is that not all phage-antibiotic combinations result in positive 
interactions. In fact, there have been several studies that have shown no interaction, or 
antagonism, between the phage and antibiotics;4,18,42,43 one study showed that the 
combination of phage and antibiotics resulted in an increase in antibiotic resistance within 
P. fluorescens.43 Therefore, there is a need for further study into PAS to understand the 
mechanism behind phage-antibiotic interactions, and how they can be applied in a clinical 
setting.  
3.2.4. Objectives 
• To determine if the combination of sub-inhibitory phage K and antibiotic 
concentrations (ciprofloxacin, vancomycin, amikacin, and amoxicillin) result in 
positive PAS interactions against three S. aureus strains.  
• To determine the efficacy of several planktonic-based bacterial assays in detecting 
PAS, and therefore if the assays can be compared to one another.  
• To determine if phage-antibiotic combinations can be used to prevent and eliminate 
biofilm formation of three S. aureus species.  
• To investigate the mechanism behind PAS by evaluating the morphology of bacterial 
cells after sub-inhibitory concentrations of antibiotics and the role of the antibiotics 





3.3.1. Bacterial and Bacteriophage Methods 
All methods relating to growth conditions of S. aureus isolates and propagation of phage K 
were outlined in Chapter 2, Section 2.2.1.3 and Section 2.2.3.2, unless otherwise stated. 
Enumeration of bacterial and phage cell density were performed as outlined in Chapter 2, 
Section 2.2.1.4 and Section 2.2.3.3.  
3.3.2. Bacteriophage Efficacy 
3.3.2.1. Spot Tests 
This protocol was adapted from Merabishvili et al,44 whereby 10 µL of a standardised 
S. aureus suspension (approx. 107 CFU/mL) was streaked over the surface of a 100 
x100 mm TSA plate previously divided into 5 x 5 grid and air-dried at room temperature 
(~25 °C) for 20 min. Subsequently, 10 µL of a phage suspension adjusted to a MOI of 0.1 in 
PBS was spotted onto each intersection and left to air-dry at room temperature for 1 h. PBS 
buffer was used as a negative control. Inoculated plates were incubated at 37 ºC for 24 h, 
after which phage activity was assessed visually (Figure 3.1). Spots at the intersections were 
given a score based on plaque formation ranging from ‘0’ (no plaques) to ‘+5’ (confluent 
lysis) as described in Table 3.4, resulting in a score out of 25. This was repeated for four 





Figure 3.1: A) Schematic of plate showing plaque scores ranging from ‘+1’ to ‘+5’. B) An example of a plate 
after 24 h incubation at 37 °C. The top row shows the positive control (host strain S. aureus H560 and phage 




Table 3.4: Scoring system for assessment of bacteriophage activity.44  
Observation Score 
Confluent lysis – bacterial streak completely broken; no bacterial colonies present at spotted 
intersection 
+5 
Overgrowth – bacterial streak completely broken, presence of singular bacterial colonies on spot +4 
Semi-confluent lysis – bacterial streak incompletely broken. +3 
Multiple small phage plaques +2 
Bacterial streak just affected i.e. little observable disruption to bacterial growth +1 
Negative result – no lysis present 0 
3.3.2.2. Detecting Temperate (Lysogenic) Phage 
S. aureus strains used in this Chapter were assessed for the presence of temperate phage 
using previously published procedures.45 Briefly, 100 µL of a bacterial culture (Chapter 2, 
Section 2.2.1.3) was mixed with 5 mL of molten top agar (65% strength TSA) and poured 
onto TSA plates. Once the top agar solidified, 10 µL of bacterial strains under investigation 
were spotted onto the plate and allowed to dry for 10 min at room temperature. The effect 
of antibiotics on the induction of temperate phage was also investigated. S. aureus strains 
were pre-incubated with ½ MIC concentrations of antibiotics for 24 h before being added 
to 5 mL molten top agar and poured onto TSA plates. The plates were then incubated 
overnight at 37 °C and subsequently analysed for the presence of lysis zones.  
3.3.2.3. Multiplicity of Infection  
Standardised isolates of S. aureus H560, MRSA252, and MSSA101 (Chapter 2, Section 
2.2.1.3) were diluted 10-fold in fresh TSB to attain bacterial concentrations of approximately 
106 CFU/mL, and 180 µL of each isolate was added to the relevant wells of a 96-well plate. 
Concurrently, a dilution series of phage K was performed to achieve concentrations of 109-
101 PFU/mL, with 20 µL of each concentration added to selected wells (to achieve MOIs of 
0.00001 – 100). Negative and positive controls were carried out in tandem. The turbidity of 
the suspensions was monitored using a SPECTROstar® Omega UV-Vis spectrometer (BMG 
LabTech, UK) at an OD of 600 nm (OD600) for 17 h at 37 °C. Readings were taken every 4 
min after a 2 s linear shake cycle.  
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3.3.3. Minimum Inhibitory Concentration 
The MIC of antibiotics against S. aureus H560, MRSA252, and MSSA101 were determined 
using methodology outlined in Chapter 2, Section 2.2.1.5. The antibiotics used in this study 
were ciprofloxacin-HCl, vancomycin, amoxicillin, and amikacin. All stocks were prepared 
in sterile deionised water (dH2O).  
3.3.4. Evaluating Phage-Antibiotic Synergy in Planktonic 
Suspensions 
3.3.4.1. Phage-Antibiotic Synergy Assay 
Stock solutions of antimicrobials were prepared at two times the MIC concentration, with 
100 µL of each antibiotic serially diluted in the wells of a 96 microtiter plate to attain 
antibiotic concentrations of MIC, ½ MIC, and ¼ MIC. Following this, phage K solutions 
were prepared in TSB (105 – 102 PFU/mL) and 20 µL added to all relevant wells. Finally, 
80 µL of sub-cultured S. aureus isolates (Chapter 2, Section 2.2.1.3) were added to the wells 
and the plate was incubated at 37 °C for 18 h. After incubation, the OD600 of each 
condition was measured and normalised against the blank control. For 
statistical analysis, each combination therapy was compared to the best-acting 
single therapeutic agent. 
3.3.4.2. Bacterial Cell Count Assay  
Bacterial isolates were grown and standardised as outlined in Chapter 2, Section 2.2.1.3, 
and subsequently diluted 10-fold in TSB to attain a bacterial concentration of 106 CFU/mL. 
Next, antibiotics and phage K were added to the bacterial suspension to achieve a final 
concentration of ½ MIC and 103 PFU/mL, respectively. The isolates were subsequently 
incubated at 37 °C for 18 h. ½ MIC antibiotic and 103 PFU/mL phage-only controls, broth 
and bacteria-only controls were carried out in tandem. After incubation, isolates were 
enumerated for bacterial and phage concentration (Chapter 2, Section 2.2.1.4 and 2.2.3.3, 
respectively), and compared to that of the bacteria-only control. For statistical analysis, 
each combination therapy was compared to the best-acting single therapeutic 
agent. 
3.3.4.3. One Step Growth Curve 
Bacterial cultures (Chapter 2, Section 2.2.1.3) were re-suspended in 10 mL TSB to attain 
concentrations of 106 CFU/mL, before subsequent addition of ½ MIC of the chosen 
antimicrobials. The cultures were incubated at 37 °C until mid-exponential growth (OD ~2), 
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at which time they were harvested by centrifugation (4 000 g, 10 min, 4 °C) and re-
suspended in 5 mL TSB. To this, 5 µL of phage K was added to obtain a MOI of 0.001 and 
allowed to adsorb for 5 min at room temperature. Subsequently, the solutions were 
centrifuged (4 000 g, 10 min, 4 °C), and re-suspended in 10 mL TSB. A sample was taken 
every 5 min for 1 h at 37 °C under constant shaking (150 rpm), and enumerated as outlined 
previously (Chapter 2, Section 2.2.3.3).  
3.3.4.4. Scanning Electron Microscopy  
Bacterial cultures with and without the presence of ½ MIC antibiotics were grown on 
Melinex® films in 2 mL TSB for 18 h at 37°C with minimal (70 rpm) agitation. After 
incubation, samples were fixed with 2.5% glutaraldehyde in 0.1 M sodium cacodylate buffer, 
post-fixed in aqueous 1% osmium tetroxide, dehydrated in an increasing acetone series (50 
– 100%), and chemically dried in hexamethyldisilazane (HMDS). Samples were stored 
under vacuum overnight to ensure complete dehydration, and subsequently sputter-coated 
with 20 nm of chromium (Edwards S150B, 60 s) to reduce charging effects and thermal 
damage. Images were obtained using a Field Emission Scanning Electron Microscope 
(FESEM) (JEOL JSM6301F) operating at 5 kV.  
3.3.5. Phage-Antibiotic Synergy Activity in Biofilms 
3.3.5.1. Minimum Biofilm Inhibition Concentration 
The MBIC of antibiotics against S. aureus H560, MRSA252, and MSSA101 was determined 
using the methodology outlined in Chapter 2, Section 2.2.2.1.1. The antibiotics used in this 
study were ciprofloxacin-HCl, vancomycin, amoxicillin, and amikacin. All stocks were 
prepared in sterile dH2O.  
To determine the MBIC for phage K, 180 µL of the sub-cultured bacterial suspension in 1% 
TSBg (c. 106 CFU/mL) was added to the wells of a 96 well plate. This was followed by 20 µL 
of different concentrations of phage K (109 PFU/mL – 101 PFU/mL), before the plate was 
incubated statically at 37 °C for 24 h. The plates were then assessed for biofilm formation 
as outlined in Chapter 2, Section 2.2.1.3. A bacteria and broth only control was carried 
out in tandem; experiments were performed in triplicate with three separate bacterial and 
phage suspensions. 
3.3.5.2. Biofilm Inhibition Phage-Antibiotic Synergy Assay 
The assay was conducted as outlined in Chapter 3, Section 3.3.4.1 with some modifications. 
In brief, stock solutions of antimicrobials were prepared at twice the MBIC in 1% TSBg, and 
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further serially diluted using 1% TSBg in the wells of a 96 microtiter plate to attain MBIC, 
½ MBIC, and ¼ MBIC antibiotic concentrations. Concurrently, phage K concentrations 
were prepared in 1% TSB (105 – 101 PFU/mL), with 20 uL of each concentration added to all 
relevant wells. Finally, 80 µL of a sub-cultured S. aureus isolate (Chapter 2, Section 
2.2.1.3) was added to the wells, and the plate was incubated at 37 °C for 18 h. After 
incubation, the biofilm inhibition was assessed via CV as outlined in Chapter 2, Section 
2.2.2.1.3. 
3.3.5.3. Minimum Biofilm Eradication Concentration  
The MBEC of antibiotics against S. aureus H560, MRSA252, and MSSA101 was determined 
using methodology outlined in Chapter 2, Section 2.2.2.1.2. The antibiotics used in this 
study were ciprofloxacin-HCl, vancomycin, amoxicillin, and amikacin. All stocks were 
prepared in sterile dH2O.  
For phage K MBEC determination, the procedure was modified. Once the plates were 
washed three times to remove planktonic bacteria, 180 µL 1% TSBg was added to the wells, 
followed by 20 µL of different dilutions of phage K (1011 PFU/mL – 105 PFU/mL). The plate 
was then statically incubated at 37 °C for a further 18 h. After incubation, the plates were 
washed three times with sterile dH2O and assessed for biofilm formation as outlined in 
Chapter 2, Section 2.2.2.1.3. A bacteria and broth only control was carried out in tandem; 
experiments were performed in triplicate with three separate bacterial and phage 
suspensions. 
3.3.5.4. Biofilm Eradiation Phage-Antibiotic Synergy Assay 
Overnight cultures of bacteria were sub-cultured into fresh 1% TSBg to attain a 
concentration of 106 CFU/mL. Next, 200 µL of the adjusted bacterial suspension was added 
into the relevant wells within the 96-well microtiter plate, and statically incubated at 37 °C 
for 24 h. After incubation the biofilms were washed three times with sterile dH2O to remove 
planktonic bacteria. Concurrently, stock solutions of antimicrobials were in 1% TSBg 
(concentration dependent on the assay) and 100 µL of each antibiotic was added to the 
relevant wells in the microtiter plate.  Subsequently, 20 µL of phage K (concentration 
dependent on the assay) and 80 µL of 1% TSBg were added to obtain a final volume of 
200 µL. The microtiter plate was incubated at 37 °C for 24 h. Antibiotic and phage-only 
controls were carried out in tandem to broth and bacteria only controls. After incubation, 




3.4. Results and Discussion  
3.4.1. Single-Therapy Efficacy 
3.4.1.1. Bacterial Sensitivity to Bacteriophage K 
Lytic phage that display broad-spectrum activity against a range of clinically relevant 
bacterial species are the most likely phage to be successful as a mass-market therapeutic. In 
this instance, phage K was used as it has previously had its genome sequenced,46,47 was 
reported to have a broad host range,48–50 and had little effect on the expression of numerous 
cytokines (IL-6, IL-8, and RANTES) and surface markers.50 
Phage K is thought to have been isolated over 90 years ago;51,52 it is also identical to phage 
Au2 isolated by Burnet and Lush,53 and the polyvalent phage 812.54   Phage K has recently 
been designated to the genus of Kayvirus, of subfamily Twortvirinae in the Herelleviridae 
family. Members of the Herelleviridae family possess a head-tail morphology with 
contractile tails and icosahedral heads; their genomes are linear dsDNA of 125 – 170 
kilobases (kb) with long terminal repeats of various lengths.55 The subfamily Twortvirinae 
generally infect Staphylococcus and Lactobacillus strains,56 with the genus Kayvirus 
specifically infecting Staphylococcus spp., mainly S. aureus.57 Phage K is the type species in 
this genus.57 It has a regular icosahedral head, approximately 66 – 77 nm in diameter, with 
a contractile tail approximately 225 – 191 nm in length (non-contracted) and 14 – 16 nm 
width, dependent on the staining technique used.58 
Phage K is a lytic,47 polyvalent phage that utilises N-acetylglucosamine in the cell wall 
teichoic acid for phage adsorption.59 As such, it possesses a broad host range,47 inhibiting 
S. aureus and coagulase-negative Staphylococci. 51,60 Literature states that phage K is active 
against 47 – 84% of S. aureus strains48–50 and can be modified to expand its host range after 
serial passage through phage-resistant cultures.60 Therefore, phage K (106  PFU/mL) was 
tested for its efficacy against 30 S. aureus strains standardised to a known concentration 
(107 CFU/mL) and given an overall score out of 100. Bacterial strains with a score between 
0-20 displayed little to no phage susceptibility (termed “resistant”), between 21 – 60 
displayed moderate susceptibility to phage (termed “intermediate”), and scores between 61 
– 100 showed good susceptibility to phage K (termed “susceptible”).  
From the results shown in Table 3.5, 46.7% of strains were susceptible, 20.0% were 
intermediate, and 33.3% were resistant to phage K activity. These results confirmed the 
broad-spectrum nature of phage K previously reported.48–50 However, there were more 
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“resistant” strains compared to literature; this result could be due to numerous factors, one 
of which could be the relatively small (n = 30) sample size, which could be improved upon 
by increasing the number of S. aureus isolates tested.  
Additionally, this study used a MOI of 0.1 (10 bacterial cells to one phage cell), while other 
reports used higher MOIs. The lower MOI was used to reduce the presence of “lysis-from-
without”, which occurs when high-multiplicity virion adsorption results in lysis without 
viral production; hence, higher MOIs could overestimate phage infectivity. 
Table 3.5: Efficacy of phage K against S. aureus isolates at a Multiplicity of Infection (MOI) of 0.1. Plates 
were incubated at 37 °C for 18 h prior to being assessed visually (n = 4). Bacterial strains with a score between 
0-20 displayed little to no bacteriophage susceptibility (termed “resistant”), between 21 – 60 displayed 
moderate susceptibility to phage (termed “intermediate”), and scores between 61 – 100 showed good 
susceptibility to phage K (termed “susceptible”). 
S. aureus strain Score / 100 S. aureus strain Score / 100 
6125 84 NCTC 10788 50 
6009 83 6138 48 
6022 80 MSSA101 41 
6124 80 MRSA252 39 
6019 79 6027 29 
6097 79 6020 8 
6007 78 6107 5 
6132 75 6133 5 
99518 73 6004 3 
6114 69 MRSA17 1 
6001 65 6021 0 
H560 65 6032 0 
6129 63 6115 0 
6135 61 6128 0 
6008 50 USA300 0 
3.4.1.2. Detection of Temperate Bacteriophage 
S. aureus H560, MRSA252, and MSSA101 were chosen for all future experiments. S. 
aureus H560 was selected as it was used to propagate phage K, and S. aureus MRSA252 
and MSSA101 were selected as they had similar susceptibility to phage K. While it is unclear 
if S. aureus H560 and MSSA101 have any prophage within their genome, S. aureus 
MRSA252 has two known prophages, ΦSa2 and ΦSa3.61,62 
Due to this, mixed host overlays (Section 3.3.2.2) were employed to ensure that any 
temperate phage present within the S. aureus isolates' genome would not affect the 
outcome of the experiments. No lysis areas were observed for any of the S. aureus strains 
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used, suggesting that without any external influence on the bacterial cells, temperate phage 
cannot be detected using the assay (Figure 3.2).  
However, prophages can be  induced by environmental stressors, such as mitomycin C and  
antibiotics.63,64  Therefore, it was important to ensure that the antibiotics used in this study 
did not induce temperate phage. All antibiotics tested (ciprofloxacin, vancomycin, 
amikacin, and amoxicillin) failed to induce temperate phage, with no visible plaques present 
on their corresponding bacterial lawns. Therefore, it can be concluded that any plaques 
formed in future studies would be due to the presence of phage K only. 
 
Figure 3.2: An example of a soft-overlay plate showing no visible lysis of S. aureus H560, MRSA252 and 
MSSA101 (top to bottom respectively) on an overlay of S. aureus MSSA101. 
3.4.1.3. Multiplicity of Infection   
The MOI is a ratio of the number of viruses to the number of host cells. As phage adsorption 
is a chance event, the MOI is displayed as an average, encompassing cases where multiple 
phage adsorb onto a single host cell, and instances where host cells remain uninfected.65 
Importantly, the calculated MOI may not correlate to MOIactual due to anti-phage 
mechanisms outlined in Chapter 1. However, MOIactual is difficult to determine 
experimentally, therefore, all MOI values quoted in this study are representative of initial 
MOI concentrations.  
Figure 3.3 shows a reduction in OD for all three bacterial strains tested upon incubation 
with increasing phage concentrations (0 – 107 PFU/mL) after 18 h incubation at 
37 °C. Bacterial growth was completely inhibited with 104 PFU/mL phage K for all bacterial 
strains, corresponding to a MOI of 0.01. This was not surprising as all three strains 
displayed similar activity in the spot test (Table 3.5). Additionally, there was no evidence of 
bacterial re-growth, indicating that there was no development of phage-resistant strains 
during this experiment.  
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Interestingly, there was no difference in trend observed when the samples were 
continuously agitated at 150 rpm, compared to when they were statically incubated. While 
there are increased OD600 values observed for shaking incubation compared to static, OD600 
isn’t linear to cell concentrations at high absorbance values – hence it is possible to assume 
similar growth was observed for both conditions. 
A) B) 
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Figure 3.3: OD600 measurements for A) S. aureus H560, B) S. aureus MRSA252 and C) S. aureus MSSA101 
upon incubation with varying phage K concentration (101 – 107 PFU/mL). Measurements taken after 18 h 
incubation at 37 °C, error bars indicate standard deviation (n = 3).  
3.4.1.4. Antibiotic Susceptibility 
The antibiotics used in this study were ciprofloxacin-HCl, vancomycin, amikacin, and 
amoxicillin. Ciprofloxacin is a fluoroquinolone, therefore works by inhibiting DNA 
topoisomerase and DNA gyrase, preventing DNA replication.66 While predominately used 
for gram-negative bacterial species (e.g., E. coli,66 Salmonella spp.,66 and P. aeruginosa67), 
it has also shown efficacy against some gram-positive bacteria.67 Vancomycin is a tricyclic 
glycopeptide antibiotic originally produced by Streptococcus orientalis.68,69 It works by 
binding to the C-terminal D-alanyl-D-alanine moieties of the N-acetylmuramic acid 
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(NAM)/N-acetylglycosamine (NAG) peptides, which in turn inhibits glucosyltransferase, 
preventing the synthesis and polymerisation of NAM and NAG within the peptidoglycan 
layer of the cell wall. Owing to this, the cell wall becomes weakened and ultimately results 
in the leakage of intracellular components and subsequent bacterial cell death.68 Amikacin 
is an aminoglycoside and therefore works by binding to the A-site on the 16S ribosomal RNA 
of the 30S ribosome;70 this in turn inhibits protein synthesis by causing premature protein 
termination and incorporation of incorrect amino acids, causing bacterial cell death.71 
Amikacin is potent towards both gram-positive and gram-negative bacteria,71 typically 
displaying bactericidal efficacy and prolonged post-antibiotic effect.72  Finally, the β-lactam 
amoxicillin targets and kills bacteria by binding, and subsequently inhibiting, penicillin 
binding proteins (PBPs); thus, preventing the crosslinking of peptidoglycan and ultimately 
leading to cell death.73,74  
To undertake PAS assays, the antibiotic concentration needs to be sub-inhibitory, therefore 
it is important to first establish the antibiotic’s respective MIC. The MIC is the lowest 
concentration of antibiotic that inhibits the visible growth of a bacterial culture after 18 h 
incubation at 37 °C. The MIC values in this study were determined using the broth micro-
dilution method as outlined in the European Committee on Antimicrobial Susceptibility 
Testing (EUCAST) guidelines.75  
A phenomenon called the inoculum effect can cause an 8-fold increase in MIC owing to 
higher-than-recommended bacterial concentrations and is commonly seen for β-lactam 
antibiotics.76 To prevent this phenomenon from occurring, the assay used approximately 
5 x 105 CFU/mL of each bacterial strain. 
The MIC concentrations for the antibiotics are shown in Table 3.6. According to the 
EUCAST breakpoints, S. aureus H560 and MSSA 101 were susceptible to amikacin, had 
intermediate susceptibility towards ciprofloxacin, and were resistant to vancomycin. S. 
aureus MRSA252 was resistant to all antibiotics tested. Amoxicillin breakpoints are not 
outlined by EUCAST, who instead recommend testing the bacterial species against 
benzylpenicillin and cefoxitin. S. aureus that are susceptible to both antibiotics can be said 
to be susceptible to all penicillins, whereas the strains that are only susceptible to cefoxitin 
are susceptible only to β-lactam/β-lactamase inhibitor combinations. However, as S. aureus 
MRSA252 has such a high MIC against amoxicillin (500 µg/mL), one can assume that the 





Table 3.6: Minimum Inhibitory Concentrations of the antibiotics used in this study 
 
Minimum Inhibitory Concentration (µg/mL) 






Ciprofloxacin 0.50 62.50 0.50 
Vancomycin 4.00 4.00 4.00 
Amoxicillin 8.00 500 4.00 
Amikacin 4.00 32.0 2.00 
 
3.4.2. Determination of Phage-Antibiotic Synergy 
3.4.2.1. Bacteriophage K Survival in the Presence of Antibiotics 
One, perhaps obvious, but overlooked, parameter in determining PAS is the survival of 
phage in the presence of antibiotics. It is often assumed that phage will remain stable when 
in solution with other antimicrobials – however, this is not always the case. For instance, 
replication of T4-like phage could be suppressed in the presence of fluoroquinolones due to 
the T4-like phage encoding for DNA topoisomerases.15 This antagonistic nature can also be 
found when certain phage are combined with protein and DNA synthesis inhibitors.77  
Suspensions of phage K were incubated with 1 mg/mL of ciprofloxacin, vancomycin, 
amikacin, or amoxicillin for up to 24 h at 37 °C prior to enumeration. Phage viability 
remained stable when incubated with amoxicillin and vancomycin (Figure 3.4). While the 
reduction in phage viability after 24 h incubation with vancomycin was statistically 
significant, it only corresponded to a 0.2 log reduction that could be explained by other 
factors such as pipetting error. 
Conversely, when phage K was incubated with amikacin there was a slight decrease in phage 
concentration after 1 h (t-test, p<0.05; 0.27 log reduction), and a further decrease after 24 h 
incubation (t-test, p<0.001; 1.88 log reduction). With ciprofloxacin, there was a significant 
decrease in phage concentration after 1 h (t-test, p<0.05; 0.49 log reduction), and a further 
substantial decrease after 24 h incubation (t-test, p<0.001; 4 log reduction). Both of these 
antibiotics target bacterial functions involved in cell transcription and translation, which 
can also be present in the phage genome.78 Due to this, phage viability may be reduced in 
the presence of these antibiotics (in these experiments, this phenomenon was observed 
































































Figure 3.4: Log PFU/mL of phage K in the presence of 1 mg/mL of ciprofloxacin, vancomycin, amikacin and 
amoxicillin. Phage counts were taken after 1 h or 24 h incubation at 37 °C. Error bars indicate standard deviation 
(n = 3). Statistical analysis was conducted using a Student’s t-test, with each variable compared to their 
respective ‘Phage only’ control. # p < 0.05 compared to phage only control at 1 h, * p < 0.05, *** p < 0.001, **** 
p < 0.0001 compared to phage only control at 24 h. 
3.4.2.2. Phage-Antibiotic Synergy Assay 
Antibiotic concentrations at ½ and ¼ their MIC were combined with varying 
concentrations of phage K (101 - 104 PFU/mL) to evaluate their ability to reduce the OD of 
S. aureus isolates. Statistical analysis was conducted by comparing the OD600 of the 
combination therapy against the individual treatment that had the lowest OD600 value, i.e., 
the more potent component of the combination. 
For S. aureus H560, ciprofloxacin, amikacin, and amoxicillin all showed positive (i.e., 
synergistic or additive) interactions with phage K (Figure 3.5). A significant reduction in 
OD600 was found when ½ MIC ciprofloxacin was combined with sub-inhibitory 
concentrations of phage K (t-test, p< 0.01) and when ¼ MIC ciprofloxacin was combined 
with 103 PFU/mL (t-test, p<0.0001). When phage K was combined with amikacin, a 
significant reduction in OD600 was seen for the ½ MIC amikacin and 103 PFU/mL phage K 
(t-test, p<0.001) and 102 PFU/mL phage K (t-test, p<0.05) combinations. A significant 
decrease in OD600 was also witnessed when ¼ MIC amikacin was combined with 
103 PFU/mL phage K (t-test, p<0.0001). These positive interactions were somewhat 
surprising, considering that phage K viability is diminished in the presence of these 
antibiotics. However, the concentration of antibiotic used for the viability assay was much 
higher, hence any inhibitory effects may be negligible at these lower concentrations. 
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When ½ MIC of amoxicillin was combined with phage K, a significant reduction in OD600 
was observed for phage K concentrations of 103 PFU/mL (t-test, p<0.0001) and 102 and 101 
PFU/mL (t-test, p<0.01). A statistical decrease in OD600 was also witnessed when ¼ MIC 
amoxicillin was combined with 103 PFU/mL phage K (t-test, p<0.0001). Conversely, no 
significant reduction in OD600 was found for all phage and vancomycin combinations tested. 
In fact, the presence of ¼ MIC vancomycin with  101 and 102 PFU/mL phage K  increased 
the optical density of the isolates – although this does not mean that the combination 
increased bacterial cell concentration, as bacterial concentration is not linearly correlated 
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Figure 3.5: OD600 measurements for S. aureus H560 upon the addition of differing concentrations of phage 
and/or antibiotic as a single therapy or in combination. OD600 measured after 18 h incubation at 37 °C. n = 3 
and error bars indicate standard deviation. Statistical analysis was conducted using a Student’s t-test, with each 




For S. aureus MRSA252, favourable interactions were observed when ½ MIC ciprofloxacin 
was combined with 103 or 102 PFU/mL phage K (t-test, p<0.0001) (Figure 3.6). However, 
the use of ¼ MIC ciprofloxacin with 101 and 102 PFU/mL phage K statistically increased the 
OD600 of S. aureus MRSA252. When ½ MIC amikacin or amoxicillin were combined with 
103 phage K, there was a significant reduction in OD600 (t-test, p< 0.01 and p< 0.001 for 
amikacin and amoxicillin, respectively). When ¼ MIC amikacin or ¼ MIC amoxicillin were 
combined with 103 PFU/mL of phage K, a significant reduction in OD600 was observed (t-
test, p<0.01 and p<0.001 for amikacin and amoxicillin, respectively). Additionally, the 
combinations of ¼ MIC amoxicillin or amikacin and 102 PFU/mL phage K resulted in a 
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Figure 3.6: OD600 measurements for S. aureus MRSA252 upon the addition of differing concentrations of 
phage and/or antibiotic as a single therapy or in combination. OD600 measured after 18 h incubation at 37 °C. n 
= 3 and error bars indicate standard deviation. Statistical analysis was conducted using a Student’s t-test, with 
each variable compared to the control which displayed the lowest OD600 value. * p < 0.05, *** p < 0.001, **** 
p < 0.0001 
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S. aureus MRSA252 was the only strain tested where ½ and ¼ MIC of vancomycin 
displayed a positive interaction with 103 PFU/mL phage K (t-test p<0.001 and p<0.01, 
respectively). Although the reason for this is, as yet, unclear, it demonstrates the strain-
specific nature of PAS interactions.  
Next, the efficacy of the combinations were tested against S. aureus MSSA101 (Figure 3.7). 
When ½ or ¼ MIC of ciprofloxacin was combined with phage K (103 – 101 PFU/mL), all 
combinations reduced the OD600 of S. aureus MSSA101 suspensions in a statistically 
significant manner in comparison to the corresponding controls. When ½ MIC of amikacin 
or amoxicillin were combined with 103 PFU/mL of phage K, a significant reduction in OD600  
of S. aureus MSSA101 was observed (t-test, p<0.01). This result was also observed when 
103 PFU/mL of phage K was combined with ¼ MIC amikacin (t-test, p<0.05) and 
amoxicillin (t-test, p<0.01). Finally, when phage K and vancomycin were used in 
combination, there was no significant reduction in OD600 for all combinations tested. In fact, 
the presence of 103 and 102 PFU/mL phage K with ½ MIC vancomycin increased the optical 
density of the isolates, showing a similar trend to that of S. aureus H560.   
Overall, the most effective combinations for the treatment of all three S. aureus species 
were ½ MIC antibiotic and 103 PFU/mL of phage K. This observation implies that the 
concentrations of antibiotic/phage need to be close to their MIC values, and that lower 
concentrations would not provide a therapeutic benefit. Furthermore, ciprofloxacin in 
combination with phage K seemed to consistently provide the best results across all three 
S. aureus strains tested. However, as ciprofloxacin seemed to have an inhibitory effect 
towards phage K in the absence of bacteria, further experiments are needed to examine this 
phenomenon.  
Other literature sources have used similar OD assays to determine PAS.79,80 Jansen et al, 
used end-OD measurements to show that there was significant inhibition of A. baumannii 
upon incubating with phage KARL-1 and meropenem. However, this PAS phenomenon was 
not observed for all combinations tested, with minimal increases in efficacy witnessed when 
KARL-1 was incubated with ciprofloxacin or colistin.15 These studies further corroborate the 
results found in this study, suggesting that PAS is not only dependent on the phage and 
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Figure 3.7 OD600 measurements for S. aureus MSSA101 upon the addition of differing concentrations of phage 
and/or antibiotic as a single therapy or in combination. OD600 measured after 18 h incubation at 37 °C. n = 3 
and error bars indicate standard deviation. Statistical analysis was conducted using a Student’s t-test, with each 
variable compared to the control which displayed the lowest OD600 value. * p < 0.05, *** p < 0.001, **** p < 
0.0001 
3.4.2.3. Bacterial Cell Counts  
One disadvantage with the PAS assay is that OD600 values are not proportional to bacterial 
cell concentrations at high OD values, with linearity usually seen for a limited CFU/mL 
range (approx. 106 – 108 CFU/mL). Therefore, results that show significant reductions in 
OD600 values might not correspond to significant decreases in bacterial concentration. 
Owing to this, other assays have been developed that determine PAS by calculating the 
concentration of bacterial isolates after incubation with phage-antibiotic combinations, or 
the individual monotherapies.28,31,79 Consequently,  106 CFU/mL of S. aureus H560, 
MRSA252, and MSSA101 were incubated with ½ MIC antibiotic, 103 PFU/mL phage K, or 
a combination of both. After 18 h incubation at 37 °C, the bacterial suspensions were 
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collected and enumerated. Statistical significance was determined by comparing the dual 
therapy to the most potent monotherapy. 
For S. aureus H560, all combination therapies produced statistically significant reductions 
in Log CFU/mL when compared to their most potent monotherapy counterparts (Figure 
3.8A). When combined with 103 PFU/mL of phage K, ½ MIC ciprofloxacin, amoxicillin, and 
amikacin resulted in average log reductions of 5.14, 2.17, and 1.65, respectively. While the 
combination of ½ MIC vancomycin and 103 phage K resulted in a statistically significant 
reduction, it only corresponded to a 0.25 log reduction, which is not clinically significant. 
For the treatment of S. aureus MRSA252, ½ MIC amikacin was the most effective antibiotic 
in combination with 103 PFU/mL phage K (log reduction of 3.95; Figure 3.8B).  The 
combination utilising ½ MIC ciprofloxacin also resulted in a statistically significant log 
reduction of 2.62. Conversely, amoxicillin failed to produce a statistically significant 
reduction in bacterial concentration when combined with 103 PFU/mL phage K.  
Perhaps the most interesting observation is that the combination of ½ MIC vancomycin 
and 103 PFU/mL phage K failed to reduce S. aureus MRSA252 concentration. This 
discrepancy between this assay and the PAS OD600 assay  could be due to a variety of 
reasons. Firstly, it could be due to the inherent variation between bacterial isolates. 
Secondly, it could be due to the disparity between methodologies, with differences in 
working volumes, and extra dilution steps required in bacterial enumeration. However, 
further work would be needed to understand this discrepancy.   
All antibiotics, except vancomycin, significantly reduced S. aureus MSSA101 bacterial 
concentration in the presence of 103 PFU/mL phage K, compared to their respective control 
(Figure 3.8C). The most effective combination was ½ MIC amoxicillin and 103 phage K (log 
reduction of 3.00). Similar efficacies were observed when ½ MIC ciprofloxacin or amikacin 
was combined with 103 PFU/mL phage K (log reductions of 2.17 and 2.15, respectively). ½ 
MIC vancomycin and 103 PFU/mL phage K was not effective in reducing S. aureus MSSA101 
cell count (log reduction of 0.12).  
Overall, the best PAS combination in reducing bacterial cell concentration across all three 
bacterial species tested was ½ MIC ciprofloxacin and 103 PFU/mL of phage K, with an 
average log reduction of 3.31 across all three strains tested.  The second-best combination 
was phage K and amikacin, with an average log reduction of 2.29. The bacterial cell counts 
further supported the results found in the OD assay (Figures 3.5 – 3.7), the differences in 
therapeutic efficacy of the same combinations against different S. aureus strains shows that 
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Figure 3.8: Log CFU/mL of A) S. aureus H560, B) S. aureus MRSA252 and C) S. aureus MSSA101 in the 
presence of ½ MIC antibiotics and 103 PFU/mL of phage K. Cultures were incubated statically for 18 h at 37 °C. 
n = 3 and error bars indicate standard deviation. Statistical analysis was conducted using a Student’s t-test, with 
each variable compared to the control which displayed the lowest OD600 value.  * p < 0.05, *** p < 0.001, **** p 
< 0.0001 
3.4.2.3.1. Mixed-Model Analysis 
Mixed-model analysis can be performed on the Log CFU/mL bacterial counts to determine 
the nature of the interaction between the antibiotic and phage when used in combination. 
These interactions can be defined as synergistic, additive, or antagonistic, as described 








COEFint is the coefficient of the interaction, ABR is the reduction in bacterial counts followed 
by the combined treatment (AB), AR is the reduction on bacterial counts due to treatment A 
and BR is the reduction in bacterial counts due to treatment B.   
If the coefficient value is > 0, the interaction was synergistic - where the combination of 
therapies led to a greater reduction in bacterial cell concentration than the sum of the 
individual therapies. An interaction was additive if the value = 0, signifying that the 
therapeutic benefit of the combination therapy was equal to the sum of the individual 
counterparts. Finally, if the value was < 0, the interaction was termed antagonistic - where 
the bacterial cell reduction was lower than the sum of the individual therapies. The 
calculated coefficients for this assay are shown in Table 3.7.  
When ½ MIC ciprofloxacin or amikacin was combined with 103 PFU/mL phage K, a 
synergistic interaction was observed for all bacterial species tested. ½ MIC amoxicillin 
provided synergistic interactions with 103 PFU/mL phage K when tested against S. aureus 
H560 and S. aureus MSSA101, and an additive interaction when tested against S. aureus 
MRSA252. Finally, ½ MIC vancomycin provided an additive interaction with phage K for 
all three bacterial species tested. These results further highlight the differences in the 
efficacy of the antibiotic and phage combinations when tested against different S. 
aureus isolates. Therefore, detailed microbiological analysis will be needed before PAS 
combinations can be used as a therapeutic technique for the treatment of bacterial 
infections. 
Table 3.7: Calculated co-efficients of interaction for S. aureus H650, MRSA252 and MSSA101 for the 
combined use of selected antimicrobials (1/2 MIC) and phage K (103 PFU/mL). Values > 0 are considered 
synergistic, = 0 are additive/no interaction and < 0 are antagonistic interactions.  
 






Ciprofloxacin 4.88 2.84 2.12 
Vancomycin 0.12 0.05 -0.11 
Amikacin 1.63 3.95 3.19 
Amoxicillin 2.60 0.90 3.69 
3.4.2.4. Bacteriophage Cell Counts  
Reports in literature have suggested that the presence of sub-lethal doses of antibiotics 
increases the phage concentration;13 therefore the number of plaques formed in the 
presence of ½ MIC of antibiotics were also investigated.  
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When 103 PFU/mL phage K was combined with ½ MIC ciprofloxacin, amikacin, or 
amoxicillin, a significant increase in phage K concentration was observed for all bacterial 
strains tested compared to the control (phage only; Figure 3.9). What is most surprising is 
that the PAS combination with ½ MIC amoxicillin displayed the greatest increase in phage 
K production, but not the largest decrease in bacterial concentration. Therefore, increased 















































































































































































































































Figure 3.9: Log PFU/mL of A) S. aureus H560, B) S. aureus MRSA252 and C) S. aureus MSSA101 in the 
presence of ½ MIC antibiotics and 103 PFU/mL of phage K. Log PFU/mL was calculated after 18 h static 
incubation at 37 °C. n = 3 and error bars indicate standard deviation. Statistical analysis was conducted using a 
Student’s t-test, with each variable compared to the phage-only control. * p < 0.05, *** p < 0.001, **** p < 0.0001 
½ MIC vancomycin did not result in any statistical difference in the production of phage K 
when incubated with S. aureus H560 and MRSA252. For S. aureus H560, this result is not 
surprising, as this PAS combination failed to display enhanced therapeutic efficacy 
compared to its monotherapy counterparts. For S. aureus MRSA252, this result reflects the 
results observed for the bacterial cell counts (Figure 3.8) but is contradictory towards the 
OD600-based assay (Figure 3.6). As previously mentioned, further work would be needed to 
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examine this phenomenon. While ½ MIC vancomycin resulted in a statistically significant 
increase in the phage K concentration with S. aureus MSSA101, it only represented an 
increase of 0.27 Log PFU/mL, which could be due to experimental inaccuracies such as 
pipetting error.  
It has been suggested that an increase in phage production is due to the filamentation of 
bacterial cells,4,81 with several studies highlighting the increase of phage concentration in 
the presence of sub-inhibitory antibiotic concentrations.4,13,81 Interestingly, this study found 
that the antibiotic which resulted in the most phage K production (amoxicillin) was not the 
most effective antibiotic in combination with phage K in reducing bacterial cell counts 
(Figure 3.8). Therefore, an increase in phage K production might not translate to increased 
efficacy in reducing bacterial cell density and as such, studies that only focus on phage 
concentration may not give a true indication of that combinations’ clinical efficacy.  
3.4.2.5. One Step Growth Curves 
One-step growth curves were performed to determine the effect of sub-inhibitory 
concentrations of antibiotics on the life cycle of phage K. It has been hypothesised that sub-
inhibitory concentrations of antibiotics result in a change in latent periods of the phage 
growth cycle and a larger burst size of phage K. Therefore, this phenomenon should result 
in the increased efficacy of phage K, and thus the therapeutic benefit of the combination 
therapy.82  
In the system established, the latent period and burst size of phage K in S. aureus H560 
without any co-incubation with antibiotics were 30 min and 39.70 ± 3.17 PFU, respectively 
(Table 3.8). When co-incubated with ½ MIC ciprofloxacin, the latent period and burst size 
were 25 min and 44.05 ± 7.53 PFU. When phage K was co-incubated with ½ MIC 
vancomycin, the latent period and burst size were fairly consistent with results obtained 
with the phage K only control, displaying a latent period of 30 min and a burst size of 43.26 
± 14.61 PFU. Interestingly, upon incubation with ½ MIC amikacin, the latent period 
reduced in time to 25 min, but an increase in burst size was also witnessed (52.62 ± 8.08 
PFU).  
Table 3.8: Latent period (min) and burst size (PFU) of phage K in S. aureus H560. n = 3 ± standard deviation 
 Latent period / min Burst size / PFU 
Phage K 30 39.70 ± 3.17 
½ MIC ciprofloxacin 25 44.05 ± 7.53 
½ MIC vancomycin 30 43.26 ± 14.61 
½ MIC amikacin 25 52.62 ± 8.08 
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For S. aureus MRSA252, the latent period and burst size of phage K without co-incubation 
with antibiotics was 35 min and 45.61 ± 11.77 PFU, respectively (Table 3.9); similar results 
were observed when phage K was incubated with ½ MIC amikacin. When phage K was 
incubated with ½ MIC ciprofloxacin, the latent period was reduced to 30 min, and an 
increase in burst size was witnessed (62.05 ± 0.82 PFU). While there was no reduction in 
latent period, when phage K was incubated with ½ MIC vancomycin, a large increase in the 
burst size was observed.  
Table 3.9: Latent period (min) and burst size (PFU) of phage K in S. aureus MRSA252. n = 3 ±  standard 
deviation 
 Latent period / min Burst size / PFU 
Phage K 35 45.61 ± 11.77 
½ MIC ciprofloxacin 30 62.05 ± 0.82 
½ MIC vancomycin 35 75.64 ± 5.46 
½ MIC amikacin 35 34.25 ± 8.36 
 
For S. aureus MSSA101, the latent period and burst size of phage K without co-incubation 
with antibiotics was 25 min and 74.72 ± 5.87 PFU, respectively (Table 3.10). When phage K 
was incubated with ½ MIC ciprofloxacin, the latent period increased to 40 min, and a 
decrease in burst size was witnessed (62.05 ± 0.82 PFU). For both ½ MIC amikacin and 
amoxicillin, the latent period increased (40 and 30 min, respectively), correlating to burst 
sizes of 57.92 ± 21.63 PFU and 30.87± 29.36 PFU, respectively. Interestingly, vancomycin 
resulted in a reduced latent period (25 min) and increased burst size (100.95 ± 22.67 PFU) 
Table 3.10: Latent period (min) and burst size (PFU) of phage K in S. aureus MSSA101. n = 3 ± standard 
deviation 
 Latent period / min Burst size / PFU 
Phage K 25 74.72 ± 5.87 
½ MIC ciprofloxacin 40 62.05 ± 0.82 
½ MIC vancomycin 25 100.95 ± 22.67 
½ MIC amikacin 40 57.92 ± 21.63 
½ MIC amoxicillin 30 30.87 ± 29.36 
 
Our results implied that that there is no consensus between phage lifecycle and the efficacy 
of the antibiotic combinations in reducing bacterial cell density. This finding is also 
observed in literature, where Kamal et al found that the addition of cefotaxime increased 
the burst size of T4 phage and reduced the latent period from 24 minutes to 18 minutes, 
ultimately reducing the time to lysis.13 The authors correlated this to bacterial cell 
filamentation13 and thus will be examined in Section 3.4.2.6. However, other authors have 
noted that the latent period of T4 phage increased by 5 minutes in combination with 
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cefotaxime, which they then attributed to the increased burst size (by 2.5-fold).39 Therefore, 
further investigations need to be undertaken to determine the relationship between phage 
lifecycle and the efficacy of phage-antibiotic combinations.  
3.4.2.6. Scanning Electron Microscopy (SEM) Images 
To further understand the phenomenon of PAS, SEM images were obtained of S. aureus 
H560, MRSA252 and MSSA101 after 18 h incubation at 37 °C with ½ MIC antibiotic on 
Melinex® films in 2 mL TSB.  
As shown in Figure 3.10, S. aureus H560, MRSA252, and MSSA101 are uniform cocci, 
approximately 2 µm in diameter. On exposure to ½ MIC ciprofloxacin, S. aureus H560 and 
MSSA101 were visibly stressed, with the bacterial cells much larger in diameter than that of 
the controls (7.4 µm and 9.6 µm for S. aureus H560 and MSSA101, respectively), and had 
very uneven cell walls. This was also observed in S. aureus MRSA252, which displayed 
‘bloated’ cells approximately 9.2 µm in diameter, as well as long filamentous cells 18.8 µm 
in diameter. 
Upon incubation with ½ MIC vancomycin, both S. aureus H560 and MSSA101 bacterial 
cells were similar in size and morphology to that of the controls. This is not surprising as 
vancomycin failed to elicit an effective therapeutic response when combined with phage K. 
Conversely, S. aureus MRSA252 cells were larger and uneven in appearance compared to 
the controls (9.3 µm versus 2.4 µm, respectively), suggesting an alteration to the cell 
structure of the bacterial isolate, which may explain why there was a “synergistic” activity 
witnessed in the OD600 assay.  
½ MIC amikacin had a marked increase in cell size for S. aureus H560 (12.6 µm), and a 
modest increase in cell diameter for S. aureus MRSA252 and MSSA101 (5.0 µm and 4.4 µm, 
respectively). All cell-wall morphologies looked deformed on inspection.  
Finally, ½ MIC amoxicillin also increased the cell size of S. aureus H560, MRSA252, and 
MSSAA101 to 13.5 µm, 16.4 µm, and 7.0 µm, respectively. Once again, the bacterial cells 
looked distressed with uneven cell shape and pitted cell walls. This was found in literature, 
where subinhibitory concentrations of penicillin inhibited lysis of the bacterial cell wall 
without inhibiting cell division; this resulted in clusters of staphylococci unable to separate, 
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Figure 3.10: SEM images of untreated S. aureus H560, MRSA252 and MSSA101 compared with their 
counterparts incubated for 18 h with ½ MIC of ciprofloxacin, vancomycin, amikacin and amoxicillin.   
All bacterial cells that elicited a positive “synergistic response” when treated with ½ MIC 
and phage K combinations were distressed in appearance and meaningfully larger. In 
literature, the increase in phage production with sub-lethal concentrations of antibiotics is 
attributed to the change in bacterial cell morphology;4,39,81 this has been observed when sub-
inhibitory concentrations of antibiotics such as β-lactams,83 fluoroquinolones,84 and 
aminoglycosides79 have been used. Cell filamentation is thought to help with phage 
production as it escalates the production of essential precursors for phage and helps ease 
the cell for lysis.4 However, like all other PAS-related assays, PAS has been observed without 
any changes to phage morphology. Kamal et al found that when sub-inhibitory 
concentrations of tetracycline were used in combination with phage KARL-1 against 
B. cepacia, no filamentation was observed although the combination exhibited PAS. 
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Therefore, while changes in cell morphology may help facilitate PAS, it is not a 
requirement.13  
3.4.3. The Efficacy of PAS Within Bacterial Biofilms 
Much of the early work on the PAS phenomenon has focused on planktonic bacteria, with 
only a recent shift towards investigating PAS in bacterial biofilms. As biofilms are 
commonly found within chronic wounds,85,86 it is imperative to determine whether PAS 
combinations would be successful in these conditions.  
3.4.3.1. Minimum Biofilm Inhibitory Concentrations  
The first PAS test to be conducted was to examine the efficacy of the sub-inhibitory 
concentration of antibiotic and phage K to prevent biofilm formation. To find the correct 
PAS concentration for each of the components, preliminary experiments were conducted to 
determine the MBIC, which was the concentration of the agent that resulted in no biofilm 
growth, as determined by the CV assay.  
The MBIC concentrations for phage K are shown in Figure 3.11. A phage K concentration of 
104 PFU/mL was needed to prevent biofilm formation for S. aureus H560, MRSA252, and 
MSSA101. This concentration was equivalent to a MOI of 0.01, which was the same 
concentration required for the complete inhibition of the bacteria’s planktonic 
counterparts.  
The MBIC concentrations for the antibiotics are shown in Table 3.11. For S. aureus H560, 
the MBICs of ciprofloxacin and amoxicillin were identical to their MIC counterparts (0.5 
and 8.0 µg/mL, respectively). Conversely, the MBICs of vancomycin and amikacin doubled 
to 8.0 µg/mL. For S. aureus MRSA252, MBICs were identical to the MICs for all antibiotics 
tested. Finally, for S. aureus MSSA101, the MBICs of ciprofloxacin and vancomycin 
remained the same as their MIC values (0.5 and 4.0 µg/mL, respectively). However, MBICs 
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Figure 3.11: Determination of the ability of phage K to disrupt biofilm formation of A) S. aureus MRSA252, 
B) S. aureus H560 and C) S. aureus MSSA101. Reduction in biofilm biomass was quantified using crystal violet 
biofilm staining by measuring the absorbance at 590 nm. Bacteria were treated with differing concentrations of 
phage K over 18 h at 37 °C. Error bars show standard deviation (n = 3).  
 
 
Table 3.11: Minimum Biofilm Inhibitory Concentration (MBIC) of the antibiotics used in this assay 
 
Minimum Biofilm Inhibitory Concentration (µg/mL) 
S. aureus 
H560 
S. aureus  
MRSA252 
S. aureus  
MSSA101 
Ciprofloxacin 0.50 62.50 0.50 
Vancomycin 8.00 4.00 4.00 
Amoxicillin 8.00 500.00 8.00 






3.4.3.2. Biofilm Prevention 
Similar to the planktonic assays, antibiotic concentrations at ½ and ¼ MIC were used in 
combination with varying concentrations of phage K (101 – 103 PFU/mL) and added to 
suspensions of S. aureus (106 CFU/mL) before subsequent incubation at 37 °C for 18 h. The 
ability of the combinations in preventing biofilm formation was assessed using CV. 
Statistical analysis was conducted by comparing the combination in question to the control 
that had the lowest OD590 value. 1 x MIC concentrations of antibiotics and 104 PFU/mL 
phage K were used as controls to ensure correct PAS concentrations were being used. 
For S. aureus H560, all antibiotics showed a positive interaction with phage K, resulting in 
statistically significant decreases in OD590 compared to the appropriate control (Figure 
3.12). When ½ MIC ciprofloxacin was used in combination with phage K (103 and 102 
PFU/mL), it resulted in a significant reduction in OD590, corresponding to a decrease in 
biofilm biomass (t-test, p<0.01 and p<0.0001, respectively). A statistically significant 
decrease in biofilm biomass was also observed when all phage concentrations were 
combined with ¼ MIC ciprofloxacin. 
Surprisingly, when ½ MIC vancomycin was investigated, it produced a statistically 
significant reduction in OD590 (t-test, p<0.01) with all phage K concentrations. This result 
implies that while phage K and ½ MIC vancomycin combinations might not be able to kill 
S. aureus H560, they are capable of preventing the cells from forming a biofilm. However, 
this effect is concentration-dependent, as no increase in efficacy was observed when ¼ MIC 
vancomycin was used in the combination.  
A significant reduction in bacterial biomass was observed when ½ MIC amikacin was 
combined with 102 PFU/mL (t-test, p<0.001) and 101 PFU/mL (t-test, p<0.01) phage K, and 
when ¼ MIC amikacin was combined with 101 PFU/mL phage K (t-test, p<0.01). These 
results were similar to that observed with the planktonic PAS assay.  
The combinations of phage K and amoxicillin were the least effective. A significant 
reduction was only observed when ½ MIC amoxicillin was combined with 102 PFU/mL 
phage K (t-test, p<0.05). These results suggest that phage K-amoxicillin combinations are 
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Figure 3.12: Determination of the ability of phage K and/or antibiotics to inhibit biofilm formation of S. aureus 
H560 as a single therapy or in combination. Reduction in biofilm biomass was quantified using crystal violet by 
measuring the absorbance at 590 nm. Bacteria were incubated for 18 h at 37 °C prior to staining. Error bars 
show standard deviation (n = 3). Statistical analysis was conducted using a Student’s t-test, with each variable 
compared to the control which displayed the lowest OD590 value. * p < 0.05, *** p < 0.001, **** p < 0.0001 
 
The same phage-antibiotic combinations were tested on S. aureus MRSA252 (Figure 3.13). 
Favourable interactions were observed when ½ MIC ciprofloxacin was combined with 103 
and 102 PFU/mL of phage K (t-test, p<0.05 and p<0.001, respectively). Statistically 
significant decreases in bacterial biomass were also observed when ¼ MIC ciprofloxacin 
was combined with 103 and 102 PFU/mL of phage K (t-test, p<0.05 for both). For 
vancomycin, the only combination that resulted in a significant reduction in biofilm 
biomass was ½ MIC vancomycin and 103 PFU/mL of phage K (t-test, p<0.05).  
Amikacin was successful in decreasing bacterial biomass when combined with varying 
concentrations of phage K. Statistically relevant combinations included:  ½ MIC amikacin 
with 103 and 102 PFU/mL of phage K (p<0.05 for both), and ¼ MIC amikacin with 103 and 
102 PFU/mL of phage K (p<0.0001 and p<0.01, respectively). A significant reduction in 
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bacterial biomass was also observed when ½ MIC amoxicillin was combined with 102 
PFU/mL phage K (t-test, p<0.05), and when ¼ MIC amoxicillin was combined with 103 
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Figure 3.13: Determination of the ability of phage K and/or antibiotics to inhibit biofilm formation of S. aureus 
MRSA252 as a single therapy or in combination. Reduction in biofilm biomass was quantified using crystal violet 
by measuring the absorbance at 590 nm. Bacteria were incubated for 18 h at 37 °C prior to staining. Error bars 
show standard deviation (n = 3). Statistical analysis was conducted using a Student’s t-test, with each variable 
compared to the control which displayed the lowest OD590 value. * p < 0.05, *** p < 0.001, **** p < 0.0001 
Finally, the efficacy of the phage-antibiotic combinations were tested against S. 
aureus MSSA101 (Figure 3.14). All combinations tested were effective when combined with 
½ MIC or ¼ MIC ciprofloxacin, consistent with results obtained in the planktonic assay. 
When ½ MIC vancomycin was in combination with 102 PFU/mL phage K, it resulted in a 
statistically significant reduction in OD590 (t-test, p<0.01), implying that while this 
combination was not able to kill planktonic S. aureus MSSA101, it was capable of preventing 
biofilm formation. For the majority of phage K-amikacin concentrations tested, a significant 
reduction in bacterial biomass was observed; these results were better than those obtained 
for the planktonic assay. When 103 PFU/mL phage K was combined with ½ or ¼ MIC 
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amoxicillin, it resulted in statistically significant reductions in biofilm biomass (t-test, 
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Figure 3.14: Determination of the ability of phage K and/or antibiotics to inhibit biofilm formation of S. aureus 
MSSA101 as a single therapy or in combination. Reduction in biofilm biomass was quantified using crystal violet 
by measuring the absorbance at 590 nm. Bacteria were incubated for 18 h at 37 °C prior to staining. Error bars 
show standard deviation (n = 3). Statistical analysis was conducted using a Student’s t-test, with each variable 
compared to the control which displayed the lowest OD590 value. * p < 0.05, *** p < 0.001, **** p < 0.0001 
Overall, there is evidence to suggest that phage K-antibiotic combinations are capable of 
preventing S. aureus biofilms. Similar to the planktonic assays, variations in efficacy were 
observed between S. aureus isolates. Interestingly, the combination of phage K (103 or 
102 PFU/mL) and ½ MIC vancomycin was able to prevent biofilm formation of all S. aureus 
isolates tested – even though it was unable to reduce bacterial cell density of S. aureus H560 
and MSSA101 in planktonic assays. These results suggest that instances of PAS using 
planktonic bacteria may not be representative of the effects witnessed in biofilm models; 
therefore, for conclusive PAS determination both planktonic and biofilm assays should be 
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3.4.3.3. Biofilm Eradication 
Some phage are capable of targeting bacteria within a biofilm.87–91 Biofilm eradication is 
inherently harder to treat via phage therapy as the presence of the EPS shields the phage 
binding sites on the bacterial cell wall. Additionally, biofilms have a heterogeneous 
microenvironment of bacterial populations, some of which exhibit reduced metabolic 
activity or dormancy, preventing phage multiplication.89  
To the best of the authors knowledge, phage K does not possess depolymerases to help with 
biofilm eradication; however, the function of many phage genes are unknown.46,47 As such, 
phage K has been exploited in the treatment of several S. aureus and S. epidermidis 
biofilms.92–94 Owing to this, the MBEC of phage K was evaluated for all three S. 
aureus strains. However, the highest concentration of phage K (109 PFU/mL) was only 
capable of eradicating biofilms of S. aureus MRSA252 (Figure 3.15) and did not affect S. 
aureus H560 or MSSA101 (not shown); this was thought to be due to the fact that S. aureus 
MRSA252 displayed the weakest biofilm of the three isolates (as it had the lowest bacterial 
biomass measured by CV).  


























Figure 3.15: Determination of the ability of phage K to eradicate S. aureus MRSA252 biofilms. Reduction in 
biofilm biomass was quantified using crystal violet biofilm staining by measuring the absorbance at 590 nm. 
Bacteria were treated with differing concentrations of phage K over 18 h at 37 °C. Error bars show standard 
deviation (n = 3).  
As MBEC concentrations of phage K were only obtained for S. aureus MRSA252, this 
bacterial strain was used to find the MBEC concentrations of the antibiotics used in this 
assay (Figure 3.16). Amoxicillin was not used as the MBEC was above the solubility of the 
drug. All MBEC values obtained were much higher than their MIC/MBIC counterparts, with 
both ciprofloxacin and vancomycin showing an 8- and 7.75-fold increase in concentration, 
respectively. S. aureus MRSA252 biofilms had the greatest tolerance to amikacin, with a 78-
fold increase in antibiotic concentration needed to eradicate the biofilm; this result is not 
surprising as it is well known that biofilm formation confers increased resistance to 
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antibiotics. For example, it is known that ciprofloxacin has limited activity against biofilms 
as it is only effective in areas adjacent to the air-biofilm interface and not the interior of the 
biofilm. This is thought to be due to the interior of the biofilm having bacterial cells with 
reduced metabolic activity, most likely due to lack of oxygen.95  
A) B) 















































































































































































































Figure 3.16: Determination of the ability of phage K to eradicate S. aureus MRSA252 biofilms. Reduction in 
biofilm biomass was quantified using crystal violet biofilm staining by measuring the absorbance at 590 nm. 
Bacteria were treated with differing concentrations of phage K over 18 h at 37 °C. Error bars show standard 
deviation (n = 3).  
To determine if phage K-antibiotic combinations could eliminate established biofilms, 
S. aureus MRSA252 biofilms were grown in 96-well microtiter plates for 24 h, before 
subsequent incubation for an additional 24 h with combinations of 108 PFU/mL phage K 
and antibiotics at their ½ MBEC concentrations (Figure 3.17).  
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The results show that there was a decrease in biofilm biomass when phage K and ½ MBEC 
ciprofloxacin or phage K and ½ MBEC vancomycin were used in combination, compared to 
the antibiotics only (Figure 3.17).  
These results suggest that phage K can be used in combination with ciprofloxacin or 
vancomycin to help eliminate S. aureus MRSA252 biofilms. While other authors have 
reported PAS when  using phage-antibiotic combinations to treat both early and established 
biofilms,7,28,77,79 the mechanism has not been elucidated, and as such further experiments 
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Figure 3.17: Determination of the ability of ½ MBEC antibiotics and 108 PFU/mL phage K as monotherapies 
and in combination to eradicate S. aureus MRSA252 biofilms. Reduction in biofilm biomass was quantified 
using crystal violet biofilm staining by measuring the absorbance at 590 nm. Bacteria were treated with differing 
concentrations of phage K over 18 h at 37 °C. Error bars show standard deviation (n = 3). Statistical analysis was 
conducted using a Student’s t-test, with each variable compared to the control which displayed the lowest OD590 











3.5. Conclusion and Future Work 
Overall, this study shows that sub-inhibitory concentrations of phage K and antibiotics can 
act in a synergistic manner to eliminate both planktonic and biofilm S. aureus isolates. 
However, the efficacy of phage-antibiotic combinations depends on the phage, antibiotic 
and bacterial strain under investigation, with not all combinations displaying a similar 
effect across all three S. aureus isolates used in this assay. Additionally, these results found 
that planktonic bacterial cell reduction (both OD and CFU/mL measurements) could be due 
to the distressed morphology of the bacterial cells in the presence of antibiotics, although 
the mechanisms behind this are not yet fully elucidated. The presence of antibiotics did alter 
phage K’s life cycle, and result in increased burst sizes; however, increased burst sizes, and 
by extension increased phage concentration, did not necessarily result in the best phage-
antibiotic combinations to reduce bacterial cell density, and therefore these assays should 
be used in tandem with bacterial cell reduction assays (e.g. OD measurements or time-kill 
assays).  
The results presented in this chapter show that sub-inhibitory concentrations of phage K 
and antibiotics can be used in combination to prevent biofilm formation of S. aureus H560, 
MRSA252, and MSSA101. Unfortunately, to examine the ability of phage-antibiotic 
concentrations in eradicating biofilms, only S. aureus MRSA252 could be used owing to the 
phage titre not being high enough for complete biofilm eradication of S. aureus H560 and 
MSSA101. While the results looked promising, with reductions in biofilm biomass observed, 
further experiments will need to be conducted to determine whether this positive 
interaction is found for other S. aureus isolates. 
Further work must be undertaken to establish the mechanism of action of PAS. This could 
be achieved by repeating this study with different phage and/or different antibiotics and 
testing them against a library of S. aureus isolates. Additionally, further experiments should 
be undertaken to establish the bacteria’s fitness upon exposure to phage-antibiotic 
combinations to determine if “evolutionary synergy” is witnessed, whereby bacterial strains 
become more susceptible to antibiotics as they develop resistance to phage, and vice versa.  
Additionally, research has shown that sequential administration of phage and antibiotics 
promoted an enhanced PAS efficacy,18 therefore future experiments should be undertaken 
with  phage K and antibiotic combinations used in this study to see if it increases the efficacy 
of combinations such as phage K and ½ MIC vancomycin, which were previously 
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Chapter 4: Antimicrobial-loaded Poly(lactic 
acid)-poly(ethylene glycol) Films for the 
Treatment of S. aureus Infections 
4.1. Overview of Chapter 
This proof-of-concept study aimed to demonstrate the utility of antimicrobial-loaded 
poly(lactic acid)-polyethylene glycol (PLA-PEG; PPEG) films as antimicrobial wound 
dressings for the treatment of S. aureus infections.  
Herein, this chapter will discuss the physical properties of the PPEG films and the effect this 
has on the release of phage K and ciprofloxacin from these films.  Additionally, this chapter 
investigated the efficacy of the antimicrobial-loaded PPEG films against three strains of 
S. aureus using a variety of microbiological assays (suspension assays, colony biofilm 
models, and ex vivo models). Finally, experiments were conducted to determine if the 
phage-antibiotic synergy between phage K and ciprofloxacin observed in Chapter 3 could 




The name ‘polymer’ is derived from two terms, ‘poly’ meaning many, and ‘mer’ meaning 
unit,1 as polymers are macromolecules formed via the chemical bonding of repeating units 
of smaller molecules (termed monomers).2 Polymers are used in numerous industries; 
however, this chapter is going to focus on the use of polymers for biomedical applications. 







Table 4.1: Commonly used synthetic polymers and their applications. Adapted from Hill et al.1  
Polymer Application 
Poly(methylmethacrylate) 
Hard contact lenses, interocular lenses, bone 
cements, denture base 
UHMWPE (ultra-high molecular weight polyethylene Bearing surfaces in artificial joints 
Polyethylene terephthalate Artificial arteries 
Polyurethanes Catheters 
Polyhydroxyethylmethacrylate 
Soft contact lenses, wound dressings, drug release, 
matrices 
Polypropylene Sutures, heart valves, finger joints 
Silicones Breast implants, facial modifications 
Poly(glycolide) Biodegradable sutures 
 
4.2.1.1. Polymer Weight 
With the exception of biological polymers, whose molecular weight (MW) is strongly 
controlled, polymerisation results in a distribution of chain lengths, and consequently, a 
distribution of molar mass.1 Polymer MW can be calculated by either the number average 
molecular weight (Mn), or the weight average molecular weight (Mw). 
Mn counts as the total number of molecules in a unit mass of polymer, irrespective of shape 





Where Mi is the molecular weight of a chain, Ni is the number of chains of that molecular 
weight, and i is the number of polymer molecules.3 Mn is used for the determination of 
boiling point elevation, freezing point depression, vapour pressure depression, and osmotic 
pressure changes.4 
The weight average molar mass is the mass of the individual chains that contribute to the 






Where Mi is the molecular weight of a chain, Ni is the number of chains of that molecular 
weight, and i is the number of polymer molecules. Mw is typically measured by light 
scattering experiments.5    
The number of monomers within the polymer can vary greatly; however, the average 
number of monomers per polymer chain can be determined by calculating the degree of 
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polymerisation.2 The degree of polymerisation can be defined in terms of either number 








Where Mmer is the molecular weight of the monomer unit.  
Additionally, the ratio of Mw/Mn can be used to calculate the polydispersity index (PDI; 
Equation 3). PDI is used as a measure of broadness of molecular weight distribution, the 





For monodisperse polymers, where all chains are the same length, the PDI is 1; biological 
examples of this include DNA and enzyme structure. Additionally, some synthetic polymers 
(such as polystyrene used for the calibration curve) have a PDI of 1.02 – 1.10.4  
4.2.1.2. Linear, Branched, and Crosslinked Polymers 
In linear polymers, the repeating units are joined together in a chain-like arrangement and 
are often more rigid compared to branched and cross-linked polymers. Typically, they arise 
when the monomer contains a single end group; some examples include, polyethylene, 
polystyrene, and polyamides.4 
Branched polymers have side chains, which often are composed of the same monomer 
within the main polymer chain. Side chains typically arise from side reactions during 
polymerisation, and monomers with two or more end groups are more likely to support this 
branching. Often, branched polymers have a lower density due to the reduced packing 
efficiency. One of the most common examples of a branched polymer is the low-density 
poly(ethylene), often used for plastic bags, containers, and textiles, etc.4  
Finally, crosslinked polymers arise when polymer chains covalently bond to one another to 
form a  large three-dimensional network; this often changes the properties of the polymer.2 
Chemical crosslinks are generally permanent and once they arise, the polymer becomes 
thermoset in nature4 Crosslinked polymers are usually characterised by their degree of 





4.2.1.3. Copolymer Arrangements 
The simplest polymer is a homopolymer, which consists of repeating units of only one 
monomer. Copolymers are composed using monomers that differ from one another and can 
exist various sequences:1,2,4 
• Random – this is where the two monomers (A and B) do not follow any specific order 
e.g., ABABBABAAABABA. 
• Alternating – occurs when the two monomers (A and B) are arranged in an 
alternating fashion, e.g., ABABABABABABAB. 
• Block – in a block copolymer, each monomer (A or B) is grouped together and can 
be thought of as two homopolymers joined together, e.g., AAAAAAABBBBBBB. 
Copolymers are often used as adhesives, surfactants, membranes, foams, and 
cosmetics.  
4.2.1.4. Polymer Classification 
There are numerous ways in which polymers are classified – but generally speaking, they 
are usually classified according to their structure. Firstly, they are differentiated between 
inorganic and organic, dependent on if the polymer backbone contains carbon atoms. Then, 
the polymers are further classified according to the specific identity or order of the atoms 
within the polymer backbone, as well as their occurrence.2  
Inorganic polymers have a polymer backbone that contains atoms other than carbon; these 
include poly(siloxanes), poly(silazanes), poly(sulphides), etc. Conversely, organic polymers 
are more common and are generally divided into either natural or synthetic. Natural 
polymers include starch, cellulose, and glycogen, while synthetic polymers include 
poly(styrene), poly(propylene), poly(glycolic acid), and poly(lactic acid). Semi-synthetic 
polymers have also been synthesised, which are generally functionalised natural polymers, 
e.g., methylcellulose and cellulose acetate.2  
Additionally, crosslinked polymers can form a three dimensional hydrophilic network that 
swells in the presence of water, termed a hydrogel. They can exist as homopolymers or 
copolymers and are generally biocompatible due to their large water content. Hydrogels can 
be tailored to produce a wide range of swelling characteristics, dependent on the 
application, as the swelling ratio alters the properties of the polymer (diffusion rates, surface 
properties, refractive indexes, mechanical characteristics, etc).2  
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4.2.1.5. Configuration and Conformation 
The configuration of a polymer is determined by its chemical structure, while the 
conformation of a polymer relates to its three dimensional structure. Many polymers are 
composed of monomers that contain chiral centres, which is where a carbon atom has four 
different groups attached to them. Owing to this, the monomer can exist in two optical 
isomers, left handed (L) and right handed (D).1  
A polymer containing monomers with chiral centres can have different conformations upon 
polymerisation. Tacticity refers to the ordering of the polymer, describing the 
stereochemistry of the pendant groups on the polymer backbone. If the chiral centres are 
linked randomly, the polymer is termed atactic; if the chiral centres are linked with the 
substituents in an alternating fashion, the polymer is termed syndiotactic; and if the chiral 
centres are linked together with the substituents in the same relative positions, the polymer 
is termed isotactic. Generally, polymers are atactic; however, steric constraints of the 
monomers and/or specialised reaction conditions can result in isotactic and syndiotactic 
polymers1,7  
Tacticity influences the thermal and mechanical properties of the polymer, including the 
glass transition temperature (Tg), melting temperature, and solubility.1 Atactic polymers are 
generally amorphous, resulting in polymers which are less brittle than their crystalline 
counterparts, exhibiting glass-like properties below their Tg and elastomeric properties 
above the Tg. 1,7 
Crystallinity is favoured by ordered/stereoregular chains; however, no polymer is 100% 
crystalline, often containing both amorphous and crystalline regions. The degree of 
crystallinity influences the mechanical properties (e.g. Young’s modulus, toughness, and 
strength) in addition to gas permeability and water uptake of the polymer. The crystallinity 
of a homopolymer can be reduced via copolymerisation with a small amount of a second 
monomer, while conversely, crystallinity can be increased by holding a polymer above its 
Tg, but below its Tm to provide more time for crystallisation to occur.1  
Tg is calculated for amorphous, or amorphous sections of a polymer and describes the 
temperature at which there is a characteristic change in the physical properties of a polymer. 
At temperatures below the Tg, the physical property of the polymer changes to that of a 
‘glassy’ or brittle and crystalline state; however, above the Tg, the polymer exists in its 
‘rubbery’ state, with soft and flexible physical characteristics owing to the long-range 
sequential motion of the polymer chains.8,9  
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4.2.1.6. Polymer Synthesis 
Polymerisation is a process where the monomer subunits are covalently bonded together to 
produce the macromolecular polymers.7 Typically, polymer synthesis can be divided into 
addition, condensation, and ring-opening polymerisation, although other types exist (e.g., 
chain transfer and plasma polymerisation).4  
Addition polymerisation is where the polymer grows exclusively by reactions between the 
monomer(s) and the reactive site(s) on the polymer chain; monomers are added once at a 
time via a chain reaction. Polymers created using addition polymerisation are generally 
produced using unsaturated monomers containing C-C double bonds and all the monomers 
are consumed without the formation of biproducts. Common examples of polymers 
synthesised through addition polymerisation include poly(ethylene), poly(vinyl chloride), 
and poly(styrene).1,4  
In addition polymerisation, the reaction occurs via three distinct steps: chain initiation, 
chain propagation, and chain termination.5 Chain initiation occurs via the use of an initiator 
to a reactive site. This could be a radical (free radical polymerisation), cation (cationic 
polymerisation), anion (anionic polymerisation), and organometallic complexes 
(coordination polymerisation). Next, in chain propagation, the monomers attach to the 
molecular chain, propagating the chain length. Finally, the chain growth is terminated 
through the neutralisation of the reactive centre.4  
Condensation polymerisation, or step-growth polymerisation, is where two monomers are 
reacted together, and molecule is eliminated – often water. The reaction progresses in a 
step-wise manner and monomers, dimers, trimers, oligomers, etc., are able to be utilised to 
create a larger molecule.6 Often, condensation polymerisation combines two different 
components, with at least two reactive sites, in an alternating fashion. Examples include 
polyamides and polyesters, proteins, and polysaccharides.1,4  
Ring-opening polymerisation (ROP) is used in industry as it yields higher molecular weight 
polymers in a relatively short space of time. ROP utilises cyclic monomers and a 
catalyst/initiator to expedite the ring-opening process. The polymers produced by ROP are 
often linear, with a narrow molecular weight range, which is typically hard to achieve via 






4.2.2. Poly(lactic acid) 
Poly(lactic acid) (PLA) is a hydrophobic polyester, first discovered in the 1700’s by 
Scheele.10,11 PLA is composed of monomers of lactic acid, produced via fermentation of 
starch from plants (e.g. corn, sugarcane, potatoes, and beets)12 and can be synthesised by 
direct polycondensation of lactic acid, or ring-opening polymerisation of the lactide dimer 
using a suitable catalyst (Figure 4.1).13  
 
 
Figure 4.1: Structures of lactic acid, lactide and poly(lactic acid) 
 
Lactic acid is a hydroxyl acid that exists as two optical isomers (L and D) due to the presence 
of a chiral carbon.13 Therefore, PLA can exist in three optical forms: PLDA, PLLA, and 
PDLLA;14 for biological applications, the L isomer is preferred as the D isomer can  be 
harmful to human metabolism and can result in decalcification and acidosis.13  
The properties of PLA, such as the rate of degradation, are dependent on the optical form 
of the monomer and the resultant polymer’s crystallinity.15 Polymerisation using the optical 
isomers of lactide (L or D) result in a polymer chain that is approximately 40% crystalline, 
whereas polymerisation using a racemic mixture (DL) of lactic acid results in an amorphous 
polymer with low mechanical strength. As the polymer tends from crystalline to amorphous, 
the melting and glass transition temperatures decrease, resulting in an alteration of physical 
characteristics such as density, heat capacity, and rheological properties.15,16 
Drug delivery systems often use PLA  due to its biodegradability, biocompatibility, low levels 
of immunogenicity and toxicity, ease of modification (either by copolymerisation or 
functionalisation),17,18 and thermal processability10,15,19  
PLA was originally used for the repair of mandibular fractures in dogs.20 Since then, PLA 
has been used in a variety of applications in orthopaedics,21,22 cardiac 
surgery,23,24dentistry,25,26 plastic surgery,27,28 and oncology.29,30 For a more comprehensive 
review, please see Tyler et al.10  PLA has also been used for wound dressings and will be 
discussed in Section 4.2.2.1.  
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PLA is often used in combination with poly(ethylene glycol) (PEG) to increase the 
hydrophilicity, toughness, and flexibility of the PLA polymer.10,12 Additionally, the 
incorporation of PEG in PLA-PEG blends enhance the degradation rate and drug release of 
the resultant films.31 PEG is derived from the polymerisation of ethylene glycol (Figure 4.2), 
and dependent on the molecular mass of the polymer, can have a linear or branched 
structure. As PEG is hydrophilic, every PEG unit is tightly associated with two or three water 
molecules, preventing any incorporated drugs from enzymatic degradation, rapid renal 
clearance, and interactions with cell surface proteins.32,33  
 
Figure 4.2: Structure of poly(ethylene glycol) 
4.2.2.1.  Poly(lactic acid) Drug Delivery Systems 
Drug delivery systems have been used in recent years to combat issues associated with 
traditional pharmaceuticals (poor solubility, non-specific targeting, high dosage, etc.) by 
protecting the drug from the physiological environment, increasing the bioavailability or 
solubility of the drug, or controlling the release of a drug from a suitable matrix.13,19 This 
section will focus on the use of PLA or delivery systems utilising conventional antibiotics 
and/or phage therapy, with a particular focus on wound dressings.  
There have been several reports of PLA-based drug delivery systems as potential candidates 
for wound dressings.19,34 Toncheva et al  created PLA and PLA-PEG membranes containing 
a variety of antimicrobials, both as single and monotherapies. When PLA films containing 
diclofenac sodium and benzalkonium chloride were incubated with S. aureus, there were 
clear zones of lysis of 33.0 ± 13.0 mm and 27.0 ± 13.0 mm, respectively.35 Additionally, PLA 
membranes containing a combination of diclofenac sodium and lidocaine hydrochloride or 
diclofenac sodium, lidocaine hydrochloride and benzalkonium chloride resulted in zones of 
inhibition of 30.0 ± 1.1 mm and 19.0 ± 1.1 mm, respectively, when treated with S. aureus.36 
Furthermore, Han et al created electrospun PLA nanofibers containing nanoparticles 
composed of tetracycline hydrochloride blended with Fe3O4-COOH. This system displayed 
antimicrobial activity against S. aureus and E. coli, with zones of inhibitions of 25.8 ± 
1.4 mm and 23.6 ± 1.6 mm, respectively.37 While Nazari et al showed that electrospun PLA-
PEG nanofibers containing cefixime had a good release profile in the presence of graphene 




PLA films have also been used to release anti-oxidant molecules to aid in wound healing.39,40 
For example, Perumal et al created electrospun nanofibers using a blend of PLA and 
hyperbranched polyglycerol for the release of curcumin for wound healing applications. 
Their results found that the nanofibers had high hydrophilicity, swelling and drug uptake, 
which in turn led to better cell viability, adhesion, and proliferation.41  
There is currently limited literature on phage encapsulation within PLA films. Jamaledin et 
al described the synthesis of microparticles of poly(lactic-co-glycolic acid) to encapsulate 
phage, whereby the phage could be used as an antigen delivery system. Their preliminary 
results suggested that phage was stable within the microspheres and retained its 
immunogenic properties.42  Additionally, Radford et al developed two phage based xanthan 
coatings on PLA films that significantly inhibited Salmonella typhimurium and Listeria 
monocytogenes growth.43 While the latter study was investigating the use of phage-based 
systems for prolonging the life of food, there is no reason to suggest that this film could not 
be utilised in a clinical setting.  
4.2.3. Aims of Study 
This study aimed to create a proof-of-concept wound dressing demonstrating the utility of 
a PLA-PEG film containing antimicrobials as an antimicrobial wound dressing capable of 
eliminating S. aureus infections. Experiments included: 
• Optimisation of the weight ratio of PEG:PLA. Following on from this, in vitro release 
kinetics and stability of the films containing phage K/ciprofloxacin, or a 
combination of the two, will be determined.  
• Microbiological analysis of PPEG films containing phage K, ciprofloxacin, or a 
combination of the two, against three clinically relevant S. aureus species (S. aureus 
H560, MRSA252, and MSSA101). Microbiological assays included: 
o Planktonic suspension assays 
o Colony biofilm wound models  





4.3.1. Bacterial and Bacteriophage Methods 
All methods relating to growth conditions of S. aureus isolates and propagation of phage K 
were followed as outlined in Chapter 2, Section 2.2.1.3 and 2.2.3.2, unless otherwise stated. 
Enumeration of bacterial and phage cell density were performed as outlined in Chapter 2, 
Section 2.2.1.4 and 2.2.3.3. 
4.3.2. Development of the PLA-PEG System 
4.3.2.1. Creating the Polymer Blend 
Antibiotic-loaded porous films (a-PPEG) were prepared by the solvent casting method.19 
Twenty microliters of ciprofloxacin (30 mg/mL), phage K (c. 1 x 1011 PFU/mL) or a 
combination of both, were dispersed into 88.8 µL of PEG 400 and mixed into 10% w/w PLA 
in dichloromethane (DCM) homogeneously at room temperature. The weight ratio of 
PEG:PLA was 2:1. The mixtures were then poured into 10 mm diameter scintillation vials 
for casting, before being placed at -20 °C for 24 h and dried at room temperature for 4 h. 
Antibiotic-free porous films (PPEG) were also prepared as controls.   
4.3.2.1.1. Encapsulation Efficacy 
a-PPEG films were placed in 2 mL PBS (pH 7.4) and incubated for 24 h at room 
temperature. After incubation, the concentration of antimicrobial released from a-PPEG 
was calculated. For phage K, this was undertaken by determining the PFU/mL and for 
ciprofloxacin this was measured using UV-Vis, with the concentration of ciprofloxacin 
determined by use of a calibration curve. Encapsulation efficacy was calculated as follows: 
𝐸𝐸 (%) = (
𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑎𝑛𝑡𝑖𝑚𝑖𝑐𝑟𝑜𝑏𝑖𝑎𝑙 𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑
𝑇𝑜𝑡𝑎𝑙 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑎𝑛𝑡𝑖𝑚𝑖𝑐𝑟𝑜𝑏𝑖𝑎𝑙
) × 100 (5) 
4.3.2.2. Swelling and Weight Loss 
A known weight (W0) of the porous matrix was subjected to degradation measurements in 
phosphate buffer solution (PBS, pH 7.4). The measurements were undertaken at room 
temperature for 24 h, 48 h, 1, 2 and 3 weeks. At each time point, the film was collected and 
blotted with filter paper to remove excess surface water and weighted (W1), allowed to dry 
to a constant weight at 60 °C and re-weighed (W2). Water sorption (%WS) and weight loss 
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(%WL) were calculated using the following equations. The measurements were performed 
in triplicate using three separate films. 
𝑊𝑆 (%) = (
(𝑊1 − 𝑊2)
𝑊2
⁄ ) × 100 (6) 
𝑊𝐿 (%) = (
(𝑊0 − 𝑊2)
𝑊0
⁄ ) × 100 (7) 
  
4.3.3. Bacteriophage Survival 
4.3.3.1.  pH 
To determine if pH had an effect on phage titre, TSB was adjusted with 1 M NaOH/HCl to 
achieve a pH range between 2 – 10 and filter sterilised with a 0.22 µM filter before use. Stock 
phage lysates (109 PFU/mL) were diluted 10-fold into the pH-adjusted TSB and incubated 
for 1 h at room temperature. After incubation, viable phage concentration at each pH was 
determined as outlined in Chapter 2, Section 2.2.3.3.  
4.3.3.2. Dichloromethane and PEG 400 
In brief, differing concentrations of dichloromethane and PEG 400 (0 – 90% v/v) in PBS 
were prepared. Subsequently phage lysate was added to achieve a final phage concentration 
of 108 PFU/mL and incubated for 1 h at room temperature. After incubation, viable phage 
concentration was determined as outlined in Chapter 2, Section 2.2.3.3. 
4.3.3.3. Temperature 
Known concentrations of phage K in PBS (108 PFU/mL) were incubated at various 
temperatures (-20, 4, 25, 32, 37, 60 °C) for 1 h. After incubation, viable phage concentration 
was determined as outlined in Chapter 2, Section 2.2.3.3. 
4.3.4. Scanning Electron Microscopy 
The porous structure of the PPEG films were assessed by SEM. Films were stored under 
vacuum overnight to ensure complete dehydration before sputter-coating with chromium 
(Edwards S150B, 60 s) to reduce charging effects and thermal damage, prior to images being 
obtained using a scanning electron microscope (JEOL SEM6480LV) operated at 10 kV.  
4.3.5. In vitro Release Studies 
In vitro phage release studies were performed at room temperature, where phage loaded-
PPEG films were placed into 2 mL buffer (PBS; pH 7.4). At pre-determined time intervals, 
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the buffer was withdrawn and replaced with equal volume of fresh solution. The removed 
buffer was assessed for phage concentration by enumeration (Chapter 2, Section 2.2.3.3) 
and the % cumulative release of phage was calculated and plotted against time. 
In vitro ciprofloxacin release studies were carried out as outlined above, with slight 
modifications. To assess ciprofloxacin concentration at each time point, the absorbance of 
the removed buffer was monitored using a UV-Vis spectrophotometer (Shimadzu UV-1800) 
and transformed into ciprofloxacin concentration by use of a calibration curve. The 
cumulative release of ciprofloxacin from films was calculated and plotted as a function of 
time.  
All in vitro release studies were carried out using three independent films and 100% 
cumulative release referred to the amount of therapeutic released from the uncoated PPEG 
after 24 h in the buffer solution (PBS, pH 7.4).  
4.3.6. Stability 
The stability of the films at 25 °C was also investigated. Briefly, a-PPEG films were created 
and placed in a 12-well microtiter plate for up to five days. At pre-determined time intervals, 
the a-PPEG films were submerged in 2 mL of PBS (pH 7.4.) for 24 h prior to phage 
enumeration and/or determination of ciprofloxacin concentration using methods outlined 
in Section 4.3.5. 
4.3.7. Microbiological Testing 
4.3.7.1. Suspension Assays 
Overnight cultures of three Staphylococcus spp., S. aureus H560, S. aureus MRSA252 and 
S. aureus MSSA101 were prepared as outlined in Chapter 2, Section 2.2.1.3. After dilution 
to an optical density of 0.2 (c. 108 CFU/mL) in PBS, the cultures were further diluted 10-fold 
into fresh TSB medium. After inoculation, antimicrobial free and antimicrobial loaded 
PPEG films, along with the relevant controls (phage K, ciprofloxacin, or a combination of 
both) were added to the relevant cultures. The bacteria were allowed to grow at 32 °C with 
150 rpm shaking for 24 h. After incubation, the bacterial and phage (if required) 
concentrations were determined as outlined in Chapter 2, Section 2.2.1.4 and Section 




4.3.7.2. Colony Biofilm Wound Model 
The colony biofilms were prepared as outlined in Chapter 2, Section 2.2.2.2. After 
inoculation of the polycarbonate membrane with AWF and bacterial culture (c 106 
CFU/mL), the membrane was left to dry at room temperature for approximately 15 minutes. 
Once dry, a-PPEG films were placed on top of the inoculated membranes and incubated at 
32 °C for 24  h. After incubation, the biofilms were stripped and enumerated as outlined in 
Chapter 2, Section 2.2.1.4  
4.3.7.3. Ex vivo Porcine Skin Models 
4.3.7.3.1. Sterilisation 
Porcine skin was washed to remove dirt and contamination and shaved to remove hair. 
After, the skin was cut into 2 x 2 cm squares and stored at -20 °C. When needed, skin was 
thawed overnight at 4 °C, before sonication for 15 min (44 KHz) in sterile dH2O; this was 
repeated three times. After, the skin was soaked for 15 min in 70% ethanol (EtOH) and 
underwent a further two rounds of 15 min sonication (44 KHz) in sterile dH2O. Finally, the 
skin was UV-sterilised for 10 min prior to use.  
4.3.7.3.2. Optimisation 
Sterilised porcine skin was placed into 10 mL PBS and sonicated for 15 min (44 KHz). Next, 
100 µL was spread onto TSA plates in duplicate, and subsequently incubated for 24 h at 
32 °C. Porcine skin was considered sufficiently free of bacteria if < 20 colonies were present. 
To assess for bacterial recovery, sterilised skin was placed onto bacteriological agar and 
10 µL of optically-adjusted S. aureus (c. 108 CFU/mL; Chapter 2, Section 2.2.1.3) was 
spotted onto the skin and left to dry at room temperature for 20 min. Once dry, the skin was 
removed from the agar, and placed into 10 mL of PBS. Then, the skin underwent a 15 min 
cycle of sonication (44 KHz), before being enumerated (Chapter 2, Section 2.2.1.4) and 
compared to the CFU/mL of the stock bacterial suspension. To circumvent any microbial 
contamination, mannitol salt agar was used in tandem with TSA for enumeration of S. 
aureus colonies.   
4.3.7.3.3. Microbiological Assay 
Sterilised skin was placed onto bacteriological agar and 10 µL of optically-adjusted S. aureus 
(c. 108 CFU/mL; Chapter 2, Section 2.2.1.3) was spotted onto the skin and left to dry at room 
temperature for 20 min. Once dry, 10 µL of the antimicrobial (phage K and/or ciprofloxacin) 
was spotted onto the skin and left to dry for a further 20 min at room temperature. The skin 
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was then placed into a sterile container and incubated at 32 °C for 24 h. After incubation, 
the skin was removed from the agar, placed into 10 mL of PBS, and sonicated (44 KHz) for 
15 minutes prior to enumeration (Chapter 2, Section 2.2.1.4). A sterilisation control (porcine 
skin without the addition of S. aureus) and a bacteria-only control (S. aureus and PBS) were 
carried out in tandem. In cases where phage were used, PFU/mL was also determined as 
outlined in (Chapter 2, Section 2.2.3.3). The assay was repeated in triplicate, and to 
circumvent any microbial contamination, mannitol salt agar was used in tandem with TSA 





4.4. Results and Discussion 
4.4.1. PLA-PEG (PPEG) Films 
The PPEG film was created via polymer blending of PLA and PEG. Polymer blending can be 
used to overcome the inherent disadvantages of PLA (poor toughness, low degradation rate, 
high hydrophobicity)44–46 by blending it with another polymer (such as PEG) to create a 
system with a more favourable morphology and physical characteristics.12,15  
Polymer blends can 47be prepared by either solvent blending or melt blending. Solvent 
blending is where the polymers are dissolved in a co-solvent and processed to form the end 
material before evaporation of the solvent; this method is useful for polymer films and 
porous materials.12,48 Melt blending is achieved through the use of a melt extruder and the 
melt-blended polymers can be cast into films via compression.12  
Polymer blends is dictated by the Gibbs-free energy equation (Equation 8): 
𝑑𝐺𝑀 =  𝑑𝐻𝑀 − 𝑇𝑑𝑆𝑀 
(8) 
 
Where dGM, dHM, and dSM are energy, enthalpy, and entropy of mixing, respectively. dG 
must be < 0 for two or more polymers to be miscible.  
Upon removal of either temperature or solvent during blend formation, phase separation 
occurs,49 and the extent of this separation dictates the morphology of the resulting blend. 
Work conducted by Phaechamud et al investigated the formation of the PLA-PEG polymer 
blends and found that PLA-PEG in DCM changed from solution into a porous film via a two-
step process (liquid-liquid phase separations and solidification). Liquid-liquid phase 
separation was thought to occur due to the increase in Gibbs free energy of the system  upon 
addition of a non-solvent (PEG 400), causing some solvent evaporation and the formation 
of a polymer concentration gradient. The liquid-liquid phase separation led to an 
interpenetrating network structure of polymer-rich and polymer-poor phases and 
continued until the two phases were combined in a stable condition with the lowest free 
energy prior to solidification; the porous structure of the PLA matric was created once the 






4.4.1.1. Pore Size 
Porosity is advantageous for wound dressings as it can help to reduce the wound contact 
area, avoiding adherence when the wound is dried. Generally, the smaller the pore size and 
porosity, the less painful the dressing change is. However, the optimum pore size and 
porosity depends on the wound type and application of the dressing as it affect other 
properties of the dressing, including the water vapour transmission rate, oxygen 
transmission rate, and drug release (if loaded with an antimicrobial).19,51  
The formation of the  PLA-PEG (PPEG) films created in this study was based on previous 
work conducted by Chitrattha et al.19 The initial weight ratio of PEG:PLA used was 1.5:1; 
however, this led to minimal release of phage from the polymer (data not shown). This was 
attributed to the lack of flexibility within the polymer; hence, the weight ratio of PEG:PLA 
was increased to 2:1.19  
The PPEG film was highly porous in nature, similar to other reports in literature (Figure 
4.3).19 Nevertheless, the pore size observed in this study was heterogenous in nature, 
primarily due to rate of DCM evaporation from the films. The porosity of the film could be 
altered using different temperatures/humidities during the solvent evaporation stage. 
However, as phage were successfully released from this film (further details below) it was 
deemed sufficient for this proof-of-concept design. Future experiments could be conducted 
















4.4.1.2. Weight Loss and Water Sorption 
The % weight loss (%WL) and % water sorption (%WS) of the PPEG films are shown in 
Figure 4.4. After 24 h, the weight loss of the polymer was ~58% and a corresponding water 
sorption of ~240% was observed. After this time, the %WL and %WS remained relatively 
stable, with values of ~60% and ~250%, respectively. Once again, these results are similar 
to those observed in literature, and substantially higher than PLA only.19 These results 
indicate the importance of PEG within this PPEG blend, increasing the hydrophilic nature 
of the film, while promoting degradation, and therefore release of any encapsulated 
materials.  







































Figure 4.4: In vitro degradation profiles of A) %WL and B) %WS of the PPEG film. n = 3, error bars indicate 
standard deviation 
4.4.2. Bacteriophage-loaded Films 
4.4.2.1. Bacteriophage Survival 
As phage are proteinaceous, they are susceptible to degradation by stimuli such as organic 
solvents and extreme temperatures. As the creation of the PPEG films required the use of 
DCM, PEG 400, and temperatures ranging from -20 and 60 °C, it was imperative to 
determine phage viability under these conditions (Figure 4.5).  
Upon incubation with varying concentrations of DCM (% v/v) in PBS, the phage K 
concentration remained comparable to the control (phage K in PBS). This agrees with other 
literature sources, who have shown that phage remain viable upon incubation with high 
concentrations of organic solvent such as DCM and chloroform (CHCl3).52 Although, this 
depends on the type of phage used, as there have been instances where phage have degraded 
in the presence of organic solvents. For example, Jurczak-Kurek et al. found that the their 
isolated phage degraded upon exposure to acetone and 50% (v/v) DMSO, while they were 
resistant to degradation from chloroform.53  
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Next, the viability of phage K was investigated in the presence of PEG 400. As PEG 8000 is 
commonly used for phage precipitation to achieve higher titres, and there have been 
examples where PEG has been used as a delivery material of phage, it was assumed that 
there would be minimal effect on phage K viability.54 Surprisingly, Figure 4.5 shows a 
significant decrease in phage titre upon PEG 400 concentrations of 80% v/v (t-test, p<0.05) 
and 90% v/v (t-test, p<0.01), compared to the control. However, this decrease in phage 
concentration was not clinically significant, as it only corresponded to a log reduction of 
0.49 and 0.73, respectively. Therefore, the decrease in concentration would not drastically 
impact the viability of phage K within the PPEG film, hence, was used in this proof-of-
concept study.  
A) B) 


































































Figure 4.5:  Phage K survival in the presence of increasing concentrations of A) DCM, and B) PEG 400. n = 3, 
error bars indicate standard deviation. Statistical analysis conducted using a One-way ANOVA. * p<0.05, 
**p<0.01 
The original methodology stated that the films had to be stored at -20 °C for 24 h prior to 
drying at 60 °C for a further 24 h.19 Phage viability is strongly dependent on temperature, 
with many studies showing decreased phage viability at higher temperatures.  
To assess this, phage K was incubated in PBS at varying temperatures between -20 °C to 
60 °C for 1 h before enumeration to determine phage survival. As shown in Figure 4.6, 
incubation at 60 °C for 1 h significantly reduced phage concentration by 5.5 log compared 
to the control (incubation at 4 °C). As this is a large reduction in phage K viability, the 
methodology was changed so that the phage K-loaded PPEG films were dried at room 
temperature for 4 h prior to use. Additionally, these results showed that phage K has good 
survival at clinically significant temperatures. For example, phage K concentration 
remained stable when incubated at 32 °C, which is the temperature of healthy skin. This is 
a promising result as it indicates that phage K would be a viable topical antimicrobial 
capable of eliminating S. aureus at the wound bed.   
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Figure 4.6:  Phage K survival after 1 h incubation in PBS at varying temperatures. n = 3, error bars indicate 
standard deviation. Statistical analysis conducted using a One-way ANOVA. **** p<0.0001 
4.4.2.2. Encapsulation Efficacy and In vitro Release 
Phage K was successfully encapsulated within the PPEG film, so the next step was to 
quantify the encapsulation efficacy and in vitro release of phage K from this film. The 
encapsulation efficacy was determined using Equation 5 and found to be 1.71 ± 1.08% 
(assuming 100% of phage K is released after 24 h). While this value initially seems 
disappointing, it corresponds to a 2-log reduction in viable phage K after incorporation into 
the PPEG film. Using the results shown above, it is possible to assume that 1-log reduction 
arose due to external environmental impacts on the phage survival, predominately 
incubation with PEG 400. The other 1-log reduction could be attributed to the formation of 
the film at -20 °C; the semi-crystalline nature of the PPEG film could affect the protein 
structure of phage K, ultimately reducing viability as its structure is intrinsically linked to 
its survival. Additionally, error could be due to the methodology used to determine 
encapsulation efficacy. The method used in this study assumes that all viable phage would 
be released from the PPEG film after 24 h incubation, when in fact, there could be viable 
phage still trapped within the film unable to diffuse out. Therefore, the ‘true’ encapsulation 
efficacy could be higher than what was obtained experimentally in this study; however, 
these phage would have minimal clinical effect as they would not be able to target the 
pathogenic bacteria. The encapsulation efficacy could be improved by introducing sugars 
into the preparation, e.g., maltose and sucrose to prevent phage denaturation upon 
formation of the film as they ‘coat’ the phage to protect their protein structure.  
Next, the in vitro release of phage K was determined, with 100% incubation defined as the 
phage concentration after 24 h incubation in PBS (pH 7.4; Figure 4.7). There was a rapid 
release of phage K from the PPEG polymer, with almost a 4 log PFU/mL release of phage K 
into the PBS upon contact with the buffer. After 2 h incubation with PBS, approximately 
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80% of phage K were released (3.86 x 107 CFU/mL), rising to 90% release after 6 h 
incubation with PBS (4.20 x 107 CFU/mL).  
A) B) 







































Figure 4.7: A) Log PFU/mL and B) % Cumulative release in vitro release profiles of phage K from PPEG films 
in PBS (pH 7.4, 25 °C). n = 3, error bars indicate standard deviation 
 
Next, mathematical models were used to evaluate the release kinetics of the PPEG system 
for phage K release. According to Table 4.2, the release profile observed in Figure 4.7 most 
closely resembled that of the Higuchi model of drug release. Higuchi developed this method 
based on the release of a drug from a thin ointment film (planar systems), therefore there 
are several assumptions including:55 
• The matrix contains an initial drug concentration much higher that the solubility of 
the drug 
• The diffusion is unidirectional 
• The thickness of the matrix is much larger than the size of the drug molecules 
• The swelling or dissociation of the matrix is negligible 
• The diffusivity of the drug is constant 
• The perfect sink conditions are attained in the release environment.  
As the initial rate of reaction happened relatively quickly, with the majority of phage 
released after 2 h, it was hypothesised that the swelling of the PPEG film at this time point 




Higuchi’s model for drug release can be described using the following equation: 
𝑓1 = 𝑄 = √
𝐷𝜀
𝜏
(2𝐶 −  𝜀𝐶𝑠)𝐶𝑠𝑡 
(9) 
Where Q is the amount of drug release on time t by area unit, ε is the porosity of matrix, τ 
is the capillary tortuosity factor, C is the initial amount of drug contained in the dosage form, 
Cs is the solubility of the active agent in the matrix medium, and D is the diffusion coefficient 
in the matrix medium.  
Hence, the amount of drug released is proportional to the square root of time: 
𝑓1 = 𝑄 = 𝐾𝐻√𝑡 (10) 
 
Where KH is the release constant of Higuchi 
This result was consistent with previous reports in literature and suggests that the release 
of phage K was governed by simple diffusion upon penetration of the solvent into the 
polymer matrix.19,50,56  
Table 4.2: Kinetic model and corresponding R2 value for the release of phage K from the PPEG system (PBS, 
pH 7.4). 
Kinetic Model R2 value 
Zero order 0.8692 






The stability of the phage K-loaded film at 25 °C was measured over 5 days in PBS (pH 7.4); 
room temperature was chosen for consistency. The results of this stability assay found that 
there was no significant decrease in phage K concentration at day 5 compared to day 0; 
therefore, phage K were stable within the PPEG polymer matrix (Figure 4.8). In fact, there 
was a statistically significant increase in phage K concentration (t-test, p<0.05), but this 
only corresponded to a 0.50 log increase in PFU/mL count, which could be attributed to 
discrepancies in loading concentration, as well as human error within the assay. This result 
was promising, as it suggests that phage K-PPEG films remain stable for long periods of 
time, making it a suitable candidate for a wound dressing as it could be created en masse.  
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However, further experiments would need to be undertaken over a longer time period to 
confirm the long-term stability of phage K within the PPEG matrix. Additionally, future 
experiments could investigate the effect of storing the PPEG-loaded films at different 


















Figure 4.8:  Phage K survival after 5 days incubation at room temperature within the PPEG film. n = 3, error 
bars indicate standard deviation. Statistical analysis conducted using a t-test. * p<0.05 
4.4.2.4. Suspension Assays 
With these promising results in hand, attention shifted towards testing the antimicrobial 
efficacy of phage K-PPEG films against planktonic suspensions of S. aureus H560, 
MRSA252, and MSSA101 (initial starting concentration of 106 CFU/mL; MOI of 0.1). The 
results displayed in Figure 4.9, show that for S. aureus H560, MRSA252, and MSSA101 
there was a >6-log reduction in viable count when the bacterial suspensions were incubated 
with phage K-PPEG films compared to the control, often reaching the limit of detection of 
the assay. These results were comparable to when phage K was used in a suspension as the 
control, indicating that there is no loss in efficacy of the phage K entrapped within the PPEG 
film when targeting planktonic bacteria. The PPEG film without any phage K did not result 
in any statistical reduction in bacterial density for S. aureus MRSA252 and MSSA101. For 
S. aureus H560, there was a statistically significant decrease in bacterial concentration 
(One-way ANOVA, p<0.01). However, this corresponded to a 0.14 log reduction in bacterial 
count, which was not clinically relevant.  
When assessing the log reductions in Figure 4.9, it is possible to conclude that the system 
behaves as an antimicrobial as the log reduction is ≥3, meeting the requirement set out by 






















































Figure 4.9: Log CFU/mL counts of A) S. aureus H560, B) S. aureus MRSA252, and C) S. aureus MSSA101 
upon incubation with PPEG films, phage K-PPEG films, and suspensions of phage K (c. 107 CFU/mL) for 24 h 
at 32°C. n = 3, error bars indicate standard deviation. Statistical analysis conducted using a One-way ANOVA  
 
Phage K were successfully released from the PPEG film and able to infect and multiply 
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Figure 4.10: Log PFU/mL of phage K released from the pH-responsive films and the phage K control after 
incubation with S. aureus H560, MRSA252, and MSSA101 for 24 h at 32°C. n = 3, error bars indicate standard 
deviation. Statistical analysis conducted using multiple t-tests. *p<0.05 
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The concentration of phage K was similar to that observed for the control, with the exception 
of when the phage K-PPEG film was incubated with S. aureus MRSA252, as the phage K 
concentration was greater than the control (t-test, p<0.05), most likely due to the variation 
in loading and environmental variation within the assay.  
4.4.2.5. Colony Biofilm Wound Model 
As the majority of bacteria within wounds exist within biofilms,58–60 it was important to 
determine if the phage K-PPEG film was capable of preventing biofilm formation through 
the use of a modified colony biofilm model. This model is a static system where colonies are 
grown over agar; it mimics biofilm development at the air-sold interface, with nutrient 
enrichment occurring from below and gaseous exchange occurring at the top of biofilm – as 
observed in wounds. Additionally, this model maintains the basic biofilm characteristics 
such as a structured environment and chemical gradients. This model is advantageous as is 
reproducible and amenable to high-throughput screening.61  
In this study, the colony biofilm model involved adding AWF onto 19 mm polycarbonate 
membranes, before subsequent inoculation with 50 µL of bacterial suspension. Once dry, 
the films were then placed on top of the membranes and incubated at 32 °C for 24 h; the 
incubation temperature of 32 °C was used to mimic healthy skin surface temperature.  
The results displayed in Figure 4.11 show that for S. aureus H560 there was a statistically 
significant decrease in biofilm concentration after incubation with phage K-PPEG films 
compared to the biofilm-only control (3.44 log reduction; One-way ANOVA, p<0.0001). 
This was a remarkable result as this log reduction is greater than the recommended >3 log 
reduction in the prEN 16756 standard, demonstrating the clinical utility of the phage K-
PPEG films. Additionally, there was no significant decrease in bacterial viability when S. 
aureus H560 was treated with the un-loaded PPEG films, indicating that any therapeutic 
benefit of these films was a result of the encapsulated phage K, and not the polymer itself.  
A similar effect was observed, albeit to a lesser extent, when S. aureus MRSA252 was 
incubated with phage K-PPEG films, exhibiting a 3.13 log reduction in cell density (One-
way ANOVA, p<0.001). While this effect was slightly lower than what was observed from 
the phage K control, it was still greater than the 3 log reduction recommended in prEN 
16756 standard. Once again, there was no statistically significant decrease in bacterial 
concentration when S. aureus MRSA252 was incubated with the PPEG control; therefore, 




For S. aureus MSSA101, there was a 2.79 log reduction of bacterial viability upon incubation 
with phage K-PPEG films. Unlike the previous bacterial strains, this did not meet the 
threshold of the 3-log reduction recommended by the prEN 16756 standard. However, the 
reduction in bacterial cell density was still significant when compared to the biofilm-only 
control (One-way ANOVA, p<0.001). Like the previous bacterial strains tested, the log 
reduction of S. aureus MSSA101 was lower compared to the phage K-only control and the 
PPEG film without phage K encapsulation did not statistically significantly reduce the 
biofilm density of S. aureus MSSA101; therefore, the therapeutic activity was due to the 
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Figure 4.11: Log CFU/membrane counts of A) S. aureus H560, B) S. aureus MRSA252, and C) S. aureus 
MSSA101 biofilms upon incubation with PPEG films, phage K-PPEG films, and suspensions of phage K (c. 107 
CFU/mL) for 24 h at 32°C. n = 3, error bars indicate standard deviation. Statistical analysis conducted using a 







4.4.2.6. Ex vivo Porcine Skin Models 
Ex vivo studies are advantageous over in vitro assays as the latter cannot always be 
correlated with results obtained in real-life situations.62,63 Ex vivo studies refer to 
experiments using tissues and performed under conditions mimicking real-world 
environments, overcoming some of the limitations associated with in vitro testing, while 
allowing for controlled experiments to be undertaken in an ethically responsible way.63,64 
Porcine skin has been used as a model for human skin,65 especially in the fields of wound 
healing66,67 and burns.66 Several studies have assessed the capability of porcine skin as an 
ex vivo model.66 Porcine skin is histologically similar to that of human skin,68 with the 
stratum corneum (SC) thickness (20 – 26 μm) and complete epidermis (30 – 140 μm) 
comparable to that of humans.66 Additionally, the average hair-follicle density in porcine 
ear skin is 20/cm2 compared to 14 – 32/cm2 in human forehead skin,68 and  the blood supply 
in the dermis of pigs is similar to that of humans.66 Porcine skin has been shown to produce 
reproducible results in a large number of studies. Other similarities are highlighted in Table 
4.3.  
Table 4.3: Comparison of human and porcine skin, adapted from Summerfield et al66 
 Human Pig 
Skin attachment Firmly attached Firmly attached 
Hair coat Sparse Sparse 
Epidermis Thick Thick 
Dermis Thick Thick 
Panniculus carnosus Absent Absent 
Healing mechanism Re-epithelization Re-epithelization 
 
Using the skin as a substrate for bacterial proliferation would produce a biofilm that more 
closely resembles that of a biofilm found within wounds. Yang et al outlined that bacterial 
biofilms should remain on the “wound bed” and not penetrate through to the bottom of the 
explants.67  
The ex vivo porcine skin experiments conducted in this study utilised bacteriological agar 
to provide moisture to the porcine skin, preventing the skin from drying out. Bacteriological 
agar was used over the traditional Franz cell experiments due to the quantity of samples 
that required assessment and the limited amount of Franz cells in the laboratory. In this 
model we placed the 2 x 2 cm sterilised porcine skin onto bacteriological agar before 
inoculation with S. aureus bacterial strains. Once dry, the films were placed on top of the 
porcine skin and incubated at 32 °C for 24 h. After incubation, these samples were placed 
into 5 mL of PBS and sonicated before enumeration.  
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To determine the effect of the recovery of S. aureus bacterial density, optimisation 
experiments were performed. Porcine skin inoculated with S. aureus H560 was 
immediately vortexed and enumerated, and subsequently compared to the bacterial 
concentration of the initial S. aureus suspension (Figure 4.12).  
There was no statistical difference in bacterial concentration of the recovered S. aureus 
H560 suspension compared to the initial S. aureus H560 suspension. This result highlights 
that the recovery method used in this ex vivo testing has negligible influence on bacterial 
cell density; therefore, any reduction in concentration witnessed in the subsequent 


















Figure 4.12: Log CFU/mL counts of the initial S. aureus H560 suspension, and the S. aureus H560 suspension 
after recovery from porcine skin. n = 3, error bars indicate standard deviation. Statistical analysis conducted 
using a t-test, no significance found 
 
When S. aureus H560 inoculated on porcine skin was incubated with PPEG, there was a 
slight reduction in bacterial density (0.83 log reduction, Figure 4.13). This decrease in 
bacterial viability could be due to reduced oxygen transmission through the film required 
for optimal S. aureus survival as they are aerobic; however, further experiments must be 
conducted before any hypothesis can be made. When S. aureus H560 was incubated with 
phage K-PPEG there was no significant reduction in bacterial density compared to 
incubation with PPEG only; therefore, any reduction in bacterial concentration was due to 
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Figure 4.13: Log CFU/mL counts of A) S. aureus H560, B) S. aureus MRSA252, and C) S. aureus MSSA101 
on porcine skin incubated with PPEG films and phage K-PPEG films for 24 h at 32°C. n = 3, error bars indicate 
standard deviation. Statistical analysis conducted using a One-way ANOVA. *p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001 
A similar observation was witnessed for S. aureus MRSA252, with no significant reduction 
in bacterial cell density witnessed when S. aureus MRSA252 was incubated with PPEG and 
phage K-PPEG (log reductions of 0.04 and 0.34, respectively, compared to the bacteria-only 
control). This experiment highlights how important it is to conduct ex vivo experiments, as 
phage K-PPEG films demonstrated good activity against planktonic and biofilm models of 
S. aureus MRSA252. However, based on these ex vivo results, the ability of phage K-PPEG 
films to eliminate S. aureus MRSA252 infections real-world setting might be low, reducing 
its clinical utility. 
Interestingly, phage K-PPEG films were able to statistically significantly reduce the bacterial 
concentration of S. aureus MSSA101 on porcine skin (1.08 log reduction vs bacteria-only 
control). This was due to the phage K, as the PPEG film did not statistically significantly 
reduce the bacterial concentration (0.22 log reduction vs bacteria-only control). This result 
was surprising, as previously, phage K-PPEG films were less effective in treating S. aureus 
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MSSA101 biofilms compared to the other two S. aureus strains under investigation. Again, 
this further supports the need for ex vivo testing, as results obtained in vitro may not 
correlate to real-life efficacy. 
Another interesting result witnessed was that of the phage K titres after S. aureus incubation 
with phage K-PPEG films (Figure 4.14). While phage K-PPEG films did not reduce S. aureus 
H560 and MRSA252 bacterial concentrations, phage K were successfully released and able 
to replicate to achieve concentrations of 7.63 and 9.00 Log PFU/mL, respectively. 
Conversely, phage K-PPEG films were capable of reducing S. aureus MSSA101 cell density; 
however, there was a lower phage K concentration observed of 6.57 Log PFU/mL. Further 
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Figure 4.14: Log PFU/mL counts of phage K after 24 h incubation of phage K-PPEG films on S. aureus H560, 
MRSA252, and MSSA101 at 32°C. n = 3, error bars indicate standard deviation. Statistical analysis conducted 
using a One-way ANOVA. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 
 
4.4.3. Ciprofloxacin-loaded Films 
While the results of the phage K-PPEG films were promising, their utility in clinical 
environments was questionable due to poor ex vivo results. In order to improve the efficacy 
of the films, our attention turned to incorporating conventional antimicrobials into the film, 
in the hope of creating a system that utilises the phage-antibiotic synergy witnessed in the 
previous chapter (Chapter 3). Owing to this, ciprofloxacin was chosen as it displayed the 
best PAS across all three S. aureus isolates tested. However, before combining the 
antimicrobials in the PPEG film, experiments were conducted to determine the efficacy of 
ciprofloxacin-loaded PPEG films in inhibiting the growth of the S. aureus strains studied, 
which will be discussed further in this section.  
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4.4.3.1. Encapsulation and in vitro Release 
It is possible to determine the concentration of ciprofloxacin using a UV-Vis 
spectrophotometer, due to its absorbance characteristic peak at ~270 nm. Owing to this a 
calibration curve was created using varying concentrations of ciprofloxacin (0 – 40 µg/mL; 
Figure 4.15).  
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Figure 4.15: A) UV-Vis spectra and B) corresponding calibration curve of increasing concentrations of 
ciprofloxacin-HCl (0 – 40 µg/mL) in PBS (pH 7.4) at 25 °C. n = 3, error bars indicate standard deviation. Y  = 
0.08947x + 0.06151, R2 0.9986 
 
In vitro release kinetics was determined for ciprofloxacin release from PPEG films at 25 °C. 
As shown in Figure 4.16, there was a rapid release of ciprofloxacin from the PPEG films, 
with over 80% of ciprofloxacin released after 1 h, rising to 98% released after 6 h incubation 
in PBS (pH 7.4).  
After 24 h incubation in PBS, ciprofloxacin-PPEG films released 411.67 ± 21.62 µg/mL of 
ciprofloxacin. As the loading concentration was 824.18 µg/mL, this corresponded to an 
encapsulation efficacy of 49.95 ± 2.62% (assuming 100% of ciprofloxacin is released after 
24 h). Again, while this encapsulation efficacy is quite low, it is still above the MIC for all 
three bacterial isolates tested (Chapter 3). Therefore, this encapsulation efficacy was 





























Figure 4.16: % Cumulative release in vitro release profile of ciprofloxacin from PPEG films in PBS (pH 7.4, 25 
°C). n = 3, error bars indicate standard deviation 
Mathematical models were used to evaluate the release kinetics of ciprofloxacin release 
from the PPEG system. According to Table 4.3, the release profile observed in Figure 4.16 
most closely resembled that of the Higuchi model of drug release, as seen for the phage K 
release in Figure 4.7. This was in agreement with results observed in literature, with 
Chitrattha et al for metronidazole and gentamicin release from PPEG films.19 However, this 
system does not fit all of Higuchi’s assumptions, as the ciprofloxacin concentration loaded 
into the film was not higher than the solubility of the drug; it was in fact, the maximum 
soluble concentration (30 µg/mL). Owing to this, it might not be possible to use this release 
model for this system, and therefore, the drug release may be modelled using zero-order 
kinetics.  
The zero order model outlines the process of constant drug release from a drug delivery 
system and can be modelled using the following equation: 
𝐶0 − 𝐶𝑡 = 𝐾0𝑡 (11) 
 
Where Ct is the amount of drug released at time t, C0 is the initial concentration of the drug 
t=0, K0 is the zero-order rate constant. 
Both the Higuchi and zero order methods are diffusion controlled; hence, it can be 
suggested that the release of ciprofloxacin was governed by simple diffusion upon 
penetration of the solvent into the polymer matrix.19 To further confirm the release profile, 
this experiment should be repeated, with focus placed on the early time points, perhaps 
measuring every 30 seconds for the first 10 minutes to get a more accurate insight into the 
rapid release of ciprofloxacin from this matrix.  
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Table 4.3 Kinetic model and corresponding R2 value for the release of ciprofloxacin from PPEG system (PBS 
pH 7.4) 
Kinetic Model R2 value 
Zero order 0.8975 





4.4.3.2. Stability  
The stability of the ciprofloxacin-loaded film at 25 °C was measured over 5 days in PBS (pH 
7.4). The results of this stability assay found that there was a significant decrease in 
ciprofloxacin concentration at day 5 compared to day 0 (t-test, p<0.0001); Figure 4.17). This 
result was surprising as phage K had previously shown to be stable and ciprofloxacin in 
combination with phage K was stable of the course of 5 days (Chapter 4, Section 4.4.2.3). 
While the reduction in ciprofloxacin concentration was significant, the concentration was 
higher than the MIC for all bacterial isolates under investigation, so, in theory, should still 
display antibacterial activity towards the bacterial isolates. However, this experiment 
should be repeated as it doesn’t follow the trend observed for the other two systems 
discussed in this chapter and could have been a result of loading-error upon fabrication of 



























Figure 4.17:  Concentration of ciprofloxacin after 5 days incubation at room temperature within the PPEG film. 





4.4.3.3. Suspension Assays 
Firstly, planktonic suspensions of S. aureus isolates were treated with ciprofloxacin-loaded 
PPEG films and the results obtained compared to the bacteria-only and ciprofloxacin-only 
controls. As 10 mL of S. aureus suspensions were used, it is important to note that 
ciprofloxacin concentration was diluted 10-fold in broth, hence the final concentration of 
ciprofloxacin released from the PPEG films was 41.17µg/mL; the concentration of 
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Figure 4.18: Log CFU/mL counts of A) S. aureus H560, B) S. aureus MRSA252, and C) S. aureus MSSA101 
upon incubation with PPEG films, ciprofloxacin-PPEG films, and ciprofloxacin control for 24 h at 32°C. n = 3, 
error bars indicate standard deviation. Statistical analysis conducted using a One-way ANOVA, *p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001 
 
The ciprofloxacin-PPEG films were successful in treating S. aureus H560 (7.62 log 
reduction compared to bacteria-only control; One-way ANOVA, p<0.0001; Figure 4.18A), 
resulting in a greater log reduction compared to the ciprofloxacin-only control (5.88 log 
reduction compared to the bacteria-only control; One-way ANOVA, p<0.0001) due to the 
higher amount of ciprofloxacin released from the PPEG films. There was no statistically 
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significant decrease in bacterial concentration with the un-loaded PPEG films; hence, the 
reduction in cell density was solely due to the release of ciprofloxacin from the films. This 
phenomenon was also observed for S. aureus MSSA101, with log reductions of  0.05, 6.92 
(One-way ANOVA, p<0.0001), and 4.90 (One-way ANOVA, p<0.0001) compared to the 
bacteria control for PPEG, ciprofloxacin-PPEG, and ciprofloxacin, respectively (Figure 
4.18C). 
For S. aureus MRSA252 there was minimal reduction of bacterial cell density when S. 
aureus MRSA252 was incubated with ciprofloxacin-PPEG (0.91 log reduction compared to 
bacteria-only control; One-way ANOVA, p<0.001; Figure 4.18B ). This was due to the 
ciprofloxacin concentration released being lower than the MIC value for S. aureus 
MRSA252 (62.50 µg/mL; Chapter 3).  
4.4.3.4. Colony Biofilm Wound Model 
Next, the efficacy of ciprofloxacin-PPEG films was investigated using in vitro wound biofilm 
models (Figure 4.19). The ciprofloxacin-PPEG films resulted in a 3.82 log reduction 
compared to the biofilm control (One-way ANOVA, p<0.0001), higher than the 3-log 
reduction recommended by the prEN 16756 standard. As before, there was minimal 
reduction in biofilm density for the PPEG film compared to the biofilm, suggesting that any 
reduction in cell density was due to the therapeutic and not the film itself.  
Like the suspension assays, there was minimal reduction in S. aureus MRSA252 biofilms 
upon incubation with ciprofloxacin-loaded PPEG films (0.84 log reduction compared to the 
biofilm control; One-way ANOVA, p<0.01). While this result is surprising, as the MBIC 
determined in Chapter 3 was 62.50 µg/mL, and the concentration of ciprofloxacin in the 
PPEG film and the control was 411.67 µg/mL and 400 µg/mL, respectively, it could be due 
to using the colony biofilm model, rather than the 96-well plates that were used to 
determine the MBIC values. As the biofilm under investigation within this study is based on 
the colony biofilm model, the biofilm produced could be more robust, and hence more 
tolerant, to antimicrobials compared to biofilms produced in a 96-well plate. However, 
further experiments should be performed to support this.  
For S. aureus MSSA101, there was a 3.49 log reduction compared to the biofilm control 
(One-way ANOVA, p<0.0001), which was higher than the 3-log reduction recommended by 
the prEN 16756 standard. Like S. aureus H560 and MRSA252, there was minimal reduction 
in bacterial cell density when S. aureus MSSA101 was incubated with the PPEG film, 
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Figure 4.19: Log CFU/membrane counts of A) S. aureus H560, B) S. aureus MRSA252, and C) S. aureus 
MSSA101 biofilms upon incubation with PPEG films, and ciprofloxacin-PPEG films for 24 h at 32°C. n = 3, error 
bars indicate standard deviation. Statistical analysis conducted using a One-way ANOVA. *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001 
4.4.3.5. Ex vivo Porcine Skin Models 
Finally, ex vivo porcine skin studies were conducted (Figure 4.20). For S. aureus H560, 
there was a slight decrease in bacterial cell concentration observed when S. aureus H560 
was incubated with PPEG films (0.83 log reduction compared to biofilm control), further 
increasing to 3.77 log reduction compared to the biofilm control when incubated with 
ciprofloxacin-PPEG films (One-way ANOVA, p<0.01). This was exciting, as it showed 
clinical significance in a real-world setting as outlined by the prEN 16756 standard.` 
For S. aureus MRSA252, there was minimal change in bacterial cell density when S. aureus 
MRSA252 was incubated with PPEG and ciprofloxacin-PPEG films compared to the 
bacteria-only control (0.04 and 0.05 log reduction, respectively). This result is not 
surprising, as all previous experiments using ciprofloxacin-loaded films for the treatment 
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of S. aureus MRSA252 planktonic and biofilm bacteria did not display any meaningful 
reduction in bacterial cell count. 
Finally, for S. aureus MSSA101, there was a minimal reduction in bacterial cell density upon 
incubation with the PPEG film (0.22 log reduction compared to the bacteria-only control) 
and a 1.4 log reduction compared to the bacteria-only control when incubated with 
ciprofloxacin-PPEG films (One-way ANOVA, p<0.001). While these results do not reach the 
3 log reduction ‘gold standard’ as outlined in the prEN 16756 standard, it is still a promising 

























































Figure 4.20: Log CFU/mL counts of A) S. aureus H560, B) S. aureus MRSA252, and C) S. aureus MSSA101 
on porcine skin incubated with PPEG films and ciprofloxacin-PPEG films for 24 h at 32°C. n = 3, error bars 







4.4.4. Combination-loaded Films 
4.4.4.1. Stability 
Phage K was stable in the PPEG film containing a combination of ciprofloxacin and phage 
K for up to 5 days, with no statistically significant decrease in phage K concentration 
observed compared to day 0 (Figure 4.21). However, there was a statistically significant 
reduction in ciprofloxacin concentration after 5 days incubation at 25 °C compared to the 
day 0 control (t-test, p<0.05), but this only responded to a loss of 8.23 µg/mL, which was 
not deemed clinically significant.  
Overall, this result shows that phage K was stable in the presence of ciprofloxacin, which 
was an effect that was not observed in Chapter 3. Therefore, it can be suggested that the 
PPEG film offers some protection of the phage from the inhibitory effects of ciprofloxacin, 











































Figure 4.21:  Concentration of A) phage K (displayed as Log PFU/mL) and B) ciprofloxacin after 5 days 
incubation at room temperature within the PPEG film. n = 3, error bars indicate standard deviation. Statistical 
analysis conducted using a t-test. **** p<0.05 
4.4.4.2. Suspension Assay 
The combination of ciprofloxacin and phage K within PPEG films was evaluated (Figure 
4.22). For these experiments, the maximum concentration of phage K and ciprofloxacin 
were used (109 PFU/mL and 824.18 µg/mL, respectively), rather than PAS combinations 
used in Chapter 3, so the results could be compared with the monotherapy results obtained 
in the earlier sections.  
For all bacterial strains tested, there was minimal reduction in bacterial density when the 
bacterial isolates were incubated with the PPEG films compared to the bacterial control (log 
reductions of 0.14, 0.09, and 0.05 for S. aureus H560, MRSA252, and MSSA101, 
144 
 
respectively). Therefore, any reduction in bacterial concentration was due to the 
combination therapy of phage K and ciprofloxacin.  
For S. aureus H560, there was a statistically significant decrease in bacterial concentration 
when incubated with PPEG films loaded with phage K and ciprofloxacin (5.88 log reduction 
compared to bacteria-only control; One-way ANOVA, p<0.0001), which was comparable to 
the combination therapy control (5.29 log reduction compared to bacteria control; One-way 
ANOVA, p<0.0001).  
For S. aureus MRSA252, there was a statistically significant decrease in bacterial 
concentration when incubated with PPEG films loaded with phage K and ciprofloxacin (3.41 
log reduction compared to the bacterial control; One-way ANOVA, p<0.0001). However, 
this was less effective than using the combination of phage K and ciprofloxacin in a 
suspension, as the control resulted in a 5.26 log reduction compared to the bacteria-only 
control (One-way ANOVA, p<0.0001).  
Finally, for S. aureus MSSA101, there was a statistically significant decrease in bacterial 
concentration when incubated with PPEG films loaded with phage K and ciprofloxacin (5.05 
log reduction compared to bacteria-only control; One-way ANOVA, p<0.0001), which was 
1-log lower than the combination therapy control (6.66 log reduction compared to bacteria 
control; One-way ANOVA, p<0.0001).  
These results were interesting, as the monotherapies (bar ciprofloxacin for S. aureus 
MRSA252) achieved log reductions of ~7 compared to the control, which was far higher 
than what was observed when phage K and ciprofloxacin were used in combination. One 
reason for this antagonistic interaction could be due to the higher concentrations of phage 
and ciprofloxacin used. PAS has been shown to be more effective when applied sequentially 
(e.g. phage first then the antimicrobial) as this gives the phage time to adsorb and replicate 
within the host bacterium. However, if high concentrations of antimicrobials are used in 
tandem, and have a quicker mechanism of action compared to phage, then they can 
eliminate the bacteria before the phage have chance to infect them, resulting in a non-
productive phage infection. However, it is worth noting that the combination met the 
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Figure 4.22: Log CFU/mL counts of A) S. aureus H560, B) S. aureus MRSA252, and C) S. aureus MSSA101 
upon incubation with PPEG films, phage K and ciprofloxacin-PPEG films, and suspensions of phage K and 
ciprofloxacin (107 CFU/mL and 30 µg/mL, respectively) for 24 h at 32°C. n = 3, error bars indicate standard 
deviation. Statistical analysis conducted using a One-way ANOVA.  
The corresponding phage concentrations are shown in Figure 4.23. Overall, for S. aureus 
H560 and MSSA101, the phage K concentrations were lower than what was observed for the 
monotherapy phage K-PPEG films. This could be due to ciprofloxacin being released faster 
than phage K, leading to a non-productive phage infection. For both these bacterial species, 
the phage K concentrations were similar to the control. While the concentration of phage K 
was statistically significantly higher in the combination-PPEG group compared to the 
control (t-test, p<0.05) for S. aureus H560, this was most likely due to the variation in 
loading and environmental variation within the assay and the release kinetics from the 
system.  
For S. aureus MRSA252, the phage K concentrations were similar to that observed for the 
monotherapy PPEGs. This was probably due to ciprofloxacin being less effective towards 
this bacterial strain, resulting in more time for phage K to launch a successful infection of 
S. aureus MRSA252 cells. Similarly to S. aureus H560, the concentration of phage K was 
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statistically significantly higher in the combination control group compared to the 
combination-PPEG film (t-test, p<0.05); this was most likely due to the variation in the 
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Figure 4.23: Log PFU/mL of phage K released from the pH-responsive films and the phage K control after 
incubation with S. aureus H560, MRSA252, and MSSA101 for 24 h at 32°C. n = 3, error bars indicate standard 
deviation. Statistical analysis conducted using multiple t-tests. *p<0.05 
4.4.4.3. Colony Biofilm Wound Model 
Next, the efficacy of phage K and ciprofloxacin-loaded films was assessed using a colony 
biofilm model of S. aureus isolates (Figure 4.24).  
PPEG films loaded with phage K and ciprofloxacin were most effective against S. aureus 
H560, achieving a log reduction of 5.95 compared to the biofilm control (One-way ANOVA, 
p<0.0001). However, it is important to note that in this experiment, the PPEG film resulted 
in a 1.19 log reduction compared to the biofilm control (One-way ANOVA, p<0.05), hence 
had slightly inhibitory effects towards S. aureus H560.  
For S. aureus MRSA252, there was a slight reduction in biofilm count upon incubation with 
the PPEG film (0.91 log reduction compared to biofilm control; One-way ANOVA, p<0.05). 
This was further increased when the PPEG film contained the combination of phage K and 
ciprofloxacin, with the log reduction rising to 2.22 compared to the biofilm control (One-
way ANOVA, p<0.001).  
For S. aureus MSSA101, there was negligible difference in bacterial concentration upon 
incubation with the PPEG films (0.37 log reduction compared to the biofilm control). 
However, upon S. aureus MSSA101 incubation with the combination of phage K and 
ciprofloxacin, a log reduction of 3.23 was observed compared to the biofilm control (One-








































































Figure 4.24: Log CFU/membrane counts of A) S. aureus H560, B) S. aureus MRSA252, and C) S. aureus 
MSSA101 biofilms upon incubation with PPEG films, phage K and ciprofloxacin-PPEG films for 24 h at 32°C. n 
= 3, error bars indicate standard deviation. Statistical analysis conducted using a One-way ANOVA. *p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001 
The combination therapy released from the PPEG film led to a greater than 3 log reduction 
in bacterial density for S. aureus H560 and MSSA101, therefore met the threshold 
recommended by the prEN 16756 standard.  
4.4.4.4. Ex vivo Porcine Skin Model  
Finally, the PPEG films containing phage K and ciprofloxacin were tested against S. aureus 
isolates inoculated on porcine skin (Figure 4.25). For S. aureus H560, there was a 0.83 and 
4.44 (One-way ANOVA, p<0.001) log reduction in bacterial concentration compared to the 
bacterial control for the PPEG and combination-PPEG films, respectively. For S. aureus 
MRSA252, there was a 0.04 and 1.91 (One-way ANOVA, p<0.001) log reduction in bacterial 
concentration compared to the bacterial control for the PPEG and combination-PPEG films, 
respectively. For S. aureus MSSA101, there was a 0.22 and 3.98 (One-way ANOVA, 
p<0.001) log reduction in bacterial concentration compared to the bacterial control for the 
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PPEG and combination-PPEG films, respectively.  It is worth noting, that for S. aureus 
H560 and MSSA101, the combination therapy released from the PPEG film led to a greater 
than 3 log reduction in bacterial density; therefore met the threshold recommended by the 

























































Figure 4.25: Log CFU/mL counts of A) S. aureus H560, B) S. aureus MRSA252, and C) S. aureus MSSA101 
on porcine skin incubated with PPEG films and phage K and ciprofloxacin-PPEG films for 24 h at 32°C. n = 3, 
error bars indicate standard deviation. Statistical analysis conducted using a One-way ANOVA. *p<0.05, 





4.5. Conclusions and Future Work  
This proof-of-concept study demonstrated the utility of PLA-PEG (PPEG) films as 
antimicrobial wound dressings for the treatment of S. aureus infections.  
Experiments showed that both phage K and ciprofloxacin were released from the PPEG 
matrix in a diffusion based manner, owing to the fast rate of release and/or the large pore 
size of the film in comparison to the size of the antimicrobials. Phage K was shown to be 
stable within the film for over 5 days at room temperature, demonstrating its utility as a 
wound dressing as it could have a long shelf-life. Additionally, phage K viability remained 
when incubated with ciprofloxacin, which was not observed when the two antibiotics were 
incubated together in solution in Chapter 3, suggesting that the PPEG film offers phage K 
some protection against the inhibitory effects of ciprofloxacin. Conversely, reductions in 
ciprofloxacin concentration were observed, and owing to this, further experiments would 
need to be investigated to determine if this was due to antimicrobial loading within this 
study, or due to passive diffusion of the ciprofloxacin out of the PPEG matrix.  
PPEG films containing phage K or ciprofloxacin demonstrated good efficacy in planktonic 
and biofilm suspensions, often meeting the ‘gold standard’ of a 3-log reduction compared 
to their corresponding bacterial control. However, their clinical utility was questionable, 
with poor results obtained using the ex vivo porcine skin model. To overcome this, PPEG 
films were made which combined phage K and ciprofloxacin in the hope of increasing the 
efficacy of the antimicrobial film. While the PPEG films containing phage K and 
ciprofloxacin displayed statistically significant reductions in bacterial density of S. aureus 
H560, MRSA252 and MSSA101 in planktonic and biofilm assays, they were lower than what 
was observed for the monotherapies. This agonistic effect was attributed to the 
concentrations of ciprofloxacin and phage K used and their conflicting mechanism of 
actions. However, surprisingly, the combination was more successful in eliminating S. 
aureus infections on porcine skin, demonstrating superior clinical efficacy compared to the 
monotherapies.  
This chapter only described a proof-of-concept system, therefore, there remain many 
experiments that could be conducted to optimise the system. Firstly, experiments could be 
conducted to investigate the role of pore size in release kinetics. Secondly, to improve phage 
K encapsulation, the role of adding in sugars to the phage solution to protect the protein 
structure should be investigated. Experiments should also be conducted to further 
investigate the weight ratio of PEG:PLA, to see if further increasing the PEG component 
results in better release profiles of phage K and ciprofloxacin. Additionally, the 
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concentrations of phage K and ciprofloxacin should be investigated when used in 
combination to see if it is possible to get an additive or synergistic interaction between the 
two antimicrobials.  
Furthermore, there was a clear difference in in vitro and ex vivo results for all 
antimicrobials tested, whether that be enhanced or reduced efficacy in ex vivo testing 
compared to in vitro. Therefore, it is important that further tests are conducted to evaluate 
the clinical utility of the antimicrobial-loaded PPEG films. In addition to those previously 
mentioned this could involve using more robust biofilm models, repeating the current ex 
vivo porcine skin methodology to gain better power for the statistical analysis, or use in vivo 
mouse models, which will also investigate the immune response to this system.  
Overall, these results show that antimicrobials can be incorporated within PLA-PEG films, 
whether that be phage or conventional antibiotics, and are capable of reducing S. aureus 
density. While further work must be carried out to optimise these films, this Chapter has 
demonstrated their utility as an antibiotic wound dressing. Furthermore, this system can be 
optimised to contain different antimicrobials to treat a variety of different microbial 
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Chapter 5: Triggered Release of Bacteriophage 
K and Ciprofloxacin from a pH-Responsive 
System 
5.1. Overview of Chapter 
This chapter describes the creation of a novel, pH-responsive wound dressing to treat 
S. aureus infections. The PLA-PEG (PPEG) film created and analysed in Chapter 4 was 
capped with a pH-responsive polymer, EUDRAGIT® FS 30 D – a co-polymer of methyl 
acrylate, methyl methacrylate and methacrylic acid. Upon an increase in pH above pH 7.0, 
the polymer swells, releasing phage K and/or ciprofloxacin that were encapsulated within 
the PPEG reservoir (Figure 5.1).  
This chapter assessed the stability and release profiles of phage K and/or ciprofloxacin upon 
incubation of the pH-responsive system in buffer solutions of pH 6.5 and pH 8.0, 
respectively. Further experiments investigated the relationship between pH and S. aureus 
biofilm formation and evaluated the release of the therapeutic from the pH-responsive 
system upon incubation with developing S. aureus biofilms.  
 
 
Figure 5.1: Schematic of a novel pH-responsive wound dressing for the treatment of chronic wounds. Upon an 
increase in pH above pH 7, the pH-responsive polymer becomes soluble and swells, resulting in the release of 
the therapeutic (phage K and/or ciprofloxacin) to treat S. aureus infections 
 
EUDRAGIT® 




5.2.1. pH  
pH is an inverse logarithmic measure of the thermodynamic activity of hydrogen ions (a 
[H+]) in solution. For solutions containing a low concentration of H+, the activity of 
hydrogen ions can be correlated to the concentration of hydrogen ions (Equation 1):1 
𝑝𝐻 =  − log10 𝛼{𝐻
+} ≈  −log10 [𝐻
+] (1) 
   
Typically, the logarithmic pH scale ranges from 0 – 14, although negative pH values have 
been recorded; solutions with a pH <7 are acidic ([H+] > [OH-]), solutions with a pH ~7 are 
neutral ([H+] = [OH-]), and solutions >7 are alkaline ([H+] < [OH-]).1  
5.2.1.1. Acid and Bases 
Acids and bases have free hydrogen and hydroxyl ions, respectively. A Brønsted-Lowry acid 
is defined as a proton donor, while a Brønsted-Lowry base is a proton accepter. In an acid-
base reaction, there is a transfer of a proton amongst the conjugate acid-base pairs.  
The strength of the Brønsted-Lowry acid is dependent on the acid’s ability to donate a 
proton and dissociate into ions (protons [H+] and anions [A-]). A strong acid can fully 
dissociate and donate a proton, whereas a weak acid has a lower tendency to donate a proton 
and is thus only partially ionised in aqueous solution. The strength of the acid in solution 
can be calculated by determining the acid dissociation constant (Ka), which is the 








The larger the value of Ka, the further the equilibrium lies to the right, the stronger the acid 
as it results in a higher dissociation of the acid. Ka can be expressed in terms of pKa; the 
lower the pKa value, the stronger the acid (Equation 3).  
𝑝𝐾𝑎 =  − log10 𝐾𝑎 (3) 
 
As previously mentioned, a Brønsted-Lowry base is a proton accepter; a strong base is fully 
ionised in aqueous solutions whereas a weak base has a lower tendency to accept a proton 
and is only partially ionised in aqueous solutions. Similarly to Brønsted-Lowry acids, a base 
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dissociation constant (Kb) can be calculated to determine the strength of the base (Equation 
4). The larger the value of Kb, the stronger the base. Kb can also be expressed in terms of 
pKb, with stronger bases having a higher pKb value (Equation 5). However, usually, the 








𝑝𝐾𝑏 =  − log10 𝐾𝑏  (5) 
5.2.1.2. Buffer Solutions 
Buffer solutions are solutions that can resist changes in pH. The Henderson-Hasselbalch 
equation is often used to show that the pH of the buffer solution is dependent on the value 
of Ka and the ratio of the [conjugate base] to [acid]. Generally, the equilibrium established 
in a weak acid is: 











Substituting into the equation for pH (Equation 5) gives,  












Substituting in pKa gives,  






Which can be re-written as: 







5.2.2. Wound pH 
Healthy skin was found to be acidic by E. Heuss in 18922  and was confirmed through further 
studies aided by the invention of the planar glass electrode in 1955.3 It is more appropriate 
to refer to skin pH as ‘apparent skin pH’ as the stratum corneum is not an aqueous solution; 
the hydrogen ions measured when evaluating skin pH are actually released by components 
of the stratum corneum (e.g., lipids and secretions from sebaceous and sweat glands).4,5  
Various values for skin pH have been reported in literature; however, they generally vary 
between pH 4.0 and 6.0.6–8 This discrepancy in pH values can be attributed to the lack of a 
standardised protocol for pH determination, anatomical location of the skin under 
investigation, and even the sex of the patient, with some studies showing that female skin is 
more acidic compared to male skin;9 however, this is  disputed in other studies.10–12 
Interestingly, there seems to be no difference in skin pH observed between different ethnic 
groups,13–15 but apparent skin pH varies with age, with neonates and the elderly often having 
an elevated skin pH.12,16,17 Fluhr et al  categorised skin pH according to anatomical location 
and found that regions with a higher density of sebaceous glands had slightly elevated pH 
values (pH 5.8 – 6.6),17 thought to be due to the high humidity within these areas decreasing 
the production of urocanic acid.10,17  
Increases in skin pH arise due to a variety of reasons; skin disorders such as eczema, atopic 
dermatitis, and irritant contact dermatitis can result in the disruption of the skin barrier 
function, consequently leading to higher pH values compared to healthy skin.17,18 
Additionally, the use of cleansers, detergents and cosmetics can alter the apparent pH of the 
skin, often causing a transient increase in pH.6 
The acidic mantle of the skin is essential in regulating the normal flora of the skin, 
preventing infection by pathogenic bacteria8 through the production of bacteriocins, toxic 
metabolites, depletion of essential nutrients, induction of a low reduction-oxidation 
potential, inhibition of translocation, and induction of the host to enhance antibody and 
cytokine production and stimulation of phagocytosis.19 The commensal flora of the skin are 
able to survive in these acidic conditions, while the growth of pathogenic bacteria is 
restricted. For example, Propionibacterium, a commensal bacterium, grows well between  
pH 6.0 – 6.5; however, pathogenic bacteria such as S. aureus have an optimum pH of 7.5 





5.2.2.1. Wound Healing and pH 
Any injury to the skin leads to a localised loss of the stratum corneum, bleeding, and 
exposure of internal tissue and interstitial fluid, all of which result in an elevated pH of the 
skin (between pH 7.0 – 8.0). In a non-infected acute wound, as the wound heals the pH 
decreases due to various factors including hypoxia and increased production of lactic acid8 
as the stratum corneum is repaired, restoring the acidic mantle of the skin.7 Conversely, 
non-healing chronic wounds have been shown to be more alkaline compared to acute 
wounds, with pH values between 7.2 – 8.9,21 and even as high as 9.3.22 These wounds do not 
transverse to an acidic pH, with alkalinity observed for a long period of time, often months.22 
Roberts et al found that the mean apparent pH of venous leg ulcers was significantly lower 
in the healing group compared to the non-healing group23 and Leveen et al found that the 
non-healing nature of surface wounds was correlated with alkaline pH.24 
The elevated pH of chronic wounds alters the biochemical reactions and cellular processes 
involved in wound healing,8,25 affecting oxygen release, angiogenesis, protease activity, 
bacterial toxicity, and antimicrobial activity.2122 For a more detailed review, please see 
Wallace et al. 22 
5.2.2.2. Microbial Biofilms and pH 
The elevated pH within chronic wounds creates an optimum environment for colonisation 
by pathogenic bacteria.8,25 It is generally accepted that pathogenic bacteria require a pH of 
>6.0 for successful proliferation, with lower pH values inhibiting the proliferation of such 
bacteria. Additionally, it has been found that the colonisation of pathogenic bacteria can 
cause the wound to become more alkaline in nature, thus perpetuating proliferation.25   
One of the most frequently cited studies involving pH in wound care is that by Tsukada et 
al,26 who found that pressure injuries tend towards an acidic pH as the wound progresses 
towards healing. As such, one of the current theories to combat chronic wound infections is 
to restore the skin to an acidic pH.22,27–29 An interventional clinical study found that 
cleansing with acidic mineral water caused a greater decrease in bacterial load compared to 
cleansing with water with a neutral pH.30 Additionally Strohal et al found that topical 
acidification of chronic wounds led to decreased microbial bioburden and decreased wound 
size; however, they did not use any controls and hence cannot be used to evaluate the 
effectiveness of acidification of chronic wounds.31 Modulation of wound pH from alkaline 
(pH 9.0) to an acidic pH by daily application of 1% acetic acid was investigated by Agrawal 
et al  and resulted in a decrease in pathogenic microorganisms and improved wound healing 
outcomes.32 While these results show that an acidic environment results in greater infection 
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control, increased oxygenation, and reduction of the toxicity of bacterial by-products,22 one 
of the drawbacks of this method is the longevity of the acidic solution. For instance, the 
moist wound dressings that contained 1% acetic acid remained acidic for only one hour, 
after which the pH rises to neutrality or above.24 In a clinical environment, a wound dressing 
can remain in situ on the wound for up to seven days; hence, acidification would need to be 
consistent throughout this time period. Therefore, there is a growing need to develop 
materials that can sense the pH of a wound environment, and release antimicrobials to treat 
the infection only when needed; this prevents the unnecessary use of antimicrobials when 
the wound is healing in a normal fashion (tending to acidic pH) and clinical intervention is 
not needed.  
5.2.2.3. Antimicrobials and pH 
pH has been shown to affect the activity of antiseptics8 and the bactericidal activity of 
antimicrobial agents.33 For example, hypochlorite requires twice as long to kill 
microorganisms at pH 8.0 compared to pH 6.0.34 pH has also been shown to affect the 
antimicrobial activity of silver, with a lower pH resulting in enhanced activity of silver (ionic 
silver) in wound dressings.35,36 Aminoglycoside antibiotics are also affected by pH, with 
gentamicin demonstrating a 90-fold increase in efficacy at pH 7.8 compared to pH 5.5.25 As 
chronic wounds almost certainly contain a biofilm requiring clinical intervention,37–39 the 
effect of pH must be considered when choosing the appropriate antimicrobial therapy.  
5.2.3. Triggered Release Systems 
The ideal antimicrobial wound dressing should release its therapeutic load in response to 
an active infection at a high enough local concentration for a set duration in order to 
eliminate the pathogenic bacteria present at the infection site.40  
To achieve this, many environmentally-responsive polymers (or ‘smart’ polymers) have 
been developed that release their therapeutic payload in response to an external stimulus. 
Often, the stimuli are physical (e.g., temperature, ultrasound, light, magnetic and electrical 
fields) or chemical (e.g., pH, redox potential, ionic strength, and chemical agents) in nature. 
Physical stimuli often induce a response by modulating the energy level of the 
polymer/solvent system, while chemical stimuli act by altering the molecular interactions 





5.2.3.1. Response Systems Based on Temperature 
The most widely reported trigger is temperature, owing to its applicability in drug delivery 
applications.40–42 One of the most reported thermo-responsive polymers is poly(N-
isopropylacrylamide) (PNIPAM), which undergoes a reversible, entropically driven phase 
transition at a lower critical solution temperature (LCST) of approximately 32 °C that leads 
to the expulsion of water and a change in polymer volume.43 Below the LCST, PNIPAM 
exists as a hydrophilic coil as water molecules are arranged in an ordered state in the local 
environment of the polymer chain.44,45 Above the LCST, there is a change in the 
hydrophilic/hydrophobic balance of the polymer chain and polymer-polymer hydrophobic 
interactions dominate.44,46 Consequently, the polymer chains collapse, and the water 
molecules are expelled from the bulk, resulting in PNIPAM existing as a hydrophobic 
globule.44 
Hathaway et al created a thermo-responsive wound dressing utilising PNIPAM 
copolymerised with allylamine (PNIPAM-co-ALA) for the selective release of phage K. 
PNIPAM was chosen as temperatures above the LCST were associated with a bacterial skin 
infection. The results found that upon incubation at temperatures above the LCST (37 °C), 
phage K-incorporated PNIPAM-co-ALA nanospheres successfully lysed S. aureus ST288, 
while at temperatures below the LCST (25 °C) bacterial growth was unaffected.47 The 
researchers further investigated the release of a combination of a truncated phage 
endolysin, CHAPK, and lysostaphin, from PNIPAM nanoparticles, and found similar results 
to their previous study; above the LCST temperature, bacterial inhibition was observed, 
whereas at temperatures below the LCST, the bacterial growth was unaffected.48  
5.2.3.2. Response Systems Based on Enzymes and Toxins 
Enzyme-responsive drug delivery systems release their therapeutic payload upon enzymatic 
degradation of the ‘smart’ polymer.49,50 Particular focus has been placed on proteases as 
triggers due to their over-expression in infectious diseases and cancer.42 Additionally, 
trypsin and hyaluronidase have been used to selectively deliver anticancer agents inside 
cancer cells.51 Bean et al also utilised hyaluronidase as a trigger to selectively release phage 
K from a dual-layer system by degrading the hyaluronic acid ‘capping’ layer.52 
Thet et al developed biosensors for the detection of S. aureus and P. aeruginosa. Briefly, 
carboxyfluorescein was entrapped within vesicles that degraded in response to 
toxin/enzyme production by the pathogenic bacteria, resulting in a fluorescence “turn-on” 
response. The selectivity of the system was due to the modification of the vesicles; by 
altering the composition of lipids and fatty acids within the membrane, the vesicles were 
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sensitised to either toxin production by S. aureus (delta toxin), enzyme production by P. 
aeruginosa (phospholipase), or both.53 Laabei et al went on to use the S. aureus-targeting 
phospholipid vesicles to develop a new method to determine agr activity,54 while Thet et al, 
went on to further develop the sensor and recently published preliminary results from a 
pilot clinical study. The probe is now named SPaCE in accordance with the sensor being 
able to detect S. aureus, P. aeruginosa, Candida albicans/auris, and Enterococcus faecalis, 
and was found to have a sensitivity of 57% and specificity of 71%. 55 
Enzymes have been used extensively for the selective ‘turn on’ for fluorescent and 
colorimetric probes. For a more detailed review, please see Chapter 7.  
5.2.3.3. Response Systems Based on pH 
pH has been used as a trigger for ‘smart’ drug delivery systems due to the variation of pH 
within the body, for instance, the stomach has a high acidic pH of approximately pH 2.0, 
whereas the small intestine has an alkaline pH of approximately 6.2 – 7.5. Additionally, it 
has been proven that diseased or inflamed tissue have a different pH profile compared to 
normal tissue,56 for example tumours have been reported to produce acidic conditions in 
the extracellular milieu (pH ~ 6.5).57 
Several researchers have created polymers that are responsive towards changes in the pH 
of the extracellular environment.40,58,59 Researchers have created pH-responsive hydrogels 
containing poly(methacrylic acid) grafted with PEG for oral protein delivery; the polymer 
hydrogel was capable of encapsulating, protecting and mediating the release of insulin,60 
calcitonin,61 and interferon beta.62 Additionally, Milo et al has successfully utilised pH to 
treat Proteus mirabilis (P. mirabilis) infections for the treatment of catheter-associated 
urinary tract infections (CAUTIs). P. mirabilis secretes urease, which in turn increases the 
urinary pH, leading to the formation of struvite and apatite crystals that become lodged in 
the biofilm and result in the blockage of urine flow through the catheter.63  The researchers 
developed a dual-layered system where a hydrogel layer containing phage was capped with 
a trigger layer of the pH-responsive poly(methyl methacrylate-co-methacrylic acid) 
(EUDRAGIT® S 100). Upon the increase in pH by P. mirabilis, phage was released from the 
technology and the time to catheter blockage doubled (13 h vs 26 h). Conversely, the 
coatings were stable in the absence of infection and in the presence of urease-negative 
bacteria.63 Milo et al went on to create an infection-detection system using this system, 
swapping out phage for the fluorescent carboxyfluorescein, and showed its effectiveness as 
a coating on the catheter64 and as a lozenge placed within the catheter drainage bag.65  
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Recently, Rasool et al have created chitosan/poly(N-vinyl-2-pyrrolidone)-based, pH-
sensitive hydrogels that exhibited increased swelling with increasing pH, resulting in the 
controlled release of silver sulfadiazine.66 Wallace et al have also developed pH-responsive 
wound dressings utilising EUDRAGIT® FS 30 D for the treatment of P. aeruginosa biofilms 
within chronic wounds. The wound dressing successfully resulted in a statistically 
significant decrease in P. aeruginosa biofilm density after 24 h incubation at  32 °C 
compared to the untreated control [manuscripts under preparation].  
5.2.4. Aims of Study 
This study aimed to create a proof-of-concept wound dressing to demonstrate the utility of 
an antimicrobial-loaded, pH-responsive system for the treatment of S. aureus infections 
within non-healing wounds where clinical intervention is needed. Experiments included: 
• Investigation of the relationship between pH and S. aureus biofilm formation 
• Development of a pH-responsive system, utilising a pH-responsive polymer 
EUDRAGIT® FS 30 D.  
• In vitro release kinetics of phage K or ciprofloxacin from the pH-responsive system 
at pH 8.0 
• Stability of antimicrobial-loaded pH-responsive system at pH 6.5 
• Microbiological analysis of the antimicrobial-loaded pH-responsive system against 






5.3.1. Bacterial and Bacteriophage Methods 
All methods relating to growth conditions and enumeration of S. aureus isolates and 
propagation of phage K were followed as outlined in Chapter 2,  Section 2.2.1.3 and 2.2.3.1 
unless otherwise stated.  
5.3.2. Evaluation of Biofilm pH 
Biofilms were prepared as outlined in Chapter 2, Section 2.2.2.2. The pH of the developing 
biofilm was measured every 2 h using a flat top surface pH electrode (VWR). After each pH 
measurement, the biofilm was stripped and enumerated as outlined in Chapter 2, Section 
2.2.1.4  
5.3.3. Development of a pH-responsive System 
Antibiotic-loaded PLA-PEG (a-PPEG) films were prepared as outlined in Chapter 4, Section 
4.3.2.1. To create the dip-coat solution, EUDRAGIT® FS 30 D was added to acetone in a 
ratio of 1:5 and stirred until dissolved. For dip-coating, the PPEG polymers were fully 
submerged in the dip-coat solution for approximately 1 s before drying at room temperature 
for 5 min to allow for the evaporation of acetone. This process was repeated up to a 
maximum of 50 times to create the pH-responsive system. After dip-coating, the films were 
allowed to dry for 1 h at room temperature before subsequent use.  
5.3.4. Bacteriophage Survival 
5.3.4.1.  pH 
To determine if pH had an effect on phage titre, TSB was adjusted with 1 M NaOH/HCl to 
achieve a pH range between 2.0 – 10.0 and filter sterilised with a 0.22 µM filter before use. 
Stock phage lysates (109 PFU/mL) were diluted 10-fold into the pH-adjusted TSB and 
incubated for 1 h at room temperature. After incubation, viable phage concentration at each 
pH was determined as outlined in Chapter 2, Section 2.2.3.3.   
5.3.4.2. Organic Solvents  
The organic solvent used in this chapter was acetone ((CH3)2CO), and the protocol was 
followed as in Chapter 4, Section 4.3.3.2.  
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5.3.5. In vitro Release Profiles 
In vitro release studies for phage K and ciprofloxacin were performed as described in 
Chapter 4, Section 4.3.5. The only modification to the assay is the pH of the buffer solution; 
PBS was pH-adjusted to a pH of 8.0 prior to the initiation of this experiment. Additionally, 
the measurements were conducted over 1 h intervals, with the final measurement occurring 
after 24 h incubation at 25 °C. When % cumulative release profiles were created, 100% 
release referred to the amount of therapeutic released from the uncoated PPEG film 
developed in Chapter 4. All in vitro release studies were carried out using three independent 
films. 
5.3.6. Stability of pH-responsive System  
The stability of the films was measured as outlined in Chapter 4, Section 4.3.6, with slight 
modifications; PBS was pH-adjusted to a pH of 6.5 prior to the initiation of this experiment 
and measurements were taken at 24 h intervals over 5 days.  
5.3.7. Colony Biofilm Wound Model  
S. aureus colony biofilms were prepared as outlined in Chapter 2, Section 2.2.2.2. The pH-
responsive films were placed on top of the bacteria prior to incubation at 32 °C for 24 h. 
After incubation, the biofilms were stripped and enumerated as previously outlined 








5.4. Results and Discussion 
5.4.1. pH Change in S. aureus Biofilms 
Dr Laura Wallace from the University of Bath, UK, investigated the usefulness of pH as a 
trigger, conducting experiments to determine the pH of developing S. aureus biofilms using 
the modified colony biofilm model (Figure 5.2). It was hypothesised that if the pH rose to 
values above pH 7 before the development of an established biofilm occurred, pH could be 
a suitable trigger for stimuli-responsive wound dressings.  
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Figure 5.2: pH values associated with developing A) S. aureus H560, B) S. aureus MRSA252, and C) S. aureus 
MSSA101 biofilms. Results are shown as mean and SD, n = 3 biological replicates 
The pH of S. aureus H560 rose above pH 7.0 after 6.8 h of biofilm development at 32 °C, 
corresponding to a concentration of approximately 2.51 x 104 CFU/membrane (CFU data 
not shown). The pH change occurred before the exponential rise in bacterial concentration, 
with the final biofilm exhibiting a density of approximately 1010 CFU/membrane and a pH 
of 7.66. As the pH rose before a significant increase in bacterial concentration, it can be 
hypothesised that the pH-responsive system could release its payload and target 
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metabolically active S. aureus H560 before the development of an established and mature 
biofilm.  
For S. aureus MRSA252, the rise in pH above pH 7.0 occurred after 9.6 h of biofilm 
development at 32 °C, corresponding to a concentration of approximately 3.16 x 109 
CFU/membrane. Unlike S. aureus H560, this pH change occurred when the bacteria were 
approaching their stationary phase of their lifecycle, with a final bacterial concentration of 
approximately 1010 CFU/membrane observed after 16 h incubation. As this pH change 
occurred later on in the biofilm development, further experiments were conducted to 
establish whether the pH-responsive system reported in this Chapter would be effective in 
targeting S. aureus MRSA252 infections; the efficacy of this system would depend on how 
fast the pH-responsive polymer EUDRAGIT® FS 30 D (Chapter 5, Section 5.4.2), would be 
able to dissolve and how quickly the reservoir PPEG film can release its therapeutic payload 
(see Chapter 4).  
Finally, for S. aureus MSSA101, the pH of the biofilm rose above pH 7.0 after 7.1 h of biofilm 
development at 32 °C, corresponding to a concentration of approximately 1.00 x 106 
CFU/membrane. This increase in pH occurred when the bacteria were in their exponential 
growth phase; therefore, there may be adequate time for the pH-responsive system to 
release its therapeutic load before the development of an established, mature biofilm. 
Although the time in which the pH increased past pH 7.0 varied, all three S. aureus had an 
alkaline biofilm pH after 16 h incubation. Therefore, pH could be used as a viable target for 
stimuli-responsive wound dressings that selectively release their antimicrobial payload in 
response to an active infection.  
5.4.2. EUDRAGIT®-coated Films 
In order to create a pH-responsive system, the PPEG film developed in Chapter 4 was dip-
coated with a pH-responsive polymer. The pH-responsive polymer used in this study was 
EUDRAGIT® FS 30 D, manufactured by Evonik (Darmstadt, Germany); it is an anionic 
copolymer based on methyl acrylate, methyl methacrylate and methacrylic acid (Figure 5.3). 
EUDRAGIT® FS 30 D was chosen due to its dissolution pH value (pH 7.0) owing to the ratio 
of carboxyl to ester groups being 1:10. 
The pH-responsive nature of EUDRAGIT® FS 30 D was due to the polymers pendent 
carboxyl groups. Upon increasing pH, the carboxyl groups are ionised, which results in a 
net overall charge of the molecule, causing the polymer to swell due to electrostatic 
repulsion. The solubility of the polymer further increases as the anionic centre of the 
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polymer is capable of forming dipole-dipole interactions with the water. The dissolution of 
this pH-responsive polymer allows the therapeutic within the PPEG film to be released in 
response to the elevated pH, subsequently eliminating S. aureus at the infection site.   
 
Figure 5.3: Chemical structure of EUDRAGIT® FS 30 D 
 
5.4.3. Bacteriophage-loaded Films 
5.4.3.1. Bacteriophage Survival 
As the antimicrobial-loaded PPEG film created in Chapter 4 was dip-coated in EUDRAGIT® 
FS 30 D and used for pH-sensing applications, it was imperative to determine phage K 
survival in the solvent system (acetone) used to create the pH-responsive polymer, and to 
ensure phage viability remains for pH values between pH 7.00 – 9.00.  
Upon incubation with varying concentrations of acetone (% v/v) for 1 h, phage K 
concentration remained comparable to the control (phage K in PBS) up to acetone 
concentrations of 40%. Past this point, there was a significant decrease in phage viability 
compared to the control, resulting in log reductions of 0.45 (One-way ANOVA, p<0.01), 1.27 
(One-way ANOVA, p<0.0001), and 4.05 (One-way ANOVA, p<0.0001) for acetone 
concentrations of 60, 80 and 90%, respectively (Figure 5.4A).  These results suggest that 
phage K viability might be affected by the dip-coating process; therefore, this may result in 
a reduction in the phage K being successfully released from the film. However, the dip-
coating process only requires minimal contact with acetone, and the solvent is fully 
evaporated before subsequent emersions in the solvent, which could minimise the negative 
effect of acetone on phage K viability. Owing to this, further experiments were conducted to 
evaluate phage K release from the pH-responsive system and the results were compared to 
that observed from the uncoated PPEG films (Chapter 5). 
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In literature, phage have been shown to be tolerant to a wide range of pH values,63,67 so it is 
no surprise that phage K viability was stable in pH-adjusted TSB pH 6.0 – 8.0 (Figure 5.4B). 
While pH 4.0 and pH 10.0 resulted in a significant decrease in phage titre (log reductions of 
0.78 and 0.79, respectively; One-way ANOVA, p<0.001 vs pH 7.0 control) these decreases 
in titre were not clinically significant and could, in part, be due to external factors such as 
human error within the methodology. At extreme pH values there was a clinical and 
significant decrease in phage K titre, with a log reduction of 6.36 observed for both pH 2.0 
and pH 12.0 when compared to the control (pH 7.0). This decrease in phage K titre reached 
the limit of detection of this assay. However, as chronic wounds only rise to pH 8.0 – 9.0, 
phage K was deemed a suitable therapeutic as it was still viable within this pH range. 
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Figure 5.4:  Phage K survival in the presence of A) increasing concentrations of acetone (in PBS), and B) 
increasing pH.of TSB. n = 3, error bars indicate standard deviation. Statistical analysis conducted using a One-
way ANOVA. * p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 
5.4.3.2. In vitro release 
The PPEG system developed in Chapter 4 was subjected to 50 dip-coat layers of 
EUDRAGIT® FS 30 D to successfully entrap both phage K and ciprofloxacin (see Section 
5.4.4). Owing to this, in vitro release studies were carried out over a 24 h period to 
determine the release kinetics of phage K from the pH-responsive polymer in PBS at pH 
8.0. 
The resultant release profiles are shown in Figure 5.5. There was a slow release of phage K 
from the pH-responsive system into the PBS (pH 8.0) over the course of 24 h. After 1 h, 4.0 
log PFU/mL of phage K were released from the system, rising to 5.73 log PFU/mL after 7 h 
incubation in PBS (pH 8.0). After 24 h, 7.62 log PFU/mL of phage K was released, 












































Figure 5.5: A) Log PFU/mL and B) % Cumulative release in vitro release profiles of phage K from the pH-
responsive films in PBS (pH 7.4, 25 °C). n = 3, error bars indicate standard deviation. 100% cumulative release 
refers to the density of phage K released from the uncoated PPEG film 
Next, mathematical models were used to evaluate the release kinetics of the pH-responsive 
system for phage K release. According to Table 5.1, the release profile with the best fit was 
Korsmeyer-Peppas. However, measurements for the in vitro release kinetics were only 
undertaken for the first 7 hours and as such, the experiment should be repeated to take 
more measurements over a longer time period to obtain a more accurate release profile, as 
the R2 values obtained in Table 5.1 are very low.  
The Korsmeyer-Peppas model is a semi-empirical model that is used to describe drug 
release from polymeric systems and is a useful model for the study of polymeric systems 
where the release mechanism is unknown or when there is more than one type of drug 




= log 𝐾 + 𝑛 log(𝑡 − 𝑙) 
(12) 
 
Where M∞ is the amount of drug at the equilibrium state, Mi is the amount of drug released 
over time t, K is the release velocity constant, n is the exponent of release in function of time 
t and l is the latency time.  
To accurately determine n, it is recommended to use the portion of release curve until the 
point where Mi/M∞ < 0.60. When n > 1, as it is for this system, it describes the Super Case 
II model of release, whereby during the sorption process there is concurrent breaking of the 
polymer chains (termed solvent crazing). Super Case II transport has been shown for planar 
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structures such as thin films and is observed when the solvent has a high affinity to the 
matrix. As a consequence, there is a rapid penetration of the solvent into the centre of the 
matrix.68  
Table 5.1: Kinetic model and corresponding R2 value for the release of ciprofloxacin from a pH-responsive 
system (PBS, pH 8.0) 
Kinetic Model R2 value 
Zero order 0.4908 




5.4.3.3. Stability  
To ensure that the pH-responsive system did not release phage K at pH values <7.0, phage 
K-loaded pH-responsive films were submerged in 2 mL of PBS (pH 6.5) for a maximum of 
5 days at room temperature and assessed for the presence of phage release daily (Figure 
5.6).  


















Figure 5.6: Log PFU/mL of phage K released from the pH-responsive system upon incubation in PBS, pH 6.5 
for up to 5 days at 25 °C. n = 3 and error bars indicate standard deviation. The limit of detection of this assay 
was 2.33 Log PFU/mL 
As shown in Figure 5.6, there was no detectable release of phage K from the polymer system 
over 5 days, with any release of phage K lower than the limit of detection of the assay. This 
result demonstrates the pH-responsiveness of the system, as phage K have been shown to 
be stable in the PPEG system for up to 5 days, with no loss in cell viability (Chapter 4). 
Additionally, this result demonstrates the utility of this system as a wound dressing, as often 
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they are left in situ for 5 – 7 days; hence, if the wound remains uninfected then the wound 
dressing would not release phage K into the surrounding environment.  
5.4.3.4. Colony Biofilm Wound Models 
As the in vitro release results suggested that phage K can be successfully released from the 
pH-responsive system at pH 8.0, the next step was to assess this system in treating 
developing S. aureus infections. Similarly to the biofilms tested in Chapter 4, a modified 
colony biofilm model was used where the film was placed onto developing S. aureus biofilms 
on polycarbonate membranes and incubated at 32 °C for 24 h (Figure 5.7).  
For all three bacterial isolates tested, there was no significant difference in bacterial viability 
when the bacterial isolates were incubated with un-loaded pH-responsive films compared 
to the biofilm only control; therefore, any reduction in bacterial biomass could be attributed 
to the release of phage K from the pH-responsive film.  
When phage K was encapsulated within the pH-responsive film, a significant log reduction 
of 1.96 was observed in S. aureus H560 biofilm density compared to the control (One-way 
ANOVA, p<0.0001).  Likewise, a 1.14 log reduction was observed when the phage K-
encapsulated pH-responsive films were incubated with S. aureus MSSA101 compared to the 
control (One-way ANOVA, p<0.01). However, when S. aureus MRSA252 was incubated 
with phage K-encapsulated pH-responsive films, a log reduction of 0.46 in biofilm density 
was observed compared to the control. While this result was significant (One-way ANOVA, 
p<0.01), the log reduction is not clinically useful as it could be due to external factors such 
as human error within the experimental methodology.  
While the log reductions in bacterial density of S. aureus H560 and S. aureus MSSA101 
corresponded to a 90 – 99% reduction in viable cells, it does not meet the recommended ≥ 
3 log reduction outlined in prEN16756, and therefore this system cannot be considered 
antimicrobial against all three bacterial isolates tested. 
One reason for this decrease in antimicrobial efficacy compared to the uncoated PPEG films 
(Chapter 4) could be due to the difference in the release profile of this pH-responsive 
system. Release of phage K from the pH-responsive system is not as fast compared to the 
PPEG film, consequently, it would take longer for the phage to reach sufficient 
concentrations required to infect and lyse the bacterial cells. This could be the reason why 
the worst results were observed for S. aureus MRSA252, even though this bacterial strain 
was the most susceptible towards the phage loaded-PPEG films evaluated in Chapter 4. By 
the time the pH change had occurred, S. aureus MRSA252 would have been towards the 
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end of its exponential growth, after which there would be a delay in phage K reaching the 
bacteria. As phage are less successful in targeting stationary-phase bacteria, this could 
explain why only a 0.46 log reduction in bacterial density was observed for this pH-
responsive system. Likewise, it could explain why the phage K loaded pH-responsive films 
were more effective towards S. aureus H560, as the pH rise above pH 7.0 occurred earlier 
in the growth cycle, allowing more time for the phage K to be released from the system and 
































































Figure 5.7: Log CFU/membrane counts of A) S. aureus H560, B) S. aureus MRSA252, and C) S. aureus 
MSSA101 biofilms upon incubation with pH-responsive systems (tPPEG) and phage K-loaded pH-responsive 
systems (tPPEG-phage K) 24 h at 32°C. n = 3, error bars indicate standard deviation. Statistical analysis 
conducted using a One-way ANOVA. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 
 
The corresponding phage counts are outlined in Figure 5.8. The phage K concentration was 
highest when the film was incubated with S. aureus H560, and lowest when incubated with 
S. aureus MRSA252. This is in line with the efficacy witnessed against these bacterial strains 
(Figure 5.7); hence, it could be hypothesised that the phage K-loaded pH-responsive film 
was more effective towards S. aureus H560 as it was able to multiply at the infection site, 
resulting in a reduction in bacterial cell density. However, only three bacterial strains have 
been used in this assay, so to further understand the relationship between pH, biofilm 
176 
 
formation, and effective phage release from the system – further repeats of these 
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Figure 5.8: Log PFU/membrane counts of phage K released from the pH-responsive film after incubation with 
S. aureus H560, MRSA252, and MSSA101 biofilms for 24 h at 32°C. n = 3, error bars indicate standard deviation 
 
5.4.4. Ciprofloxacin-loaded Films  
5.4.4.1. Thickness of pH-responsive Layer 
It was important to ensure that the pH-responsive EUDRAGIT® FS 30 D layer was of 
sufficient thickness to prevent any passive diffusion of ciprofloxacin through the system into 
the external environment. Owing to this, ciprofloxacin-loaded PPEG films were dip-coated 
0 – 50 times in EUDRAGIT® FS 30 D before subsequent emersion in 2 mL PBS (pH 6.5) for 
24 h at 25 °C. All ciprofloxacin concentrations were determined using UV-Vis and the 
appropriate calibration curves.  
Upon increasing layers of EUDRAGIT® FS 30 D, there was a decrease in ciprofloxacin 
passively released from the pH-responsive films at pH 6.5, with a 92.43% reduction in 
release compared to the uncoated control for 20 layers, rising to 98.48% with 50 layers 
(Figure 5.9). As 50 layers resulted in a minimal non-specific release of ciprofloxacin, this 
was the thickness chosen for all experiments conducted.  
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Figure 5.9: Concentration of ciprofloxacin released from pH-responsive systems with increasing EUDRAGIT® 
FS 30 D layers, incubated in 2 mL PBS (pH 6.5) for 24 h at 25 °C. n = 3, error bars indicate standard deviation 
5.4.4.2. In vitro Release 
Next, the in vitro release kinetics was determined for ciprofloxacin release from pH-
responsive films in pH (pH 8.0) at 25 °C. As shown in Figure 5.10, there was a gradual 
release of ciprofloxacin from the film, with 6.14% of ciprofloxacin released after 30 minutes, 
rising to 10.94% and 30.62% after 1 and 4 h, respectively. After 19 h, 42.02% of ciprofloxacin 
was released from the film, where 100% was defined as the concentration of ciprofloxacin 
released from the uncoated PPEG film (411.67 ± 21.62 µg/mL; Chapter 4).  
























Figure 5.10: In vitro % cumulative release profile of ciprofloxacin from pH-responsive films in PBS (pH 8.0, 
25 °C). n = 3, error bars indicate standard deviation. 100% cumulative release refers to the concentration of 
ciprofloxacin released from the uncoated PPEG film 
Next, mathematical models were used to evaluate the release kinetics of the pH-responsive 
system for ciprofloxacin release. According to Table 5.2, the release profile with the best fit 
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was first-order kinetics, but it is interesting to note that for Korsmeyer-Peppas, the n value 
obtained was 0.577, which suggests non-fickian diffusion; therefore, there was an element 
of polymer swelling and erosion. 
Table 5.2: Kinetic model and corresponding R2 value for the release of ciprofloxacin from a pH-responsive 
system (PBS, pH 8.0) 
Kinetic Model R2 value 
Zero order 0.9857 





In first order kinetics, the rate is directly proportional to the concentration of drug, i.e., the 




=  𝐾𝑖𝐶 
(13) 
 
Where Ki is the first order rate constant, expressed as time-1.  
The equation can be further derived to:  






Where Q1 is the amount of active agent released on time t,  Q0 is the initial amount of drug 
dissolved, and Ki is the first-order constant.  
Equation 14 corresponds to linear kinetics, and the graph of log (% drug remaining) versus 
time would result in a straight line, with an angular coefficient of Ki/2.303 and a linear 
coefficient equal to log Q0.68  
5.4.4.3. Stability 
Similarly to phage-loaded pH-responsive films, experiments were undertaken to determine 
the stability of the ciprofloxacin-loaded pH-responsive films at pH 6.5. These films were 
submerged in 2 mL of PBS (pH 8.0) for a maximum of 5 days at room temperature and the 
solution was assessed for the presence of ciprofloxacin daily. In this instance, 100% 
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cumulative release was the concentration of ciprofloxacin released from the un-coated 
PPEG film (411.67 ± 21.62 µg/mL; Chapter 4).  

























Figure 5.11: % Cumulative release of ciprofloxacin from the pH-responsive system upon incubation in PBS, 
pH 6.5 for up to 5 days at 25 °C. n = 3 and error bars indicate standard deviation. 100% cumulative release refers 
to the concentration of ciprofloxacin released from the uncoated PPEG film 
The results show that there was minimal passive diffusion of ciprofloxacin at pH 6.50, with 
only 6.89% of ciprofloxacin released after 5 days incubation (corresponding to 16.42 
µg/mL). Therefore, it can be concluded that the pH-responsive film only releases its 
therapeutic load in response to an increase in pH above pH 7.0. Further experiments could 
be conducted in the future to reduce the amount of passive diffusion from the film, but this 
may alter the film and subsequently reduce the efficacy of the film against S. aureus 
biofilms.  
5.4.4.4. Colony Biofilm Wound Models 
The effectiveness of ciprofloxacin-loaded pH-responsive films were investigated against 
developing S. aureus biofilms (Figure 5.12).  
As seen for phage-loaded pH-responsive films, there was no significant difference in 
bacterial viability when the bacterial isolates were incubated with un-loaded pH-responsive 
films compared to the biofilm only control for all bacterial isolates tested; therefore, any 
reduction in bacterial biomass could be attributed to the release of ciprofloxacin from the 
pH-responsive film. For S. aureus H560, there was a statistically significant log reduction 
in bacterial density compared to the biofilm control (log reduction of 3.13; One-way 
ANOVA, p<0.0001). This log reduction was similar to that observed for the uncoated PPEG 
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film (Chapter 4) and met the recommended ≥ 3 log reduction outlined in prEN 16756; 
therefore, this system can be considered antimicrobial against S. aureus H560. 
For S. aureus MRSA252, there was a statistically significant log reduction in bacterial 
density observed upon incubation with the ciprofloxacin-loaded pH-responsive film (log 
reduction of 1.23; One-way ANOVA, p<0.0001). This result was similar to that observed for 
the uncoated PPEG film (Chapter 4). Similarly, there was a significant log reduction in S. 
aureus MSSA101 bacterial density upon incubation with ciprofloxacin-loaded pH-
responsive system (log reduction 2.45; One-way ANOVA, p<0.0001); however this was one 
log lower than what was observed for the uncoated PPEG film (3.49, Chapter 4). These log 
reductions do not meet the criteria outlined in prEN 16756; therefore this system cannot be 
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Figure 5.12: Log CFU/membrane counts of A) S. aureus H560, B) S. aureus MRSA252, and C) S. aureus 
MSSA101 biofilms upon incubation with pH-responsive systems (tPPEG) and ciprofloxacin-loaded pH-
responsive systems (tPPEG-ciprofloxacin) for  24 h at 32°C. n = 3, error bars indicate standard deviation. 




5.4.5. Combination-loaded Films  
5.4.5.1. Stability  
To ensure that the pH-responsive system did not release phage K and ciprofloxacin at pH 
values <7.0, the antimicrobial-loaded pH-responsive films were submerged in 2 mL of PBS 
(pH 6.5) for a maximum of 5 days at room temperature and the solution assessed for the 
presence of phage K and ciprofloxacin daily. 
 As shown in Figure 5.13, there was no detectable release of phage K from the polymer 
system over 4 days, with any release of phage K lower than the limit of detection of the assay. 
At day 5, there was an observable increase in phage K concentration within the solution; 
however, it only corresponded to an average increase of 0.3 log PFU/mL. As this release is 
minimal, the film was deemed sufficient for this proof-of-concept, pH-responsive design as 
the polymer became unstable towards the end of its therapeutic lifetime.   
















Figure 5.13: Log PFU/mL of phage K released from the pH-responsive system upon incubation in PBS, pH 6.5 
for up to 5 days at 25 °C. n = 3 and error bars indicate standard deviation. The limit of detection of this assay 
was 2.33 Log PFU/mL 
There was no difference in stability of ciprofloxacin within the pH-responsive systems when 
encapsulated with phage K compared to without (Figure 5.11 vs Figure 5.14). After 5 days 
incubation in PBS (pH 6.5) there was 7.76% release of ciprofloxacin from the system 
(corresponding to a mean ciprofloxacin concentration of 31.93 µg/mL).  
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Figure 5.14: % Cumulative release of ciprofloxacin from the pH-responsive system upon incubation in PBS, 
pH 6.5 for up to 5 days at 25 °C. n = 3 and error bars indicate standard deviation. 100% cumulative release refers 
to the concentration of ciprofloxacin released from the uncoated PPEG film 
5.4.5.2. Colony Biofilm Wound Models 
The efficacy of the phage K and ciprofloxacin-loaded pH-responsive films were evaluated 
against developing S. aureus biofilms (Figure 5.15).  
As mentioned previously, there was no significant difference in bacterial viability when the 
bacterial isolates were incubated with un-loaded pH-responsive films compared to the 
biofilm only control for all bacterial isolates tested; therefore, any reduction in bacterial 
biomass could be attributed to the release of ciprofloxacin or phage from the pH-responsive 
film.  
For S. aureus H560, there was a significant log reduction in bacterial biomass compared to 
the control (log reduction of 1.89; One-way ANOVA, p<0.0001); this was similar to what 
was observed for the uncoated PPEG films (log reduction of 1.19; Chapter 4). There was also 
a significant log reduction in S. aureus MSSA101 biofilm biomass upon incubation with the 
phage K and ciprofloxacin-loaded pH-responsive films (log reduction of 2.04; One-way 
ANOVA, p<0.001); this was less effective than the uncoated PPEG film (log reduction of 
3.23; Chapter 4), probably due to the delay in treatment while waiting for the pH of the 
biofilm to rise to a pH above 7.0.  
Finally, for S. aureus MRSA252 there was a log reduction of 0.89 in bacterial biomass 
compared to the control; however, this reduction was not statistically significant. As the 
uncoated PPEG film containing phage K and ciprofloxacin resulted in a 2.22 log reduction, 
the difference in bacterial density could be attributed to the delay in the release of the 
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Figure 5.15: Log CFU/membrane counts of A) S. aureus H560, B) S. aureus MRSA252, and C) S. aureus 
MSSA101 biofilms upon incubation with pH-responsive systems (tPPEG) and phage K and ciprofloxacin-loaded 
pH-responsive systems (tPPEG-combination) for 24 h at 32°C. n = 3, error bars indicate standard deviation. 
Statistical analysis conducted using a One-way ANOVA. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 
Furthermore, mixed-model analysis can be performed on the Log CFU/mL counts to 
determine the nature of the interaction between the antibiotic and phage within the 
combination therapy (synergistic, additive, or antagonistic), as described by Kumaran et 






COEFint is the co-efficient of the interaction, ABR is the reduction in bacterial counts followed 
by the combined treatment (AB), AR is the reduction on bacterial counts due to treatment A 
and BR is the reduction in bacterial counts due to treatment B.   
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An interaction was defined as being synergistic if the value > 0, additive if the value = 0, and 
antagonistic when the value < 0. The calculated co-efficients for this assay are shown in 
Table 5.3.  
The calculated co-efficients highlight the results obtained in Figure 5.15, for all bacterial 
isolates tested the combination of phage K and ciprofloxacin resulted in an antagonistic 
interaction as all co-efficient values are negative. Further optimisation assays, i.e., altering 
the concentrations of phage K and ciprofloxacin could be conducted in the future to 
investigate whether it would be possible to achieve PAS within this pH-responsive system.  
Table 5.3: Co-efficient of the interaction between phage K and ciprofloxacin from mixed-model analysis. An 
interaction was defined as being synergistic if the value > 0, additive if the value = 0, and antagonistic when 
the value < 0 
Bacterial strain Co-efficient  
S. aureus H560 -3.20 
S. aureus MRSA252 -0.81 
S. aureus MSSA101 -2.15 
 
The corresponding phage concentrations are shown in Figure 5.16. There is a marked 
decrease in phage concentration compared to the phage K released in the monotherapy pH-
responsive polymer (Figure 5.8), especially for S. aureus MRSA252 and MSSA101, which 
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Figure 5.16: Log PFU/membrane counts of phage K released from the pH-responsive film after incubation 
with S. aureus H560, MRSA252, and MSSA101 biofilms for 24 h at 32°C. n = 3, error bars indicate standard 
deviation 
This result could be due to the release profiles of phage K and ciprofloxacin being different, 
with ciprofloxacin releasing at a faster rate compared to phage K. As briefly mentioned in 
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Chapter 3 and Chapter 4, phage-antibiotic synergy has been shown to be dependent on the 
release of both antimicrobials, with greater PAS witnessed when phage is released prior to 
the conventional antimicrobial to allow time for effective phage replication. Therefore, the 
antagonistic effect observed in the combination therapy (Figure 5.15) could be due to the 
fact that ciprofloxacin was the first antimicrobial to reach the S. aureus infection, 
eliminating the bacterial cells before phage K has a chance to launch a successful attack. 
Therefore, further work would need to be conducted to investigate the optimal 
concentrations of phage K and ciprofloxacin loaded into the pH-responsive system in order 







5.4. Conclusions and Future Work 
This proof-of-concept study demonstrated the utility of pH-responsive wound dressings for 
the treatment of developing S. aureus infections. This chapter found that pH could be used 
as a possible release trigger, as all three S. aureus isolates tested were shown to have an 
increase in pH upon biofilm formation. However, to ensure that it is possible to generalise 
this statement to all S. aureus isolates, further experiments should be conducted to measure 
the pH change in biofilm formation of multiple S. aureus strains.  
The PLA-PEG (PPEG) film encapsulating phage K and/or ciprofloxacin were dip-coated 
with 50 layers of EUDRAGIT® FS 30 D to prevent the non-triggered passive release of the 
therapeutics from the pH-responsive system. This coating prevented the release of phage K, 
and resulted in minimal release of ciprofloxacin, for 5 days at pH 6.5 – a pH lower than the 
dissolution value of EUDRAGIT® FS 30 D.  
When incubated at pH 8.0, the release profiles of phage K and ciprofloxacin were different, 
with phage K exhibiting Korsmeyer-Peppas release, while ciprofloxacin resulted in faster, 
first-order release. While both release models are diffusion-based, the difference in release 
profiles could be due to the relative size of the antimicrobials; phage K is much larger in 
comparison to ciprofloxacin, hence the release from the matrix is dependent on the polymer 
eroding and creating larger pores to allow for phage diffusion into the surrounding 
environment. Conversely, ciprofloxacin is smaller, so the polymer doesn’t need to degrade 
to the same extent to allow for ciprofloxacin to be released from the matrix into the 
surrounding environment. However, the release profile obtained for phage K should be 
repeated to confirm this result, as the R2 values calculated from the mathematical modelling 
were low, lowering the confidence in this result.  
Finally, these pH-responsive polymers were tested against three developing S. aureus 
biofilms. While the efficacy of the monotherapies encapsulated within the pH-responsive 
system were lower than those observed for the non-triggered PPEG system, the films still 
displayed a significant reduction in bacterial biomass.  
In order to try and improve the efficacy of the pH-responsive film, a combination of phage 
K and ciprofloxacin was used at the same loading concentrations as the monotherapies. 
Unfortunately, the combination was not able to increase the efficacy of the system, in fact 
the combination displayed an antagonistic interaction. This was thought to be due, in part, 
to the slower release of phage K from the system compared to the ciprofloxacin, preventing 
the phage from being able to act effectively.  
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Finally, it would be useful to have a system that utilises the phage K – ciprofloxacin PAS 
observed in Chapter 3, to minimise the spread of antibiotic resistance. Owing to this, several 
studies could be conducted to improve the efficacy of the combination. Firstly, 
investigations should be carried out to determine the effect of different loading 
concentrations of ciprofloxacin and phage K. Additionally, it could be possible to create a 
modified wound dressing, whereby the individual therapies are contained within their own 
pH-responsive system, and then combined to create the wound dressing. The advantage of 
this approach is less Eudragit® FS 30 D coating on the phage pH-responsive polymer; as 
phage are larger molecules, a thinner coating would be needed for complete encapsulation. 
Owing to this, the release of phage K from the polymer would be quicker, increasing the 
efficacy of the combination of phage K and ciprofloxacin by potentially producing a 
synergistic effect, resulting in a greater reduction in S. aureus biofilm density.  
Overall, these results show that pH can be used as a trigger for the selective release of 
antimicrobials from a pH-responsive system. Additionally, the antimicrobial-loaded pH-
responsive systems were capable of reducing S. aureus biofilm density, both as a 
monotherapy and as a combination therapy. While further work must be carried out to 
optimise these films, this Chapter has demonstrated their utility as an antimicrobial wound 
dressing. Furthermore, this system can be optimised to contain different antimicrobials to 
treat a variety of different microbial infections, it is not limited to S. aureus infections or 
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Chapter 6: TCF-based Fluorescent Probe for 
the Detection of Alkaline Phosphatase 
6.1. Overview 
The research presented in this chapter describes the synthesis of the novel fluorescent and 
colorimetric probe, TCF-ALP (Scheme 6.1). Experiments were conducted with TCF-ALP 
to determine its limit of detection, selectivity, and kinetic parameters towards alkaline 
phosphatase (ALP). As TCF-ALP was also found to be active towards acid phosphatase 
(ACP), further experiments were conducted to determine the selectivity of TCF-ALP 
towards both ACP and ALP at each enzyme’s optimal pH (pH 5.0 and pH 9.2, respectively) 
and at neutral pH (pH 7.1).  
The aim of this chapter was to build a foundation of knowledge so TCF-ALP could be 













6.2.1.1. Basics of Fluorescence 
Luminescence is the emission of light from electronically exited states of any substance and 
can be divided into two categories, fluorescence and phosphorescence.1 The process of 
fluorescence and phosphorescence (absorption, excitation and emission) is best illustrated 
with a Jablonski diagram (Figure 6.1).  
 
Figure 6.1: A Jablonski diagram showing S0, S1, and S2 singlet energy levels and the T1 triplet level. Internal 
conversion and intersystem crossing, which lead to fluorescence and phosphorescence, respectively, are 
depicted. Figure reproduced from Gardner et al with permission2  
The singlet ground, first, and second electronic states are depicted by S0, S1, and S2, 
respectively. At each of these energy levels, there are a number of vibrational energy levels, 
denoted by 0, 1, 2, etc. The transitions between states are often shown as vertical lines as 
transitions occur within a time-frame too short for significant displacement of nuclei 
(Franck-Condon principle).1  
For both fluorescence and phosphorescence, the first step is absorption. Absorption of a 
photon occurs when an external light source emits light of a sufficient wavelength, and 
typically occurs in molecules with the lowest vibrational energy. This excites an electron to 
a higher vibrational level of either S1 or S2, before rapid relaxation to the lowest vibrational 
level of S1 in a process called internal conversion (IC).1 This occurs as the electron is an 
unstable configuration and consequently adopts a more semi-stable configuration in a 
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slightly lower energy level via non-radiative processes such as vibrational relaxation or heat 
to the solvent.1  Additionally, IC occurs faster than fluorescence lifetimes, therefore it is 
generally complete prior to emission.1 This excited state is higher in energy than the ground 
state, resulting in a thermodynamic driving force towards the ground state.3  
For fluorescence, the electron of the excited orbital is of the opposite spin to the electron in 
the ground state orbital (paired), therefore, the return to the ground state is spin-allowed 
and occurs rapidly by emission of a photon via fluorescence.1 
On the other hand, phosphorescence occurs when the electron in the S1 state undergoes a 
spin conversion to the excited triplet state T1 in a process called intersystem crossing (ISC). 
This process is spin-forbidden as the electron now has the same spin orientation as the 
electron in the ground state. As a result of this, the rate of emission is slower, and generally 
shifted towards longer wavelengths, compared to fluorescence (10-3 – 100 s-1). Molecules 
containing heavy atoms such as bromine and iodine are frequently phosphorescent.1 
Fluorescence spectral data are generally presented as emission spectra. According to Kashas 
rule, upon excitation of an electron into the higher energy levels, the excess energy is quickly 
dissipated, leaving the fluorophore in the lowest vibrational level of S1. Because of this rapid 
relaxation, emission spectra are usually independent of excitation wavelength. Additionally, 
the symmetric nature of these spectra is a result of the same transitions being involved in 
both absorption and emission and the similarities of the vibrational energy levels of S0 and 
S1. (Figure 6.2)1  
 
Figure 6.2: Diagram depicting the excitation and emission spectra of a fluorescent molecule, and the 
corresponding stokes shift 
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Excitation occurs in a shorter time frame compared with structural relaxation; hence, the 
exited state is initially formed at the optimal structure for the ground state. However, as the 
excited state molecules subsequently undergo structural relaxation,3 emission leads to the 
formation of the ground state that has the optimal structure of the excited state. These 
effects narrow the energetic separation of the ground and excited state, which leads to 
emission at longer wavelengths compared to absorption – termed the stokes shift.3  
6.2.1.2. Design of Fluorescent Probes 
Many substrates, particularly those with delocalised electronic structures, e.g., conjugated 
π systems, exhibit fluorescent properties.3 Owing to this, fluorescence spectroscopy has 
become a useful tool for the detection of certain analytes via the creation of fluorescent 
probes.2  
Fluorescent probes change their fluorescence emission in response to a trigger, such as a 
binding event, chemical reaction, or change in the immediate environment.4 In the 
literature, triggers have included reactive oxygen and nitrogen species, metal ions, and 
enzymes – with both in vitro and in vivo studies performed.5–10 
Fluorescent probes are often used in drug discovery and medical applications as they offer 
high selectivity  and sensitivity,11,12 are easy to use,3 are non-invasive,13 and capable of real-
time monitoring11,12 with minimal disruption to the sample.1,14 Additionally, they are easy to 
synthesise and modify depending on the target or use of the probe.15 
Fluorescent probes are generally comprised of three units, a receptor, linker and a reporter.2 
The receptor unit should be specific towards the target analyte by being designed in such a 
way to minimise off-target reactions and be non-toxic to avoid damage to the biological 
system under investigation. The receptor is connected to a reporter unit via a linker, 
designed to optimally position the two units and modulate solubility2.  The reporter unit of 
the probe is the fluorophore; like the receptor unit, it should be non-toxic to avoid damaging 
the biological system. The choice of fluorophore is important; fluorophores that have 
absorption and emission wavelengths in or near the near-infrared (NIR) region are often 
advantageous as they are more biocompatible, have deeper tissue penetration, and have 
minimal interference from background auto-fluorescence of the sample.16–19  
Several requirements need to be considered when designing fluorescent probes, including 
efficient excitation, limited auto-fluorescence, limited cellular photodamage, a high molar 
extinction coefficient and quantum yield (enabling the use of lower concentrations and 
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therefore reduced toxicity), and the presence of a highly-selective functional group that 
recognises the target.3,20  
6.2.1.3. Fluorescence Mechanisms 
There are four fluorescence mechanism commonly used in the design of fluorescent probes: 
Photoinduced Electron Transfer (PET), Forster Resonance Energy Transfer (FRET), 
Excited State Intramolecular Proton Transfer (ESIPT), and Internal Charge Transfer (ICT). 
6.2.1.3.1. Photoinduced Electron Transfer 
Suppression of photoinduced electron transfer (PET) is one of the most commonly used 
methods for converting a non-fluorescent molecule into a fluorescent molecule.21 PET 
involves excitation of an electron from the highest occupied molecular orbital (HOMO) of a 
fluorophore (acceptor) to its lowest unoccupied molecular orbital (LUMO). In the 
fluorescent probes ‘off’ state, an electron from the HOMO of the receptor (donor) moves to 
fill the HOMO of the fluorophore, resulting in fluorescence quenching and the election in 
the LUMO of the fluorophore returning to the ground state via a non-radiative pathway 
(Figure 6.3).21,22 For this to occur, the HOMO of the receptor must be slightly higher than 
the HOMO of the fluorophore.21,22 This is called a-PET; d-PET can also occur where the 
receptor is excited, however, the same mechanisms happen, and the fluorescence is 
quenched.15,23  Upon binding of the target, the redox potential of the receptor is raised so 
that the relevant HOMO becomes lower in energy compared to the HOMO of the 
fluorophore. Consequently, PET is no longer possible, and fluorescence occurs.3  
 
Figure 6.3: Photoinduced electron transfer (PET) quenching by a donor (D). Adapted from Fu et al with 
permission by The Royal Society of Chemistry©21 
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6.2.1.3.2. Förster Resonance Energy Transfer 
Förster resonance energy transfer (FRET) is a non-radiative energy transfer process that 
does not rely on the classic photon emission/absorption phenomenon.24 Instead, a FRET 
molecule consists of a donor and acceptor fluorophore,3 which transfer their energies via 
long-range dipole-dipole resonance interactions.2,20  
If the FRET acceptor is not close enough to the donor fluorophore when the donor 
fluorophore is exited, the exited electron decays to the ground state via a non-radiative 
pathway.20 However, if the distance between the donor and acceptor fluorophores is 
between 10 – 100 Å,20,21 the energy transfers from the donor to the acceptor fluorophore 
with a lower energy excited state, via a non-radiative dipole-dipole coupling mechanism, 
provided that there is a matching acceptor excited state vibrational level available.3,21,25 After 
excitation, the excited acceptor emits a photon and returns to the ground state (Figure 6.4). 
The efficiency of this energy transfer is inversely proportional to ×106 distance between the 
two FRET units.26–28 
 
 
Figure 6.4: Energy diagram for FRET. The double-headed arrow denotes the energy-matching of the lowest 
energy vibrational state of the donor excited state with a high energy vibrational level of the acceptor excited 
state. Adapted from Fu et al with permission by The Royal Society of Chemistry©21 
To enhance FRET efficiency, there needs to be good overlap between the emission spectra 
of the donor and the absorption spectra of the acceptor, correct orientation of the transition 
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dipoles of the donor and acceptor fluorophore, and the donor fluorophore needs to have a 
high extinction coefficient and a high quantum yield.20,21  
6.2.1.3.3. Excited-state Intramolecular Proton Transfer 
Excited-state intramolecular proton transfer (ESIPT) is a four-level photochemical process 
involving a fluorophore that can tautomerize, often utilising switching between enol and 
keto forms; therefore, it must contain an intramolecular hydrogen bond between a 
hydrogen donor and acceptor (Figure 6.5). The ground state fluorophore typically exists in 
the enol form, but upon excitation, the electron density is redistributed, ensuing the greater 
acidity of the hydrogen bond donor group and basicity of the hydrogen acceptor group. As 
a result, a rapid enol to keto phototautomerization occurs, with the excited enol form (E*) 
converting to the excited keto form (K*), which is stabilised by the intermolecular hydrogen 
bond.29 After radiative decay, a reverse proton transfer takes place to produce the original 
enol form.30 However, exceptions do exist where the fluorescence observed for ESIPT 
molecules is a result of the enol form.31  
 
Figure 6.5: Schematic representation of the ESIPT process. Adapted from Sedgwick et al with permission by 
The Royal Society of Chemistry©30  
6.2.1.3.4. Internal Charge Transfer 
Fluorescent probes utilising internal charge transfer (ICT) have both electron donating and 
electron accepting groups as ICT relies on the intramolecular movement of charge, often 
due to these “push-pull” groups.23 Upon excitation, there is charge transfer from the 
electron donor to the electron acceptor, thereby changing the emission peak of the 
fluorescence spectra (Figure 6.6).31,32 If the target analyte interacts with the electron 
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donating group, there is a blue-shift (increase in energy, decrease in wavelength) in the 
absorption spectrum and concurrent decrease of the extinction coefficient. Conversely, if 
the target analyte interacts with the electron accepting group, there is a red-shift (decrease 
in energy, increase in wavelength) and concurrent increase of the extinction coefficient.15  
 
Figure 6.6: Energy diagram correlating ICT with solvation, in polar solvents. Adapted from Fu et al with 
permission by The Royal Society of Chemistry©21 
6.2.1.3.4.1. TCF-based Fluorescent Probes 
Dicyanomethylene-3-cyano-4, 5, 5-trimethyl-2, 5-dihydrofuran (TCF)-based probes are 
examples utilised in the literature that exploit the ICT mechanism of fluorescence. TCF has 
three conjugated, electron-withdrawing cyano groups,33,34 and its derivative TCF-OH has a 
donor-π-acceptor (D-π-A) structure suitable for ICT.35–37  
TCF has been used to construct colorimetric and long-wavelength probes, resulting in 
reduced  interference from the auto-fluorescence of the samples.17,34,37–39 TCF has also been 
used to develop non-linear optical materials,40,41 and has been used in red fluorophore 
bioimaging42,43  and pH sensing.44 Recently, a variety of TCF-based probes have been used 
for biological imaging.33,34,36,37,45,46  
6.2.2. Enzymes 
Enzyme are proteinaceous biological catalysts (also called biocatalysts), capable of 
accelerating chemical reactions that facilitate many biological processes within living cells 
without being consumed or altered.46 Enzymes are highly specific, both in the reactions they 
catalyse and the substrates that they target.47 As enzymes are proteins, they can lose their 
catalytic activity upon exposure to high temperatures, extreme pH, and denaturing agents.48 
Additionally, some enzymes contain a non-protein component, known as a co-factor. These 
co-factors are typically metals, such as iron, manganese, cobalt, copper or zinc; however, 
203 
 
other organic molecules have been known to act as co-factors – in which case, it is called a 
co-enzyme.49 
Enzymes work by lowering the activation energy required to reach the intermediate or 
transition state, therefore more molecules reach this transition state, increasing the rate of 
the reaction (Figure 6.7). Additionally, enzymes achieve this without modifying the net 
energy change or altering the equilibrium position of the reaction, which is 
thermodynamically determined.48,50  
 
Figure 6.7: Energy diagram depicting a catalysed (red) and un-catalysed reaction (blue), with the reaction 
proceeding from left to right. In the presence of an enzyme the activation energy is lowered, resulting in an 
increase in rate 
 
During the course of the reaction, the substrate binds non-covalently to the active site of the 
enzyme to form a transient enzyme-substrate [ES] complex. The substrate bound to the 
enzyme then undergoes structural changes, resulting in the formation of the product and 




Enzymes are highly specific due to their complex protein structure, with two main binding 
models proposed. The first model is the “lock and key” hypothesis, proposed by Fischer in 
1894 (Figure 6.8A).48 This model presumes that the catalytic site of the enzyme is rigid, and 
the substrate has the correct shape to fit into this site.48 However, this model requires a high 
level of rigidity that is incompatible with current knowledge of enzymes’ molecular 




Another model termed the “induced fit” hypothesis has been proposed by Koshland, which 
is more accepted in the academic community (Figure 6.8B). 50 It hypothesises that the 
enzyme structure is flexible, not rigid. Upon contact with the correct substrate, 
conformational changes within the enzyme occur (i.e., the enzyme adapts its structure to 
the optimal conformation required to form the ES complex).50  
 
Figure 6.8: Schematic of enzyme-substrate binding: A) the lock-and-key model and B) the induced-fit 
model, where substrate binding distorts the conformations of both substrate and enzyme 
6.2.2.1. Enzyme Kinetics 
Enzyme kinetics is the study of various factors that determine the speed of enzyme-
catalysed reactions.49 The activity of an enzyme can be determined experimentally by 
measuring the initial velocity of the conversion of differing concentrations of substrate 
against a fixed concentration of enzyme.49 In steady-state kinetics, this is the phase where 
the rate of formation of intermediates and the rate of decomposition remain the same, thus 
the concentrations of reactive intermediates remains the same.48 During this reaction, 
substrate concentration is greater than enzyme concentration.48 This substrate-activity 
relationship is well known, with Michaelis-Menten first describing this phenomenon. Put 
simply, at high concentrations of substrate, a maximum velocity of reaction is reached (first 
order48); however, upon increasing substrate concentration, a point is reached where all the 
enzymes’ active sites are occupied, thus the enzyme becomes saturated.50 If the substrate 
concentration continues to increase past this point, a steady-state is achieved, and the 
reaction rate does not increase any further – the reaction behaves as zero order.50 Therefore, 
steady-state enzyme kinetics assumes that a catalytic reaction remains constant if the 
reaction is not exposed to continuous change.48  
    






Michaelis and Menten were the first people to derive simple assumptions about enzymatic 
reactions from first principles.49 The main concept of Michaelis-Menten kinetics is that the 
reaction takes place via the formation of the ES complex, which once formed can create the 
product (k2) or dissociate in the reverse direction without the formation of the product (k-1) 
(Equation 1).  
The Michaelis-Menten derivation requires two important assumptions: firstly, it only 
considers the initial velocity of the reaction, where the product concentration will be 
negligible ([S] > [P]). Therefore, it is possible to ignore the possibility of the product 
reverting back to the substrate. Secondly, it assumes that the concentration of the substrate 
exceeds the concentration of enzyme ([S] > [E]).49 
The derivation begins with an expression of the initial rate for the formation of the product. 








The concentration of ES is unknown; hence, it needs to be expressed in terms of known 
values. In a steady-state approximation it is possible to assume that [ES] remains constant, 
even though [S] and [P] concentrations can vary.49 The rate of formation of ES and the rate 
of its breakdown must therefore balance, where: 
𝑅𝑎𝑡𝑒 𝑜𝑓 𝐸𝑆 𝑐𝑜𝑚𝑝𝑙𝑒𝑥 𝑓𝑜𝑟𝑚𝑎𝑡𝑖𝑜𝑛 =  𝑘1[𝐸][𝑆] (3) 
and  
𝑅𝑎𝑡𝑒 𝑜𝑓 𝐸𝑆 𝑐𝑜𝑚𝑝𝑙𝑒𝑥 𝑏𝑟𝑒𝑎𝑘𝑑𝑜𝑤𝑛 = (𝑘−1 + 𝑘2)[𝐸𝑆] (4) 
Hence, at steady state: 
𝑘1[𝐸][𝑆] = (𝑘−1 + 𝑘2)[𝐸𝑆] (5) 
Solving for [ES]: 
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The Michaelis constant, Km, can be defined as follows: 




Thus, equation (6) can thus be simplified to: 




Since [S] > [E], the concentration of free substrate [S] is almost equal to the total 
concentration of substrate, and the concentration of uncombined enzyme [E] is equal to the 
total enzyme concentration [E]T minus [ES]. Including these terms into Equation 8 and 
solving for ES gives: 




We can then introduce this term into Equation 2 









The Michaelis constant, Km, is used to define the relationship between initial velocity and 
substrate concentration.49 Km corresponds to the substrate concentration at which the 
reaction rate reaches a value equal to half the maximum. The Km value is characteristic for 
each enzyme and each of its substrates when determined under the same experimental 
conditions,50 and is typically in the lower millimolar range.49 The value is inversely related 
to the affinity of the enzyme for its substrate; higher affinity to a substrate is indicated by a 
lower Km value.50  
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To reiterate, Vmax is the point of maximal velocity, where the enzyme is becoming close to 
saturation with the substrate. It is important to note that Vmax is a theoretical limit that 
cannot be achieved experimentally.49  
6.2.2.2. Clinical Diagnostic Applications of Enzymes 
Enzymes can be used for the detection and/or diagnosis of disease.51 Abnormalities in the 
normal physiology within the human body may cause a disruption to the concentration of 
particular enzymes, which can be exploited for disease diagnosis.52 Certain enzymes specific 
to diseased organs can be released into blood circulation; therefore, measuring these 
enzyme activities has been employed to aid clinical diagnosis of disease.51 There are a wide 
range of diseases where enzymes are used as ‘markers’, including cancer, diabetes, 
autoimmune diseases, and liver and heart malfunctions.52 For example, lactose 
dehydrogenase has two different isozymes in heart and skeletal muscle; any increase of this 
enzyme in the blood indicates tissue damage and the presence of the heart isozyme is 
indicative of a heart attack. Additionally, enzymes have been used as markers to determine 
the pathology of disease. For example, creatine kinase has been associated with myocardial 
infarction and muscle diseases, while alanine aminotransferase is known to be a liver-
specific indicator of disease.53 Commonly used enzymes for the diagnosis of various disease 
are outlined in Table 6.1.  
Table 6.1: Enzymes commonly used in the clinical diagnosis of disease. Adapted from Sarup Singh et al51   
Enzyme Disorder/disease Reference 
Acid phosphatase Malaria 54 
Alkaline phosphatase Chronic kidney disease 55 
Amylase Pancreatitis 56 
Aspartate aminotransferase Hepatic diseases 57 
Creatine kinase Myocardial damage 58 
Lactate dehydrogenase Necrosis  59 
Leukocyte esterase Urinary tract infection 60 
Lipase Skin disorders 61 
Lysozyme Rheumatoid arthritis 62 
6.2.2.3. Alkaline Phosphatase 
Alkaline phosphatase (ALP) was the earliest serum enzyme to be recognised to have clinical 
significance; in the 1920s it was discovered in high concentrations for bone and liver 
disease.53 ALP is a ubiquitous enzyme found in the majority of human tissues63 and catalyses 
the dephosphorylation process of various substrates, such as nucleic acids, proteins and 
small molecules.64 It also plays an important role in signal transduction and regulation of 
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intracellular processes (cell growth, apoptosis and signal transduction pathways).65 ALP is 
thus regarded a key biomarker in medical diagnosis.64,66 Abnormal levels of ALP in serum 
are an indicator of several diseases including bone disease,67 liver dysfunction,68 breast and 
prostatic cancer,69,70 and diabetes.71 Therefore, there is an increasing need to develop a novel 
system for the rapid and selective detection of ALP activity for use in clinical diagnosis.   
There have been numerous approaches to determining ALP levels, including 
colorimetric,72,73 chemiluminescence,74 electrochemical,75 surface-enhanced Raman 
spectroscopy76 and fluorescence.77,78 While there have been many fluorophores developed 
for assaying ALP activity (organic dyes,79,80 conjugated polymers,81 inorganic 
semiconductor dots,82 noble metal clusters83), many need high probe concentrations and 
have short wavelength emission, which limit their application in biological systems. Owing 
to this, focus has been placed on developing long wavelength/NIR probes, as they enable 
deeper tissue penetration and have reduced background interference from autofluorescence 
of living cells.84–86  
6.2.3. Aims of Study 
The  aim of this chapter was to design a novel fluorescent and colorimetric probe that could 
be used for the detection of ALP to aid in the diagnosis of clinically-relevant diseases. This 
Chapter aimed to: 
• Synthesise a novel fluorescent and colorimetric probe (termed TCF-ALP) 
• Optimise the conditions of the assay required for efficient ALP detection 
• Determine TCF-ALP sensitivity and selectivity 
• Determine the rate of reaction and kinetic parameters for TCF-ALP (Michaelis-
Menten kinetics) 
• To explore the use of ALP in clinically-relevant cell lines  
Additionally, the aim of this Chapter was  to build a foundation of knowledge so TCF-ALP 
could be further exploited for the detection of S. aureus species; discussed in greater detail 






6.3.1. Synthesis of TCF-ALP 
For the corresponding NMR spectra, please see Figures S1 – S9 in the Appendix. Briefly, 
TCF-ALP was synthesised in four steps with an overall yield of 27% (Scheme 6.2).  
 
 
Scheme 6.2: Synthetic route to TCF-ALP 
 
6.3.1.1. 2-(3-Cyano-4,5,5-trimethylfuran-2(5H)-ylidene) 
malononitrile (1)  
NaOEt (0.391 g, 5.75 mmol) was added to a solution of 3-hydroxy-3-methyl-2-butanone 
(4 mL, 38 mmol) and malonitrile (4.9 g, 74 mmol) in EtOH (10 mL) and stirred for 1.5 h. 
The reaction mixture was refluxed for 1 h, then cooled to room temperature and the solid 
precipitate filtered to afford the title compound (1) as a pale grey solid (4.92 g, 24.70 mmol, 






Two drops of piperidine were added to a mixture of 4-hydroxybenzaldehyde (0.122 g, 1 
mmol) and TCF (1) (0.228 g, 1.15 mmol) in EtOH (10 mL). The reaction mixture was heated 
in the microwave for 15 min at 100 °C and allowed to cool to room temperature. The solid 
precipitate was filtered off to afford the title compound (2) as a red solid (0.22 g, 0.72 mmol, 
72%)  
6.3.1.3.  (E)-4-(2-(4-Cyano-5-(dicyanomethylene)-2,2-dimethyl-2,5-
dihydrofuran-3-yl)vinyl)phenyl diethyl phosphate (3)  
Intermediate 2 (0.20 g, 0.66 mmol) was dissolved in a solution containing THF (10 mL) and 
NEt3 (0.3 mL). This was followed by the addition of DMAP (0.050 g). The resulting solution 
was cooled to 0 °C and diethylchlorophosphate (0.14 mL, 1 mmol) was added dropwise over 
the course of 15 min. The reaction mixture was monitored via TLC, and once the starting 
material was consumed (~ 2 hrs), EtOAc (50 mL) and H2O (50 mL) were added to the 
reaction mixture. The organic layer was washed with H2O (2 x 50 mL) and brine (50 mL). It 
was then dried (MgSO4) and concentrated in vacuo to afford the crude material. This crude 
material was purified via column chromatography over silica gel EtOAc:petroleum ether 
(30:70) to afford the title compound (3) as an orange solid (0.22 g, 0.50 mmol, 76%). 
6.3.1.4.  (E)-4-(2-(4-Cyano-5-(dicyanomethylene)-2,2-dimethyl-2,5-
dihydrofuran-3-yl)vinyl)phenyl phosphate (TCF-ALP) 
A solution of 3 (0.15 g, 0.34 mmol) in DCM (5 mL) was cooled to 0 °C before the dropwise 
addition of TMSI (0.1 mL, 0.68 mmol). The reaction mixture was stirred for 1 h before the 
solvent was removed in vacuo to afford the crude solid, which was purified via trituration 
(diethyl ether) to afford an orange solid (0.10 g, 0.26 mmol, 77 %).  
6.3.2. Mass Spectrometry 
High resolution mass spectrometry (HRMS) results were acquired on an externally 
calibrated Bruker Daltonics micrOTOF time-of-flight mass spectrometer coupled to an 
electrospray source (ESI-TOF). Calibration was achieved using sodium formate solution. 
Samples were introduced either by syringe pump or flow injection using an autosampler in 
an Agilent 1100 LC system. Bruker Daltonics software, DataAnalysis, was used to process 
the data. In this study, HRMS analysis was carried out on TCF-ALP before and after 
addition of ALP.  
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6.3.3. UV-Vis Spectroscopy of TCF-ALP 
UV-Vis measurements were carried out on a SPECTROstar Omega (BMG Labtech). UV-Vis 
spectra of TCF-ALP were obtained before and after the addition of 1 U/mL of ALP. The 
measurements were conducted in triplicate, in 50 mM Tris-HCl (pH 9.2) at 25 °C. 
6.3.4. Fluorescence of TCF-ALP Over Time 
In brief, 180 µL of differing concentrations of ALP (0.0 – 0.8 U/mL) in 50 mM Tris-HCl, pH 
9.2, were added to a black 96-well microtiter plate. The fluorescence intensity of these 
enzyme solutions were measured using a BMG Labtech CLARIOstar with excitation and 
emission wavelengths of 542 nm and 606 nm, respectively. After 3 min, 20 µL of 100 µM 
TCF-ALP in 50 mM Tris-HCl, pH 9.2 was added to the enzyme solutions and the 
fluorescence intensity was measured for 1 h at 1 min intervals at 25 °C. Blank (50 mM Tris-
HCl, pH 9.2) and negative (10 µM TCF-ALP and 50 mM Tris-HCl, pH 9.2) controls were 
conducted in tandem. All measurements were performed in triplicate.  
6.3.5. Limit of Detection (LOD) 
To determine the limit of detection, TCF-ALP (10 µM) was added to various concentrations 
of ALP (0.0 – 0.2 U/mL) in 50 mM Tris-HCl, pH 9.2 and incubated for 15 min at 25 °C. After 
incubation, the solutions were transferred to a black 96-well plate and emission spectra 
were obtained. Blank and negative controls were conducted in tandem. All measurements 
were performed in triplicate. 
After the spectra were obtained, the relative fluorescence intensity (RFI) at 606 nm was 
plotted versus concentration of enzyme, and the limit of detection (LOD) was calculated 
using the following formula (Equation 12): 
𝐿𝑂𝐷 =  3𝜎 𝑠𝑙𝑜𝑝𝑒⁄  (12) 
6.3.6. Inhibition Assay 
A stock solution of 4 mM of sodium orthovanadate (Na2VO3) was prepared in dH2O, and 
the pH adjusted to pH 10 with 1 M NaOH. The resultant yellow solution was then heated 
until the solution turned colourless. After cooling, the pH was checked, and the process 
repeated until the solution remained colourless after pH-adjustment. After, ALP (0.8 U/mL, 
50 mM Tris HCl, pH 9.2) was pre-incubated for 30 minutes with varying inhibitor 
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concentrations (0 – 2000 µM) at room temperature before the addition of TCF-ALP (10 
µM). The solution was incubated for 1 h at room temperature prior to fluorescence analysis 
to determine ALP activity.  
6.3.7. Enzyme Kinetics Assay 
Increasing concentrations of TCF-ALP (0.0– 20.0 µM) were added to 0.2 U/mL ALP in 50 
mM Tris-HCl, pH 9.2 and the subsequent enzymatic reaction was monitored through 
change of fluorescence intensity at 606 nm every 60 s for 30 min. The initial reaction 
velocities were obtained from the resultant kinetic curves and plotted against substrate 
concentration. The kinetic parameters (Km and Vmax) were determined by using nonlinear 
fitting models provided by the software package GraphPad Prism 6.0. The kinetic constants 
were reported as the mean ± standard deviation of triplicate experiments. 
6.3.8. Selectivity of TCF-ALP 
To determine the selectivity of TCF-ALP, 40 µL of 100 µM TCF-ALP was added to 360 µL 
of various biologically relevant enzymes (ALP, acid phosphatase [ACP], protease from 
Streptomyces griseus, porcine liver esterase, proteinase K) and non-specific binding 
proteins (bovine serum albumin and trypsin) at a concentration of 0.4 U/mL or equivalent 
(in 50 mM Tris HCl at pH 9.2, 7.1, or 5.0 dependent on experiment). The resultant solutions 
were incubated for 30 min at 25 ° C. After incubation, the solutions were transferred to a 
black 96-well plate and emission spectra were obtained. Blank and negative controls were 
conducted in tandem; all measurements were performed in triplicate. 
6.3.9. Cell Culture 
HeLa cells (human epithelial adenocarcinoma) were purchased from the Korean Cell Line 
Bank (Seoul, Korea). Cells were cultured in Eagle's Minimum Essential Medium (MEM) 
supplemented with heat-inactivated 10% fetal bovine serum, 100 U/mL penicillin and 
100 U/mL streptomycin. All cells were kept in 5% CO2 at 37 ℃. 
6.3.10. Confocal Microscopy Imaging  
Cells were seeded in  35-mm glass bottomed dishes at a density of 3.0 x 105 cells per dish in 
culture media. After culturing for 24 h, cells were incubated with 10 μM of the probe for 
30 min and washed with DPBS. Fluorescence images were recorded by means of confocal 
laser scanning microscopy (FV1200, Olympus, Japan). To prevent intracellular ALP activity, 
a 30 min pretreatment with 5 mM levamisole or 0.5 mM Na3VO4 (ALP inhibitors) was 
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carried out. To acquire the fluorescence image, cells were excited with a 559 nm laser and a 
575-675 nm emission filter was used.   
6.3.11.   Cytotoxicity Tests 
Cells were seeded in a 96-well plate with culture media. After culturing overnight, cells were 
incubated with various concentrations of sample for 24 h. To identify cell viability, reagents 
were removed and 0.5 mg/mL of MTT (Sigma) was added to the cells, which were then 
incubated for 4 h at 37 ℃ in a CO2 incubator. The formazan produced was dissolved in 
0.1 mL of dimethylsulfoxide (DMSO) and read at OD 650 nm with a Spectramax Microwell 
plate reader. Absorbance was determined and the mean cell viability was calculated as a 





6.4. Results and Discussion 
As shown in Scheme 6.3, TCF-ALP was based on the conjugation of TCF to an electron-
donating moiety, a phosphorylated phenol. This conjugation afforded an ICT D-π-A system, 
whose fluorescence properties varied dramatically following ALP-mediated phosphate 
group cleavage.  
 
 
Scheme 6.3: A TCF-based fluorescent probe (TCF-ALP) for the detection of alkaline phosphatase and/or 
acid phosphatase 
6.4.1. pH Optima 
Once TCF-ALP was synthesised, optimisation assays were performed to ensure the correct 
conditions were employed for successful colorimetric and fluorescent ALP detection by 
TCF-ALP. As TCF was originally used as a pH sensing fluorescent probe,44 it was not 
unreasonable to assume that pH would have an effect on TCF-based fluorescence; hence, 
the effect of pH on the rate of ALP-mediated hydrolysis of TCF-ALP was evaluated (Figure 
6.9).  
Without ALP, TCF-ALP displayed a negligible increase in fluorescence intensity between 
pH 3.0 – 10.0. However, upon incubation with ALP, a sharp increase in fluorescence 
intensity was observed between pH 6.0 – 10.0, with a maximum intensity observed at pH 
9.2. This was thought to be due to the combination of TCF-OH becoming deprotonated and 
ALP having an optimum pH of ~9.2. Consequently, all further in vitro experiments were 





Figure 6.9: Relative fluorescence intensity of TCF-ALP (10 µM) as determined with and without alkaline 
phosphatase (0.8 U/mL) in 50 mM Tris-HCl buffer at pH 3.0 – 10.0.  Measurements taken 1 h after incubation 
at 25 °C. λex = 542 (bandwidth 15) nm/ λem = 606 nm. Error bars indicate standard deviation (n = 3) 
6.4.2. Confirmation of ALP-mediated Hydrolysis 
Confirmation of the ALP-mediated hydrolysis of TCF-ALP was further confirmed by NMR 
(Figure 6.10). 31P NMR studies found that upon incubation with ALP, there was a decrease 
in TCF-ALP concentration (~2.4 ppm) and an increase in product formation (H3PO4;  ~0.5 
ppm) over 1 h. These results confirm that ALP was able to cleave the phosphorylated phenol; 
hence, the fluorescence of TCF-ALP was due to ALP-mediated hydrolysis forming the 
fluorescent, deprotonated TCF-OH.  
 
Figure 6.10: 31P NMR monitoring of TCF-ALP in the presence of ALP in 50 mM Tris-HCl buffer, pH 9.2. Scans 
were performed at 25 °C every 4 min for 1 h. The spectra show decreasing TCF-ALP concentration (~-2.4 ppm) 
with increasing product formation (H3PO4; ~0.5 ppm) over time 
The ALP-mediated hydrolysis of TCF-ALP was also confirmed via HRMS (Table 6.2). The 
results showed that upon incubation with ALP, the phosphate moiety of the TCF-ALP 
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probe was successfully cleaved, leaving behind the deprotonate, fluorescent TCF-OH 
moiety.  
Table 6.2: HRMS (FTMS-NSI) of TCF-ALP before incubation with ALP (m/z calculated for C18H14N3O5P: 
requires 382.0598 for [M-H]-, found 382.0604), and after 1 h incubation with ALP (m/z calculated for 





















0 C18 H14 N3 O5 P 0.80 382.0677 383.0677 383.0671 1.57 99.59 
60 C18 H13 N3 O2 0.79 302.0941 303.1014 303.1008 2.15 99.25 
Mass errors of between -5.00 and 5.00 ppm with isotope match scores above 60% are considered confirmation of molecular formulae. 
6.4.3. UV-Vis Spectroscopy 
Once it was confirmed that TCF-ALP could be successfully cleaved by ALP, UV-Vis 
titrations were performed. As shown in the UV-Vis spectra (Figure 6.11), TCF-ALP was 
found have an absorption maxima of ~430 nm. Upon incubation with 0.8 U/mL ALP, a 
bathochromic shift in the UV absorption maximum was observed (from 430 to 580 nm), 
which was accompanied by a colour change from yellow to purple.  






















Figure 6.11: UV-Vis spectra of TCF-ALP (10 µM) with (red) and without (black) 0.8 U/ml of ALP in 50 mM 







6.4.4. Fluorescence Assays 
6.4.4.1. Time Drive 
Next, fluorescence measurements were undertaken to determine the fluorescence response 
of TCF-ALP upon incubation with ALP. In brief, 10 µM of TCF-ALP was incubated with 
varying concentrations (0.0 – 0.8 U/mL) of ALP and the fluorescence intensity measured 
every minute for 1 h (Figure 6.12). There was a concentration-dependent increase in RFI 
with increasing concentrations of ALP. Additionally, the RFI increased with longer 
incubation times, with the higher ALP concentrations (0.4 – 0.8 U/mL) plateauing at ~ 
50000 after ~20, 40, and 60 minutes, respectively.  
 
Figure 6.12: Time drive of TCF-ALP (10 µM) with the addition of ALP (0.0 – 0.8 U/mL) in 50 mM Tris HCl, 
pH 9.2 at 25 °C. λex = 542 (bandwidth 15) nm / λem = 606 (bandwidth 20) nm. 
6.4.4.2. Limit of Detection 
As there was a concentration-dependent increase in RFI upon increasing ALP 
concentration, further studies were undertaken to determine the LOD of TCF-ALP. 
Various concentrations of ALP (0.0 – 0.2 U/mL) were incubated with 10 µM of TCF-ALP 
for 15 minutes at 25 °C before fluorescence spectra were obtained (Figure 6.13). As expected, 




Figure 6.13: Fluorescence spectra of TCF-ALP (10 µM) produced via the addition of ALP  (0 – 0.2 U/mL) in 
50 mM Tris-HCl buffer, pH 9.2 at 25 °C. λex = 542 (bandwidth 15) nm. All measurements were made 15 min after 
the addition of ALP 
 
 
Figure 6.14: Relative fluorescence intensity seen for TCF-ALP (10 µM) upon the addition of ALP (0.0 – 
0.2 U/mL) in 50 mM Tris-HCl buffer, pH 9.2 at 25 °C. λex = 542 (bandwidth 15) nm/ λem = 606 nm. Error bars 
indicate the standard deviation (n = 3). The measurements were made 15 min after the addition of ALP 
Using Equation 12, the LOD was calculated to be 0.12 mU/mL. This sensitivity seemed to 
be in accordance with other fluorescent-based methods found in the literature, even 
displaying increased sensitivity in comparison to other fluorescent probes (Table 6.3). As 
the majority of ALP probes in the literature have focused on detecting ALP as a biomarker 
for human disease, it was important to ensure that TCF-ALP could reliably detect ALP in 
serum. It is widely accepted that serum ALP levels in heathy adults lies between 39 – 117 
U/mL;87,88 thus, owing to the LOD of TCF-ALP, it can be suggested that TCF-ALP is 
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capable of detecting clinically relevant levels of ALP, and therefore could be used in clinical 
assays.  









AIE 495 0.0077 60 89 
Carbon dots ~ 445-465 0.90 15 90 
Carbon dots 500 0.0003 20 91 
ESIPT 400 1.3 40 78 
FRET 494/548/624 0.06 8 92 
FRET/AIE 570 0.2 10 93 
ICP nanoparticles 738 3.00 20 94 
Quenching 402 0.27 10 95 
ICT 738 3.00 20 96 
ICT 700 0.07 30 86 
ICT 550/650 3.8 30 97 
ICT 606 0.12 15 This Work 
 
6.4.5. Inhibition of TCF-ALP 
To further confirm that the hydrolysis of TCF-ALP was due to ALP activity, inhibition 
studies were performed using sodium orthovanadate, Na2VO3, a common  competitive 
inhibitor for ALP.98  Competitive inhibitors work by increasing the value of the Michaelis-
Menten constant without modifying the maximum velocity of the enzyme. Competitive 
inhibitors achieve this through three different mechanisms:50 
• Competitive inhibitors can be structurally similar to the substrate and compete for 
the enzyme’s active site 
• Competitive inhibitors do not possess a similar structure to the substrate; however, 
they still compete for the enzyme’s active site 
• Competitive inhibitor and substrate bind to different sites on the enzyme, but the 
binding of one prevents the binding of the other, likely by inducing protein 
conformational changes 
As Na2VO3 can adopt a stable trigonal bipyramidal structure similar to that of phosphate, it 
inhibits by replacing ALP as a substrate, leading to the formation of unstable analogues of 
the enzyme-substrate complex.99  
220 
 
ALP (0.8 U/mL, 50 mM Tris HCl, pH 9.2) was pre-incubated for 30 min with varying 
inhibitor concentrations (0.0 – 2000.0 µM). After pre-incubation, TCF-ALP (10 µM) was 
added and the change in fluorescence was measured over 1 h (Figure 6.15).  
 
Figure 6.15: Fluorescence intensity of  TCF-ALP (10 µM) in the presence of 0.8 U/mL of ALP pre-treated for 
30 minutes with Na3VO4 (0.0 – 2000 µM). Measurements were taken every minute for 1 h at 25 °C in 50 mM 
Tris HCl, pH 9.2. λex = 542 (bandwidth 15) nm/ λem = 606 (bandwidth 20) nm 
As shown in Figure 6.15, there was a decrease in RFI with increasing inhibitor 
concentrations. At the 30 min time point, the RFI was plotted as a function of natural 
logarithm of inhibitor concentration (Figure 6.16) so the half maximal inhibitory 
concentration (IC50) could be determined. The IC50 measures the potency of a substance at 
inhibiting a specific biological or biochemical function. For this system, it was found to be 
6.23 µM (R2 = 0.9932), which was similar to values quoted in the literature.75,86  
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Figure 6.16: Inhibition study with TCF-ALP (10 µM) in the presence of different concentrations of Na3VO4. 
Fluorescence Intensity was recorded after 30 min incubation time with TCF-ALP. All reactions were performed 
with 0.8 U/ml ALP in 50 mM Tris-HCl pH 9.2 at 25 °C. λex = 542 (bandwidth 15) nm/ λem = 606. Error bars 
indicate standard deviation (n = 3) 
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IC50 can be converted to an absolute inhibition constant Ki using the Cheng-Prusoff equation 









Where Ki is the binding affinity of the inhibitor, IC50 is the functional strength of the 
inhibitor, [S] is the fixed substrate concentration and Km is the concentration of substrate at 
which enzyme activity is at half maximal.  
Ki is often used as it is an absolute value, whereas IC50 may vary between experiments 
depending on experimental conditions. Ki values relate to the dissociation of the inhibitor-
bound enzyme complex,100 with smaller values denoting tighter binding affinity of the 
inhibitor. For this study Ki was calculated to be 4.87 µM, which is similar to other values 
reported in the literature.101 
6.4.6. Selectivity of TCF-ALP 
To determine the selectivity of TCF-ALP, it was incubated with ALP and the fluorescence 
intensity compared to TCF-ALP incubated with biologically relevant enzymes and non-
specific binding proteins (at their optimal pH values), after 30 minute incubation at 25 °C. 
As shown in Figure 6.17, TCF-ALP displayed high selectivity towards ALP over other 
common enzymes or non-specific binding proteins (58-fold increase in fluorescence, pH 
9.2). Interestingly, TCF-ALP produced a 20-fold increase in fluorescence intensity when 
treated with ACP at pH of 5.0.  
As ACP displayed activity towards TCF-ALP, further experiments were undertaken to 
determine the selectivity of TCF-ALP at a neutral pH of 7.1. As shown in Figure 6.18, TCF-
ALP proved capable of detecting ACP (25-fold fluorescence enhancement) and ALP (38-
fold enhancement) at a physiological pH of 7.1. These results suggest that TCF-ALP can be 
used to detect both ALP and ACP at physiological pH, with a preference towards ALP. 
















Figure 6.17: A) Fluorescence spectra and B) selectivity bar chart of TCF-ALP (10 µM) recorded in the 
presence of  1. alkaline phosphatase (50 mM Tris-HCl, pH 9.2), 2. acid phosphatase (50 mM Tris-HCl, pH 5.0), 
3. bovine serum albumin (0.1 mg/mL), 4. protease from Streptomyces griseus, 5. porcine liver esterase, 6. 
proteinase K, 7. trypsin (0.8 BAEE U/mL). 8-10. negative controls at pH 5.0, 7.1 and 9.2, respectively. All 
enzymes were standardised to 0.8 U/mL in Tris-HCl buffer pH 7.1 unless otherwise stated. λex = 542 (bandwidth 
15 nm)/ λem  = 606 nm. The measurements were made 30 min after enzyme addition. Error bars indicate the 














Figure 6.18: A) Fluorescence spectra and B) selectivity bar chart of TCF-ALP (10 µM) recorded in the 
presence of  1. alkaline phosphatase, 2. acid phosphatase, and 3. negative control. All enzymes were 
standardised to 0.8 U/mL in Tris-HCl buffer pH 7.1 unless otherwise stated. λex = 542 (bandwidth 15 nm)/ λem  
= 606 nm. The measurements were made 30 min after enzyme addition. Error bars indicate the standard 
deviation (n = 3) 
According to current standards, determination of ALP and ACP is undertaken at the 
phosphatase’s optimum pH. For example, the Centers for Disease Control and Prevention 
(CDC) procedure for ALP determination is carried out in 2-amino-2-methyl-1-propanol 
(AMP) buffer at pH 10.3.102 Likewise, ACP determination is carried out at pH 4.0 – 6.0.103  
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Following these observations, further studies were conducted to determine selectivity at pH 
5.0 and 9.2 (Figures 6.19 – 6.20). Results showed that TCF-ALP acts selectivity towards 
ACP at acidic pH, and ALP at alkaline pH. Therefore, TCF-ALP can be used to selectively 
detect ALP/ACP in clinical assays, or live cell systems (provided the buffer solution is 












Figure 6.19: A) Fluorescence spectra and B) selectivity bar chart of TCF-ALP (10 µM) recorded in the 
presence of  1. alkaline phosphatase, 2. acid phosphatase, and 3. negative control. All enzymes were 
standardised to 0.8 U/mL in Tris-HCl buffer pH 5.0. λex = 542 (bandwidth 15 nm)/ λem  = 606 nm. The 













Figure 6.20: A) Fluorescence spectra and B) selectivity bar chart of TCF-ALP (10 µM) recorded in the 
presence of  1. alkaline phosphatase, 2. acid phosphatase, and 3. negative control. All enzymes were 
standardised to 0.8 U/mL in Tris-HCl buffer pH 9.2. λex = 542 (bandwidth 15 nm)/ λem  = 606 nm. The 




6.4.7. Enzyme Kinetics 
As TCF-ALP was selective towards ACP and ALP, further studies were needed to determine 
the kinetic parameters of TCF-ALP towards these enzymes. Firstly, kinetic parameters 
were obtained for ALP at pH 9.2, and to confirm TCF-ALP was more selective towards ALP 
versus ACP at neutral pH, kinetic parameters were obtained for both ALP and ACP at pH 
7.1.  
The kinetics of ALP towards TCF-ALP at pH 9.2 were determined via fluorescence 
spectroscopy. Various concentrations of TCF-ALP (0 – 20 µM) were incubated with 0.2 
U/mL of ALP and the RFI was measured for 30 minutes. The initial velocity was calculated 
from the resultant data, and subsequently fitted to the Michaelis-Menten equation 
(Equation 11). 
As shown in Figure 6.21, fluorescence increased with increasing TCF-ALP concentration 
upon incubation with 0.2 U/mL ALP in 50 mM Tris-HCl, pH 9.2. Once the initial velocities 
were determined and plotted, the Vmax was calculated to be 3029 ± 157.3 RFI/min and the 
Km 35.81 ± 2.63 µM. These results denote a strong binding between the substrate and 
enzyme, as Km values for the majority of enzymes lie between 10-1 and 10-7 M.47  
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Figure 6.21: A) Time-dependent fluorescence intensity seen for increasing concentrations of TCF-ALP (0 – 
20 µM) in the presence of 0.2 U/mL of ALP in 50 mM Tris-HCl buffer, pH 9.2. B) Plot of initial velocity (υ0) 
against TCF-ALP concentration. Measurements taken at 25 °C, λex = 542 (bandwidth 15 nm)/ λem = 606 
(bandwidth 20) nm. Error bars indicate standard deviation (n = 3) 
To confirm TCF-ALP was more selective towards ALP than ACP at neutral pH, kinetic 
experiments were conducted at pH 7.1, and the resultant Km and Vmax were compared 
(Figures 6.22 and 6.23). It was found that ALP has a smaller Km value in comparison to ACP 
(0.38 ± 0.042 µM and 99.22 ± 13.16 µM, respectively) and a lower Vmax (208 ± 3.81 min-1 
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and 1962 ± 223.6 min-1, respectively). Hence, ALP has higher affinity towards TCF-ALP 
compared to ACP, thus is more selective towards ALP at physiological pH. 
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Figure 6.22: A) Time-dependent fluorescence intensity seen for increasing concentrations of TCF-ALP (0 – 
20 µM) in the presence of 0.2 U/mL of ALP in 50 mM Tris-HCl buffer, pH 7.1. B) Plot of initial velocity (υ0) 
against TCF-ALP concentration. Km = 0.38 ± 0.042 µM, Vmax = 208.00 ± 3.81 min-1. R2 = 0.9804. Measurements 
taken at 25 °C, λex = 542 (bandwidth 15 nm)/ λem = 606 (bandwidth 20) nm. Error bars indicate standard 
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Figure 6.23: A) Time-dependent fluorescence intensity seen for increasing concentrations of TCF-ALP (0 – 
20 µM) in the presence of 0.2 U/mL of ACP in 50 mM Tris-HCl buffer, pH 7.1. B) Plot of initial velocity (υ0) 
against TCF-ALP concentration. Km = 99.22 ± 13.16 µM, Vmax = 1962 ± 223.6 min-1.R2 =  0.9989. Measurements 
taken at 25 °C, λex = 542 (bandwidth 15 nm)/ λem = 606 (bandwidth 20) nm. Error bars indicate standard 




6.4.8. Cell-based Assays 
While the principle aim of this probe was for it to be used as a diagnostic marker for bacterial 
infections (see Chapter 7), the detection of ALP also has a clinical utility in the diagnosis of 
other diseases. Owing to this, TCF-ALP was sent to Juyoung Yoon at Ewha Womans 
University, Seoul, South Korea to perform cell culture experiments. Firstly, the cytotoxicity 
of TCF-ALP was assessed using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-
tetrazolium bromide (MTT) assay (Figure 6.24). The MTT assay measures cellular 
metabolic activity; it is often used to determine the cell viability and proliferation of specific 
cells in response to incubation with a substrate (e.g., fluorescent probe), and therefore can 
be used to determine parameters such as cytotoxicity. The MTT assay is a colorimetric assay 
based on the reduction of a yellow tetrazolium salt to purple formazan crystals by 
metabolically active cells via oxidoreductase enzymes. The more intense the purple colour, 
the greater the number of viable, metabolically active cells.104  
Figure 6.24 shows that negligible cell toxicity was observed for TCF-ALP concentrations 
between 0 – 5 µM, and cell viability was only slightly reduced (cell viability: 91%) when 
incubated with 10 µM TCF-ALP – indicating good biocompatibility.  
 
Figure 6.24: HeLa cells were incubated with increasing concentrations of TCF-ALP for 24 h. After incubation, 
cells were treated with MTT media and cultured for another 4 h. Absorbance of the untreated cells were 
determined as 100 % live. n = 3 ± standard deviation 
 
For cell imaging, 10 µM of TCF-ALP was incubated with HeLa cells as they are known to 
overexpress ALP.  As shown in Figure 6.25, TCF-ALP was cell permeable in HeLa cells, and 
provided a clear ‘turn on’ response. To determine whether this increase in fluorescence was 





















‘turn on’ response was observed when cells were pre-incubated with 0.5 mM of Na3VO4, with 
further reduction in fluorescence intensity observed upon increasing inhibitor 
concentration. The decrease in TCF-ALP activity upon increasing inhibitor concentrations 
supports the hypothesis that any increase in TCF-ALP fluorescence levels seen for HeLa 
cells in the absence of Na3VO4 was due to ALP activity. We thus conclude TCF-ALP is 
capable to selectively detect ALP activity in cellular imaging.  
 
 
Figure 6.25: Images of HeLa cells incubated under the following conditions: (a) No treatment. (b) TCF-ALP 
(10 μM, 30 min). (c) Pre-treated with Na3VO4 (5 mM, 30 min), followed by the addition of TCF-ALP (10 μM, 30 
min). (d) Pretreated with Na3VO4 (0.5 mM, 30 min) and TCF-ALP (10 μM, 30 min). Cells were washed with 
DPBS before their fluorescence images were acquired using a confocal microscope. Top half: fluorescence 
images, bottom half: fluorescence images merged with its corresponding DIC image. Ex. 559 nm/ em. 575-675 
nm. Scale bar : 20 μm. DIC - differential interference contrast 
Next, the focus shifted towards myogenic murine C2C12 cells; they are a subclone from a 
myoblast line established from normal adult C3H mouse leg muscle (Figure 6.26). 
Treatment of C2C12 cells with TCF-ALP resulted in a low fluorescence ‘turn-on’, indicating 
low ALP levels. Upon pre-treatment of C2C12 cells with bone morphogenic protein-2 (BMP-
2) (300 ng/mL, 3 days) resulted in a significant increase in TCF-ALP-derived fluorescence 
intensity, indicative of high ALP levels. BMP-2  is capable of inducing osteoblast 
differentiation in a variety of cell types and regulates the expression of genes activated 
during osteoblast differentiation.17 Additionally, BMP-2 has been shown to increase ALP 
mRNA expression and ALP activity,106,107 which could explain why pre-treatment with BMP-
2 resulted in increased levels of ALP activity and corresponding fluorescence intensity upon 
incubation with TCF-ALP. 
Once again, pre-incubation with an ALP inhibitor (levamisole) led to a limited fluorescence 
response being observed in the cells treated with TCF-ALP (with or without BMP-2), 
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further providing support for the theory that TCF-ALP is capable of imaging endogenous 
ALP activity, including ALP activity induced by BMP-2. 
 
 
Figure 6.26: Images of C2C12 cells incubated under the following conditions: (a) TCF-ALP only (b) levamisole 
+ TCF-ALP, (c) BMP-2 + TCF-ALP (d) BMP-2 + levamisole + TCF-ALP. Top : fluorescence images, bottom: 


















6.5. Conclusions and Future Work 
This chapter describes the novel synthesis of TCF-ALP, a fluorescent and colorimetric 
probe used to detect phosphatase activity. The hydrolysis of TCF-ALP by ALP was 
confirmed via 31P NMR and mass spectrometry.  
 Subsequent experiments found that TCF-ALP was capable of detecting ALP, with a LOD 
of 0.12 mU/mL; a concurrent colorimetric response from yellow to purple was also 
observed. Additionally, inhibition experiments using sodium orthovanadate further 
confirmed the dephosphorylation and subsequent activation of TCF-ALP with ALP, as 
there was a decrease in fluorescence intensity upon increasing inhibitor concentrations, 
with IC50 and Ki values similar to that reported in the literature. 
 TCF-ALP displayed high selectivity towards ALP compared to other biologically relevant 
enzymes and non-specific binding proteins at their optimal pH, with the exception of ACP. 
Owing to the increase in fluorescence intensity when TCF-ALP was incubated with ACP, 
further experiments were conducted to evaluate the selectivity of TCF-ALP towards ALP 
and ACP at pH 9.2, 7.1, and 5.0. It was found that TCF-ALP was more selective towards 
ALP at pH 9.2, while it was more selective towards ACP at pH 5.0. At physiological pH, the 
selectivity assay showed that TCF-ALP was more selective towards ALP vs ACP, and this 
was confirmed by calculating their corresponding Km and Vmax values.  
Finally, TCF-ALP was investigated using human HeLa cells and murine C2C12 cells pre-
treated with BMP-2 to increase ALP activity. The results showed that TCF-ALP was cell 
permeable and capable of detecting ALP activity within the cells at concentrations (10 µM) 
that were non-toxic. These results suggest that TCF-ALP could be used as a tool for 





6.6.1. Nuclear Magnetic Resonance (NMR) Spectra 
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Figure S3: 1H NMR of (E)-2-(3-Cyano-4-(4-hydroxystyryl)-5,5-dimethylfuran-2(5H)-ylidene)malononitrile 












































































































Figure S4: 13C NMR of (E)-2-(3-Cyano-4-(4-hydroxystyryl)-5,5-dimethylfuran-2(5H)-ylidene)malononitrile 

















































Figure S5: 1H NMR of (E)-4-(2-(4-Cyano-5-(dicyanomethylene)-2,2-dimethyl-2,5-dihydrofuran-3-


























































































































Figure S6: 13C NMR of (E)-4-(2-(4-Cyano-5-(dicyanomethylene)-2,2-dimethyl-2,5-dihydrofuran-3-






































Figure S7: 1H NMR of (E)-4-(2-(4-Cyano-5-(dicyanomethylene)-2,2-dimethyl-2,5-dihydrofuran-3-









































































































Figure S8: 13C NMR of (E)-4-(2-(4-Cyano-5-(dicyanomethylene)-2,2-dimethyl-2,5-dihydrofuran-3-












Figure S9: 31P NMR of (E)-4-(2-(4-Cyano-5-(dicyanomethylene)-2,2-dimethyl-2,5-dihydrofuran-3-
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Chapter 7: Using TCF-ALP for the Detection of 
Staphylococcus aureus 
7.1. Overview of Chapter 
The research presented in this chapter describes the initial proof-of-concept studies for the 
use of the novel fluorescent probe TCF-ALP in the detection of S. aureus alkaline 
phosphatase (Scheme 7.1). Herein, TCF-ALP underwent extensive microbiological 
examination to determine its ability to detect S. aureus. Experiments included selectivity 
and sensitivity assessments via planktonic suspension assays, biofilm studies, and ex vivo 
testing on porcine skin. Owing to promising results, TCF-ALP was immobilised within a 
poly (vinyl alcohol) (PVA) hydrogel and the resultant material was examined for its 
feasibility as a point-of-care (PoC) diagnostic device. The TCF-ALP hydrogel system 
underwent the aforementioned microbiological tests and was deemed successful if an 
increase in fluorescence intensity, and a corresponding colour change from yellow to purple, 
was witnessed.  
 
 
Scheme 7.1: A TCF-based fluorescent probe (TCF-ALP) for the detection of S. aureus alkaline phosphatase 
7.2. Introduction 
7.2.1. Detecting Pathogenic Bacteria 
Traditionally, the gold-standard method to detect pathogenic bacteria in a clinical setting is 
via the use of culture and counting methods.1 Bacterial isolates are routinely grown on agar 
plates (non-differential, differential, selective, chromogenic, or a combination of all four) 
and incubated at a set temperature and time. If needed, observable colonies are then 
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subjected to further investigation (e.g. microscopy and biochemical tests) to identify the 
pathogenic bacteria present.2 Despite the accuracy of these tests, they are time consuming, 
require highly skilled personnel, and are only applicable to pathogens that can be routinely 
grown in a laboratory environment.1,2 
An improvement over conventional culture-based methods was seen with the introduction 
of molecular diagnostic methods that identify microbial pathogens using genomic makers. 
These methods include: Enzyme-linked Immunosorbent Assays (ELISA), hybridisation-
based detection systems, Polymerase Chain Reaction (PCR) amplification methods, and 
DNA microarrays. While they are rapid and offer high sensitivity and selectivity, there are 
drawbacks, including high cost, complicated methodology, and requiring specialised 
equipment and personnel.3–6  
Consequently, research has shifted towards the development of biosensors and organic-
based fluorescent probes for the detection of pathogenic bacteria. Biosensors are composed 
of a biorecognition unit that recognises the bacterial target (such as a nucleic acid, antibody, 
enzyme, or whole cell) and a transducer that converts the recognition event into a 
measurable readout (e.g., optical, electrochemical, thermal, or mechanical).7  As shown in 
the previous chapter, organic-based fluorescent probes can recognise pathogenic bacteria 
through the detection of compounds such as enzymes, which upon recognition of the target 
molecule result in the formation of a fluorescent compound. Both biosensors and organic-
based fluorescent probes are advantageous as they can confirm the presence of a bacterial 
infection without the need for isolation or pre-incubation, reducing the time of the assay.8–
10 Additionally, they are easy to synthesise, relatively low-cost, have a high degree of 
selectivity and sensitivity, and most importantly, can be used as a point-of-care (PoC) device 
without the need of a specialist user. 8–10 For the purposes of this work, the focus will be on 
the use of fluorescent and colorimetric probes for the detection of pathogenic bacteria.  
7.2.2. Use of Fluorescent and Colorimetric Probes for the 
Detection of Pathogenic Bacteria 
Dyer11 and Bascomb12 were some of the first researchers to develop fluorescent probes for 
the detection of bacterial enzymes. Certain bacteria possess enzymes that are unique to their 
species or overexpress certain enzymes during the course of an infection, and as such can 
be used as a target for bacterial detection.  
The introduction to this chapter will discuss the development of novel colorimetric and 
fluorescent-based probes for the detection of bacterial enzymes. While all probes are 
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predominately used in liquid suspension, some have been utilised for the development of 
chromogenic or fluorescent media, or as PoC devices via the use of paper and/or 
nanoparticles.  
7.2.2.1. Glycosidases 
7.2.2.1.1. β-D-Glucuronidase  
E. coli is an indicator of faecal contamination, and as such there is a pressing need to be able 
to identify it in food and water samples. One method is through the detection of β-D-
Glucuronidase (GUD), a glycosidase that catalyses the hydrolysis of β-D-
glucopyranosiduronic derivatives into their corresponding aglycons and D-glucuronic 
acid.13 While the majority of Enterobacteriaceae do not possess GUD activity (excluding 
Shigella, Salmonella, and Yersinia spp.),13 it is present in 94 – 96% of E. coli strains,14 
making it is an attractive target for fluorescent and colorimetric probes. However, it is 
important to note that some pathogenic E. coli strains such as E. coli O157:H7 do not 
possess GUD activity,15 hence the detection of GUD is often performed in parallel with the 
detection of β-galactosidase (β-gal; Section 7.2.2.1.2.). 
The most commonly used substrate for GUD detection is 4-methylumbelliferyl-β-D-
glucuronide (MUG; Figure 7.1), which upon hydrolysis by GUD yields the quantifiable 4-
methylumbelliferone (4-MU) fluorogenic product.13 The use of MUG for E. coli 
identification is advantageous over conventional culture-based methods as E. coli found in 
natural waters can lose its ability to be cultured, a condition known as viable but non-
culturable (VBNC) bacteria. However, VBNC bacteria can still retain metabolic activity, and 
hence MUG can still be  used to detect GUD16,17 as shown by George et al, who found that 
the presence of low concentrations of VBNC bacteria within freshwater samples resulted in 
a higher enzymatic activity per culturable coliform in contaminated waters.18  Additionally, 
MUG has been utilised in the development of hand-held fluorimeters for the rapid on-site 
identification of E. coli in drinking water.19,20  
However, an inherent disadvantage of 4-MU is its relatively high pKa value of 7.8, which at 
physiological pH (pH 7.4) results in partial dissociation of 4-MU to the highly fluorescent 
anion. To improve upon this, Perry et al synthesised 6-chloro-4-methylumbelliferyl-β-D-
glucuronide (CMUG; Figure 7.1) and investigated its ability to detect GUD-producing E. 
coli.21 Of the 38 E. coli strains investigated, 90% tested positive for GUD after 18 h 
incubation,  and all strains exhibited a higher fluorescence with CMUG compared to MUG, 




Figure 7.1: Chemical structure of 4-methylumblliferyl-β-D-glucuronide (MUG) and 6-chloro-4-
methylumbelliferyl-β-D-glucuronide (CMUG) 
 
There are also a variety of colorimetric probes that have been utilised for the detection of E. 
coli. Magro et al developed resorfin-β-D-glucuronide (REG 4; Scheme 7.2), which 
underwent a colour change from orange to deep pink upon hydrolysis by GUD.22 REG 4 
was selective for E. coli, with the negative controls of P. aeruginosa and K. pneumonia not 
displaying a colour change. Like CMUG, the deprotonated form of REG 4 predominates at 
physiological pH, therefore making it a favourable probe over the conventional MUG.  
 
 
Scheme 7.2: Hydrolysis of resorfin-β-glucuronide (REG 4) in the presence of GUD-producing Escherichia 
coli 
 
A PoC paper-based device (µPAD) for the detection of E. coli has also been developed 
utilising 5-bromo-4-choro-β-D-glucuronic acid (X-β-gluc; Figure 7.2).23 When a sample 
contaminated with E. coli was placed on the device, the bacterial cells were lysed, releasing 
the intracellular GUD, which subsequently reacted with X-β-gluc, turning the paper sheet 
blue. Experiments showed that without enrichment of the sample the LOD of this system 
was 107 CFU/mL, but with up to 12 h of enrichment in growth medium, the LOD was 








Figure 7.2: A) Chemical structure of 5-bromo-4-choro-β-D-glucuronic acid (X-β-gluc) and B) Schematic of 
the paper-based device showing the layers of the point-of-care device for the detection of GUD from Escherichia 
coli. Adapted from Kim et al with permission by the Royal Society of Chemistry©23  
7.2.2.1.2. β-D-Galactosidase  
β-D-Galactosidase (β-GAL) catalyses the breakdown of lactose into galactose and glucose 
and is commonly used as a target for detection of the coliform group within 
Enterobacteriaceae.13 Like GUD, β-GAL is predominately used to measure the hygienic 
quality of water and food samples.24  
Fluorescent probes based on 4-MU are predominately used to detect β-GAL (e.g. 4-MU-
GAL). However, Chilvers et al synthesised other coumarin-based fluorescent probes and 
found that they were less inhibitory towards bacteria compared to 4-MU-GAL and 
displayed enhanced fluorescence.25 In particular ethyl-7-hydroxycoumarin-3-carboxylate-
β-D-galactoside (EHC-GAL) showed promising results in the identification of coliform 
bacteria.  
Further fluorescent probes have also been developed such as 2-arylbenzothiazone 
derivatives, which were able to identify coliform bacteria, especially E. coli, Enterobacter 
cloacae, and Serratia marcescens.26 Additionally, novel colorimetric probes have been 
synthesised for the development of chromogenic agar. Alazarin-β-galactopyranoside (Aliz-
gal; Scheme 7.3) can be hydrolysed by β-GAL, releasing alizarin, subsequently complexing 
with various metal ions to form brightly coloured chelates.27 Aliz-gal was able to detect 
100% (n=182) of strains that displayed β-GAL activity, producing localised, bright violet 




Scheme 7.3: Hydrolysis of Alazarin-β-galactopyranoside (Aliz-gal) and subsequent complexation with iron 
(Fe)27 
Another colorimetric probe that is frequently used to detect β-GAL is chlorophenol red β-
galactopyranoside (CPRG), as it is faster and more sensitive than the colorimetric O-
nitrophenyl-β-galactopyranoside (ONPG) and the fluorescent 4-MU-GAL.28,29 Further 
derivatives of CPRG have been developed, for instance, Sicard et al found that when CPRG 
was hydrolysed by β-gal, the sulphonated pyranine of chlorophenol red (CPR) can interact 
with poly-L-arginine (pR) forming a CPR-pR complex which is strongly fluorescent, 
creating an ‘off-on’ fluorescent probe for the detection of E. coli (Scheme 7.4).30 While the 
complex was inhibitory towards actively growing bacteria (due to cell lysis by 1 wt% pR), it 
could be used for bacteria that had been previously cultured and/or isolated. When E. coli 
was incubated with CPR-pR complex for 30- or 60- min, with and without the addition of 
B-PER (a lysing agent), results showed a ~10-fold increase in fluorescence intensity in 
samples with lysed bacteria, due to the release of intracellular β-GAL. The activity of CPR-
pR was typically 40-fold better than the other dyes used in this experiment (ONPG, 4-MU-
GAL, CPRG) for the detection of E. coli. 
 
Scheme 7.4: Hydrolysis of chlorophenol red β-galactopyranoside (CPRG) and subsequent complexation 
with poly-L-arginine (pR) to form the fluorescent CPR-pR in the presence of β-galactosidase 
POC µPADs have been developed that utilise CPRG for the detection of coliform bacteria.31 
Samples of E. coli were isolated and cultured in enrichment media for 4.5 h before 
subsequent lysing of the cells and placement onto the µPAD. The device was able to detect 
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pure cultures of E. coli, indicated by a colour change from yellow to red, with the overall 
assay time (including enrichment and detection) between 8 – 12 h. This device was 
improved upon by Jahanshahi-Anbuhi et al, who included a layer of paper containing a 
lysing agent (B-PER) in the stacked µPAD.32 This device could detect coliform bacteria, 
detecting E. coli concentrations as low as 105 CFU/mL (with no previous enrichment). Kim 
et al utilised a different colorimetric substrate (5-bromo-6-chloro-3-indoxyl-β-galactose 
(Magenta-β-gal) for their µPAD and found that without enrichment it could detect 107 
CFU/mL of E. coli, lowered to 101 CFU/mL with enrichment – indicated by a colour change 
from colourless to purple.23  
7.2.2.1.3. β-D-Glucosidase  
β-D-glucosidase (β-Glu) is present in numerous bacterial species and has been used in the 
differentiation of Streptococci spp.,33 coagulase-negative Staphylococci (CoNS)34 and the 
differentiation of Salmonella from other Enterobacteria spp.35  
While 4-methylumblliferyl-β-D-glucosidase (MU-GLU) has been used for the 
identification of β-Glu,33 Perry et al synthesised four other coumarin-based fluorescent 
probes (Figure 7.3) and evaluated their ability to detect β-Glu activity in Enterococci spp.21 
A total of 42 Enterococci strains were tested, including Enterococcus faecalis (E. faecalis) 
and Enterococcus faecium (E. faecium). Streptococcus spp. were used as a negative control. 
Results showed that all Enterococci spp. displayed β-Glu activity after 18 h incubation with 
the fluorescent probes, and that probes 2 – 4 displayed, on average, a higher fluorescence 
signal than the conventional MU-GLU.  
 
 
Figure 7.3: Chemical structure of 4-MU and the corresponding coumarin derivates 1-4 
 
In colorimetric assays, p-nitrophenyl-β-glucopyranoside (pNPG) is frequently used for the 
identification of β-GLU bacteria.36 pNPG entrapped within an agarose gel has been utilised 
for the detection of E. faecium,37 whereby upon hydrolysis the liberated p-nitrophenol 
(pNP) becomes trapped within the agarose gel and a colour change from colourless to 
yellow can be observed by the naked eye. An initial inoculum of 1.0 – 1.5 x 104 CFU/mL, and 
an incubation time of approximately 18 h was needed to observe a detectable colour change.  
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7.2.2.1.4. α-Amylase and α-Glucosidase 
α-amylase is frequently utilised in the detection of Bacillus spp. The standard method to 
detect α-amylase is the colorimetric assay using dinitrosalicylic acid (DNS).38,39 However, 
Xia et al developed a fluorescence in situ enzyme-staining approach using a boron 
dipyrromethene (BODIPY) fluorescein-labelled (FL) DQTM starch.40 Upon incubation with 
Bacillus spp., α-amylase hydrolysed the probe and fluorescence was observed. However, 
this assay was only suitable for Bacillus spp. in their vegetative state, as the endospores were 
not fluorescent.  
Assays for α-glucosidase (α-Glu) have been used to differentiate Bacillus anthracis from 
Bacillus mycoides and Bacillus thuringiensis, and 4-methylumbelliferyl-α-D-glucoside 
(MUGlu)41 has been used as a component within a selective and differential media for the 
identification of Enterobacter sakazkii.42  
Giovannini et al described the synthesis of an ‘off – on’ fluorescent-based sensor where 
streptavidin-coated magnetic microparticles were functionalised with a biotinylated 
coumarin-derived probe with glucose as the recognition moiety (Glu-C-MPs; Scheme 
7.5).43 This probe was able to detect α- and β-glucosidase at a concentration of 75 CFU/mL 
for E. coli, K. pneumonia, and P. aeruginosa after 1 h incubation,  whereas 3 h was required 
for the detection of Enterococcus spp. and S. aureus.  
 
 
Scheme 7.5: Streptavidin-coated magnetic microparticles functionalised with coumarin-based glucosidase 
probe 
A PoC µPAD has also been developed for the colorimetric detection of Cronobacter spp. as 
α-Glu activity can distinguish it from other Enterobacteriaceae bacteria.44 Bacterial 
cultures were grown overnight, lysed and placed onto the paper-based device. The released 
α-Glu subsequently hydrolysed 5-bromo-4-chloro-3-indolyl-α-D-glucopyranoside 
(XαGlu), producing a purple colour in the presence of oxygen. For Cronobacter sakazakii, 
the µPAD had a LOD of 106 CFU/cm2, but if combined with an enrichment process it was 
capable of detecting bacterial concentrations as low as 10 CFU/cm2.  
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7.2.2.2. Esterases and Lipases 
Esterases and lipases are found in the majority of bacterial species13 and numerous probes 
have been developed to detect esterase activity including fluorogenic probes based on 
coumarin, fluorescein, rhodamine and resorufin,45 and colorimetric probes based on p-
nitrophenol (pNP).46 These fluorescent molecules are usually masked by acetate esters that 
often suffer from auto-hydrolysis, resulting in high levels of background noise and failure 
to detect low levels of esterase activity.  
The detection of C8 esterase is used in the identification of Salmonella spp.31 Novel 
fluorescent probes based on 2-arylbenzothiazone have been developed to detect C8 esterase 
within Salmonella spp.;26 however, the most widely used fluorescent probe is 4-
methylumbelliferyl caprylate (MUCAP).35 In the presence of a C8 esterase the substrate is 
cleaved, resulting in the formation of the fluorescent 4-MU. This probe had a sensitivity of 
95% and specificity of 91% when tested with 83 Salmonella strains and 349 non-Salmonella 
strains.47 This was further supported by Olsson et al, who tested 750 Salmonella strains and 
130 other Enterobacteriaceae species with MUCAP.48 It was found that 99.7% of 
Salmonella strains tested positive with MUCAP, with one false-positive reported with 
Hafnia alvei, although the signal was weaker compared to the majority of Salmonella 
strains. Pseudomonas spp. and Proteus spp. are normally responsible for false-positive 
results,49 P. aeruginosa and Proteus mirabilis were tested in this study; the former 
displayed a positive result with MUCAP, and the latter a negative result.48  
Other fluorescent probes have been developed for the detection of bacterial esterases. One 
such example is by Tallman et al who developed two fluorescent probes derived from  7-
hydroxy-9H-(1,3-dichloro-9,9-dimethylacridin-2-one) (DDAO), termed DDAO-AME 1 
and DDAO-AME 2, for the detection of Mycobacterium tuberculosis (Figure 7.4).45 They 
were tested against lysates from Mycobacterium spp. that were both members and non-
members of the Mycobacterium tuberculosis complex (MTBC). All species tested displayed 
esterase activity by  hydrolysing the acetoxymethyl ether on both probes, resulting in a 
detectable fluorescent signal within 10 min.  
 
Figure 7.4: Chemical structures of 7-hydroxy-9H-(1,3-dichloro-9,9-dimethylacridin-2-one) (DDAO)-derived 




Aminopeptidases (AP) are enzymes that catalyse the cleavage of amino acid residues at the 
N-terminal position of peptides and proteins. A wide variety of amino acids have been used 
for the detection of different bacterial species50–52 e.g. L-pyrrolidonyl peptidase has been 
used in the identification of Salmonella spp.,53 Enterococci spp., and Group A 
Streptococci;54,55 L-γ-glutamic acid aminopeptidase is used to differentiate Shigella spp.; 
and finally, proline aminopeptidases have been used for the detection of Neisseria 
menigitidis56 and bacterial vaginosis.57 The majority of novel colorimetric and fluorescent 
probes synthesised have been utilised in the development of chromogenic and fluorogenic 
agar to improve current conventional microbiological culturing techniques, some of which 
will be discussed here.  
One key area of interest is the differentiation of gram-positive and gram-negative bacteria, 
and this can be achieved via the detection of L-alanine APs, with only the latter possessing 
L-alanine AP activity. Colorimetric probes58 such as L-alanyl-p-nitroanilde59 have been 
utilised to detect gram-negative bacteria, but other probes based on the chromogenic moiety 
9-(4’-aminophenyl)acridines have also been developed.52 While these probes inhibited 
gram-positive bacteria, it needed to be protonated by acetic acid to produce various shades 
of red-coloured colonies for E. coli, Klebsiella pneumonia, P. aeruginosa, and Burkholderia 
cepacia.  
Fluorescence-based methods have also been employed for the detection of L-alanine AP to 
identify gram-negative bacteria.60 Cellier et al synthesised two substrates based on 2-2(-
hydroxyphenyl)heterocycles (Figure 7.5; 5 and 6), which upon hydrolysis by L-alanine AP 
fluoresce via the ESIPT mechanism.61 The probes were inhibitory towards gram-positive 
bacteria and gave moderately  to strongly blue fluorescent colonies; however, there was 
diffusion into the agar that could make identification of gram-negative bacteria difficult in 
clinical samples.  
 
Figure 7.5: Chemical structures of 2-2(-hydroxyphenyl)heterocycle-derived probes, 5 and 6 
Other fluorescent probes have been developed, with derivatives of 2-arylbenzothiazone 
producing moderately fluorescent colonies of gram-negative bacteria, while being 
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inhibitory towards gram-positive bacteria and certain gram-negative bacteria such as E. coli 
and Salmonella typhimurium.26 Additionally, Cellier et al synthesised L-alanyl derivatives 
of 2-aminoacridone that supported the growth of gram-negative bacteria (although growth 
of E. coli and K. pneumoniae was inhibited) and produced yellow fluorescent colonies, 
without any diffusion through the agar, increasing the clinical utility of this dye as a 
component in fluorogenic agar.60  
Additionally, β-alanine (β-Ala) AP activity has been detected for P. aeruginosa, and has 
been used as a target for colorimetric and fluorescent-based probes.26,52,58,60,62,63 Currently, 
a β-alanyl pentylresorufamine (β-Ala-PRF; Scheme 7.6) colorimetric probe is used 
commercially to detect P. aeruginosa (chromID P. aeruginosa, bioMérieux) that results in 
the formation of red/purple colonies.64,65 When tested, β-Ala-PRF was capable of detecting 
99% of P. aeruginosa strains, but also showed varying activity against Burkholderia spp., 
other Pseudomonas spp., Ralstonia spp., and Moraxella spp.64  
 
Scheme 7.6: β-alanyl pentylresorufamine (β-Ala-PRF) hydrolysis in the presence of β-alanine producing 
bacteria 
One disadvantage of this colorimetric probe was that it diffused into the agar, making the 
identification of P. aeruginosa colonies difficult. Owing to this, the authors developed a 
series of 7-amino-phenozacin-3-one (7) and 8-aminophenoxacin-3-one (8) colorimetric 
probes, which in the presence of β-Ala produced pale red/orange and pink/purple colonies, 
respectively (Figure 7.6).66 All probes were able to detect P. aeruginosa, with 7 and 8 
detecting 100% and 80% of P. aeruginosa strains, respectively (n = 30 strains). Although 8 
was less sensitive, there was a lack of diffusion through the agar, making it a useful substrate 
for chromogenic agar, whereas 7, and β-Ala-PRF could be used in solution-based assays, 
where localisation would not be required.  
 
Figure 7.6: Structures of 7-amino-phenozacin-3-one (7) and 8-aminophenoxacin-3-one (8) 
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The authors followed on this work by producing fluorescent substrates to overcome the 
inherent disadvantages of chromogenic agar (i.e. time taken to produce a visible signal, 
interference from agar colour).67 The fluorescent probes were derived from coumarin 
(Scheme 7.7)  and upon hydrolysis by β-Ala a 1,6-elimiation occurred and fluorescence was 
observed. 9a was able to discriminate between β-Ala producers, with P. aeruginosa giving 
a positive result and S. marcescens giving a negative result. 9b resulted in fluorescence for 
P. aeruginosa, S. marcescens, and B. cepacia.  
 
Scheme 7.7: Coumarin-based fluorescent probes 9a and 9b for the detection of β-alanine 
Pyroglutamyl AP (PYRase) can be used for the differentiation of Enterobacteriaceae,13,68 
and the detection of Enterococci and Streptococcus pyogenes from most other gram-
positive cocci.69,70 4-aminophenol derivatives were synthesised (Scheme 7.8) and added to 
agar along with 1-napthol and NaOH, before subsequent inoculation with 108 bacteria and 
incubation at 37 °C for 24 h.58 Upon incubation with PYRase-producing bacteria, the 
colorimetric probe was hydrolysed, which in turn reacted with 1-naphthol, and following 
oxidation in situ, pink colonies were observed. A positive result was observed for 
Enterococcus faecium, E. faecalis, and Bacillus subtilis. Some Enterobacteriaceae also 
produced pink colonies, including K. pneumoniae and Serratia marcescens.  
 







7.2.2.4. Antibiotic-resistance Enzymes 
One emerging trend is the development of colorimetric and fluorescent probes for the 
detection of antibiotic-resistance enzymes in pathogenic bacteria; the focus has 
predominately been on the detection of β-lactamases.71–76 Shao et al developed three 
fluorogenic probes (termed LRBL 1 – 3) encompassing a fluorophore and quencher 
(Scheme 7.9), which produced FRET-based fluorescence in the presence of β-lactamase 
producing E. coli.76 
 
Scheme 7.9: FRET-based fluorescent probes LRBL 1 – 3 hydrolysis in the presence of β-lactamase bacteria.  
 
Recently, a fluorescent probe was designed to detect AmpC β-lactamase, a β-lactamase that   
primarily hydrolyses the third generation cephalosporins, ampicillin, and cefox.77,78 The 
probe, termed CDC-559 (Figure 7.7), was tested against two sensitive S. aureus strains, 
and two resistant bacterial strains (one S. aureus, one Enterobacter cloacae [E. cloacae]).77 
When CDC-559 was incubated with the susceptible strains, no noticeable change in 
fluorescence was observed. A slight decrease in fluorescence intensity was detected when 
incubated with the resistant S. aureus, although it was not as strong as the rapid decrease 
in fluorescence intensity when incubated with E. cloacae. This was due to their differing 
mechanisms of resistance, with S. aureus expressing PBP2a proteins, whereas Enterobacter 
cloacae produces large amounts of AmpC β-lactamase. 
 
 
Figure 7.7: Chemical structure of CDC-599 
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Carbapenemase-sensitive fluorescent probes have also been synthesised Mao et al who 
developed CB-1 (Figure 7.8) that employed an alkenyl-linked BODIPY dye as the active 
fluorophore.79 CB-1 was tested with a variety of carbapenemase-producing bacteria (CPO), 
and CB-1 was able to distinguish between CPOs and other bacterial strains. Mao et al then 
synthesised a carbapenem-sensitive umbelliferone-based probe (CPC-1; Figure 7.8), which 
showed specificity to metallo-β-lactamases over other serine-β-lactamases.80 CPC-1 
produced fluorescence when incubated with  metallo-β-lactamase producing E. coli and K 
pneumoniae. Recently, Kim and co-workers further developed this work by synthesising a 
probe they termed 1b.81 Probe 1b had excellent selectivity towards CPO compared to non-
CPO, displaying higher sensitivity than CPC-1 (i.e., 97.1% versus 58.3% for the detection of 
carbapenemase-producing Enterobacteriaceae, respectively).   
 
Figure 7.8: Chemical structure of CB-1, CPC-1, and 1b 
β-lactamase detection has also been useful in the identification of Mycobacteria spp.82,83 
Kong and co-workers utilised a reporter-enzyme fluorescence test using a FRET-based, 
near-infrared fluorogenic substrate (CNIR5), which allowed for real-time detection of 
mycobacteria in mice.84 Cheng et al synthesised the fluorescent probe CDG-3,85 which 
became the fluorogenic probe used in the TB REaDTM assay for the detection of 
Mycobacterium tuberculosis; this assay was then used by Nabeta et al who investigated the 
accuracy of  TB REaDTM compared to conventional culture-based methods;86 while Cheng 
et al and Sule et al reported good sensitivity and selectivity of CDG-3,85,87 this study 
reported a lower sensitivity and selectivity of 58.6% and 59.5%, respectively.86  
7.2.3. Alkaline Phosphatase 
While ALP has been used excessively for the detection of conditions such as cancer and 
diabetes, it has been under-explored for the detection of pathogenic bacteria. ALP is present 
in numerous bacterial species to help with the uptake of essential phosphate into the 




7.2.3.1. Pho Regulatory system 
Phosphorous is one of the main elements present in microbial cells; it is important for 
several biological functions including energy metabolism, membrane integrity, regulation 
of protein activity, and maintenance of acid-based homeostasis.88,89 Bacteria have evolved 
mechanisms to acquire and store the orthophosphate anion (PO43-), often known as 
inorganic phosphate (Pi),88 through governance by the Pho regulon, first characterised in 
E. coli.90 The Pho system activates enzymes capable of obtaining Pi from organic 
phosphates, Pi-specific transporters (including Pi-specific ATP-binding cassette 
transporter [PstSCAB]),91 and enzymes involved in the storage of the nutrient.  
The Pho regulon is controlled by a two-component regulatory system (TCS) that enables the 
bacteria to adapt to changing environmental phosphate levels.92 This system has a variety 
of names dependent on the bacteria under investigation (PhoRB in E. coli,93 PhoRP in 
Bacillus subtilis,94 and PhoPR in S. aureus),95 but is essentially composed of a histidine 
kinase that receives sensory input and a response regulator protein that controls output. 
Upon Pi limitation, the response regulator is phosphorylated by the sensor kinase and is 
able to activate or repress the transcription of genes.88 Among the Pi scavengers, alkaline 
phosphatases, phospholipases, glycerophosphodiester phosphodiesterases, phytases, and 
5’nucleotides are the most common enzymes induced in response to Pi starvation in 
bacteria.90  
7.2.3.2. Alkaline Phosphatase Expression 
The majority of the knowledge of ALP stems from the study of an ALP obtained from 
E. coli.96  ALPs are metalloenzymes, thought to contain Zn2+ or Mg2+;97 they are usually 
homodimeric, however, monomeric97 and oligomeric98 forms have been described. In 
E. coli, synthesis of ALP is under the control of one structural (phoA) and two regulator 
(phoR and phoX) genes.99,100 Upon Pi-limitation, ALP synthesis is up-regulated through the 
transcription of the phoA gene, which is mediated through the Pho regulon.96  The main 
responsibility of ALP is to breakdown organic phosphate esters to release Pi,89,90 although 
ALP can exhibit transphosphorylase101 and pyrophosphorylase102 activities. 
ALP is present in numerous bacterial species, such as E. coli,96  P. aeruginosa,103 
S. aureus,104 and B. subtilis.105,106 While the majority of ALP enzymes are repressed in the 
presence of Pi,100,104,107 some studies have described the presence of constitutive 
ALP.108,109ALP is located in the periplasmic space between the cell wall and the cell 
membrane in E. coli 110 and generally thought to be located here in other gram-negative 
bacteria.111,112 For gram-positive bacteria, such as S. aureus, ALP is usually associated with 
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the surface of the cell membrane.104,113 Additionally, the expression of ALP has been shown 
to be heterogenous in bacterial biofilms in response to phosphate starvation.114 
7.2.3.2.1. Staphylococcus aureus Alkaline Phosphatase 
S. aureus ALP is located in the cell membrane.115 In phosphate deficient media phoB (ALP) 
and phoP (encoding an ALP synthesis transcriptional regulatory protein) are upregulated. 
Prunty et al showed that the phoB operon is expressed at very low levels in parental S. 
aureus Newman; however, expression is upregulated ~9.16-fold in strain dphoR, indicating 
that the expression is under the positive control of PhoPR. 89 ALP activity was found to 
increase with size of inoculum and time of incubation.116 Additionally, the amount of 
phosphatase produced by S. aureus has been correlated with coagulase production as a 
biochemical index of pathogenicity and implicated as a virulence factor for S. aureus.117,118  
7.2.3.3. Use of Alkaline Phosphatase Reported in the Literature 
One of the main uses of ALP reported in literature is to determine bacterial cell 
permeability.119 As ALP is located in periplasmic space (gram-negative bacteria), or cell-
membrane bound (gram-positive bacteria), there should be minimal ALP activity in the 
extracellular environment of heathy, structurally-intact, bacterial cells. When healthy 
bacteria are incubated with certain antimicrobials, the antimicrobial creates pores, or 
disrupts the structural integrity of the cell wall, resulting in the release of ALP into the 
extracellular environment. Therefore, an increase in extracellular ALP is related to the 
structural integrity of the cell wall of the bacteria under investigation.  
Additionally, ALP has been used as a ‘reporter enzyme’ in immunoassays120 and DNA-based 
probes.121 ALP has also been used in aptamer/DNA based electrochemical studies,122 and 
the phoA gene has been used in general ‘fusion studies’123 and polypeptide124 fusion studies. 
However, there have been limited studies on the detection of ALP for the identification of 
bacteria.125,126 Kang et al were able to synthesise a phosphorylated fluorescent probe (2-
hydroxychalcone [HCAP]) and conjugate it to an adhesive cationic polymer (HCAP-PVP) 
to detect ALP in bacterial species.127 Upon incubation with E. coli and S. aureus, the 
phosphate group was cleaved and the green/yellow emission ratiometrically changed to a 
deep-red emission; this system was able to detect 103 and 105 S. aureus and E. coli, 
respectively. Furthermore, Cellier et al synthesised a phosphatase probe based on 2-
arylbenzothiazone for the detection of Staphylococcus spp., particularly S. aureus. 
However, fluorescence and blue colonies were witnessed for all gram-negative and gram-
positive bacteria tested, suggesting that this assay was not specific for S. aureus detection.26  
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One commercial diagnostic product  that utilises ALP for the detection of S. aureus is 
RapdiDEC® Staph (Biomérieux). The test provides a 2 h presumptive identification of 
S. aureus, S. epidermidis, and Staphylococcus saprophyticus on the basis of fluorogenic 
coagulase, ALP, and galactosidase tests, respectively.128  
7.2.4. Aims and Objectives 
The aim of this study was to further develop knowledge of ALP for the detection of bacteria, 
specifically S. aureus. TCF-ALP was used as it had previously shown to be effective in 
detecting ALP using both enzyme suspensions and cell-based assays (HeLa and C2C12 
cells). The objectives of this chapter are: 
• To optimise TCF-ALP to detect ALP in bacterial cells 
• To determine if TCF-ALP can detect ALP in planktonic, biofilm, and ex vivo porcine 
skin models 
• To evaluate the selectivity of TCF-ALP against a library of clinically-relevant 
bacterial isolates 
• To develop a hydrogel incorporating TCF-ALP for use as a diagnostic wound 






7.3.1. Synthesis of TCF-ALP 
TCF-ALP was synthesised as outlined in Chapter 6. Stock solutions of TCF-ALP were 
stored in DMSO at 4 °C until required.  
7.3.2. Preparation of TCF-ALP Based PVA Hydrogels 
A 10% w/v PVA solution was prepared by dissolving PVA in 50 mM Tris HCl (pH 9.2). After 
the resultant solution had cooled to room temperature, aliquots of 1 mL were transferred 
into a 12-well microtiter plate and 38.5 µL of TCF-ALP (2.6 mM in DMSO) was added to 
produce homogenous yellow solutions. These solutions were placed at -80 °C and 
underwent one freeze-thaw cycle to produce mechanically stable hydrogels, which were 
protected from light and stored at 4 °C prior to use.  
7.3.3. Bacterial Growth Conditions 
Bacterial strains were stored at –80 °C in broth containing 15% (v/v) glycerol until required. 
Working stocks of S. aureus and S. epidermidis were prepared by streaking TSA, while P. 
aeruginosa and E. coli were plated onto Luria Bertani (LB) agar before incubation at 37 °C 
for 24 h. Plates were stored at 4 °C for up to a month for further use. Overnight cultures of 
bacterial strains were routinely propagated by transferring a single colony to 5 mL Müeller-
Hinton broth and incubating at 32 °C for 18 h. Cultures were washed via centrifugation 
(4000 g, 10 min) before being re-suspended in 50 mM Tris-HCl (pH 9.2) to an optical 
density at 600 nm of ~ 1 (c. 5.0 x 108 CFU/mL). 
7.3.4. Bacterial Enumeration 
Estimation of the total viable count of bacterial cultures were determined as outlined in 
Chapter 2, Section 2.2.1.4.  
7.3.5. Effect of Broth on Alkaline Phosphatase Production 
Overnight cultures of S. aureus NCTC 10788 were grown in either Tryptic Soy Broth (TSB), 
Luria Bertani (LB) broth, or Mueller Hinton broth at 32 °C for 18 h. After incubation, 
bacterial cells were washed and re-suspended in 50 mM Tris-HCl (pH 9.2) to an optical 
density at 600 nm of ~ 1 (c. 5.0 x 108 CFU/mL). Prior to testing, bacterial cells underwent 
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centrifugation (4000 g, 10 min) and were re-suspended in an equal volume of 10 µM TCF-
ALP in 50 mM Tris-HCl (pH 9.2).  Bacterial cultures were then protected from light and 
incubated at 32 °C for a further 24 h. Analysis of ALP production was performed after 1 and 
24 h incubation with TCF-ALP. A 200 µL aliquot was removed and centrifuged at 10 000 
g for 3 min. The supernatant was subsequently placed into a black 96-well microtiter plate 
and the fluorescence was measured using a CLARIOstar fluorimeter (BMG LabTech, UK),  
λex = 542 nm, λem = 606 nm. 
7.3.6. Detecting Alkaline Phosphatase in Planktonic 
Bacteria 
Optically-adjusted bacterial cultures (Chapter 2, Section 2.2.1.3) underwent centrifugation 
(4000 g, 10 min) and were re-suspended in an equal volume of 10 µM TCF-ALP in 50 mM 
Tris-HCl (pH 9.2). For TCF-ALP hydrogel analysis, 2 mL of the bacterial culture in 50 mM 
Tris HCl (pH 9.2) was transferred to a 12-well microtiter plate containing a 100 µM TCF-
ALP based PVA hydrogel. These suspensions were subsequently protected from light and 
incubated at 32 °C for 24 h, unless stated otherwise. After incubation, 1 mL was removed 
from each suspension and centrifuged at 10 000 g for 3 min. The supernatant was 
subsequently placed into a black or clear 96-well microtiter plate for fluorescence and UV-
Vis analysis, respectively. The fluorescence was measured using CLARIOstar fluorimeter 
(BMG LabTech, UK),  λex = 542 nm, λem = 606 nm, and the UV-Vis by SPECTROstar Omega 
(BMG LabTech, UK). Appropriate controls were carried out in tandem and a minimum of 
three biological replicates per bacterial strain were used. 
7.3.7. Detecting Alkaline Phosphatase in 96-well Plate 
Biofilm Models 
7.3.7.1. Alkaline Phosphatase Activity of Biofilm  
Overnight cultures of S. aureus NCTC 10788 were sub-cultured into fresh Mueller Hinton 
broth to attain a concentration of 106 CFU/mL, before being placed into a 96-well microtiter 
plate and incubated at 32 °C for 18 h. After incubation, planktonic bacteria were discarded, 
and the remaining biofilm was washed three times with sterile dH2O. Plates were left to dry 
at room temperature for 20 min, before subsequent addition of 220µL of 10 µM TCF-ALP 
in 50 mM Tris-HCl (pH 9.2) and further incubation at 32 °C for 24 h. Analysis of ALP 
production was performed as outlined in Section 7.3.6. The experiment was carried using 
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three biological replicates, and the assay performed in duplicate to ensure fluorescence 
readings at both 1 h and 24 h.  
7.3.7.2. Inhibition of Alkaline Phosphatase Activity 
7.3.7.2.1. Preparation of Sodium Orthovanadate 
A 50 mM stock of sodium orthovanadate was prepared in dH2O. Once dissolved, the pH was 
adjusted to 9.2 with 1 M NaOH and the resultant yellow solution (indicative of dimers) was 
boiled until colourless. Upon cooling, the pH was re-measured and adjusted if needed. This 
was repeated until the solution remained colourless.  
7.3.7.2.2. Minimum Inhibitory Concentration 
The Minimum Inhibitory Concentration of sodium orthovanadate was determined as 
outlined in Chapter 2, Section 2.2.1.5, with Mueller Hinton used as the broth.  
7.3.7.2.3. Minimum Biofilm Inhibitory Concentration 
The Minimum Biofilm Inhibitory Concentration of sodium orthovanadate was determined 
as outlined in Chapter 2, Section 2.2.2.1, with Mueller Hinton used as the broth.  
7.3.7.2.4. Inhibition of Alkaline Phosphatase Activity 
Biofilms of S. aureus NCTC 10788 were prepared as outlined in Chapter 2, Section 2.2.2.1. 
After 24 h incubation planktonic bacteria were discarded, and the remaining biofilm was 
washed three times with sterile dH2O and left to dry for 20 min at room temperature. Next, 
wells were pre-treated with various concentrations of sodium orthovanadate (0 – 3.75 mM; 
pH 9.2) for 30 min at room temperature, before addition of 10 µM TCF-ALP in 50 mM 
Tris-HCl (pH 9.2).  Bacterial cultures were then protected from light and incubated at 32 °C 
for a further 24 h. Analysis of ALP production was performed as outlined in Section 7.3.6 
7.3.8. Colony Biofilm Wound Model 
First, 19 mm polycarbonate membranes were UV sterilised for 10 min on Mueller Hinton 
agar, before being inoculated with 30 µL Artificial Wound Fluid (AWF; 50% fetal bovine 
serum in 50% peptone water [0.9% sodium chloride in 0.1% peptone]). Once dry, 50 µL of 
sub-cultured S. aureus NCTC 10788, P. aeruginosa PA01, or E. coli NSM56 (106 CFU/mL 
in 50 mM Tris HCl pH 9.2) was placed on the membrane and allowed to dry at room 
temperature.  The inoculated polycarbonate membranes were then incubated for 24 h at 32 
°C. Next, biofilms were removed from the agar plate, and placed into 2 mL of 10 µM TCF-
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ALP in 50 mM Tris-HCl (pH 9.2), before being protected from light and incubated at 32 °C 
for 24 h. After, 1 mL of the suspension was removed and centrifuged at 10 000 g for 3 min. 
The supernatant was subsequently placed into a black 96-well microtiter plate for 
fluorescence analysis of ALP production. For TCF-ALP hydrogel analysis, biofilms were 
transferred to a 12-well microtiter plate containing bacteriological agar (to prevent the 
drying out of the biofilm). A 100 µM TCF-ALP based PVA hydrogel was subsequently 
placed on top of the biofilm. After being protected from light and incubated for 24 h at 32 °C, 
the hydrogels were removed from the biofilm and directly measured for fluorescence 
intensity using wavelengths as outlined previously.  
To determine bacterial concentration, 24 h old biofilms were placed into 10 mL of PBS (pH 
7.4) and stripped by sonication (44 KHz) for 15 min twice, with a 60 s interval of vortexing. 
Viable cells were quantified as outlined in Chapter 2, Section 2.2.1.4.  
7.3.9. Ex vivo Porcine Skin Model  
7.3.9.1. Sterilisation 
Porcine skin was washed with H2O before being cut into 2 x 2 cm squares, and subsequently 
underwent three 15-minute vortex cycles of washing in sterile dH2O. After, porcine skin was 
vortexed once for 15 min in 70 % ethanol, before a further two washes with sterile dH2O. 
Finally, the skin was UV-irradiated using a commercial UV source (Hamanatsu, Japan) 
equipped with a 254 nm UV lamp for 10 min before use. 
7.3.9.2.  Alkaline Phosphatase Activity 
A 10 µL aliquot of S. aureus NCTC 10788 (108 CFU/mL in 50 mM Tris HCl pH 9.2) was 
added to the sterilised skin and left to dry for 20 min at room temperature. Next, 1 mL of 10 
µM TCF-ALP in 50 mM Tris-HCl (pH 9.2) was added to the skin via use of a Franz Cell.  
Inoculated porcine skin was then protected from light and incubated at 32 °C for 24 h. After, 
the suspension was removed and centrifuged at 10 000 g for 3 min. The supernatant was 
subsequently placed into a black 96-well microtiter plate for fluorescence analysis of ALP 
production. For TCF-ALP hydrogel analysis, a 100 µM TCF-ALP based PVA hydrogel was 
subsequently placed on the top of the inoculated skin. After being protected from light and 
incubated for 24 h at 32 °C, the hydrogels were removed from the skin and directly 




7.4. Results and Discussion 
7.4.1. UV-Vis of TCF-ALP  
To determine whether the colorimetric change witnessed in Chapter 6 could be applied to 
whole-cell bacterial sensing, a stationary phase culture of S. aureus NCTC 10788 was 
harvested, washed, and resuspended in 1 mL of 10 µM TCF-ALP in 50 mM Tris-HCl (pH 
9.2). The concentration of TCF-ALP and pH of the buffer remained the same as the 
enzymatic assays undertaken in Chapter 6; however, the incubation time and temperature 
were different for optimal bacterial sensing and will be discussed further in this chapter.  
After 24 h incubation at 32 °C, the bacterial suspensions were centrifuged, and the 
supernatant removed to obtain the UV-Vis spectra of TCF-ALP (Figure 7.9). A clear 
bathochromic shift of UV absorption occurred, which corresponded to a colour change from 
yellow to purple. This result is indicative of ALP production within S. aureus NCTC 10788, 
and further supports literature reports that ALP production is membrane-bound as the cells 




Figure 7.9: UV-Vis spectra of TCF-ALP (10 µM) after 24 h incubation at 32 °C with S, aureus NCTC 10788 





7.4.2. Optimisation of Assay 
7.4.2.1. Role of Bacterial Growth Media on Alkaline Phosphatase 
Production 
It is known that the addition of inorganic phosphate into culture media can result in reduced 
ALP activity in bacteria due to the repressive-nature of the enzyme.115 To confirm this 
phenomenon, S. aureus NCTC 10788 was grown in three different broths, with different 
phosphate concentrations: Mueller Hinton, LB, and TSB. After incubation, bacterial cells 
were washed, resuspended in 10 µM TCF-ALP (50 mM Tris-HCl, pH 9.2), and incubated 
for 1 or 24 h at 32 °C. After incubation, ALP activity was determined by measuring 
fluorescence intensity.  
After 1 h incubation with TCF-ALP (Figure 7.10), a statistically significant increase in 
fluorescence intensity was observed for bacterial isolates propagated in Mueller Hinton 
broth compared to LB and TSB (One way ANOVA; p<0.01). After 24 h incubation (Figure 
7.11), bacterial isolates grown in Mueller Hinton had a statistically significant increase in 
fluorescence (One way ANOVA; p<0.0001) compared to TSB, while there was no statistical 
difference between Mueller Hinton and LB.  
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Figure 7.10: Staphylococcus aureus NCTC 10788 (108 CFU/mL) was grown in: Mueller Hinton, LB or TSB 
before being inoculated for 1 h with TCF-ALP (10 µM) in 50 mM Tris-HCl buffer pH 9.2 at 32 °C. A) 
Fluorescence spectra and B) corresponding change in fluorescence (I/I0). λex = 542 (bandwidth 15) nm. λem = 
606 nm. Error bars indicate standard deviation (n = 3). Statistical significance was assessed by performing a 
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Figure 7.11: Staphylococcus aureus NCTC 10788 (108 CFU/mL) was grown in either Mueller Hinton, LB or 
TSB before being inoculated for 24 h with TCF-ALP (10 µM) in 50 mM Tris-HCl buffer pH 9.2 at 32 °C. A) 
Fluorescence spectra and B) corresponding change in fluorescence (I/I0). λex = 542 (bandwidth 15) nm. λem = 
606 nm. Error bars indicate standard deviation (n = 3). Statistical significance was assessed by performing a 
One-way ANOVA followed by Turkey post-hoc test. p values are indicated ***, p<0.001, ****, p<0.0001 
As TSB contains 2.5 g/L of dipotassium hydrogen phosphate, it was expected that this broth 
would hinder ALP production during S. aureus growth. This correlates with the results 
obtained in Figures 7.10 and 7.11, as fluorescence intensity was significantly lower than the 
other media tested, suggesting lower amounts of ALP were produced.   
The chemical compositions of Mueller Hinton and LB are different; hence, it is difficult to 
pinpoint what variable resulted in reduced phosphatase activity in LB compared to Mueller 
Hinton. However, it can be assumed that the differences in ALP production at 1 h is due to 
the differing amounts of trace phosphate levels in the growth medium. Unlike Mueller 
Hinton, LB contains yeast extract to supply vitamins, amino acids and trace elements, 
including phosphate.130 This additional phosphate could have resulted in ALP being 
repressed in the early stages of growth, before being induced once the medium became 
phosphate-deficient.  
Additionally, it has been shown by Sen et al that broth composition can have an effect on 
the morphology of bacterial cells,131 while Ray et al132 and Oogai et al133 have suggested that 
the growth medium used for bacterial propagation has major effects on the expression of 
virulence and regulatory genes. Therefore, further study is needed to fully comprehend the 
relationship between growth media and the expression of ALP in S. aureus. Nevertheless, 
for the duration of this study Muller Hinton was utilised as the growth medium as it 
displayed the highest levels of ALP production.  
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7.4.2.2. Washing Steps 
Next, experiments were undertaken to ensure that residual growth-medium did not affect 
ALP detection, hence washing steps were employed to remove the growth medium and any 
secreted ALP produced by S. aureus. Results show that washing the bacterial pellet had no 
statistical effect on the Log CFU/mL of S. aureus NCTC 10788, nor did it have any statistical 
effect on the fluorescence intensity when incubated with TCF-ALP (Figure 7.12). It was 
therefore concluded that upon harvesting, bacterial pellets would be washed once with 50 
mM Tris HCl buffer (pH 9.2) before undergoing incubation with TCF-ALP to remove 
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Figure 7.12: A) Log CFU/mL of Staphylococcus aureus NCTC 10788 after different amounts of wash cycles (0 
– 3) and B) Change in fluorescence (I/I0) of TCF-ALP (10 µM) after 24 h incubation with washed suspensions 
of Staphylococcus aureus NCTC 10788 (108 CFU/mL) in 50 mM Tris-HCl buffer pH 9.2 at 32 °C. λex = 542 
(bandwidth 15) nm. λem = 606 nm. Statistical significance was assessed by performing a One-way ANOVA 
followed by Turkey post-hoc test  
7.4.2.3. Incubation Temperatures 
An investigation was undertaken to assess the role of temperature on ALP production. As 
previously mentioned, S. aureus grows at an optimum temperature of 37 °C, while the 
surface of the skin is cooler – with healthy skin having an average temperature of 32 °C. 
Therefore, to determine if there was any difference in ALP production at these two 
temperatures, S. aureus NCTC 10788 was incubated in Mueller Hinton broth at both 
temperatures prior to ALP determination.  
Once the bacteria were grown, they were re-suspended in 50 mM Tris HCl buffer (pH 9.2) 
containing 10 µM of TCF-ALP. The bacteria and probe were then incubated at the following 
274 
 
temperatures: 25 °C, to assess the efficacy of TCF-ALP as a PoC test at the hospital bedside; 
32 °C, to assess efficacy of TCF-ALP at wound-bed temperatures; and 37 °C, to assess the 
efficacy of TCF-ALP at the optimum temperature for S. aureus growth.  
After 1 h incubation with 10 µM TCF-ALP (Figure 7.13A) there was no statistical difference 
between the ALP activity measured for bacteria grown at 32 °C compared to 37 °C for all 
TCF-ALP incubation temperatures measured. Although it seems that TCF-ALP 
incubation at 37 °C provides a faster detection of ALP for bacteria originally grown at 32 °C 
and 37 °C, the difference was not statistically significant. By 24 h (Figure 7.13B) all variables 
tested resulted in similar fluorescence intensities, and hence similar ALP activities. There 
was a statistical difference for bacteria grown at 37 °C and then subsequently incubated with 
TCF-ALP at 25 °C compared to 37 °C; however, the p value was 0.0499. 
Overall, the results show that there is no difference in ALP production for S. aureus NCTC 
10788 when grown at 32 °C compared to 37 °C. Likewise, TCF-ALP incubation 
temperatures did not have a substantial effect on ALP detection. Therefore, for the duration 
of this study, the bacterial cultures were incubated at 32 °C and once grown, incubated at 
32 °C with TCF-ALP to mimic TCF-ALP being used as a wound dressing.  
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Figure 7.13: Change in fluorescence (I/I0) of TCF-ALP (10 µM) after A) 1 h and B) 24 h incubation with 
Staphylococcus aureus NCTC 10788 (108 CFU/mL) in 50 mM Tris-HCl buffer pH 9.2. Bacterial cultures were 
grown at either 32 °C or 37 °C and incubated with TCF-ALP (10 µM) at 25°C, 32 °C or 37 °C. λex = 542 
(bandwidth 15) nm. λem = 606 nm. Statistical significance was assessed by performing a t-test with Welch’s 




7.4.3. Time-dependant Alkaline Phosphatase Detection  
A known concentration of S. aureus NCTC 10788 (108 CFU/mL) was incubated with 10 µM 
of TCF-ALP (50 mM Tris-HCl, pH 9.2) and the fluorescence intensity measured over the 
course of 24 h (Figure 7.14). There was a noticeable increase in fluorescence intensity after 
1 h incubation, rising linearly until a plateau after approximately 8 h. After this time, the 
fluorescence intensity remained constant for a further 16 h.   
From this data it was concluded that fluorescence measurements using  TCF-ALP were to 
be conducted at 1 h and 24 h. The time point of 1 h was chosen as it was the first time point 
capable of detecting ALP activity at this bacterial concentration and represented a ‘rapid’ 
detection of ALP activity and thus S. aureus NCTC 10788 infection. The longer incubation 
time of 24 h was chosen to allow for TCF-ALP to detect ALP activity in bacterial strains 
that have lower ALP expression, which could be missed at the 1 h timepoint.  
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Figure 7.14:  A) Fluorescence spectra of TCF-ALP (10 µM) recorded over the course of 24 h upon addition of 
Staphylococcus aureus NCTC 10788 (108 CFU/mL) in 50 mM Tris-HCl buffer pH 9.2 at 32 °C. B) Corresponding 
change in fluorescence (I/I0) of TCF-ALP (10 µM) upon addition of Staphylococcus aureus NCTC 10788 (108 
CFU/mL) in 50 mM Tris-HCl buffer pH 9.2 at 32 °C.. λex = 542 (bandwidth 15) nm / λem = 606 nm. Error bars 
indicate standard deviation (n = 3) 
7.4.4. Relationship Between Alkaline Phosphatase 
Production and Bacterial Concentration 
To determine the concentration of S. aureus NCTC 10788 required to elicit a ‘turn on’ 
response of TCF-ALP, S. aureus NCTC 10788 was propagated, washed, and resuspended 
to achieve final bacterial densities of 105 – 1010 CFU/mL in 10 µM of TCF-ALP  (50 mM 
276 
 
Tris-HCl buffer, pH 9.2). The fluorescence intensity of each bacterial concentration was 
measured after 1 h and 24 h incubation at 32 °C. After, the intensities were normalised and 
plotted against a Log CFU/mL scale; the linear section of the graph was obtained, and the 
LOD was defined as the x-intercept.  
After 1 h incubation, a linear, concentration-dependent increase in fluorescence intensity 
was seen for bacterial titres greater than 107 CFU/mL (Figure 7.15). Upon performing linear 
regression, it was found that the X-intercept was 7.50 (95 % Confidence Interval (CI) of 7.47 
– 7.53), which corresponded to 3.17 x 107 CFU/mL (95 % CI of 2.95 – 3.40 x 107 CFU/mL).  
 
A) B) 


























6 0 0 6 5 0 7 0 0
0
5 0 0 0 0
1 0 0 0 0 0
1 5 0 0 0 0
2 0 0 0 0 0
C o n c e n tra tio n
 
L o g  [C F U /m L ]
I/
I 0






Figure 7.15: A) Fluorescence spectra of TCF-ALP (10 µM) after 1 h incubation with various concentrations of 
Staphylococcus aureus NCTC 10788 (105 – 1010 CFU/mL) in 50 mM Tris-HCl buffer pH 9.2 at 32 °C, and B) 
corresponding selectivity graph at 606 nm. λex = 542 (bandwidth 15) nm. λem = 606 nm. (X-intercept 7.501 = 
3.17 x 107 CFU/mL; Y = 11.52X – 86.38; R2 0.9983) 
 
After 24 h incubation with TCF-ALP, the LOD of S. aureus NCTC 10788 decreased (Figure 
7.16), with the X-intercept becoming 6.57 (95 % CI of 6.32 – 6.76), which corresponded to 
3.70 x 106 CFU/mL (95 % CI of 2.08 – 5.79 x 106 CFU/mL). However, at high bacterial 
concentrations (1010 CFU/mL) the fluorescence intensity decreased. One possible reason for 
this could be due to the assay methodology, whereby the bacterial suspension containing 
TCF-ALP was centrifuged and the supernatant removed for fluorescence measurements. 
Therefore, it is possible that at higher bacterial cell density there was a greater increase in 
uptake of TCF-ALP into the bacterial cells, and thus resulted in a lower fluorescence 
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Figure 7.16: A) Fluorescence spectra of TCF-ALP (10 µM) after 24 h incubation with various concentrations 
of Staphylococcus aureus NCTC 10788 (105 – 1010 CFU/mL) in 50 mM Tris-HCl buffer pH 9.2 at 32 °C, the 
dotted line represents 1010 CFU/mL. B) corresponding selectivity graph at 606 nm. λex = 542 (bandwidth 15) 
nm. λem = 606 nm. (X-intercept 6.568 = 3.70 x 106 CFU/mL; Y = 14.45X – 94.88; R2 0.9759) 
 
The LOD of TCF-ALP was compared to the LOD of other chemiluminescent, colorimetric, 
and fluorescent probes that detected bacteria via enzymes (Table 7.1).  Most of the recent 
publications have focused on the detection of E. coli through the use of several enzymes (β-
galactosidase and β-glucuronidase), and the detection of antibiotic-resistant bacteria 
through the use of β-lactamase and carbapenemase. As shown in Table 7.1, most of the 
fluorescent and colorimetric probes developed have a similar LOD between 105 – 107 
CFU/mL. Some fluorescent probes that could detect concentrations as low as 101 CFU/mL 
were only able to do so after an ‘enrichment’, where the initial bacterial suspension (101 
CFU/mL) was added to broth and allowed to grow for a set period of time. Therefore, the 
concentration after the enrichment process is significantly higher than what is recorded as 
the LOD. This is evident with Kim et al, where without enrichment the LOD was 107 
CFU/mL, and with a 7 h enrichment it was lowered to 101 CFU/mL.23  
Additionally, some of these fluorescent and colorimetric probes detect enzymes that are 
intracellular, such as β-galactosidase and β-glucuronidase. Owing to this, the bacterial cells 
must be lysed prior to testing with the probe, resulting in a complicated system where the 
bacteria must be pre-treated for detection to occur, which can be costly and difficult to 
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It has long been theorised that the healing of chronic wounds is directly related to the 
number of colonising bacteria – often termed the critical colonisation.139,140 However, there 
remains much debate over this term, as the threshold concentration for the bacterial burden 
to progress from contamination to localised infection is ambiguous. An alternative school 
of thought is that the presence of an infection is dependent on the bacterial species present 
and not the bacterial bioburden within the wound. The most probable rationale is that the 
progression to infection is a result of several factors: what pathogenic bacteria are present 
at the wound site, the pathogen’s ability to cause disease (virulence), the concentration of 
these pathogens, and the host’s ability to mount an immune response.141  
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While there is a debate over the number of bacteria required to result in a localised infection, 
it is generally accepted that it lies between 104 to 106 CFU/mL, depending on the bacterial 
species and the location of the wound.142 Work conducted by Robson et al found that the 
healing of pressure ulcers and surgical site infections could be predicted by quantifying the 
bacteria in biopsied tissue; this formed the basis of the 105 guideline, which is the theory 
that 105 viable bacterial cells per gram of tissue is necessary to cause wound infections.  
Additionally, biofilms are present in approximately 60 to 90% of chronic wounds and 
contribute to the pathogenicity of the invading bacterial species.143–145 Biofilms usually have 
higher bacterial cell density, with results in our laboratory showing bacterial concentrations 
as high as 1011 CFU/membrane – significantly higher than the 105 standard needed to cause 
infection. However, one main issue with chronic wounds is that there is no gold-standard 
tests available to diagnose wound infections.144,146 TCF-ALP could potentially be able to 
diagnose such infections, with a clear “turn-on” response witnessed at concentrations 
higher than 106 CFU/mL after 24 h incubation. As concentrations below this fluorescence 
response are not indicative of a localised infection, TCF-ALP might be able to accurately 
diagnose wounds that are clinically infected, helping health care professionals accurately 
diagnose and treat infected wounds.  
7.4.5. Selectivity of TCF-ALP  
To ensure that TCF-ALP is selective towards S. aureus species, selectivity assays were 
performed using 108 CFU/mL of different bacterial isolates. Initially, six S. aureus, three 
S. epidermidis, three P. aeruginosa, and three E. coli strains were tested using TCF-ALP 
(50 mM Tris-HCl, pH 9.2). After 24 h incubation, all S. aureus and S. epidermidis strains 
were capable of eliciting a fluorescence response, while negligible fluorescence was 
observed for E. coli and P. aeruginosa strains. This negligible fluorescence response was 
not due to a decrease in bacterial concentration, with cell counts showing a minimal 
decrease in bacterial density after 24 h incubation with TCF-ALP (Appendix).  
The results shown in Figure 7.17 were interesting, as all bacterial strains were shown to 
produce ALP;88,104 however, gram-positive bacterial species produced a higher fluorescence 
response compared to gram-negative species. One hypothesis for this variance is that 
Staphylococcal spp. produce more ALP compared to their gram-negative counterparts and 
therefore displays a stronger response to TCF-ALP. Alternatively, the differences in 
fluorescence response could be due to the differences in cell wall structure and location 
of ALP within the bacterial cell. S. aureus and S. epidermidis are both gram-positive 
organisms with a thick peptidoglycan layer; ALP is normally membrane-bound, hence is 
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easily accessible. For  gram-negative bacteria, TCF-ALP would have to pass through the 
outer membrane via passive diffusion or through the use of efflux pumps in order to be de-
phosphorylated by the ALP within the periplasmic space.111 Therefore, it could be possible 
that these transporter proteins are unable to recognise TCF-ALP and consequently 
the fluorescent probe is unable to enter the bacterial cell. However, further work is required 




Figure 7.17: Selectivity bar chart of TCF-ALP (10 µM) in 50 mM Tris-HCl buffer pH 9.2 after 24 h incubation 
with various bacterial strains (108 CFU/mL) at 32 °C. λex = 542 (bandwidth 15) nm. λem = 606 nm. Error bars 
indicate standard deviation (n = 3) 
 
To ensure that TCF-ALP was selective to S. aureus, further experiments were conducted 
using a larger library of S. aureus isolates. In total, 42 S. aureus strains were tested, and the 
fluorescence intensity measured after 1 and 24 h incubation with TCF-ALP. For all S. 
aureus strains tested, there was an increase in fluorescence intensity after 1 h incubation 
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Figure 7.18: Selectivity bar chart of TCF-ALP (10 µM) in 50 mM Tris-HCl buffer pH 9.2 after 1 h incubation with various bacterial strains (108 
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Figure 7.19: Selectivity bar chart of TCF-ALP (10 µM) in 50 mM Tris-HCl buffer pH 9.2 after 24 h incubation with various bacterial strains (108 
CFU/mL) at 32 °C. λex = 542 (bandwidth 15) nm. λem = 606 nm. Error bars indicate standard deviation (n = 3). 
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The results above show that TCF-ALP was capable of producing a fluorescence response in 
the presence of all 42 S. aureus strains tested. Interestingly, the majority of S. aureus strains 
were capable of producing at least a 20-fold increase in fluorescence intensity, regardless of 
the phenotype. This suggests that ALP is conserved within S. aureus and therefore could be 
used as a tool for S. aureus detection within an infected wound.  
One interesting observation is the fact that S. aureus Agr- (RN6911) has a decreased 
fluorescence response compared to its counterpart, S. aureus Agr+ (RN6390B). In these 
studies, S. aureus Agr- is a derivative of S. aureus Agr+, where the accessory gene regulator 
(agr) system has been replaced with a tetracycline resistance gene. The agr system controls 
and regulates a variety of S. aureus virulence factors that contribute to S. aureus 
pathogenicity through coordinated expression of specific virulence genes. Often cell surface 
adhesins are synthesised and expressed before the secretion of toxins and enzymes.147 Agr- 
mutants have been isolated in clinical and laboratory settings,148,149 exhibiting increased 
fitness, especially under antibiotic stress,150 which can therefore be linked to higher patient 
mortality.147 While in a chronic infection arg- phenotype strains have increased persistence, 
agr+ phenotype strains seem to be important for bacterial virulence to create an established 
infection.151  
In these studies, S. aureus Agr- and Agr+ both display a fluorescence “turn-on” in response 
upon incubation with TCF-ALP. Therefore, it can be suggested that ALP expression is not 
under the control of agr. However, ALP production could be agr-dependent as the ALP 
activity of S. aureus Agr- was observed to be lower than that of S. aureus Agr+. One 
hypothesis for this observation is that as the agr system is dependent on phosphorylation, 
it needs inorganic phosphate to operate successfully.151 In order to aid this phosphorylation, 
ALP production may need to be increased in S. aureus Agr+, while the same level of ALP is  
not needed for S. aureus Agr- as the agr operon is not present. However, there are other 
mechanisms within S. aureus that rely on phosphorylation of a protein to function; 
therefore, further exploratory analysis is required to investigate the relationship between 
ALP and regulation systems within S. aureus.   
7.4.6. Alkaline Phosphatase Production in Established 
Biofilms 
As previously mentioned, approximately 60% of chronic wounds contain a biofilm. 145,152,153 
To determine the clinical utility of the probe, all work herein utilised 24 h old biofilms to 
investigate the efficacy of TCF-ALP in detecting ALP activity in bacterial biofilms. 
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The role of ALP in S. aureus biofilm formation is currently unknown.154 A variety of factors 
are known to influence biofilm formation, including pH, temperature and nutrient 
availability.155 Interestingly, studies have found that phosphorous concentration is also 
important for successful biofilm formation,156 with Li et al corroborating this theory by 
showing that ALP activity is elevated in S. aureus biofilms compared to their planktonic 
counterparts,157 and Danikowski et al finding that the use of an ALP inhibitor greatly 
disrupted biofilm formation.154 Furthermore, ALP has been shown to possess 
phosphodiesterase activity, which has been linked to hyper-formation of biofilms in 
Serratia marcescens and S. aureus.154,158 Therefore, it can be hypothesised that ALP is 
required for S. aureus biofilm formation. While ALP could become a target for anti-biofilm 
therapeutics, it could also be used to target S. aureus in chronic wounds to help guide 
infection treatment for patients, leading to improved clinical outcomes.  
7.4.6.1. 96-well Microtiter Plate Biofilm Model 
To investigate ALP activity within S. aureus biofilms, a standard static biofilm model was 
used employing a 96-well microtiter plate. Muller Hinton broth was used in line with 
planktonic assays, with the addition of glucose evaluated prior to the start of this assay 
(Appendix). Glucose supplementation was ineffective in enhancing bacterial biofilm 
formation, thus was not used in these experiments. Briefly, 24-h old biofilms were treated 
with TCF-ALP (10 µM, 50 mM Tris-HCl, pH 9.2) for 1 h and 24 h before the solution was 
transferred to a fresh black 96-well microtiter plate and the fluorescence intensity recorded 
(Figures 7.20 and 7.21).  
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Figure 7.20: A) Fluorescence spectra of TCF-ALP (10 µM) after 1 h incubation with a 96-well plate biofilm of 
S. aureus NCTC 10788 in 50 mM Tris-HCl buffer pH 9.2 at 32 °C, and B) corresponding selectivity bar chart. 
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Figure 7.21: A) Fluorescence spectra of TCF-ALP (10 µM) after 24 h incubation with a 96-well plate biofilm 
of S. aureus NCTC 10788 in 50 mM Tris-HCl buffer pH 9.2 at 32 °C, and B) corresponding selectivity bar chart. 
λex = 542 (bandwidth 15) nm. λem = 606 nm. Error bars indicate standard deviation (n = 3) 
 
Figure 7.20 shows an increase in fluorescence intensity of TCF-ALP after 1 h incubation 
with S. aureus NCTC 10788, which increased further after 24 h incubation (Figure 7.21). 
This study proved that ALP is produced within a biofilm, which corresponds with  literature 
reports suggesting that ALP is involved in S. aureus biofilm formation.154  
To ensure that TCF-ALP was activated only in response to ALP, further experiments were 
conducted using a known ALP inhibitor – sodium orthovanadate. Briefly, 24 h biofilms of 
S. aureus NCTC 10788 were grown in 96-well microtiter plates before subsequent 
incubation with various sub-inhibitory concentrations of sodium orthovanadate (Appendix) 
for 30 min. After, TCF-ALP (10 µM) was added (200 µL) and incubated for a further 24 h 
at 32 °C, before the biofilms were assessed for fluorescence activity. 
Figure 7.22 and 7.23 show that upon increasing concentrations of phosphate inhibitor there 
is a corresponding decrease in fluorescence intensity, suggesting that ALP production 
within S. aureus biofilms is reduced in the presence of a phosphatase inhibitor. The effect 
is more pronounced after 24 h incubation with TCF-ALP, although the trend is the same. 
In conclusion, fluorescence response observed in S. aureus biofilms incubated with TCF-
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Figure 7.22: A) Fluorescence spectra of TCF-ALP (10 µM) in 50 mM Tris-HCl buffer pH 9.2 after 1 h at 32 °C 
incubation with S. aureus NCTC 10788 (108 CFU/mL) pre-incubated for 30 min with  various concentrations of 
sodium orthovanadate (0.00-3.50 mM), and B) corresponding selectivity bar chart. λex = 542 (bandwidth 15) 
nm. λem = 606 nm. Error bars indicate standard deviation (n = 3). 
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Figure 7.23: A) Fluorescence spectra of TCF-ALP (10 µM) in 50 mM Tris-HCl buffer pH 9.2 after 24 h at 
32 °C incubation with S. aureus NCTC 10788 (108 CFU/mL) pre-incubated for 30 minutes with various 
concentrations of sodium orthovanadate (0.00-3.50 mM), and B) corresponding selectivity bar chart. λex = 542 
(bandwidth 15) nm. λem = 606 nm. Error bars indicate standard deviation (n = 3). 
7.4.6.2. Colony Biofilm Model 
The colony biofilm model is a static biofilm model was used as it is more indicative of a 
wound environment than traditional static biofilm models using 96-well plates. Sub-
cultured S. aureus NCTC 10788 (c. 106 CFU/mL) was added to 19 mm sterile membranes 
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pre-treated with AWF and incubated at 32 °C for 24 h. After, the membranes were 
transferred to a 12 well microtiter plate containing bacteriological agar to ensure that the 
bacterial biofilm did not dry out throughout the remainder of the experiment, thus 
preventing premature cell death. Next, 1 mL of TCF-ALP (10 µM, 50 mM Tris HCL, pH 9.2) 
was added to the surface of the biofilms and incubated for 1 h or 24 h at 32 °C before 
undergoing fluorescence measurements. It is important to note that incubation with TCF-
ALP did not significantly decrease the viable count of S. aureus NCTC 10788 compared to 
the untreated controls (bacterial biofilms incubated with 50 mM Tris-HCl, pH 9.2; see 
Appendix).  
Upon incubation of S. aureus NCTC 10788 with TCF-ALP, there was a sharp increase in 
fluorescence intensity (Figure 7.24) that remained for the duration of the study (Figure 
7.25). The ratio of the RFI of the sample to the RFI of the negative control (I/I0) the values 
were similar (~30-fold increase), signifying that the probe was saturated with ALP before 
the 1 h measurement, indicating a high level of ALP activity within the biofilm compared to 
its planktonic counterpart.  
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Figure 7.24: A) Fluorescence spectra of TCF-ALP (10 µM) after 1 h incubation with biofilms of S. aureus 
NCTC 10788 (1011 CFU/membrane) in 50 mM Tris-HCl buffer pH 9.2 at 32 °C and B) corresponding selectivity 
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Figure 7.25: A) Fluorescence spectra of TCF-ALP (10 µM) after 24 h incubation with biofilms of S. aureus 
NCTC 10788 (1011 CFU/membrane) in 50 mM Tris-HCl buffer pH 9.2 at 32 °C, and B) corresponding selectivity 
bar chart. λex = 542 (bandwidth 15) nm. λem = 606 nm. Error bars indicate standard deviation (n = 3) 
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Figure 7.26: Images taken of negative controls (Membrane and Artificial Wound Fluid (AWF) only) and 
biofilms of S. aureus NCTC 10788 (1011 CFU/membrane) after 0, 1, and 24 h incubation with 10 µM TCF-ALP 
in 50 mM Tris-HCl buffer pH 9.2 at 32 °C 
 
Figure 7.26 shows the distinct colour change from yellow to purple of TCF-ALP after 1 h 
incubation with S. aureus NCTC 10788, which was maintained for up to 24 h post-















Biofilms exhibit an altered phenotype compared to planktonic bacteria,159 thus experiments 
were conducted using biofilms of E. coli NSM59 and P. aeruginosa PAO1 to re-examine the 





Figure 7.27: A) Fluorescence spectra of TCF-ALP (10 µM) after 1 h incubation with biofilms of E. coli NSM59 
and P. aeruginosa PAO1 (1011 CFU/membrane) in 50 mM Tris-HCl buffer, pH 9.2 at 32 °C and B) corresponding 






Figure 7.28: A) Fluorescence spectra of TCF-ALP (10 µM) after 24 h incubation with biofilms of E. coli NSM59 
and P. aeruginosa PAO1 (1011 CFU/membrane) in 50 mM Tris-HCl buffer pH 9.2 at 32 °C and B) corresponding 
selectivity bar chart. λex = 542 (bandwidth 15) nm. λem = 606 nm. Error bars indicate standard deviation (n = 3) 
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Figure 7.29: Images taken of negative controls (Membrane and Artificial Wound Fluid (AWF) only) and 
biofilms of E. coli NSM59 (EC) and P. aeruginosa PAO1 (PA) (1011 CFU/membrane) after 0, 1, and 24 h 
incubation with 10 µM TCF-ALP in 50 mM Tris-HCl buffer, pH 9.2 at 32 °C 
 
Figure 7.27 shows that after 1 h incubation with TCF-ALP, there was minimal turn-on 
response for both E. coli NSM59 and P. aeruginosa PAO1, with I/I0 values similar to the 
control. Additionally, there was no visible colour change, with the solutions of TCF-ALP 
remaining yellow (Figure 7.29).  After 24 h (Figure 7.28), a ~10-fold and ~5-fold increase in 
fluorescence intensity was observed for E. coli NSM59 and P. aeruginosa PAO1, 
respectively. However, this was 3-fold lower than what was observed for S. aureus NCTC 
10788 at the 24 h time-point, and it can be speculated that the fluorescence intensity of S. 
aureus NCTC 10788 would be higher if TCF-ALP was not saturated. This is supported by 
Figure 7.29, which shows a faint colour change from yellow to pink/purple for E. coli 
NSM59 and P. aeruginosa PAO1. Therefore, it can be concluded that while TCF-ALP is 
able to detect E. coli NSM59 and P. aeruginosa PAO1 biofilms, the fluorescence response is 
quicker, and more intense, for S. aureus NCTC 10788 – allowing the user to distinguish 
between the gram-positive S. aureus bacteria and the gram-negative bacteria with relative 
ease.  
7.4.7. Ex vivo Porcine Skin Assay 
To test the viability of TCF-ALP in realistic situations, experiments were carried out using 
an ex vivo porcine skin model. A 10 µL suspension of S. aureus NCTC 10788 (108 CFU/mL) 
was inoculated onto porcine skin and allowed to dry at room temperature for 20 min. Next, 
1 mL of 10 µM of TCF-ALP was added to the skin via the use of a Franz cell, and 
subsequently incubated for 24 h at 32 °C.  
-VE EC PA -VE EC PA -VE EC PA 
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The results in Figure 7.30 show that after 24 h incubation with TCF-ALP, S. aureus-
inoculated pig skin had a marked increase in fluorescence intensity compared to the 
negative control. This was confirmed by Figure 7.31, where an observable colour change 
from yellow to purple was observed.  
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Figure 7.30: A) Fluorescence spectra of TCF-ALP (10 µM) in 50 mM Tris-HCl buffer pH 9.2 after 24 h 
incubation with S. aureus NCTC 10788 inoculated porcine skin at 32 °C, and B) corresponding selectivity bar 
chart. λex = 542 (bandwidth 15) nm. λem = 606 nm. Error bars indicate standard deviation (n = 3) 
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Figure 7.31: Images of negative control (no bacteria) and S. aureus NCTC 10788 on porcine skin after 24 h 
incubation at 32 °C with 10 µM TCF-ALP in 50 mM Tris-HCl buffer pH 9.2 
This study shows the potential of TCF-ALP as a diagnostic tool for the detection of 
S. aureus in an ex vivo setting. The lower fluorescence intensity observed in this model can 
be attributed to the fact that the concentration of bacteria inoculated onto the porcine skin 
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was lower than the preceding studies; the small inoculum volume (10 µL) of S. aureus NCTC 
10788 used equates to a final concentration of 106 CFU/mL, compared to planktonic assays 
where 108 CFU/mL was used.  Owing to the bacteria remaining on the porcine skin for the 
duration of the incubation with TCF-ALP, the bacterial isolates grew approximately 1 log 
during this time period, consistent with results obtained during the optimisation of this 
assay. Upon incubation with TCF-ALP, there was a slight reduction in cell count of S. 
aureus NCTC 10788, although this reduction was not statistically significant (t-test, p = 
0.1728), therefore it is possible to assume that TCF-ALP doesn’t inhibit bacterial growth 
on porcine skin (see Appendix).  
7.4.8. TCF-ALP Based Hydrogels 
Hydrogels are three-dimensional macromolecular structures that are produced by chemical 
or physical crosslinking of natural or synthetic hydrophilic polymers. Hydrogels typically 
have a water content between 90 – 95% by mass,160 have a range of physical forms,161 and 
are biocompatible;162 hence, are frequently used in a variety of clinical applications. 
Furthermore, it is possible to use hydrogels to encapsulate drugs for controlled-release 
system that can be controlled via the degree of crosslinking in the gel.161  
Hydrogels have been utilised in wound care as they can protect the wound site from further 
damage and provide a moist environment, thereby preventing scar formation.160,163  They 
are frequently used for the management of pressure ulcers,164 diabetic foot ulcers165 and 
burns.166 Additionally, hydrogels can facilitate autolytic debridement by increasing the 
moisture content of necrotic tissue.167 Hydrogels can also act as soothing and cooling agents 
for cutaneous wounds168,169 and are thought to reduce the inflammatory process.169 Other 
advantages of hydrogels include ease of removal, acceleration of the wound healing process, 
reduction of pain, and ease of development and handling.168 However, hydrogels also have 
drawbacks which include being semi-permeable to gases and water vapour, acting as a poor 
barrier to bacterial infection, and in some instances having poor mechanical stability.168  
Wichterle and Lim were the one of the first researchers to develop hydrogels using 2-
hydroxyethyl methacrylate (HEMA), which has since been used in a variety of biomedical 
applications.170 HEMA was further developed by Winter, who produced the first-generation 
of polymeric dressings.171 Since then, a variety of hydrogels have been created for wound 
care, leading to several commercial hydrogels, including: TachoSil® and Apligraft®.167 
In this study PVA was used to create a hydrogel matrix. PVA is a synthetic-water soluble, 
biocompatible polymer.172 PVA is versatile, hence it has been used extensively in the 
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creation of wound dressings,168 wound management,168 drug delivery systems,173 
biosensors,174 artificial organs,175 and contact lenses.176 PVA can be chemically crosslinked, 
with agents such as maleic acid, formaldehyde or glutaraldehyde,172 or undergo physical 
crosslinking via freeze-thaw cycles. This study used the latter method to create 
biocompatible polymers which can be used in wound care. In the freeze-thawing process ice 
crystals are formed within the hydrogel; these ice crystals result in the polymer chains being 
packed together, forming polymer crystallites where hydrogen bonds are formed between 
the chains. These crystallites act as physical crosslinks, holding the amorphous chains 
together.177  
Hydrogels have been shown to help with the disadvantages associated with colorimetric and 
fluorescent-based probes (i.e., non-specific interactions, auto-fluorescence, and low 
stability in reaction environments), which reduce the sensitivity, and therefore accuracy, of 
the probes.178 Hydrogels also help minimize auto-fluorescence and provide an aqueous 
environment that is biologically-compatible, while preventing non-specific protein 
adsorption.178 Additionally, hydrogels are porous, which allows enzymes and/or bacteria to 
penetrate the hydrogel to react with the probe. Hydrogel-based fluorescent detection 
systems have been shown to enhance sensitivity and reduce detection time.178  
Gunda et al developed a hydrogel system which contained a colorimetric probe, growth 
medium, and a lysing agent to detect E. coli in contaminated water samples.137 The system 
was capable of detecting 400 CFU/mL of E. coli, via a visual colour change, after 1 h. Also, 
Bhattacharya et al, developed a carbon-dot hydrogel hybrid for the detection of bacteria.179 
Secreted bacterial esterases and lipases fluidised the hydrogel, resulting in aggregation and 
fluorescence quenching of the carbon dots; this system was capable of detecting multiple 
bacterial species, including Bacillus cereus, Bacillus subtilis, P. aeruginosa and S. aureus. 
When Bacillus cereus was used as the model system, a LOD of 105 was observed.  
As shown in previous sections of this chapter, TCF-ALP has proven to be capable of 
detecting S. aureus isolates. Therefore, the attention of this study turned towards creating 
a wound dressing capable of detecting S. aureus via the incorporation of TCF-ALP into a 
PVA-based hydrogel. 
Bacterial colonisation is heterogenous within a wound; S. aureus is as an early-coloniser 
predominately located near the surface of the wound, and gram-negative bacteria (e.g., 
P. aeruginosa) are late-stage colonisers, located within the deep regions of the wound.180 
Owing to this, it was hypothesised that a diagnostic wound dressing would be able to 
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preferentially detect S. aureus and other gram-positive bacteria over gram-negative 
pathogenic bacteria present in a wound.  
A diagnostic wound dressing is advantageous over current swab and biopsy methods as the 
current methods are not able to determine the aetiology of the wound infection; they do not 
give a representative indication of the pathogenic bacteria present within a wound owing to 
the small wound surface area sampled.142 The PVA-based TCF-ALP diagnostic wound 
dressing would be in contact with the whole surface of the wound, and therefore would be 
capable of detecting localised S. aureus infection across the wound. 
PVA was dissolved in PBS buffer (pH 7.4), and after incubation with S. aureus NCTC 10788 
there was a colour change from yellow to green due to the protonation of the TCF moiety 
(Figure 7.32). This was a disadvantage as the colour change was less noticeable, and TCF-
ALP in neutral and acidic environments displays reduced fluorescence intensity. Therefore, 
10 % PVA was dissolved in Tris HCl (pH 9.2) keeping the hydrogel environment alkaline in 
nature, allowing for deprotonation of the TCF moiety of the probe. 
Negative Control S. aureus NCTC 10788 
  
 
Figure 7.32: 10% w/v PVA hydrogel loaded with 100 µM of TCF-ALP in PBS, pH = 7.4  after 24 h incubation 
at 32 °C with porcine skin inoculated with and without S. aureus NCTC 10788. 
For this research, 100 µM TCF-ALP was used to ensure probe stability for the duration of 
the freeze-thaw cycle of hydrogel preparation and to provide an enhanced colour change 
from yellow to purple to identify the presence of a S. aureus infection. As this system is 
designed to be an easy PoC test for diagnosing an infection, without the use of specialised 
equipment, it is vital that the colour change of the hydrogel is noticeable to signal to the 
healthcare provider that the wound has an established infection and requires medical 
intervention. In brief, a stock solution of TCF-ALP in DMSO was prepared (2.6 mM), and 
38.5 µL transferred to 1 mL of 10% w/v PVA and mixed to produce a homogenous yellow 
PVA solution. While the hydrogel contained DMSO, it had a minimal effect on bacterial 




7.4.8.1. Detecting Planktonic Staphylococcus aureus 
Planktonic suspension assays were undertaken to assess the viability of the TCF-ALP 
hydrogel as a PoC for wound infections. S. aureus NCTC 10788 was grown in Mueller 
Hinton broth overnight, centrifuged and resuspended in 50 mM Tris HCl (pH 9.2) to attain 
a final concentration of 108 CFU/mL. Thawed TCF-ALP hydrogels were placed in 1 mL 
aliquots of bacterial suspensions before being incubated at 32 °C for 24 h. Figure 7.33 shows 
the colour of the TCF-ALP hydrogels at regular time points during the 24 h incubation with 
S. aureus NCTC 10788. The results show that upon incubation with bacteria, TCF-ALP 
undergoes a colour change from yellow to purple – visible to the naked eye at approximately 
5 – 6 h; after 24 h the colour of the hydrogel is a deep purple.  
It is also worth noting that some leaching of TCF-ALP occurred and was evident by the 
bacterial suspension also turning purple in colour. This could be attributed to only one 
freeze-thaw cycle being performed to crosslink the 10% w/v PVA solution, which would 
result in a more porous hydrogel than if it was subjected to multiple cycles. While 10% w/v 
PVA was chosen as it has previously been shown to have good structural integrity,181 further 
experiments could be undertaken to determine the appropriate number of freeze-thaw 
cycles required to prevent leaching while retaining a high degree of porosity for the bacteria 
to penetrate the hydrogel and cleave the TCF-ALP probe. For the purposes of this proof-
of-concept study, one freeze-thaw cycle was deemed to be sufficient as leeching was minimal 
and TCF-ALP was retained within the hydrogel, allowing visualisation of the colour change 
within the hydrogel.   
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Figure 7.33: Images of 10% w/v PVA hydrogels loaded with 100 µM TCF-ALP in 50 mM Tris-HCl buffer pH 
9.2 at 0 – 8 h and 24 h incubation at 32 °C with S. aureus NCTC 10788 planktonic culture (c. 108 CFU/mL).  
After 24 h incubation, the TCF-ALP hydrogels were removed from the planktonic 
suspension, rinsed with 50 mM Tris HCl (pH 9.2), and assessed for fluorescence intensity. 
As evident in Figure 7.34, upon incubation with S. aureus NCTC 10788, TCF-ALP 
displayed over a 30-fold increase in fluorescence intensity compared to the negative control. 
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This correlates to the colour change observed in Figure 7.33 and results obtained using the 
solution-based TCF-ALP outlined previously.  
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Figure 7.34: A) Fluorescence spectra of TCF-ALP (100 µM) in a 10% w/v PVA hydrogel after 24 h incubation 
at 32 °C with planktonic cultures of S. aureus NCTC 10788, and B) corresponding selectivity bar chart. λex = 
542 (bandwidth 15) nm. λem = 606 nm. Error bars indicate standard deviation (n = 3). 
7.4.8.2. Colony Biofilm Wound Model 
Owing to the success of the planktonic suspension assays, next the utility of the TCF-ALP 
hydrogel to detect S. aureus biofilms was assessed. Bacterial biofilms were grown on 19 mm 
polycarbonate membranes supplemented with AWF. After 24 h incubation at 32 °C for 24 h 
the biofilms were transferred from Mueller Hinton agar to bacteriological agar within a 12-
well microtiter plate. Bacteriological agar was used to prevent the bacterial biofilms from 
drying out.  
TCF-ALP hydrogels were placed onto the biofilms and incubated at 32 °C for 24 h. At 
periodic intervals the biofilms were photographed to assess colour change (Figure 7.35). 
Colour change was evident within the hydrogel after 1 h incubation with S. aureus NCTC 
10788 biofilms, probably due to the high cell concentration (1010 CFU/membrane). 
Throughout the incubation period the negative control remained yellow in colour, while the 
TCF-ALP hydrogels incubated with S. aureus NCTC 10788 progressively turned purple, 
originating from the centre of the hydrogel. However, as this experiment was repeated in 
triplicate, while all hydrogels displayed a colour change at 1 h, the colour didn’t always 
originate from the centre of the hydrogel. In fact, it seemed to be the section of the hydrogel 
which was in the closest contact with the bacteria. At 24 h the whole hydrogel was deep 
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purple in colour. Unfortunately, leaching occurred and the bacteriological agar underneath 
the biofilms turned purple in colour.  
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Figure 7.35: Images taken of 10% w/v PVA hydrogels loaded with 100 µM TCF-ALP in 50 mM Tris-HCl buffer 
pH 9.2 at 0 – 8 h and 24 h incubation at 32 °C with S. aureus NCTC 10788 biofilms.  
 
After 24 h incubation, hydrogels were removed from the biofilms and rinsed with 50 mM 
Tris HCl (pH 9.2) before being assessed for fluorescence. As expected, there was a noticeable 
increase in fluorescence for the TCF-ALP gels incubated with S. aureus NCTC 10788 
compared to the negative control (Figure 7.36), suggesting that ALP activity within S. 
aureus biofilms could still be measured with TCF-ALP entrapped within a hydrogel matrix. 
This result is promising, as a simple and clear PoC prototype diagnostic hydrogel wound 
dressing was created, which clearly displays S. aureus infection via a visible colour change 
that is easy to detect by either the patient or healthcare provider without any specialised 
equipment. If necessary, the wound dressing could be removed with ease, and with minimal 
discomfort to the patient,168 and fluorescence of the gel measured to semi-quantitatively 
determine the S. aureus bacterial bioburden within an infected wound.  
Concurrently, bacterial biofilms were stripped and the viability of S. aureus NCTC 10788 
was determined by using a standardised enumeration assay. The presence of a 10% w/v PVA 
hydrogel did not affect bacterial viability, nor did a 10% PVA hydrogel containing 100 µM 
TCF-ALP (Appendix). Thus, it is possible to conclude that the TCF-ALP hydrogel would 
not cause bacterial cell death if used as a wound dressing and hence provide a semi-
quantitative determination of bacterial density within the wound. Future studies would 
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Figure 7.36: A) Fluorescence spectra of TCF-ALP (100 µM) in a 10% w/v PVA hydrogel after 24 h incubation 
at 32 °C with S. aureus NCTC 10788 biofilms, and B) corresponding selectivity bar chart. λex = 542 (bandwidth 
15) nm. λem = 606 nm. Error bars indicate standard deviation (n = 3). 
7.4.8.3. Ex vivo Porcine Skin Assay 
Finally, the ability of TCF-ALP hydrogels to determine ALP activity of S. aureus NCTC 
10788 on porcine skin was investigated. A 10 µL suspension of S. aureus NCTC 10788 (108 
CFU/mL) was inoculated onto porcine skin and allowed to dry at room temperature for 20 
min. Once dry, TCF-ALP hydrogels were added to the surface of the skin and subsequently 
incubated for 24 h at 32 °C. The bottom half of a Franz cell was used, as it contained 1 mL 
sterile dH2O to provide moisture, preventing the porcine skin from drying out.  
Figure 7.37 shows that upon incubation with S. aureus NCTC 10788 TCF-ALP hydrogels 
underwent a colorimetric change from yellow to purple, indicative of ALP activity on the 
surface of the skin which was not detected on the negative control. Even though a smaller 
initial inoculum was used the colour change was clear, with a distinct deep purple colour 
observed after 24 h incubation. While the hydrogels did not lose their structural integrity, 
they did appear to dehydrate during the course of this experiment due to being exposed to 










Figure 7.37: Images taken of 10% w/v PVA hydrogels loaded with 100 µM TCF-ALP in 50 mM Tris-HCl buffer 
pH 9.2 after 24 h incubation at 32 °C A) without and B) with S. aureus NCTC 10788 incubated on porcine skin.  
After 24 h incubation, as described previously, hydrogels were washed with 50 mM Tris HCl 
(pH 9.2) and the fluorescence measured. As already observed, incubation with S. aureus 
NCTC 10788 resulted in an approximately 7.5-fold increase in fluorescence intensity of 
TCF-ALP compared to the negative control (Figure 7.38). Bacterial concentration on the 
porcine skin was also investigated, and there was no significant difference between the 
control (porcine skin without hydrogel) and porcine skin incubated with 10% w/v PVA with 
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Figure 7.38: A) Fluorescence spectra of TCF-ALP (100 µM) in a 10% w/v PVA hydrogel after 24 h 
incubation at 32 °C with S. aureus NCTC 10788 inoculated onto porcine skin, and B) corresponding selectivity 
bar chart. λex = 542 (bandwidth 15) nm. λem = 606 nm. Error bars indicate standard deviation (n = 3).  
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7.5. Conclusions and Future Work  
To conclude, this chapter demonstrates that TCF-ALP could be utilised to detect S. aureus 
infections.  This is of great clinical importance as new diagnostic methods are needed for 
the timely detection of infections within wounds. This chapter has shown that TCF-ALP is 
capable of being optimised to detect bacterial pathogens at clinically significant 
temperatures (37 °C for “classic” microbiology, 32 °C for wound infections, and 25 °C for a 
point-of-care device) without the need for extensive preparation.  
Solutions of TCF-ALP were capable of detecting planktonic S. aureus NCTC 10788, with 
an excellent colorimetric and fluorescence response, corresponding to a limit of detection 
of 3.7 x 106 CFU/mL after 24 h incubation. TCF-ALP was selective towards gram-positive 
bacteria, albeit in a limited sample size, compared to gram-negative E. coli and P. 
aeruginosa. TCF-ALP was also capable of rapidly detecting S. aureus NCTC 10788 biofilms 
(both 96-well plate and colony biofilm models), with a clear fluorescence “turn-on 
response” and colour change from yellow to purple within 1 h of incubation time. With these 
promising results in hand, ex vivo models were conducted showing the utility of TCF-ALP 
in detecting S. aureus NCTC 10788 in clinically-significant situations, therefore 
demonstrating the capability of TCF-ALP in diagnosing S. aureus wound infections. 
Expanding on this, TCF-ALP was encapsulated in PVA-based hydrogels as a proof of 
concept for “smart” wound dressing applications. The same experiments mentioned above 
were conducted for TCF-ALP-based hydrogels and similar results were found. TCF-ALP-
based hydrogels were capable of detecting planktonic S. aureus NCTC 10788 after ~4 h and 
colony biofilm models of S. aureus NCTC 10788 after 1 h of incubation. Ex vivo models 
displayed a similar result, with a clear colour change of the hydrogel from yellow to purple 
observed after 24 h.  
Future work would need to be conducted to further examine the selectivity of TCF-ALP, 
with future experiments focusing on different clinically significant bacteria such as Bacillus, 
Klebsiella, and other Enterobacteria spp. Additionally, focus should be shifted to determine 
the genetic mechanism behind ALP-production, and why TCF-ALP was able to detect 
gram-positive bacteria over gram-negative bacteria. Finally, TCF-ALP-based hydrogels 
would need to be optimised further to prevent leaching of TCF-ALP into the extracellular 
environment; studies would also have to be conducted to demonstrate the hydrogel has no 






7.6.1. Cell Count for Selectivity Assay  
Cell counts were performed for bacterial strains that were unable to elicit a fluorescence 
response upon incubation with TCF-ALP. Figure S1 shows that the bacterial concentration 
of all E. coli strains (NCTC 10418, NSM59, and DH5α) were unaffected after 24 h incubation 
with TCF-ALP. All P. aeruginosa strains (PAO1, P260, P885) had a statistically significant 
reduction in bacterial concentration; however, this correlated to a 1-log reduction, which 
should have a minimal effect on the efficacy of TCF-ALP. Therefore,  bacterial 
concentration is not the primary explanation for  E. coli and P. aeruginosa failing to produce 
a “turn-on” response of TCF-ALP.  
 
 
Figure S1: Log CFU/mL of P. aeruginosa (PAO1, P260, and P885) and E. coli (NCTC 10418, NSM59, and 
DH5α) before and after 24 h incubation with 10 µM TCF-ALP in 50 mM Tris-HCl, pH 9.2 at 32°C. Error bars 
show standard deviation (n = 3). Statistical significance was assessed by performing a t-test. p values are 
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7.6.2. Glucose Supplementation for 96-well Biofilm Models 














Figure S2: Evaluation of glucose supplementation on the formation of Staphylococcus aureus NCTC 10788 
biofilms. Biofilm biomass was quantified using crystal violet biofilm staining by measuring the absorbance at 
590 nm. Error bars show standard deviation (n = 3). 






Figure S3: A) Minimum Inhibitory Concentration (MIC) of sodium orthovanadate for Staphylococcus 
aureus NCTC 10788. MIC was found to be 6.25 - 3.13 mM.  B) Minimum Biofilm Inhibitory Concentration 
(MBIC) of sodium orthovanadate for Staphylococcus aureus NCTC 10788. Biofilm biomass was quantified 
using crystal violet staining by measuring the absorbance at 590 nm MBIC was found to be 3.13 – 1.56 mM.  
Error bars show standard deviation (n = 3). 




































































































Figure S4: Log CFU/membrane of S. aureus NCTC 10788, E. coli NSM59, and P. aeruginosa PAO1 biofilms 
after 24 h incubation at 32°C with solutions of TCF-ALP (10 µM) in Tris-HCl, pH 9.2. Error bars show 
standard deviation (n = 3). Statistical significance was assessed by performing a t-test. p values are indicated *, 
p< 0.05 




Figure S5: Log CFU/mL of S. aureus NCTC 10788 incubated on porcine skin for 24 h at 32°C with a solution 
of TCF-ALP in 50 mM Tris-HCl, pH 9.2 (10 µM; 1 mL). The negative control was undertaken using a solution 



















1 5 B e fo re  a d d itio n  o f T C F -A L P










N e g a t iv e
C o n tr o l









7.6.6. Hydrogel Detection 
7.6.6.1. Colony Biofilm Assays 
 
 
Figure S6: Log CFU/membrane of S. aureus NCTC 10788 colony biofilm model biofilms after 24 h 
incubation at 32°C with 10% w/v PVA hydrogels loaded with TCF-ALP (100 µM). Error bars show standard 
deviation (n = 3).  
 
7.6.6.2. Porcine Skin 
 
 
Figure S7: Log CFU/mL of S. aureus NCTC 10788 on porcine skin after 24 h incubation at 32°C with 10% 
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Chapter 8: Overall Conclusions and Future 
Work 
The overall aim of this thesis was to create and evaluate a novel stimuli responsive system 
that could be used as a “smart” wound dressing for the treatment of S. aureus within chronic 
wounds.  
The first three results chapters of this thesis set out to design a therapeutic system utilising 
the antibacterial properties of bacteriophage. Herein, we found that bacteriophage K was 
able to act in a synergistic manner with four different antibiotics: ciprofloxacin, 
vancomycin, amikacin, and amoxicillin, resulting in increased bacterial cell reductions 
compared to their monotherapy counterparts. This synergistic interaction was also capable 
of preventing S. aureus biofilm formation, and in some cases, reducing the bacterial 
biomass of an established infection. However, these results also highlighted the fact that the 
efficacy of the phage-antibiotic concentrations are dependent upon the strain of the bacteria 
under investigation; hence, there could be issues with this therapy in a clinical setting where 
it is not known what strain of bacteria is causing an infection.  
With those promising results in hand, focus turned to developing a system whereby the 
antimicrobials can be released in a burst-like manner upon recognition of bacterial 
pathogens. The reservoir film used in this study was a blend of PLA and PEG as it was shown 
to have good biocompatibility and excellent drug release properties. Both phage K and 
ciprofloxacin were successfully encapsulated within this film and were shown to be capable 
of reducing bacterial density in planktonic, biofilm, and ex vivo studies.  
To create a stimuli-responsive system, the PLA-PEG film was coated with a pH-responsive 
polymer. Earlier work conducted by Dr Wallace (University of Bath, UK) had suggested that 
pH could be a suitable trigger for drug release as it correlated with the formation of a 
biofilm. The PLA-PEG film was successfully coated with EUDRAGIT® FS 30 D and the 
resultant system was shown to be pH sensitive, within minimal diffusion of the 
antimicrobials from the system and pH values less than 7.0. However, one drawback of this 
film was that it hindered antimicrobial release from the polymer system, resulting in lower 
log reductions of bacterial concentrations. However, with further optimisation assays 
investigating the effect of polymer thickness and antimicrobial concentrations, this system 
has great potential to be used in a clinical setting. 
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Concurrently, work was being undertaken to develop a novel colorimetric and fluorescent 
probe for the detection of S. aureus. Alkaline phosphatase was chosen as it had been 
previously used in literature for the detection of S. aureus species. We were successfully 
able to synthesise a probe, TCF-ALP, that was capable of detecting ALP, and to a lesser 
extent, ACP, which could be easily monitored via the colour change of yellow to purple. 
What is exciting is that we were able to use this probe to selectively detect S. aureus in 
planktonic, biofilm, and ex vivo studies. Further work needs to be undertaken to determine 
the specificity and selectivity of TCF-ALP, but this thesis has demonstrated its capabilities 
as a probe for the diagnosis of wound infections via incorporation into a PVA-based 
hydrogel.  
Moving forward, it is my hope that the two systems could be combined to create a novel 
theranostic dressing. This could potentially be achieved by creating a ‘checkerboard’-type 
wound dressing that is composed of both polymer systems. Therefore, upon S. aureus 
infection, the theranostic system would be able to detect S. aureus by multiple triggers (pH 
and ALP), releasing its therapeutic payload and alerting the patient, or heath care provider, 
to the presence of an infection. I feel that this system has potential in the field of wound 
care, as it can be easily adapted to suit the clinical need.  
 
